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Summary of the thesis  
Surfactant protein D (SP-D) belongs to the family called Collectins (collagen-containing lectins). It 
has a primary structure characterised by an N-terminal cysteine-rich region, triple-helical 
collagen region composed of Gly-X-Y repeats (where X and Y can be any amino acid), an a-helical 
coiled-coil neck region, and a C-terminal carbohydrate recognition domain (CRD). The primary 
subunit oligomerizes to form a trimeric structure that can further acquire a cruciform 
organization and multimers (dodecamers). SP-D is a potent innate immune molecule whose 
presence in the lungs as well as at a range mucosal surfaces and extrapulmonary tissues allows 
immune surveillance against pathogens, apoptotic/necrotic cells, allergens, and cancer cells. A 
recombinant fragment of human SP-D (rfhSP-D) composed of 8 Gly-X-Y repeats, neck and CRD 
region, expressed in E. coli, is well known to act against a range of pathogen and allergen 
challenge in vitro, in vivo and ex vivo.  
In this thesis, we have examined the interaction between rfhSP-D and two subtypes (pH1N1 and 
H3N2) of Influenza A Virus (IAV) (Chapter 3). rfhSP-D interacted with haemagglutinin, 
neuraminidase and matrix protein 1; inhibited their infectivity against lung epithelia cell lines; 
and suppressed the cytokine storm induced by the viral challenge. The protective role of rfhSP-D 
against IAV as an entry inhibitor was further validated by the use of pseudotyped lentiviruses 
containing haemagglutinin and neuraminidase of the two IAV subtypes. Continuing with the 
theme of innate immune surveillance by SP-D against lung, pancreatic, ovarian, and prostate 
cancers, we extended on recent studies to breast cancer using HER2 over-expressing (SKBR3), 
triple-positive (BT474) and triple-negative (BT20) breast cancer cell lines (Chapter 4). rfhSP-D 
induced apoptosis at 24 h in SKBR3 and BT747 cells (but not in BT20) via intrinsic apoptosis 
pathway. However, this protective effect of rfhSP-D was fully negated by the presence of 
hyaluronic acid, a major extracellular matrix component within the tumour microenvironment 
(Chapter 5). This thesis highlights the therapeutic potential of rfhSP-D in influenza A Virus 
infection as well as breast cancer and merits pre-clinical trials in murine models. 
 
 

































1.1 Innate Immunity  
The innate immunity is the primordial form of the mammalian immune system that represents 
the first-line defense barrier against invading pathogens. The anti-microbial resistance 
mechanisms include cellular and physical barriers comprised of skin, mucosal epithelia, and anti-
microbial peptides.  These epithelial barriers secrete a range of anti-microbial glycoproteins 
(mucins), protective enzymes (lysozymes), and peptide antibiotics (defensins, cathelicidins and 
histatins), which inhibit the growth of microbes (Dale and Fredericks, 2005).  
1.1.1 Innate immune cellular factors  
The innate immune cells such as macrophages and dendritic cells require their pattern 
recognition receptors (PRRs) to recognize and clear pathogens as well as cellular debris. PRRs are 
subdivided into membrane bound PRRs, such as Toll like receptors (TLRs), and C-type lectin 
receptors (CLRs); and cytoplasmic PRRs, including NOD-like receptors (NLRs) and RIG-I-like 
receptors (RLRs) (Figure 1). PRRs, in turn, detect distinct conserved features on pathogens, 
commonly termed as Pathogen-Associated Molecular Patterns (PAMPs), or Damage-Associated 
Molecular Patterns (DAMPs) (Marcus et al., 2014). PAMPs are highly conserved within different 
microorganisms, and can consist of protein, lipid, carbohydrate moieties or nucleic acids 
recognized by TLRs:13 TLRs have been discovered so far, and these TLRs are expressed on 
macrophages, DCs, and NK cells (Hug et al., 2018, Joosten et al., 2016).  
Upon recognition of PAMPs on the pathogens, cell surface PRRs induce phagocytic or pro-
inflammatory anti-microbial responses by triggering a wide range of intracellular signaling 
cascades, through activation of adaptor molecules, kinases, and transcription factors (Akira et al. 
2004). Thus, PRR-triggered signaling further results in the expression of multiple genes, 
culminating in secretion of cytokines, chemokines, cell adhesion molecules, as well as immune-
receptors (Mogensen, 2009). PAMP-PRR engagement also enhances the expression of major 
histocompatibility complex (MHC) class II molecules, as well as expression of co-stimulatory 
molecules such as cluster of differentiation 40 (CD40), CD80 and CD86 (Elgueta et al., 2009) that 
prepares antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs) for 
forming immunological synapse with naïve T cells in the lymph nodes. 


























Figure 1: A schematic representation to demonstrate soluble and membrane-bound pattern-recognition receptors (PRRs). 
Extracellular PRRs include the soluble C-type lectins, such as collectins (lung surfactant proteins A and D, and MBL), Ficolins and 
Pentraxins (serum amyloid-P, C-reactive proteins, and long pentraxin 3), and lectin-membrane receptors (DC-SIGN, dectin 1, and 
mannose receptor). Other membrane bound surface receptors demonstrated are scavenger, TLRs, natural killer (NK) cell, and 
complement receptors. The intracellular NOD-like receptors (NLRs) and Toll-like receptors (TLRs) are rich in leucine repeats, which 
trigger immune genes through nuclear factor- B (NF- B). These soluble and membrane bound PRRs can regulate the interactions with 
non-self-cells that could lead to induction of a wide range of immune mechanisms for pathogen clearance and (taken from (Vasta, 
2009). 





1.1.2 Innate immune humoral response  
The innate immune humoral response is comprised of the serine protease-driven cascades of the 
complement system, as well as naturally occurring antibodies (NAb), collectins and pentraxins 
(Shishido et al., 2012).   
The complement system can be initiated via three distinct pathways, classical (CP), lectin (LP), 
and alternative (AP), resulting in the formation of C3 convertase. C3 convertase cleaves C3, 
leading to C3b production and C5 convertase. C5 cleavage by C5 convertase leads to deposition 
of C5b and result in initiation of the common terminal pathway. The terminal pathway results in 
the membrane attack complex (MAC), lading to lysis of the pathogenic cell. The formation of C3 
and C5 convertase also yields C3a and C5a, two well-known and potent anaphylatoxins. 
Complement receptor 3 (CR3) found on macrophages and neutrophils enrich the innate immune 
response via recognizing C3b opsonized pathogens (Carroll, 2004, Kimura et al., 2003). CR2 
recognition of iC3b, C3dg and C3d significantly increases antibody production, thus acting as an 
adjuvant (Dempsey et al., 1996, Molina et al., 1996).  
Naturally occurring antibodies (NAb) are produced by subclasses of B lymphocytes (B1), that are 
involved in innate humoral response. Nab are well-known germline-encoded antibodies, which 
exhibit   restricted epitope specificities, and can also be produced without stimulations of 
external antigens (Avrameas, 1991). There are different isotypes of Nab, of which IgM is the most 
common, with IgA and IgG being less abundant (Avrameas, 1991). natural IgM antibodies can 
mediate the clearance of cellular debris, or apoptotic cells via recruitment of complement 
components resulting in opsonization (Binder et al., 2005). Pathogen recognition by NAb can also 
modulate the adaptive immune response via interacting with T, B and DCs (Ochsenbein et al., 
1999). Moreover, NAb are also potent initiators of the complement pathways. 
Pentraxins are conserved multifunctional acute phase proteins, and well-known PRRs 
synthesized during tissue damage, infection, and inflammation (Du Clos and Mold, 2004). Each 
pentraxin is characterised by calcium dependent ligand binding, composed of a common domain 
in the C-terminal region. The presence and absence of this additional domains subdivide the 




family into long or short pentraxins (Du Clos and Mold, 2004).. C-reactive protein (CRP) and serum 
amyloid P protein (SAP) have been identified as short pentraxins are synthesized by the liver (Du 
Clos and Mold, 2004). Pentraxin 3 (PTX3) belongs to the long pentraxin subfamily, which was 
initially identified as an IL-1 or TNF-inducible gene. Pentraxins have similar functions as NAb, such 
as recognition and binding to a diverse range of pathogens and intrinsic ligands, including 
extracellular matrix components (ECM) and apoptotic cells (Bassi et al., 2009, Hirschfield et al., 
2003, Pepys and Baltz, 1983). CRP, SAP and PTX3 can interact via Fcγ receptors on macrophages 
and other innate immune cells (Moalli et al., 2010, Mold et al., 2002, Mold et al., 2001). 
Pentraxins binding to targets can facilitate clearance of cell debris and pathogens through 
complement activation (Bassi et al., 2009).  
1.2 Collectins  
Collectins represent an important group of humoural PRRs, which bind to oligosaccharide 
structures on the surface of microorganisms as well as altered self. Collectins are multimeric 
proteins, involved in pathogen clearance by aggregation/agglutination, opsonization, enhanced 
phagocytosis, complement activation, and modulation of inflammation (Murugaiah et al., 2020b, 
Nayak et al., 2012). Collectins are collagen containing C-type (calcium dependent) lectins, 
structurally characterised by three polypeptide chains, each containing four domains. The first 
domain is comprised of NH2-terminal sequences, containing cysteine residues responsible for 
structural units to form oligomers via disulphide bonds. The collagenous region is the second 
domain, which consists of Gly-X-Y triplet repeats, where X and Y represent any form of amino 
acid (Colley and Baenziger, 1987). The triple-helical collagen region also offers rigidity and 
stability to the molecule. Another key structural feature of the collagenous region is that it can 
be O-glycosylated (Colley and Baenziger, 1987).  The third structural domain contains an alpha-
helical coiled-coil neck region, and the fourth domain at the C-terminal end contains a 
carbohydrate recognition domain (CRD), also known as C-type lectin domain (Figure 2) (Kishore 
et al., 2006). The interactions of collectins with a range of pathogens are mediated through their 
CRDs. A broad spectrum of carbohydrate specificity is necessary for collectins to recognize and 
bind a large repertoire of PAMPs, which is accomplished by an open and flexible trough-like 
binding pocket presented within the CRDs region. However, recognition and selection of ligands 




by this site is mostly depends on the positioning of the vicinal hydroxyl groups of carbohydrates 
(Ng et al., 1996), which tend to form coordination bonds with the ligated calcium ions, hydrogen 
bonds and a polar Van der Waals contact (Ng et al., 1996, Murugaiah et al., 2020b).   
To date, the collectin family contains nine members, including mannose binding lectin (MBL), 
lung surfactant protein A (SP-A) and SP-D, conglutinin, Collectin-43 (CL-43) and CL-46, and newly 
discovered collectin kidney 1 (CL-K1), collectin liver 1 (CL-L1) and collectin placenta 1 (CL-P1) 
(Figure 2). Various biological functions of collectins have been summarized in Table 1.  
1.3 Lung Surfactant Protein D (SP-D) 
Human SP-D, a member of the collectin family, is a large hydrophilic and multimeric protein; its 
single polypeptide chain is 43 kDa, containing cysteine-linked N-terminus region, collagenous 
region, neck region, and the CRD region (Kishore et al., 2006).  Three identical polypeptide chains 
of 43 kDa form a trimer of 130 kDa subunit. Four such homotrimeric subunits are then connected 
through their N-terminal regions to form a further tetrameric structure of 520 kDa, assuming an 
overall cruciform structure (Kishore et al., 2006, Nayak et al., 2012). The trimeric CRD module  
can interact with pathogens by binding terminal carbohydrate residues, whilst the collagen 
region of SP-D can bind to its putative receptor, surface-expressed calreticulin-CD91 complexes 
(Gardai et al., 2003) and brings about effector functions, such as pro-inflammatory cytokine 
production (Gardai et al., 2003).  
Human SP-D is primarily synthesized and secreted into the air space of the lungs by alveolar type 
II and Clara cells (Crouch et al., 1992, Voorhout et al., 1992). SP-D presence has also been 
reported at extra-pulmonary sites. Immunohistochemically, SP-D expression has been 
demonstrated in human brain, heart, kidneys, trachea, salivary gland, testis, pancreas, and small-
intestine (Fisher and Mason, 1995, Madsen et al., 2000, Herías et al., 2007). A lower SP-D 
expression has been reported in uterus, adrenal gland, spleen, and mammary glands (Fisher and 
Mason, 1995, Madsen et al., 2000, Herías et al., 2007). In addition, SP-D immunoreactivity has 
also been demonstrated in the epithelial cells of large and small ducts of the parotid gland, sweat 
and lacrimal glands, epithelial cells of gall bladder and intra-hepatic bile ducts, as well as exocrine 
pancreatic ducts, esophagus and in the urinary tracts (Madsen et al., 2000).  




SP-D interacts with a diverse range of pathogens triggering clearance mechanisms, including 
agglutination/aggregation, enhanced phagocytosis and superoxidative burst, as well as direct 
growth microbial inhibition (Nayak et al., 2012, Kishore et al., 2006). Involvement of SP-D has also 
been reported in the control of pulmonary inflammation (allergy and asthma) (Kishore et al., 
2002, Qaseem et al., 2013). Furthermore, SP-D can also link innate immunity with adaptive 
immunity via modulating dendritic cell (DC) maturation and function, and polarization of helper 
T-cell (Qaseem et al., 2013, Qaseem et al., 2017). 
1.3.1 SP-D interaction with Pathogens  
A number of in vitro and in vivo studies have established a key role of SP-D in the protection 
against respiratory pathogens (Table 1). SP-D acts as an opsonin, enhancing phagocytic uptake 
and killing of the target pathogens (Crouch, 2000, Lawson and Reid, 2000, Crouch and Wright, 
2001, Shepherd, 2002).  
1.3.2 SP-D interaction with Bacteria  
Both Gram-negative and Gram-positive bacteria are recognized by SP-D, triggering their 
phagocytosis by alveolar microphages (AMs) (Pikaar et al., 1995). SP-D binds rough 
lipopolysaccharide (LPS) via its CRDs, resulting in agglutination of E. coli (Kuan et al., 1992). Direct 
growth inhibition of several Gram-negative bacteria by SP-D has been reported via enhanced the 
membrane permeability of the bacterial cell wall as well as inhibition of biosynthetic functions in 
E. coli, K. pneumoniae and Enterobacter aerogenes (Wu et al., 2003).  
SP-D can also bind to lipoteichoic acid and peptidoglycan, two Gram-positive bacterial ligands, 
via its CRD region (de Wetering et al., 2001), and to lipoarabinomannan (LAM) from 
Mycobacterium avium and M. tuberculosis (Ferguson et al., 1999, Ferguson et al., 2002, Kudo et 
al., 2004). SP-D also interacts with cell membrane lipids of M. pneumoniae (Chiba et al., 2002). 
SP-D binds and agglutinates M. tuberculosis, while triggering inhibition of phagocytosis via 
blocking the LAM interaction with macrophage mannose receptor (Ferguson et al., 1999, 
Ferguson et al., 2002). SP-D also directly stimulates phagocytosis by enhancing cell surface 
phagocytic receptors such as mannose receptors present on macrophages, without requiring the 
need for microbial binding (Kudo et al., 2004).


















Figure 2: Molecular structural representation and biological functions of human collectins 
Collectins are shown as monomeric subunits, followed by trimeric subunits, composed of an N-terminal domain (7-28 amino acid 
residues), collagen like region (composed of Gly-X-Y triplets repeats), α-helical coiled coil neck region and C-terminal carbohydrate 
recognition domain (CRD). For most collectins, the subunits are homotrimers, which are composed of three identical polypeptides. 
However, heterotrimers can be found in the case of SP-A (made up of highly homologous SPA-1 and SPA-2 polypeptides). 
Heterotrimers can also be found in CL-10 and CL-11.  Biological functions of each domain are also briefly described (Murugaiah et al., 
2020b). 




Table 1: Origin of collectins and their tissue distribution. 
Collectins  Tissues of origin  Tissues of 
presentation  




Liver and small intestine 
 
Serum 
Two variants of MBL (A and C) have been identified in 
most animals, while only one is found in humans and 
chimpanzee. MBL is the recognition subcomponent of the 
complement lectin pathway 









These bovine collectins plays an important role in the 
first line of defense against rumen microbes without 





SP-A and SP-D 
Clara cells, type II 
pneumocytes, 
intestinal mucosa, 
thymus, prostate gland, 
Eustachian tube, 






Extrapulmonary expression of SP-A is limited to a few 




(Kishore et al., 









CL-P1 is the only membrane bound collectin with an 
intracellular domain. May have a function in bacterial 
recognition or act as a scavenger receptor for 
desialylated target.  
(Ohtani et al., 








Interacts with negatively charged molecules, including 
nucleic acid ligands. It is involved in opsonization of 
apoptotic cells by recognizing a combination of 
carbohydrate or nucleic ligands. 
(Venkatraman 
Girija et al., 
2015, Henriksen 




Liver and hepatocyte 
 
Ubiquitous 
May be involved in host defense by recognizing 
numerous pathogens and interacting with effector 
proteins, including complement components. 
(Hansen et al., 
2016) 









Figure 3: Domain organization of human SP-D 
The human SP-D is first shown as monomer, trimer, and oligomer. SP-D is composed of oligomers 
of a 130 kDa subunit containing three identical polypeptide chains of 43 kDa. The primary 
structure of SP-D includes an N terminus domain, collagenous region, helical neck, and C terminus 








1.3.3 SP-D interaction with Viruses 
Direct interaction of SP-D with a number of viruses, leading to viral neutralization and 
phagocytosis has been described. SP-D binds to  gp120 and inhibits HIV-1 infectivity and 
replication in a calcium dependent manner (Meschi et al., 2005), whilst a recombinant fragment 
of human SP-D (rfhSP-D) (containing homotrimeric neck and three CRD region) was also shown 
to bind gp120 and inhibit infection of U937 monocytic cells, Jurkat T cells and PBMCs, in addition 
to suppressing HIV-1 triggered cytokine storm (Pandit et al., 2014). A direct interaction between 
DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) and 
rfhSP-D has been shown to modulate HIV-1 capture and its transfer to CD4+ T cells in vitro 
(Dodagatta-Marri et al., 2017). rfhSP-D can also prevent and restrict HIV-1 transfer across the 
vaginal epithelial barrier, via modulating the gene expression signature of the vaginal epithelium 
(Pandit et al., 2014).  
Increased levels of serum SP-D have been detected in patients infected with severe acute 
respiratory syndrome (SARS) coronavirus (Wu et al., 2009). SARS corona virus spike glycoprotein 
is recognized by SP-D (Leth-Larsen et al., 2007). Interaction between SP-D and HCoV-229E, 
another coronavirus strain, leads to inhibition of viral infection in human bronchial epithelial 
(16HBE) cells (Funk et al., 2012). Binding of SP-D to bovine strains of the non-enveloped rotavirus, 
via the VP7 glycoprotein has been also reported (Reading et al., 1998). However, binding of 
human as well as porcine SP-D to glycoprotein of Ebola virus can enhance viral infection and 
dissemination (Favier et al., 2019). Interestingly, bovine SP-D can also bind bovine rotaviruses via 
the VP7 glycoprotein and neutralise viral infectivity (Reading et al., 1998). SP-D can bind A27 
protein of vaccinia virus; SP-D gene-knockout (−/−) mice challenged with vaccinia virus show an 
increased mortality rate, compared to SP-D wild type (+/+) mice (Perino et al., 2013). In addition, 
rfhSP-D has been shown to bind spike glycoprotein (S1) of SARS-CoV-2 and its receptor binding 
domain (RBD) in a dose dependent manner (Hsieh et al., 2020; Madan et al., 2020). Furthermore, 
rfhSP-D treatment inhibited interaction of S1 glycoprotein with HEK293T cells overexpressing 
Angiotensin Converting Enzyme 2 (ACE2) receptor (Hsieh et al., 2020, Madan et al., 2020). Thus, 
rfhSP-D can act as an entry inhibitor of SARS-CoV-2 as evident from a RLU fold (~0.5) reduction 




of luciferase reporter activity using pseudotyped lentiviral particles expressing SARS-CoV-2 S1 
protein (Hsieh et al., 2020).  
The SP-D binding to Influenza A Virus (IAV) has been extensively studied using SP-D-/- mice. 
However, the anti-viral effects of SP-D seem to be dependent on the viral subtypes and 
glycosylation levels of the virulence factors. These include differences of glycosylation found in 
hemagglutinin (HA) and neuraminidase (NA) glycoproteins (York et al., 2019). SP-D treatment in 
a murine model of IAV infection showed an enhanced clearance of the virus in the lungs (van Eijk 
et al., 2019). SP-D neutralizes the IAV and also inhibits the release of IAV virions from infected 
host cells, via mannose resides of HA or NA (Malhotra et al., 1994). Hemagglutination activity of 
IAV is also inhibited by SP-D, causing aggregation of IAV viral particles (Hartshorn et al., 1994). 
NA activity is also restricted by SP-D; this effect can be inhibited in the presence of D-mannose 
(Reading et al., 1997). Anti-IAV activity by SP-D is suggested to occur via its CRD region binding to 
carbohydrate pattern (mannosylated, N-linked) on HA and NA of IAV (Hartshorn et al., 1994, 
Hartshorn et al., 2000). SP-D also restricts the enzymatic activity of HA and NA, neutralizing the 
ability of pH1N1 IAV subtype to infect human A549 airway epithelial cells line (Job et al., 2010). 
However, SP-D has been reported to enhance infection in the case of some pandemic pH1N1 
strains, which correlates with the differences in N-glycosylation found in the globular head region 
of HA (Job et al., 2010). Porcine SP-D is very potent in its ability to inhibit seasonal IAV subtypes, 
several pandemic and avian strains of IAV (van Eijk et al., 2002, Hillaire et al., 2013).   
1.3.4 SP-D involvement in lung hypersensitivity and inflammation   
SP-D gene knock-out mice, murine models of lung infection and hypersensitivity, structural and 
functional characterization of cell surface associated receptors have emphasized a key diverse 
role played by SP-D in the pulmonary immune response and control of lung inflammation. Mice 
genetically deficient in SP-D showed chronic pulmonary inflammation, ten-fold higher levels of 
hydrogen peroxide by foamy alveolar macrophages, enhanced activity of matrix 
metalloproteinases (MMP), emphysema, and formation of fibrosis in the lungs (Wert et al., 2000).   
In addition to its protective role against lung pathogens, SP-D may also have actively involved in 
the initial protective immunity against airway inflammation and asthma. The most well 




characterized functional studies of SP-D have been shown using allergy and infection models with 
reference to opportunistic fungal pathogens. Native full-length SP-D has shown to bind to 
glycoproteins on A. fumigatus and house dust mite (Dermatophagoides pteronyssinus) via its CRD 
region, and enhancing uptake, phagocytosis, and oxidative burst by neutrophils and alveolar 
macrophages (Madan et al., 1997a), thus, inhibiting specific immunoglobulin E (IgE) binding to 
these allergenic extracts, and blocking subsequent allergy-induced histamine release from 
isolated sensitized basophils (Wang et al., 1996, Madan et al., 1997a, Madan et al., 1997b). An 
inhibitory effect of SP-D on allergen-induced peripheral blood mononuclear cells (PBMC) 
proliferation has also been reported in mite-sensitive asthmatic children (Wang et al., 1998). 
Suppressive effect of SP-D on the secretion of IL-2 by peripheral blood mononuclear cell (PBMC) 
was also observed (Borron et al., 2000). 
The therapeutic effects of exogenous administration of human SP-D and a recombinant fragment 
of human SP-D, composed of homotrimeric neck and CRD regions (rfhSP-D), was examined in an 
allergic bronchopulmonary aspergillosis (ABPA) murine model. An extensive infiltration of 
lymphocytes and eosinophils were seen in the lung sections of the ABPA mice, which were 
significantly reduced following SP-D/rfhSP-D treatment. Decreased levels of IL-2, IL-4 and IL-5, 
and an increased level of interferon gamma (INF- γ) in supernatant of the cultured splenocytes 
were reported, highlighting Th2 to Th1 polarization (Madan et al., 2005). One of the highlights of 
these studies was that rfhSP-D, representing a small portion (60kDa) of the full-length native 
human SP-D molecule (540kDa), was also able to protect ABPA mice from allergen provocation. 
This truncated rfhSP-D was reported to mimic the same therapeutic effect as full-length SP-D; it 
can therefore bind directly to allergens, prevents interaction between allergens and IgE, block 
sensitized basophils-mediated histamine release, as well as suppress proliferation of 
lymphocytes in vitro (Madan et al., 1997b, Wang et al., 1998). Similar protective effects of rfhSP-
D have also been observed in a murine model of pulmonary hypersensitivity induced by Derp 
allergens (Singh et al., 2003). A significant reduction in Derp-specific IgE levels, eosinophilia and 
pulmonary cellular infiltration were seen with rfhSP-D treatment (Singh et al. 2003). IL-4 and IL-
5 levels were decreased, while supernatant of the cultured splenocytes showed an enhanced 
level of IL-12 and INF-γ, suggesting a Th2-Th1 polarization (Singh et al., 2003). 




1.3.5 SP-D interaction with tumour cells  
Studies using in vivo and in vitro cancer models have convincingly demonstrated an involvement 
of SP-D in the immune surveillance against tumour cells. Anti-leukemic properties by both native 
and rfhSP-D have been reported using an eosinophilic cell line, AML14.3D10 (Figure 4) (Mahajan 
et al., 2013, Mahajan et al., 2014). rfhSP-D was observed to bind AML14.3D10 cell line in a dose 
and calcium-dependent manner. rfhSP-D treatment caused G2/M arrest, with an enhanced p21 
level, and Try15 phosphorylation of cdc2 (Figure 4). Activation of pro-apoptotic markers, 
including cleaved caspase 9 and 3, was also noted following the rfhSP-D treatment, suggesting 
the involvement of intrinsic apoptotic pathway. rfhSP-D also caused down-regulation of pro-
survival HMGA1 (high-mobility group A1) protein, in addition to reducing cell viability of acute 
lymphoid leukemia cell lines (Jurkat and Raji) and human breast epithelial cell line (MCF-7). 
However, rfhSP-D treatment did not cause any cell viability reduction in human PBMCs from the 
healthy controls. Pandit et al. subsequently revealed that rfhSP-D could induce apoptosis in 
activated PBMCs, but not in non-activated PBMCs by regulating the expression of 
immunomodulatory receptors and cytokines (Pandit et al., 2016). rfhSP-D treatment significantly 
downregulated pro-inflammatory receptors, such as CD65, TLR2, TLR4 and CD11c, down-
regulated Th1 cytokines, IFN- γ, as well as TNF-α (Tumor necrosis factor alpha) and IL-6 following 
rfhSP-D. However, Th2 cytokines including IL-4, and anti-inflammatory cytokines, IL-10 as well as 
TGF- β (Transforming growth factor beta) levels were not significantly affected (Pandit et al., 
2016). These studies highlighted the possible immune surveillance role of SP-D against activated 
cells.     
Down-regulation of epidermal growth factor (EGF) signaling by exogenous SP-D treatment has 
also been reported (Hasegawa et al., 2015). SP-D was able to prevent the interaction between 
EGF and EGFR (epidermal growth factor receptor), and suppressed cell proliferation, invasion, 
and migration of A549 cells. SP-D appeared to bind the N-glycans of EGFR via its CRD regions, 
leading to downregulation of EGF signaling (Hasegawa et al., 2015). Kaur et. subsequently 
reported anti-tumour role of SP-D against pancreatic cancer, using p53 mutant (mt) and wild-
type (wt) pancreatic adenocarcinoma cell lines (Kaur et al., 2018a). rfhSP-D treatment resulted in 
G1 cell cycle arrest and triggered up-regulation of pro-apoptotic markers including TNF-α. and 




NF-κB. NF-κB translocation from the cytoplasm into the nucleus of Panc-1, MiaPaCa-2, and 
Capan-2 pancreatic cancer cells was also evident. Activation of Fas following rfhSP-D treatment 
resulted in cleavage of caspase 8 and 3, leading to induction of apoptosis regardless of the p53 
status via extrinsic pathway at 48h (Kaur et al., 2018a). In addition, suppression of epithelial–to-
mesenchymal transition (EMT) and related gene signatures by rfhSP-D treatment has also been 
reported (Kaur et al., 2018a). Reduction in the cell invasiveness of Panc-1 and MiaPaCa-2 cells 
was also observed following rfhSP-D treatment, as evident from downregulation of TGF-β; 
Vimentin, Zeb1, and Snail expressions when compared to untreated cells were considerably 
reduced (Kaur et al., 2018b) . Another study using an ovarian cell line, SKOV3, reported apoptosis 
induction by rfhSP-D via Fas-mediated pathway (Kumar et al., 2019). Activation of caspase 3 
cleavage and expression of Fas and TNF-α were observed in rfhSP-D treated SKOV3 cells. rfhSP-
D treatment  also triggered downregulation of mTOR (mammalian target of rapamycin) pathway 
in both pancreatic and ovarian cell lines as evident by decreased mRNA levels of Rictor 
(rapamycin-insensitive companion of mTOR) and Raptor (regulatory-associated protein of mTOR) 
in treated cells, explaining the possible inhibitory mechanisms  of cell growth and proliferation 
(Kumar et al., 2019, Kaur et al., 2018a).  
Anti-cancer effects of rfhSP-D has also been reported in androgen-resistant and androgen-
responsive prostate cancer cells involving p53 and pAkt pathways (Figure 5)  (Thakur et al., 2019). 
Upregulation of BAX, Bcl2, cytochrome C and cleaved caspase 7 expression was seen with rfhSP-
D treatment, suggesting the apoptotic trigger via intrinsic pathway. In a bioinformatics study, 
elevated SP-D mRNA expression in ovarian and lung cancers appeared to correlate with a 
favorable prognosis (Mangogna et al., 2018). Recently, Murugaiah et al. reported protective 
effects of rfhSP-D against breast cancer cell lines (Murugaiah et al., 2020a). rfhSP-D induced 
apoptosis in triple-positive (ER+/PR+/HER2+) and HER2+-over-expressing breast cancer cell lines 
(BT474 and SKBR3) via intrinsic pathway, while no effect in triple-negative breast cancer cell line 
(BT20). Hyaluronic acid (HYA), an abundant component of the extracellular matrix (ECM), was 
found to interact with rfhSP-D; this interaction negated the anti-tumour properties of rfhSP-D 
against BT474 and SKBR3 breast cancer cell lines (Murugaiah et al., 2020a). rfhSP-D treated cells 
in the presence of HYA were unable to induce apoptosis in both BT474 and SKBR3 cell lines. These 




studies therefore suggest the potential immune surveillance role of SP-D against a wide range of 
tumour cells and modulation of downstream signaling pathways.   
Figure 4: Proposed mechanism for apoptosis induction by rfhSP-D in AML14.3D10 leukemic 
cell line. 
Increased oxidative stress and HMGA1 downregulation was observed in rfhSP-D treated 
AML14.3D10 cells. P21 levels were upregulated following rfhSP-D treatment, which resulted in 
cell cycle arrest at G2/M phase. Phosphorylation of P53 and activation of cleaved caspase 9 
further triggered cleavage of Poly (ADP-ribose) polymerase (PARP), and subsequent apoptosis 
induction by rfhSP-D treatment (Mahajan et al., 2013).  






Figure 5: Proposed mechanisms for rfhSP-D mediated apoptosis in prostate cancer cells. 
rfhSP-D treatment induces upregulation of p53 and downregulation of pAkt pathway, leading in 
increased expression levels of Bad, Bax, and release of cytochrome c, thus, result in cleavage of 
caspase 7. Interaction of SP-D with HMGA1, SIRPα, CD14, and EGFR has been reported in previous 
studies and may be important as part of the proposed mechanisms of p53 and Akt (Thakur et al., 
2019). 
 




1.4 Influenza A Virus (IAV) 
Influenza A virus (IAV) is an enveloped RNA virus and a member of Orthomyxoviridae family that 
possess eight single-stranded RNA segments in negative orientation (Le et al., 2005), which 
encode up to thirteen viral proteins, including two surface glycoproteins, an ion Chanel protein, 
nucleocapsid protein, structural scaffolding protein, a tripartite polymerase complex, two non-
structural proteins, and three non-essential proteins (Le et al., 2005). Influenza viruses are 
classified into five different genera, such as influenza A, influenza B, influenza C, Thogotovirus, 
and Isavirus (Shao et al., 2017). Among all the five genera of influenza viruses, IAV infection is 
most common and it causes severe respiratory infection in humans, swine and avian species. 
Being diverse in host specificity, it is also well known to cause pandemic. IAV was shown as a 
major human respiratory pathogen during 1918 pH1N1 influenza pandemic (Taubenberger and 
Kash, 2010), which is believed to have resulted from zoonotic transmission of an avian virus 
(Taubenberger and Kash, 2010). However, the pathogenicity of the 2009 H1N1 pandemic virus 
(H1N1) is reported to be more severe compared to seasonal IAV in humans.  
1.4.1 Structure of IAV 
The IAV genome is composed of eight single stranded viral RNA segments (Table 2), encoding for 
the eleven viral genes; hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1), matrix 
protein 2 (M2), nucleoprotein (NP), non-structural protein 1 (NSP1), nuclear export protein (NEP), 
polymerase acidic protein (PA), RNA-polymerase subunit 1 (PB1), RNA-polymerase subunit 2 
(PB2), and  RNA-polymerase subunit 1-frame 2 (PB1-F2) (Samji, 2009, Nayak et al., 2009, 
Scheiffele et al., 1999, Palese et al., 1974). 
The IAV is organized within a lipid bilayer that is comprised of three transmembrane proteins: 
HA, NA and M2 (Figure 6) (Scheiffele et al., 1999) (Zhang et al., 2000). HA is a viral envelope 
glycoprotein (80 kDa monomer), a spike-shaped trimer extending outward from the envelope or 
lipid layer (Scheiffele et al., 1999). HA protein initiates the life cycle of IAV by binding to sialic acid 
receptors on host cell surface. It also plays a crucial role in mediating fusion between the 
endocytic vesicle and viral membrane during penetration, thereby, facilitating the release of the 
viral genome into the cytoplasm (Zhang et al., 2000). Proteolytic cleavage of HA from HA0 
generates two domains; HA1 and HA2, which, performs essential functions for viral entry into 




infection-susceptible cells and the form globular head structure by HA1 at the end of the HA 
protein, which is responsible for the virus attachment to sialic acid residues of host cell 
glycoproteins (Samji, 2009).   
NA is an exo-sialidase (60 kDa monomer), which cleaves α-ketosidic linkage between the sialic 
acid (also referred as to N-acetylneuraminic acid) and an adjacent sugar residue (Shtyrya et al., 
2009). The well-established nine subtypes of NA are divided into two phylogenic groups: the first 
group containing N1, N4, N5 and N8 subtypes, and the second one with N2, N3, N6, N7 and N9 
subtypes (Shtyrya et al., 2009). The NA molecule comprises 470 amino acid residues and 
oligomerizes to form a homotetramer that has cytoplasmic, transmembrane, head and stem 
domains. In addition, the N-terminus of NA anchors to the viral membrane and the head domain 
consists of enzymatic activity which is required for the cleavage of sialic acid (McAuley et al., 
2019). NA protein is also critical for the budding of newly synthesized viral particles, as well as 
for preventing viral aggregation (Palese et al., 1974). While coming across the respiratory tract 
mucins, NA cleaves neuraminic acid residues, which facilitates movements of viral particles to 
the target cell (McAuley et al., 2019). 
M2 is a type-III integral membrane protein which has important roles in virus entry, assembly 
and budding. M2 consists of a short ectodomain, a transmembrane domain, and a cytoplasmic 
tail (Park et al., 1998, Iwatsuki-Horimoto et al., 2006). Like HA and NA, it is translated in the ER 
membrane and delivered to the apical plasma membrane, but it does not associate with lipid 
rafts. M2 can stabilize the site of budding, and enables polymerisation of the matrix protein, as 
well as formation of filamentous virions (Rossman and Lamb, 2011). In addition, it is also crucial 
for altering membrane curvature at the neck of the budding virus, resulting in membrane scission 
and causing the release of the progeny virion (Rossman and Lamb, 2011). M2 has also been 
shown to form a tetrameric proton ion channel that enables acidification of the interior of the 
virion, resulting in conformational changes and uncoating of the ribonucleoprotein complexes 
(RNP) viral complex (Pielak and Chou, 2011).  
M1 protein, the most abundant protein, lies beneath the lipid layer, and it is, essential for viral 
stability and integrity.  M1 can bind to cytoplasmic tails of HA and NA molecules (Enami et al. 




1996), therefore, it can polymerise and form the emerging viral interior structure. Additionally, 
the cytoplasmic tail-bound M1 serves as a docking site for the recruitment of the viral RNPs 
through its C-terminal domain (Zhang et al., 2017). M1 localizes at the apical plasma membrane 
(Kerviel et al., 2016) through its interaction with lipids and cytoplasmic-exposed portions of HA, 
NA and M2 (Kerviel et al., 2016). Once at the plasma membrane, subunits of M1 proteins interact 
with each other to form a scaffolding matrix for the assembly of newly synthesized viral particles 
(Pohl et al., 2016).   
Other IAV proteins that make up viral RNPs, including NP, PA, PB1 and PB2, have nuclear 
localization signals, which can interact with cellular nuclear import machinery. For the influenza 
genome to be transcribed, the negative sense RNA is converted into positive sense RNA, which 
can serve as a template for viral RNA production. The synthesis of viral RNA is then triggered by 
viral RNA-dependent RNA polymerase (RdRp) (Pohl et al., 2016). Once the viral RNPs are exported 
from the nucleus, the enveloped virions use the plasma membrane of the host cells to form new 
viral particles that can infect other cells. One of the crucial steps that occurs before newly made 
virions leave the plasma membrane is the cleavage of sialic acid residues by NA, which is essential 
for the export of the viral particles from the plasma membrane (Palese et al., 1974).  
 














Figure 6: Life Cycle of Influenza A Virus (IAV). 
The surface of the virus is covered with the glycoproteins- hemagglutinin (HA) that looks like a 
spike, and mushroom-shaped neuraminidase (NA) frequently intersperesed with matrix 2 (M2) 
proteins. The interior of the virus contains the ribonucleoprotein (RNP) complex, which is a 
complex formed with the binding of the vRNA, RNA polymerase complex and influenza virus 








1.4.2 Replication of IAV 
Infection and multiplication of IAV involves receptor binding and cell entry, membrane fusion and 
uncoating of the viral core, RNA replication and translation, assembly and budding of progeny 
virions (Figure 7). Binding of the viral HA to sialic acid residues on glycoproteins on the host cell 
surface. The HA binding specificity depends on the nature of the terminal glycosidic linkage 
between the sialic acid and the penultimate galactose residues on the glycan receptors on the 
host cell (Byrd-Leotis et al., 2017). Following receptor binding, the uptake of the virus occurs 
through receptor mediated endocytosis, where viral particles are engulfed by the plasma 
membrane of the host cell. As a result, the virus is transported to the endosomal lumen (Byrd-
Leotis et al., 2017). The uptake of substances by endocytosis generally ends up in lysosomes and 
degraded by hydrolytic enzymes. However, the IAV genome escapes degradation through viral 
fusion with the endosomal membrane and enters the cell.  
The acidic pH present in the endosomal vesicles triggers fusion of the viral membrane with the  
host, by inducing conformational changes in HA, exposing the fusion peptide, the HA2 domain of 
HA (Samji, 2009). The acidic environment of the endosome also opens the matrix 2 (M2) protein 
ion channel. Opening M2 channel facilitate acidification of interior of the viral core. This leads to 
the release of the viral RNP (vRNP) complex, which is free to enter the host cell’s cytoplasm 
(Samji, 2009). The vRNP complex consists of viral proteins such as NP, PA, PB1 and PB2, and these 
proteins are known to have nuclear localization signals (NLSs). The released vRNP complex is 
delivered to the nucleus, where trimeric viral polymerase complex (PB1, PB2 and PA) transcribes 
viral RNAs to positive sense mRNAs. The mRNAs are then delivered back to the cell cytosol and 
translated to viral proteins. Subsequently, M1 protein initiates its interaction with C-terminal 
domain of HA and NA found on plasma membrane, leading to formation of high -density patches 
of HA and NA (Das et al., 2010). Following the attachment of newly formed vRNPs to M1 on the 
cell plasma membrane, new virus particles are assembled. NA protein is also involved in the 
cleavage of sialic acid, either from host cells or virion glycoprotein, resulting in the release of 
virion, thus prevents their aggregation (Matsuoka et al., 2013). NS1 is also known to play a critical 




role in the regulation of influenza virus replication, although it is not incorporated into the virion 
(Matsuoka et al., 2013). 
 
Figure 7: Life Cycle of Influenza A Virus (IAV). 
1,2: Hemagglutinin (HA) protein binding to sialic acid attaches virus to cell. 3: Virion is internalized 
by endocytosis and fusion. 4: M2 channel opening allows proton flow across the viral membrane. 
This leads to fusion of viral and endosomal membranes which releases the viral genes which is 
transported to the nucleus. 5: Proteins and genes assemble and bud as virions from the 
cytoplasm. 6: Viral neuraminidase (NA) cleaves sialic acid receptors from the cell membrane 








1.4.3 Host innate defense mechanisms against IAV 
Both innate and adaptive responses are stimulated when IAV infects the cells of the respiratory 
tract. The innate immunity is critical in the early stage of infection and induces the production of 
cytokines and chemokines, either by infected epithelial cells or monocytes/macrophages (Figure 
8). Several soluble innate inhibitors provide an initial infection barrier. Dendritic cells (DCs), 
phagocytes and natural killer (NK) cells, attracted to the site of infection, also mediate viral 
clearance, and promote innate and adaptive responses. Activation of these responses requires 
Toll-like receptors 3/7 (Figure 8) and cytoplasmic RNA sensors (Paulson et al., 2012). Following 
influenza virus infection, NK cells enhance responses of both DCs and adaptive T cells (Elton et 
al., 1999). Macrophages infected with IAV produce chemokines such as monocyte 
chemoattractant protein-1 (MCP-1), RANTES (CCL5), monocytes, and macrophage inflammatory 
protein 1 alpha (MIP-1α). This leads to recruitment of mononuclear cells to the lungs, to facilitate 
viral clearance (Kaufmann et al., 2007). NKT cells, CD8+ T cells, and macrophages prevented IAV 
infected mice from severe influenza induced diseases (Tessmer et al., 2009). Type I interferon is 
also essential for NK cell responses of both IFN-γ and granzyme B in response to influenza 
infection (Madera et al., 2016). DC can be also infected by influenza viruses; however, the 
infection is abortive and does not produce progeny virus (Taubenberger and Kash, 2010). Some 
studies have demonstrated that highly pathogenic H5N1 viruses can replicate in both human and 
mouse DCs, leading to cytopathic effects (Peiris et al., 2009). 
1.4.4 Role of cytokines and chemokines in IAV infection 
Cytokines and chemokine play a pivotal role in establishing virus-specific immunity. However, 
uncontrolled activation of immune cells may result in dysregulated homeostasis, leading to 
pathological manifestations. In vitro experiments have revealed conflicting evidence of influenza 
virus mediated cytokine responses. IAV infection was shown to induce up-regulation of pro-
inflammatory IL-1β, IL-6, TNF-α, CCL-2 (MCP-1), CCL3 (RANTES), CCL3 (MIP1-α) and CXCL10 (IP-
10) (Perrone et al., 2008). IL-17, involved in the activation and migration of neutrophils, has 
pathological effects following infection  (Lamichhane and Samarasinghe, 2019). A bronchial 
epithelial cell line (NCI-H292), infected with IAV (H3N2), produces significant amount  of IL-6, IL-
8 and RANTES (Matsukura et al., 1996). In addition, interferons are produced at the site of viral 




infection, which are classified in two subtypes; type I (IFN-ß and IFN-α) and type II (IFN-γ) (Figure 
8) (Matsukura et al., 1996). In addition, potent antiviral properties are possessed by type-I IFN, 
which is pivotal in controlling infection with IAV. 
 
 
Figure 8: Innate Immune Response against Influenza A Virus (IAV) Infection. 
Recognition of intracellular IAV infection by the host pathogen recognition receptors (PRRs) 
triggers NF-κB, interferon regulatory factor 3 (IRF3), and IRF7. Retinoic acid-inducible gene-I 
protein (RIG-I), melanoma differentiation-associated gene 5 (MDA5), and toll-like receptors 
(TLRs) are well known PRRs. Activated transcription factors, in turn, activate type I and type II 
interferons (IFNs), which are secreted by the infected cells. Interaction of IFNs with their 
receptors leads to activation of Janus kinase (JAK)-signal transducer, further triggering the 
transcription signaling pathways that induces the expression of other IFN-stimulated genes (Chen 
et al., 2018b).




 Table 2: Influenza A Virus (IAV) genome structure and function. 
Genome Segment Protein Location in virion Functions 
1 RNA-polymerase subunit 2 (PB2) Internal Trascription/capping/ replication 
2 RNA-polymerase subunit 1 (PB1) 





3 RNA-polymerase subunit (PA) Internal Trascription/replication 
4 Hemagglutinin (HA) Transmembrane Receptor/uncoating 
5 Nucleoprotein (NP) Internal RNA-synthesis 
6 Neuraminidase (NA) Transmembrane Viral release 
7 Matrix Protein 1 (M1) 





8 Non-structrual protein 1 (NS1) 









1.5 Innate immune surveillance in cancer  
The ability of innate immune system to recognise and eliminate cancer cells has been studied for 
many years using in vitro, in vivo and ex vivo models. Thus, immune cells, effector molecules, and 
signalling pathways work together as extrinsic tumour suppressor mechanisms. Carciogensis is 
associated with accumulation of genetic and epigentic events. Such events rapidly change the 
phenotye of the cells via the modification in the morphology, structure, and membrane 
components of the cell (including abnomal glycosylation and orgin tumour-drived antigens 
(Hakomori, 2002).   The major roles of the innate immune system against carcinogenesis include 
eliminating or inhibiting viral infections; tumour elimination based on the expression of tumour-
specific antigens induced by cellular stress, and tumour immune surveillance (Gonzalez et al., 
2018). However, the formation of tumours can also be caused in the presence of functioning 
immune system, and whereby tumour immunoediting (Figure 9) (Swann and Smyth, 2007). has 
been discovered to explain the complete role of immune system during tumour development. 
The tumour immunoediting concept is subdivided into three main phases; elimination, 
equilibrium and escape (Figure 9) (Swann and Smyth, 2007). The elimination phase includes both 
innate and adaptive responses, where the immune system detects and eliminates tumour cells 
as a result of failed intrinsic tumour suppressor mechanisms. For example, innate effectors NK, 
NKT and Gamma delta (γδ) T cells are activated as a result of pro-inflammatory cytokines, which 
are released by macrophages, stromal and tumour cells. The cytokines in turn, recruit additional 
immune cells, where they produce interlukins 12 (IL-12) and interferon gamma (IFN-γ) to 
eliminate the invading tumour cells. In addition, Perforin-, FasL- and TRAIL-mediated killing of 
tumour cells result in the release of tumour antigens, which further leads to adaptive immune 
responses (Kim et al., 2007). As a result of cross-interaction between NK and dendritic cells (DCs), 
maturation of DCs is promoted by NK cells; thus, resulting in tumour antigen presentation to 
naïve T cells.  
During the equilibrium process, the newly produced tumour variants that have overcome the 
elimination phase enter into the dynamic equilibrium, whereby tumour cells with reduced 
immunogenicity undergo immune selection (Mittal et al., 2014). During this process, both 
lymphocytes and IFN-γ plays a crucial role in exerting immune selection pressure tumour cells. 




Thus, original tumour variants are killed, while new variants with mutations increase their 
resistance to immune attack, thus, proceed to the escape phase. In the escape phase, tumour 
cells continue to grow and proliferate progressively amidst an immunosuppressive tumour 
microenvironment (Rabinovich et al., 2007). 
Figure 9: Extrinsic tumour suppressor mechanisms by the immune system. 
Cancer immunoediting is subdivided into three main phases: elimination, equilibrium, and 
escape. Normal healthy cells undergo aberrant transformation in response to oncogenic stimuli. 
During the initial stage of tumour development, tumour specific antigens and markers is 
expressed by these transformed cells, thus, may secrete danger signals. This initiates 
immunoediting process, which begins with elimination phase, whereby transformed cells are 
subjected to elimination by the innate and adaptive immune system. As a result of incomplete 
event of elimination, the cancer cells enter the equilibrium phase, whereby, they alter the 
immune responses and causes production of new tumour variants. During the escape phage, the 
newly produced tumour variants become resistant over the immune responses (Swann and 
Smyth, 2007). 




1.5.1 Breast cancer  
Breast cancer is the foremost regularly diagnosed cancer among women around the world (Ferlay 
et a. 2008), causing approximately 60% mortality in lower-income countries (Coleman et al. 
2018). There is an estimated 5-year survival rate of ~80% in developed nations, and below ~40% 
in low-income nations (Coleman et al., 2018).  
Breast cancer is characterised by an irregular development of abnormal cells within the 
mammary glands. The physiological conditions that lead to breast tumorigenesis incorporate 
acquired hereditary transformation and epigenetic alterations, which can lead to premalignant 
change in mammary cells. The transformed cells then undergo elimination by intrinsic or extrinsic 
tumour mechanisms (Figure 9). Thus, development of advanced breast tumour is a consequence 
of immune selection and immune evasion.  Breast cancer is subdivided into five different 
molecular subtypes; luminal A, luminal B, triple negative, human epidermal growth factor 
receptor (HER) 2 enriched, and normal-like breast cancer (Table 3). The progression and 
metastasis of breast tumours appear to be affected by intrinsic innate immune surveillance 
molecules and inflammatory mediators within the tumour microenvironment (described in 
section 1.4) (Goldberg and Schwertfeger, 2010).  
1.5.2 Conventional Modalities of Treating Breast cancer  
There are several conventional treatment options available for breast cancer patients, including 
surgery, radiation therapy (RT), chemotherapy (CT), endocrine (hormone) therapy (ET), and 
targeted therapy (Dhankhar et al., 2010). Breast conservation surgery is performed for localized 
breast tumours (Matsen and Neumayer, 2013), thus, the surgery is preceded by adjuvant therapy 
to shrink the tumour mass and prevent metastasis (Dhankhar et al. 2010). Tumour cells that may 
not be detected during surgery can be eliminated by RT to minimize the risk of local cancer 
recurrence (Dhankhar et al., 2010). Combination of RT and CT after surgery can also shrinks the 
tumour (Akram and Siddiqui, 2012), with some side effects, including reduced sensation in the 
breast tissues, and other skin-related problems. ET is administered to either balance or block the 
respective hormones (Dhankhar et al., 2010). Tamoxifen is used as an ER antagonist in 
premenopausal women, which is also associated with an increased risk of endometrial 




hyperplasia, endometrial cancer, and other thromboembolic complications (Hirsimaki et al., 
2002). Fulvestrant is prescribed to postmenopausal women diagnosed with hormone receptor-
positive and HER2-negative metastatic breast cancer (Rocca et al., 2018, Nathan and Schmid, 
2017). 
Trastuzumab has been developed to treat early-stage or advanced-stage/metastatic HER2+ 
positive breast cancer patients (Boekhout et al., 2011). Pertuzumab is also used as an adjuvant 
therapy to treat patients with HER2‑positive early-stage breast cancer (Swain et al., 2015). These 
anti-HER2 therapies have shown promising results via inhibiting HER2/HER3 dimerization, and 
ligand-dependent signaling, as well as antibody-dependent cell-mediated cytotoxicity (Baselga 
and Swain, 2009, Scheuer et al., 2009). The use of anti-HER2 blockade therapies associated with 
CT (trastuzumab/lapatinib, or trastuzumab/pertuzumab) has shown improved outcome when 
compared to CT associated with using one anti-HER2 agent (Tsang and Finn, 2012). Dysregulation 
of mammalian target of rapamycin (mTOR) and phosphatidylinositol 3-kinase (PI3K) pathways 
has been reported in breast cancer (Vinayak and Carlson, 2013). mTOR inhibitor (everolimus) has 
shown promising anti-tumour activity in numerous cancers, including hormone receptor positive 
breast cancer (Yardley, 2013). Additionally, targeting cyclin -dependent kinases (CDKs) for cancer 
treatment has emerged as an effective option for treating hormone positive breast cancer 
patients (Mayer, 2015). Palbociclib-letrozole combination as an endocrine-based therapy has 
been used in post-menopausal women with HER2−/ER+ advanced breast cancer (Mayer, 2015). 













 Table 3: Summary of molecular subtypes of breast cancer, correlation with KI-67 staining by immunohistochemistry (IHC). 
  
Molecular Subtype of Breast 
Cancer 
Grade IHC Status  Prevalence 
(%)   
Reference  
Luminal A 1|2 [ER+|PR+] HER2- 
KI67- 
23.7 (Cheang et al., 2009) 






(Cheang et al., 2009) 
HER2+ over-expression 2|3 [ER-|PR-] HER2+ 11.2 (Cheang et al., 2009) 
Basal, Triple negative 3 [ER-|PR-] HER2-, 
basal marker+ 
12.3 (Cheang et al., 2009) 
Normal-like 1|2|3 [ER+|PR+] HER2- 
KI67- 













Figure 10: Illustration of the adjuvant therapy options used in breast cancer patients according to the molecular subtypes (Senkus 
et al., 2013). 
 




1.5.3 Role of TAMs and MDSCs in breast cancer TME 
TAMs in the breast cancer TME are involved in initiation of breast cancer progression and 
metastasis. Breast cancer epidemiological study has reported TAMs correlation with a poor 
clinical prognosis (Obeid et al., 2013). Anti-tumour T cell response suppression by TAM-derived 
anti-inflammatory cytokines is one of the known mechanisms of tumour evasion (Figure 11). 
Previous in vivo studies using animal models of breast cancer have suggested that IL-10 secreted 
by TAMs suppress the activation of CD8+ T cell (Ruffell et al., 2014, DeNardo et al., 2011). Other 
studies have also suggested that decreased tumoricidal TAM activity is associated with tumour 
immune evasion. Down-regulation of IL-12 and iNOS (inducible nitric oxide synthase) is evident 
in macrophages isolated from the mouse breast cancer tissue (Handel-Fernandez et al., 1997, 
Dinapoli et al., 1996). Increased TAM infiltration is associated with enhanced angiogenesis (Leek 
et al., 1996, Ch'ng et al., 2011) in human breast cancer. As evident by a gene expression profiling 
study, TAMs (isolated from late-stage breast cancer) secreted 2-fold levels of angiogenesis-
related mediators when compared to control cells (Ojalvo et al., 2009). Furthermore, human 
breast ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) showed increased 
expression levels of urokinase receptor (uPAR) in TAMs found in the peritumoral region (Rabbani 
and Xing, 1998). In addition, cancer stem cells (CSCs) are triggered by various TAMs-derived 
cytokines, which affects the prognosis of breast cancer (Sainz et al., 2016). TAMs-derived IL-6 can 
promote prolongation of CSC-like features of cancer cells in both the premalignant and 
metastatic stages (Sainz et al., 2016). Furthermore, a proteomics study has reported the 
interaction of TAMs with breast CSCs in mediating ephrin type-A receptor 4 (EphA4) responses, 
thus, promoting tumorigenesis, as well as facilitating maintenance of CSCs (von Boehmer et al., 
1989). In addition, TAMs are correlated with distant metastasis in triple-negative breast cancer 
(TNBC) tissues (Yuan et al., 2014). Enhanced number of TAMs-derived CD68+/ VEGF-C+ has been 
detected in human breast cancer tissues with lymph node metastasis (Yang et al., 2015, Ding et 
al., 2012). TAMs-derived CXCL1 [chemokine (C-X-C motif) ligand 1] has been suggested to 
increase metastasis in mouse and human breast cancer cell lines via nuclear factor (NF)-κB 
signaling (Wang et al., 2018).  




In breast cancer, MDSCs play an important role in cancer development and progression (Figure 
12). Recruitment of MDSCs to the tumour site is directed by various chemokines (Kumar et al. 
2016, 26858199), such as CXCL5 (C-X-C motif chemokine 5) (Yang et al., 2008), CXCL12 (Ouyang 
et al., 2016), and C-C Motif Chemokine Ligand 2 (CCL2) (Huang et al., 2007). Higher levels of 
MDSCs is evident in breast cancer patients and is significantly associated with metastasis (Almand 
et al., 2000, Diaz-Montero et al., 2009). Furthermore, breast cancer patients undergoing 
chemotherapy show reduced levels of granulocytic MDSCs; lower levels of baseline MDSCs are 
also reported in chemo-responsive patients (Montero et al., 2012). Most tumour, including 
breast tumour, show an abundant level of granulocytic MDSCs in peripheral blood (Messmer et 
al., 2015); however, prostate cancer displays an increased level of monocytic MDSCs compared 
to granulocytic MDSCs (Solito et al., 2014).  
In breast cancer, granulocytic MDSCs are triggered by IL-17 from tumor-infiltrating γδ T-cells, 
causing CD8+ T-cell inhibition and promoting lymph node and lung metastasis (Coffelt et al., 
2015). A study using murine model of breast cancer has reported the MDSC interaction with NK 
cells enhanced cancer metastasis by lowering the cytotoxicity of NK cells (Sceneay et al., 2012). 
The AKT signaling pathway is triggered by MDSCs in a mouse model (treated with human breast 
cancer cell line), which causes upregulation of matrix metallopeptidase (MMPs), thus, 
promoteing invasion and metastasis of cancer cells (Liu et al., 2012).MDSCs are also recruited by 
CCL3 derived from breast cancer cells, which triggers the PI3K-AKT-mTOR cascade, causing EMT 












Figure 11: The role of tumor-associated macrophages (TAMs) in breast carcinogenesis. 
The diagram underlines the key immunogenic mechanisms of TAM-derived IL-10 in breast cancer, 
which inhibits the T-cell response, and antigen presentation by downregulating the levels of 
major histocompatibility complex (MHC) class II. Non-immunological events include angiogenesis 
via VEGF and hypoxia-inducible factor (HIF)-2α production; extracellular matrix (ECM) 
remodeling via urokinase receptor (uPAR) and type I collagen release; cancer stemness evoking 
through secretion of IL-6, epidermal growth factor (EGF) and EGF receptor (EGFR) signaling. 
Cancer invasion and metastasis is contributed by TAMs via CCL18 (Chemokine ligand 18), and 
CXCL1 (C-X-C Motif Chemokine Ligand 1). Breast cancer progression is also promoted by TAM 
metabolites, including ROS (reactive oxygen species), lactic acid, lipocalin (LCN), and reactive 
nitrogen intermediates (RNI). TAMs-induced treatment resistance is supported by IL-
10/STAT3/Bcl-2 signaling pathways and other immune factors [CCL18, thymidine phosphorylase, 
fibroblast growth factor, and urokinase-type plasminogen activator (uPA)] (Chanmee et al., 
2014).  
 







Figure 12: The role of myeloid-derived suppressor cells (MDSCs) in breast carcinogenesis. 
The key immunogenic pathways activated by MDSCs during the progression of breast cancer are 
the immunosuppression induction by NOS, iNOS, ROS, IL-10, PD-L1 and TGF-β, causing immune 
evasion of cancer cells. Non-immunogenic events such as enrichment of tumour stemness by 
activator of transcription 3 (STAT3) cascade, matrix metallopeptidase (MMP) 9 and the nitric 
oxide (NO)-induced Notch/ signal transducer, as well as facilitation of cancer invasiveness by the 
phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR), and IL-
6/IL6Rα/STAT pathway. During metastasis process, MDSCs can polarize into osteoclasts, causing 
osteolytic bone metastasis, thus, promotes TGF-β1, VEGF, MMP, and IL-10 production (Cha and 








1.5.4 TAMs and MDSCs as therapeutic target in breast cancer  
TAMs and breast cancer cells within the TME respond to cancer treatment differently, whereby 
polarization of TAMs influences the impact of treatment responses and outcome to 
chemotherapy (Chanmee et al., 2014, Whiteside, 2008). IL-10 secreted by TAM shows an 
increased bcl-2 (B-cell lymphoma 2) and STAT3 (Signal transducer and activator of transcription 
3) expression, leading to TAM-mediated treatment resistance in human breast cancer cell lines 
(T47D, BT549) (Yang et al., 2015). TAMs are shown to be correlated with tamoxifen resistance in 
breast cancer patients (Xuan et al., 2014). Recruitment of CD8+ cytotoxic T-cells are suppressed 
by TAMs, leading to drug resistance in MMTV-PyMT (mouse mammary tumor virus-polyoma 
middle tumor-antigen) breast cancer model (DeNardo et al., 2009). Moreover, suppression of 
TAM-derived angiogenesis-inducing factors has revealed promising improvement in the 
chemotherapy efficacy (Bolat et al., 2006, Tsutsui et al., 2005). IL-6 inhibitor (curcumin) has been 
developed to inhibit secretion of IL-6 in breast tumour cells, which lowers the number of MDSCs 
(Singh et al., 2013). R84 is a well-known VEGF inhibitor has been designed to inhibit VEGF binding 
to VEGFR2, which is promising in controlling the growth of tumour cells and preventing 
infiltration of MDSCs, Treg and macrophages (Roland et al., 2009). R84 inhibitor downregulates 
the expression of IL-6, IL-1β and CXCL1 (Roland et al., 2009). SB-265610 and Sulforaphane are 
potent inhibitors of CXCR2 and macrophage migration inhibitory factor (MIF), which can prevent 
migration of MDSCs (Liu et al., 2012, Simpson et al., 2012). Furthermore, Silibinin plays an 
important role in breast cancer cells by suppressing the expression of CCR2 in MDSCs, thus, 
preventing recruitment of MDSCs at the tumour sites (Forghani et al., 2014). Additionally, the 
use of anti-CCL5 antibody has shown reduced MDSC activity, thus, evoked T cell proliferation, 
which is suggested to be a promising therapeutic measure for triple-negative breast cancer 
(Zhang et al., 2013b).  
1.6 Hyaluronic acid (HYA) and tumour microenvironment 
Tumour microenvironment, which primes survival, growth and tumour invasion, plays a crucial 
role in the development of tumorigenesis. Hyaluronic acid (HYA) (also known as hyaluronan), an 
abundant component of extracellular network and TME, plays an imperative part in 




inflammation, angiogenesis, fibrosis, and cancer progression (Ghatak et al., 2015, Petrey and de 
la Motte, 2014). 
1.6.1 Structure of HYA 
HYA is an anionic molecule, and a member of the glycosaminoglycan (GAG) family, composed of 
repeating polymeric disaccharide, where both glucuronic acid and N-acetylglucosamine are 
linked together via alternating β-1, 3 and β-1, 4 linkages (Figure 13)  (Itano and Kimata, 2002). 
The total number of disaccharides in each HYA molecule is reported to be 2000-25000, thus, is a 
linear chain GAG with molecular weight of 105-107 Da (Toole, 2002). Specific stable tertiary 
structures of HYA have been reported in aqueous solutions (Scott and Heatley, 1999). Polymers 
of HYA exist in numerous configurations, depending on their size, pH, salt concentration and 
associated cations (Scott and Heatley, 1999). HYA encompasses a higher biocompatibility, 
viscoelasticity, moisture retention capacity, as well as hygroscopic properties, even at lower 
concentrations (Turino and Cantor, 2003, Jiang et al., 2011). 
1.6.2 Biosynthesis and distribution of HYA 
HYA is synthesized by membrane-bound internal protein, known as hyaluronan synthase (HAS) 
(Prehm, 1984). There are three isoforms of HAS reported in vertebrates, including HAS-1, HAS-2, 
and HAS-3; each isoform exhibits distinct enzymatic properties varying in different sizes (Weigel 
et al., 1997, Itano et al., 1999, Itano and Kimata, 2002). Furthermore, different size of HYA is also 
synthesized by these HAS isozymes, which are also differentially regulated at transcriptional, 
translational as well as post-translational levels, including sub-cellular localization, alternative 
splicing and epigenic processes.  EHA is detected in the lymphatic system and blood stream, thus, 
can interact with specific receptors present on cell surfaces (George and Stern, 2004). HYA is also 
found in the skin structure, joints, ligaments, skeleton as well as distributed between other 
organs, including brain, lung, muscle, kidney, and liver (Fraser et al., 1997). 
During initiation and progression of tumorigenesis, a transcriptional switch in HAS- derived 
isoforms has been reported in transformed malignant cells (Itano and Kimata, 2002, Itano et al., 
1999). Overexpression of HAS 2 in mammary glands of a transgenic mouse resulted in an 




aggressive growth of mammary tumour, thus, accelerating tumour angiogenesis through stromal 
cell recruitment (Koyama et al., 2007).  
 However, overexpression of HAS 2 has also been suggested to suppress the tumorigenesis of 
glioma cells (Enegd et al., 2002). Clinical samples have revealed an increased deposition of HYA 
in TME, which is associated with malignant tumour progression in several cancers, including 




Figure 13: A schematic representation showing the chemical structure (A) and biosynthesis of 
Hyaluronan, also known as Hyaluronic acid (HYA). 
HYA is composed of chemical properties of repeating polymeric disaccharide, linking β-1,4-D-
glucuronic acid, and β-1,3-N-acetylglucosamines units. HYA is produced by membrane-bound 
internal hyaluronan synthase (HAS), of which vertebrates have three isoforms; HAS-1, HAS-2, and 
HAS-3, each having two separate binding domains for UDP-sugars. HYA polymerization seems to 
take place at the inner side of the plasma membrane, where HAS can add UDP-GlcA and UDP-
GlcNAc monomers to the reducing end of HYA polymer. Thus, non-reducing end of sugar is then 
translocated into the extracellular space in the HAS structure (Zhang et al., 2014). 




1.6.3 Biological roles of HYA and its receptors  
In the TME, HYA provides a molecular 3D-framework for cells and mediates modulation of 
stromal as well as tumour cells (Itano and Kimata, 2002, Itano et al., 1999). Functions of HYA are 
well- established in transmitting cell signaling, and regulating cell adhesion, motility, growth, and 
differentiation (Turley, 1992). Exposure of HYA to tumour cells triggers several intracellular 
signaling cascades, including c-Src, Ras, and mitogen-activated protein (MAP) kinases through 
interaction with cell-surface receptors. It results in genomic transcription relating to the cell 
growth and survival, cell induction of cytoskeletal rearrangement, and membrane ruffling, 
leading to migration. Increased HYA synthesis has been reported during wound healing and tissue 
injury (Weigel et al., 1986, Slevin et al., 2002). Thus, HYA regulates tissue repair by activating 
inflammatory cells to increase immune response (McKee et al., 1996, Teriete et al., 2004). HYA is 
also involved in providing framework for formation of blood vessels (Slevin et al., 2002), and 
migration of fibroblasts (Li et al., 2006, Turley, 1989) that may be involved in progression of 
tumour cells (Knudson, 1996). Furthermore, HYA found on the surface of cancer cells is 
significantly associated with metastatic behavior (Zhang et al., 1995). 
The interaction of extracellular HYA with cell surface receptors, such as cluster of differentiation 
44 (CD44), HYA‐mediated motility (RHAMM) (Figure 14), and intercellular adhesion molecule 1 
(ICAM-1) has been reported (Savani et al., 2001). CD44 is a well-established receptor for HYA, 
with diverse roles in cell-to-cell, and cell-to-matrix interactions (Misra et al., 2015). Interaction of 
CD44 with a wide range of ligands, including collagens, osteopontin, and MMPs (Goodison et al., 
1999) has also been described. CD44 exists in several isoforms generated through splicing of 
messenger RNA (Warzecha et al., 2009). A CD44 variant (CD44v) isoform comprising v3 or v6 
(sequence encoded by variant exon 3 or 6) has been suggested to undergo modification. CD44v3 
has been reported to interact with growth factors, such as fibroblast growth factor and heparin-
binding epidermal growth factor-like growth factor (HB-EGF) (Bennett et al., 1995). CD44v6 can 
act as a co-receptor for the receptor tyrosine kinase c-Met (Orian-Rousseau et al., 2002). CD44v6 
has been shown to promote tumour progression, and metastatic invasion in lung, breast, and 
colon cancer (Chen et al., 2018a, Ma et al., 2019). Engagement of HYA-CD44 in breast cancer cells 
leads to overexpression of P-glycoprotein (multidrug resistance gene) and Bcl, which further 




promotes proliferation and survival of tumour cells (Bourguignon et al., 2009). HYA 
oligosaccharides from tumour cells enhances cleavage of intracellular CD44, thus, tumour cell 
motility (Sugahara et al., 2006). Furthermore, HAS-1 modulates growth, invasion, and 
angiogenesis of bladder cancer cells through downregulation of CD44 isoforms: CD44 variant 
exon 3 (CD44v3), CD44v6, and CD44s (Golshani et al., 2008).  
RHAMM is another key receptor for HA and various isoforms of RHAMM have been established 
(Hardwick et al., 1992, Turley, 1992, Yang et al., 1993). HYA- RHAMM interaction has been 
suggested to control the cell growth and migration by several signal transduction events, as well 
as interactions with cytoskeleton (Mohapatra et al., 1996). HYA has also shown to directly 
promote cell locomotion through HYA- RHAMM interaction (Samuel et al. 1993, 7693717). 
RHAMM is also important for CD44 localization to the cell surface, thus, leading to the formation 
of CD44-ERK1/2 complexes, suggesting that RHAMM is a crucial regulator of ERK1/2 signaling 
cascade (Tolg et al., 2006). T-cell responses directed against RHAMM in patients with acute 
myeloid leukemia is correlated with improved clinical outcome (Spranger et al., 2012). 
Immunotherapies including adoptive transfer of RHAMM-T cells or peptide vaccination has been 
suggested to improve the immune response of AML patients  (Casalegno-Garduno et al., 2012).  
 
1.7 Main Aims of this Study  
1. Expression of a recombinant fragment of human SP-D (rfhSP-D) under bacteriophage T7 
promoter in E. coli and purification to homogeneity, free from LPS. 
2. Demonstration of rfhSP-D as an entry inhibitor of IAV and modulator of cytokine storm.  
3. Demonstration of the ability of rfhSP-D to induce apoptosis in breast cancer cell lines, and 
dissection of the mechanisms of apoptosis induction.  
4. Assessment of the modulation of protective properties of rfhSP-D in the presence of HYA. 

















Figure 14: A schematic diagram demonstrating receptor-mediated signaling by Hyaluronic acid (HYA), also known as hyaluronan, 
through binding interaction with cell-surface HYA binding receptors. 
HA interaction with its receptors CD44 and RHAMM induces clustering of CD44 receptor and triggers intracellular RHAMM-regulated 
MAPK cascade, resulting in phosphorylation of extracellular signal-regulated kinase (ERK), and downstream activation of NFκB and 
activator protein 1 (AP-1). Trigger of NFκB and AP-1 result in cell migration, thus, release of inflammatory cytokines (Golshani et al., 
2008).
 
















Methods and Materials 
 




2.1 Expression and Purification of rfhSP-D  
Expression and purification of rfhSP-D (composed of the 8 Gly-X-Y repeats, neck, and CRD region) 
involves steps including preparation of competent cells, transformation, pilot-scale expression, 
large-scale production, bacterial lysis, sonication and preparation of inclusion bodies, 
denaturation/renaturation procedure, rfhSP-D purification by affinity chromatography, and 
endotoxin removal. 
2.1.1 Competent Cells 
A single colony of Escherichia coli BL21 (λDE3) pLysS (Invitrogen) was inoculated in Luria Broth 
(LB) medium (10 ml) containing chloramphenicol (34 µg/ml) (Sigma-Aldrich) (Sigma-Aldrich) and 
grown at 37°C overnight on a shaker. The next day, a primary inoculum of 500 µl bacterial culture 
was inoculated into fresh 10 ml of LB medium containing chloramphenicol (34 µg/ml) and grown 
to A600 of 0.3-0.4. The bacterial culture was subjected to centrifugation for 10 mins at 2000 × g, 
followed by resuspension the bacterial pellet in 1 ml of 0.1M CaCl2 (Fisher-Scientific), and then 
adjusting to a final volume of 12.5 ml of 0.1M CaCl2. The CaCl2 resuspended bacterial pellet was 
incubated on ice for 1 h, then centrifuged for 10 mins at 2000 ×g, followed by resuspension in 
2ml of CaCl2 (0.1M) and kept on ice until further use.    
2.1.2 Transformation  
Plasmid pUK-D1 (2 µl) (Mahajan et al., 2013), containing cDNA sequences for the 8 Gly-X-Y 
repeats, neck and CRD regions of human SP-D was added to Escherichia coli BL21 (λDE3) pLysS 
competent cells (200 µl).and incubated on ice for 1 h, followed by heat shock at 42°C for 90 sec. 
Next, 800 µl of LB medium was added to the cells and incubated for 45 mins at 37°C with gentle 
shaking at regular intervals. Post incubation transformed bacterial cells were spread on an agar 
plate containing ampicillin (100 µg/ml) (Thermo-Scientific) and chloramphenicol (34 µg/ml). The 
agar plates were then incubated at 37°C incubator overnight to allow growth of transformed 
bacterial colonies. The grown colonies were then used to carry out pilot and large-scale 
expression analysis.       




2.1.3 Pilot-Scale Expression  
For pilot-scale expression, a single colony was inoculated in 5 ml of LB medium, containing 
ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml) and grown at 37°C overnight in a shaker. 
Next day, 500 µl of primary inoculum was added to fresh 10 ml of LB medium containing 
antibiotics and incubated for 3h at 37°C on a shaker until A600 of 0.6-0.8 was reached. An 
uninduced sample (1 ml) was collected as a control and the remaining bacterial culture was 
induced with 0.5mM Isopropyl β-D-1- thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3h at 37°C 
on a shaker; the bacterial cells were centrifuged at 13,800 ×g for 10 minutes. The cell pellet from 
uninduced and induced samples were resuspended in 2 × treatment buffer (50 mM Tris pH 6.8, 
2% β-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, and 10% glycerol) (Sigma-Aldrich), and 
heated for 10 minutes at 100°C. 20 µl of each sample was subjected to 15% (v/v) SDS-PAGE for 
90 minutes at 120V for assessing the expression of rfhSP-D.  
2.1.4 Large-Scale Expression  
For large-scale expression analysis, a single colony was inoculated in 25 ml of LB medium with 
chloramphenicol (34 µg/ml) and ampicillin (100 µg/ml) and grown overnight at 37°C on a shaker. 
The next day, a primary inoculum (12.5 ml) was mixed with fresh LB medium (500 ml) with both 
antibiotics and grown to A600 of 0.6-0.8. 1ml of uninduced sample was collected from the grown 
bacterial culture and the remaining culture was induced with 0.5mM IPTG, followed by 
incubation at 37°C for 3h on a shaker. After 3h of incubation, 1ml of bacterial cells was collected 
from uninduced and induced samples and subjected to centrifugation at 13,800 ×g for 10 mins. 
The bacterial cell pellet was treated with 2× treatment buffer and heated for 10 mins at 100°C. 
The heated samples (20 µl) were then subjected to 15% (v/v) SDS-PAGE for 90 minutes at 120V 
for assessing the expression of rfhSP-D protein. Additionally, the remaining induced bacterial 
culture was centrifuged at 15,000 ×g for 30 minutes at 4°C, and the bacterial cell pellet was stored 
at −20°C to process for the rfhSP-D purification later.     
2.1.5 Lysis and Sonication 
The bacterial cell pellet, stored at −20°C, was resuspended in lysis buffer (50ml) (50mM Tris-HCl, 
200mM NaCl, 5mM EDTA, 0.1% v/v Triton X-100, 0.1mM PMSF, pH 7.5 and 50 μg/ml lysozyme) 
(Sigma-Aldrich), and incubated at 4°C for 1 h on a rotary shaker. The lysed bacterial cell 




suspension was sonicated (equipment details here) for 30 sec at 60Hz with 2 mins interval and 
repeated it for 12 cycles. The sonicated bacterial cell suspension was centrifuged at 15,000 ×g for 
20 mins at 4°C.  
2.1.6 Denaturation and Renaturation cycle 
The inclusion bodies containing rfhSP-D was suspended in 25 ml of solubilization buffer (50mM 
Tris-HCl pH 7.5, 100mM NaCl, 10mM 2-Mercaptoethanol and 8M urea) for 1 h at 4°C and then 
centrifuged at 15,000 × g for 20 mins at 4°C. The supernatant was then dialysed for 2h at 4°C 
stepwise against 4 M, 2 M, 1 M and no urea buffer containing (50mM Tris-HCl pH 7.5, 100mM 
NaCl, and 10mM 2-Mercaptoethanol). The final dialysis was carried out against solubilization 
buffer containing 5 mM CaCl2 for 3 h at 4°C; the dialysate was then centrifuged at 15,000 ×g for 
20 minutes to remove aggregates and stored at 4°C. 
2.1.7 rfhSP-D Purification by Affinity Chromatography  
A maltose agarose column (5ml) (Sigma-Aldrich) was equilibrated with 50 ml of high salt buffer 
(50 mM Tris-HCL, pH 7.5, 1 M NaCl) and followed by 50 ml of affinity buffer (50 mM Tris-HCL, pH 
7.5, 0.1 M NaCl,5 mM CaCl2). The dialysate was loaded onto the maltose agarose column, and 
the bound rfhSP-D was eluted using elution buffer (50 mM Tris–HCl pH 7.5 and 100 mM NaCl 
containing 10 mM EDTA). The OD280 was measured to determine the concentration of eluted 
rfhSP-D fractions. To assess the purity, the purified rfhSP-D protein (5 µg/well) was resuspended 
in 2× treatment buffer and denatured by heating at 100°C for 10 mins and run on 15% (v/v) SDS-
PAGE and subjected to western blotting to analyze and confirm the purity of the purified rfhSP-
D protein.   
2.2 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The resolving (10 ml) and stacking (5 ml) layers were prepared by mixing a varied volume of 
components (Table 3). The glass plates (tall and short glass plates) were clamped into the casting 
stands ensuring there was no leakage. The resolving polyacrylamide solution was first pipetted 
to fill the space between the two glass plates using a plastic transfer pipette until the resolving 
gel solution reached above the green clamps. After loading the resolving solution, deionized 
water was added gently on top of the resolving layer so smoothen the surface during 




polymerization. After 10 mins, water was poured off and the stacking gel solution was loaded 
over the polymerized resolving gel; a 10-well comb was inserted. After the polymerization of the 
stacking gel, the comb was carefully removed, and the glass plates were put in the buffer dam 
and the tank using 1 liter of 1 × running buffer (25 mM Tris, 192 mM glycine and 0.1% SDS). The 
samples were treated with 2 × treatment buffer (50 mM Tris pH 6.8, 2% β-mercaptoethanol, 2% 
SDS, 0.1% bromophenol blue, and 10% glycerol) and heated for 10 mins at 100°C; samples were 
loaded into the wells along with a standard protein marker (Thermo Fisher). The samples were 
run for 90 mins at 120V until the blue dye front reached the end of the gel. The gel was stained 
for 2 h in the staining solution (0.1% w/v Coomassie, 10% v/v acetic acid, 40% v/v methanol and 
50% H2O); destaining was carried out in de-staining solution made with (10% acetic acid, 40% 
methanol and 50% H2O).    
Table 4: The required volume of resolving and stacking components for 12 and 15 % of SDS-
PAGE. 
Resolving Gel 12% 15% Stacking Gel 12% 15% 
dH2O 3.3 
ml 
2.3 ml dH2O 3.4 ml 3.4ml 
30% Bis-Acrylamide mix 4 ml 5 ml 30% Bis-Acrylamide mix 0.83 ml 0.83 ml 
1.5M Tris-HCl, pH8.8 2.5 
ml 
2.5 ml 1.0M Tris-HCl, pH6.8 0.63 ml 0.63 ml 




0.1 ml 10% SDS (Sodium dodecyl 
sulphate) 
0.05 ml 0.05 ml 




0.1 ml 10% APS (Ammonium 
Persulfate) 













2.3 Endotoxin Removal from the rfhSP-D preparation and Limulus Amebocyte Lysate Assay 
The eluted fractions of purified rfhSP-D were subjected to removal of lipopolysaccharide (LPS) 
using Pierce™ High-Capacity Endotoxin Removal Resin (Qiagen). The endotoxin removal resin was 




packed in a 5ml bed volume column and washed with sterilized H2O (50 ml), followed by 1% 
sodium deoxycholate (50 ml) (Sigma-Aldrich) and 50 ml of sterilized H2O. Purified rfhSP-D 
fractions showing higher concentration were loaded onto the column and OD280 in the flow-
through was determined using Nanodrop (Thermo-Scientific). The endotoxin levels in the rfhSP-
D flow-through fractions were measured via QCL-1000 Limulus amebocyte lysate (LAL) kit 
(Lonza). The LAL proenzyme is activated by the catalytic activity of Gram-negative bacterial 
endotoxin. The activated enzyme further catalyses the release of p- nitroanilides (NA) from the 
substrate. The released pNA is measured at an absorbance of 405-410 nm (Young et al., 1972). 
Briefly, rfhSP-D (5 µg/ml) was mixed with the LAL (50 µl) and incubated for 10 mins at 37°C. A 
chromogenic substrate solution (100 µl) was then added and incubated at 37°C for 6 mins. The 
reaction was stopped using a stop reagent (100 µl), and the presence of endotoxin in the sample 
was concomitant with a yellow colour read at 405-410 nm. The concentration of the endotoxin 
was calculated using a standard curve, where 1 EU/ml was equivalent to 0.1ng endotoxin/ml.  
2.4 Extraction of full-length native SP-D from human bronchoalveolar lavage fluid 
Human full-length native SP-D (hFL-SP-D) was purified as published earlier (Strong et al., 1998). 
Bronchoalveolar lavage fluid (BAL) collected from pulmonary alveolar proteinosis patients was 
made up with buffer I, containing 20 mM Tris−HCl and 10 mM EDTA (helps solubilize any 
aggregated SP-D), pH 7.4, and stirred for an hour at room temperature. The turbid solution was 
then centrifuged at 10,000 × g at 4°C for 40 mins to separate pellet rich in SP-A from supernatant 
which contains most of the SP-D.  Prior to loading on to a maltose-agarose column, the SP-D 
containing supernatant was made 20 mM with respect to CaCl2, followed by adjusting the pH to 
7.4. The column was washed with buffer II (20 mM Tris–HCl, pH 7.4, 10 mM CaCl2, 0.02% (w/v) 
sodium azide), followed by washing again with buffer II containing 1 M NaCl to remove any non-
specifically bound albumin or a 9 kDa fragment of histone H4 that has been identified in BAL. The 
maltose-bound SP-D was eluted 50 mM MnCl2, 20 mM Tris–HCl, 0.02% (w/v) sodium azide 
(Sigma-Aldrich), pH 7.4. The pooled SP-D fractions were then dialysed against 20 mM Tris–HCl, 
100 mM NaCl, 5 mM EDTA pH 7.4.  




2.5 Purification of full-length SP-D from cancer cells  
A maltose agarose column (5ml) (Sigma-Aldrich) was equilibrated with 50 ml of high salt buffer 
(50 mM Tris-HCL, pH 7.5, 1 M NaCl) and followed by 50 ml of affinity buffer (50 mM Tris-HCL, pH 
7.5, 0.1 M NaCl,5 mM CaCl2). The culture supernatant (200 ml) from the cancer cell lines, BT20, 
BT474 and SKBR3 was collected and centrifuged at 5,000 ×g for 30 mins at 4°C. The centrifuged 
supernatant was then loaded onto the maltose-agarose column, and the bound full-length SP-D 
(FL-SP-D) was eluted using elution buffer (50 mM Tris–HCl pH 7.5 and 100 mM NaCl containing 
10 mM EDTA). The OD280 was measured to determine the concentration of eluted FL-SP-D 
fractions. To assess the purity, the purified FL-SP-D protein (5 µg/well) was resuspended in 2× 
treatment buffer and subjected to western blotting to analyze and confirm the purity of the 
purified FL-SP-D protein.   
2.6 Western Blotting  
2.6.1 Determination of rfhSP-D or full-length SP-D immunoreactivity  
Purified rfhSP-D (10 µg/well) or full-length SP-D (FL-SP-D) (5 µg/well) isolated from BT474 cell line 
was resuspended in 2 × treatment buffer and heated for 10 mins at 100°C. BSA was used as a 
negative control protein. The heated samples were subjected to 15% (v/v) SDS-PAGE and then 
electrophoretically transferred onto a nitrocellulose membrane (320mA for 2h) (Sigma-Aldrich) 
in 1 × transfer buffer containing 25mM Tris–HCl pH 7.5, 190 mM glycine, and 20% v/v methanol. 
The membrane was incubated in 1× PBS containing 5% v/v dried milk powder (Sigma-Aldrich) for 
2h at 4°C to block non-specific binding. After blocking, the membrane was washed with PBS three 
times (5 mins each wash). The membrane was incubated with polyclonal rabbit anti-human SP-D 
primary antibody. The unbound primary antibodies were removed by washing the membrane 
with PBS+ 0.05% Tween 20 (PBST) (3 times, 10 min each wash). The membrane was then probed 
with secondary Goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugate (1:1000; Fisher 
Scientific) at RT for 1 h. Following washes, the membrane-bound proteins were visualized by 
developing the membrane using 3′-diaminobenzidine (DAB) substrate kit (Thermo Fisher). 
2.6.2 Determination of Caspase Activation   
BT20, BT474 and SKBR3 cells (0.4×106) were seeded in 6-well plates and incubated with rfhSP-D 
(20μg/ml) in serum-free RPMI medium, along with untreated controls for 12h and 24h. Next, the 




medium was discarded, and the cells were washed gently with PBS. The washed cells were then 
lysed within the wells using lysis buffer (50 mM Tris-HCl pH 6.8, 2% v/v SDS, 2% v/v β-
mercaptoethanol, 10% v/v glycerol and 0.1% w/v bromophenol blue). The cell lysate was then 
sonicated for 15s, followed by heating for 10 mins at 100°C and were subjected to 12% (v/v) SDS-
PAGE. Western blotting was performed as mentioned in section 2.6.1, with respective antibodies- 
rabbit anti-human caspase (anti- cleaved caspase 9 and anti-cleaved caspase 3; Cell Signaling) 
primary antibodies (1:1000 in PBS) and Protein-A HRP-conjugate (1:1000) at room temperature 
(RT) for 1 h. The membrane was developed with DAB.  
2.7 Viruses and Reagents  
IAV subtypes used in this study, including A/England/2009 (pH1N1) and the A/HK/99 (H3N2), 
were provided by Dr Wendy Barclay (Imperial College London) and Dr Leo Poon (University of 
Hong Kong). The plasmids used to generate the lentiviral particles pseudo-typed by H1+N1 were 
obtained from Addgene. The pHIV-Luciferase backbone plasmid was obtained from Dr Bryan 
Welm (Addgene plasmid # 21375); the packaging plasmid, psPAX2 was offered by Dr Didier Trono 
(Addgene plasmid # 12260); Vesicular Stomatitis Virus (VSV-G) was a gift from of Dr Bob 
Weinberg (Addgene plasmid #8454). Monoclonal Anti-Influenza Virus H1 HA, 
A/California/04/2009 (pH1N1) pdm09, Clone 5C12, NR-42019 and Polyclonal Anti-Influenza Virus 
H3 HA, A/Hong Kong/1/1968 (H3N2) (antiserum, Goat), NR-3118 were acquired from BEI 
Resources, NIAID, NIH, USA. 
2.8 Cell Culture and Treatments for IAV  
Madin Darby Canine Kidney (MDCK), human embryonic kidney (HEK) 293T, and Adenocarcinomic 
human alveolar basal epithelial cells (A549) cell lines were cultured in complete Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) [100 U/ml penicillin (Sigma-Aldrich), 
100 µg/ml streptomycin (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 2 mM l-
glutamine, and 10% v/v fetal bovine serum (FBS) (Sigma-Aldrich)]. The cells were left to grow at 
37°C under 5% (v/v) CO2 for approximately 3 days until the desired confluency was achieved. 
Since these cells were adherent, they were subjected to trypsinization using 2× Trypsin-EDTA 
(0.5%) (Fisher Scientific) for 10 min at 37°C. The detached cells were then diluted in complete 
DMEM, followed by centrifugation for 5 min at 1,200 rpm and re-suspension of the cell pellet in 




complete DMEM. The cell count and viability were determined by mixing an equal volume of cell 
suspension and Trypan Blue dye (0.4% w/v) (Fisher Scientific). The cells were counted using a 
hemocytometer with Neubauer rulings (Sigma-Aldrich). Required number of cells were re-
suspended in complete DMEM for further use. 
2.9 Purification of IAV Subtypes 
MDCK cells at 80% confluency were incubated with pH1N1 (2 × 104) or H3N2 (3.3 × 104) 
(600 µl/flask) at 37°C for 1 h. Unbound viral particles were washed off three times using sterile 
PBSs. The virus bound MDCK cells were incubated at 37°C for 3 days in 25 ml of infection medium 
[DMEM containing 1% penicillin/streptomycin, 0.3% bovine serum albumin (BSA), and 1 µg/ml of 
l-1-Tosylamide-2-phenylethyl-chloromethyl ketone (TPCK)—Trypsin] (Sigma-Aldrich). The culture 
supernatant containing the IAV particles was centrifuged twice at 3,000 × g at 4°C for 15 min. 
Viral supernatants (25ml) was slowly added to ultra-clear tubes containing 30% w/v sucrose 
(8 ml/tube) (Sigma-Aldrich), and centrifuged at 25,000 × g for 90 min at 4°C. Both upper phase of 
the supernatant and the sucrose phase were carefully removed. The IAV particles, which 
remained at the bottom of ultra-clear tubes, were suspended in sterile PBS (100 µl/ tube). The 
purified IAV suspension (10 µl) was analysed by 12% v/v SDS-PAGE and ELISA.  
2.10 Production of H1+N1 Pseudotyped Lentiviral Particles 
HEK293T cells (0.4 × 106) were co-transfected with pcDNA3.1-swineH1-flag (H1 from swine 
pH1N1 A/California/04/09) (20 µg) (Invitrogen), pcDNA3.1-swine N1-flag (N1 from swine pH1N1 
A/California/04/09) (20 µg) (Invitrogen), pHIV-Luciferase backbone (20 µg) (Addgene). The pHIV-
Luciferase backbone carries modified proviral HIV-1 genome with env deleted and is designed to 
express the firefly luciferase reporter, and psPAX2 (Addgene). psPAX2 is a well-known lentiviral 
packaging plasmid (second-generation) and can be used with second or third generation lentiviral 
vectors and envelope expressing plasmid. VSV-G lentivirus as a control was generated in a similar 
way as described above, without H1+N1 pcDNAs. The released H1+N1 pseudotyped and VSV-G 
lentiviral particles were harvested in the supernatant at 24 and 48 h. The harvested virus particles 
were then centrifuged at 5,000 ×g for 10 min to remove any cell debris, and clear supernatant 
was concentrated via ultra-centrifugation at 25,000 ×g for 90 min. The ultra-centrifuged lentiviral 




particles were resuspended in sterilized 1 × PBS and analyzed via TCID50 assay, western blotting, 
and luciferase activity assay.   
2.11 Tissue Culture Infectious Dose 50% (TCID50) Assay 
Tissue Culture Infectious Dose 50% (TCID50) Assay was performed to determine the titer of viral 
particles and their cytopathic effects (CPE) on infected cells (Hollý et al. 2017). Purified stocks of 
pH1N1 and H3N2 viruses or pseudotyped lentiviral particles were prepared with an initial dilution 
of 10−2 in DMEM using a Maxisorp 96-well microtiter plate and 146 μl of the diluted virus was 
added to all wells. Uninfected MDCK cells were used as a control. 46 μl of pH1N1, H3N2 or 
lentiviral particles were serially diluted (1/2log10 to 10−7) and incubated in a microtiter plate at 
37°C for 1 h. MDCK cells (1 × 105), suspended in 2 × infection medium, were added to each well 
and incubated at 37°C under 5% v/v CO2 for 3-5 days, and examined under microscope to record 
positive and negative dilutions for CPE. 
2.12 Far western Blotting  
rfhSP-D (5μg) or 10 μl of concentrated H1N1/H3N2 (1.36×106 pfu/ml) were ran separately on a 
12% (w/v) SDS-PAGE and then transferred onto a nitrocellulose membrane and membrane was 
blocked and washed as described above. The membrane was incubated with 5μg/ml rfhSP-D for 
1 h at RT and 1 hour at 4°C. Following PBST wash, the membrane was probed with monoclonal 
anti-influenza virus H1 (BEI-Resources), polyclonal anti-infuenza virus H3 (BEI-Resources) or 
polyclonal rabbit anti-human SP-D (1:1000) in PBS for 1 h at RT. The membrane was again washed 
three times with PBST, 10 minutes each before probing with secondary antibodies, Protein-A 
HRP-conjugate, or anti-mouse IgG HRP-conjugate (1:1000) (Fisher Scientific) in PBS (100μl/well) 
for 1 h at RT. For detecting M1 expression, untreated (A549 cells + virus) and treated samples 
(A549 cells + virus + 10 µg/ml rfhSP-D) were collected following 6 h post treatment. The collected 
cells were lysed, sonicated and the cell lysates were run on a 12% (w/v) SDS-PAGE, and 
transferred onto a nitrocellulose membrane, as described above. The M1 expression was 
detected using anti-M1 monoclonal antibody (BEI-Resources) (1:1000) diluted in PBS. After 
washing with PBST, the blot was developed either using DAB or Enhanced Chemiluminescence 
(ECL) (Thermo-Fisher). 




2.13 rfhSP-D-IAV interaction via enzyme-linked immunosorbent assay (ELISA) 
A decreasing concentration of rfhSP-D (5, 2.5, 1.25, and 0.625 µg/well) was coated in a Maxisorp 
96-well microtiter plate (Thermo-Scientific) in carbonate/bicarbonate (CBC), pH 9.6 buffer 
overnight at 4°C, followed by blocking with 2% w/v BSA in PBS at 37°C for 2h. The microtiter wells 
were washed with PBST three times. 20 µl of concentrated pH1N1, H3N2 (1.36 × 106 pfu/ml), or 
purified recombinant HA (2.5 µg/ml) were diluted in 200 µl of PBS; 10 µl of diluted virus was 
added to each well and incubated for 2h at RT in buffer containing 50 mM Tris-HCL, pH 7.5, 100 
mM NaCl and 5 mM CaCl2. VSV-G pseudotyped lentivirus was used as a negative control. The 
wells were washed with PBST three times. The binding between rfhSP-D and IAV subtypes were 
determined by probing with primary antibodies, polyclonal anti-influenza virus H3 (BEI-
Resources), and monoclonal anti-influenza virus H1 (BEI-Resources)  antibody (1:5,000 dilution in 
PBS) for 1 h at 37°C. after washing the wells with PBST three times, the corresponding wells were 
incubated with secondary antibody: Protein A-HRP-conjugate (Fisher Scientific), and anti-mouse 
IgG-Horseradish peroxidase (HRP)-conjugate (1:5,000) (Fisher Scientific)  in PBS (100 µl/well) for 
1 h at 37°C. The colour was developed using 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (100 
µl/well) (Sigma-Aldrich), and stopped using 2 N H2SO4 (100 µl/well). The absorbance was read at 
450 nm using iMark™ microplate absorbance reader (Bio-Rad). 
2.14 Cell-rfhSP-D-IAV Binding Assay 
A549 cells (1 × 105/well) were seeded in a 96-microtiter well plate in complete DMEM containing 
10% FBS and grown overnight. The complete medium was gently removed, and the cells were 
washed gently with PBS three times. A varied concentration of purified rfhSP-D (10, 5, 2.5, and 
1.25 µg/ml) was pre-incubated with pH1N1 or H3N2 virus (1.36 × 106 pfu/ml) diluted in 200 µl of 
PBS + 5 mM CaCl2. 10 µl of diluted virus was added to the corresponding wells and incubated for 
2h at RT. In a parallel experiment, maltose-binding protein (MBP) (10, 5, 2.5, and 1.25 µg/ml), 
pre-incubated with pH1N1 or H3N2 virus (1.36 × 106 pfu/ml), was used as a negative control. 
After removing unbound proteins, the microtiter wells were then washed with PBS three times, 
followed by fixation with 4% PFA for 10 min at RT. After PBS washes, the wells were blocked with 
2% w/v BSA diluted in PBS for 2 h at 37°C. The wells were washed again using PBST three times 
and then incubated with monoclonal anti-influenza virus H1 (BEI-Resources) or polyclonal anti-




influenza virus H3 (BEI-Resources) in PBS (1:5,000) (100 µl/well) for 1 h at 37°C. After PBST 
washing step, goat anti-mouse IgG-HRP-conjugate (Thermo-Fisher), or Protein A-HRP conjugate 
(1:5,000) in PBS was added to the corresponding wells and incubated for 1 h at 37°C. The wells 
were washed again with PBST three times and the colour was developed using TMB substrate 
(100 µl/well); the reaction was stopped using 2 M H2SO4, followed by absorbance reading at 
450 nm. 
2.15 Titration Assay 
Maxisorb 96-well plates were incubated with 0.01% w/v collagen (100 µl/well) (Sigma-Aldrich) at 
RT for 3 h. The excess unbound collagen was removed, the wells were washed twice with PBS. 
A549 cells (1×105) were seeded and grown at 37°C overnight under 5% (v/v) CO2, until 80% 
confluency. After washing the cells with PBS twice, pH1N1 or H3N2 virus (MOI of 1), diluted in 
DMEM with 10 µg/ml rfhSP-D, was added to cells, respectively. The plates were covered with an 
aluminium foil and incubated for 1 h at 37°C. The unbound virus/rfhSP-D mix was removed, and 
the wells were washed twice with PBS, followed by addition of infection medium (200 µl) to the 
cells, and incubation at 37°C for 24 h with 5% (v/v) CO2. The medium of the infected cells with 
and without rfhSP-D was collected and viral titer was estimated by TCID50 for treated and 
untreated samples. 
2.16 Quantitative Real-time (qRT) Polymerase Chain Reaction (PCR) Analysis 
A549 cells (0.5 x 107) were grown in DMEM medium containing 10% v/v FBS until 85% cell 
confluency was reached. The following day, the medium was removed, and the dead cells were 
washed off using PBS. A549 cells were incubated with rfhSP-D (10 µg/well) in DMEM containing 
5 mM CaCl2 with MOI 1 of pH1N1 or H3N2 virus, and incubated first for 1h at RT, and then for 1h 
at 4°C. The unbound rfhSP-D protein and virus (pH1N1/H3N2) were removed carefully, cells were 
washed with sterilized PBS twice, followed by addition of infection medium, and incubation for 
2 and 6 h at 37°C. The treated A549 cells were detached using a sterile cell scrapper (Sigma-
Aldrich), centrifuged at 1,500 × g for 3 min, and the cell pellet was frozen at −80°C for RNA 
extraction later.  




2.16.1 Total RNA Extraction 
The infected A549 cell pellets were subjected to RNA extraction using the GenElute Mammalian 
Total RNA Purification Kit. The cell pellets were lysed using lysis solution (250 µl/ 0.3 x 107 cells) 
containing 2-mercaptoethanol (2.5 µl) and vortexed until the clumps disappeared. The cell 
lysates were then mixed with 70% ethanol (250 µl), vortexed gently and added to the RNA binding 
columns. The columns containing the lysates (mixed with 70% ethanol) were centrifuged at 13, 
000 × g for 15 sec. The columns were then washed twice with washing buffer I, and second 
washes with buffer II (provided in the RNA extraction kit). The columns were transferred to fresh 
2 ml Eppendorf tube, and RNA was extracted using elution solution (50 µl/tube) by centrifuging 
for 1 min at 13, 000 ×g.       
2.16.2 DNase Treatment and cDNA Synthesis  
Contaminating DNA was removed by DNase treatment with DNase 1 (SLBC 3g35 DMPD kit) 
(Sigma-Aldrich). DNase I enzyme (5 µl) and 10 x buffer (5 µl), provided in the kit, were added to 
total RNA (50 µl) and mixed gently by tilting the Eppendorf. DNase 1 treated samples were then 
incubated at RT for 15 mins, followed by addition of stop solution (5µl/tube). The samples were 
heat-inactivated at 70°C. The concentration of total RNA was measured at A260 nm using 
NanoDrop 2000/2000c (Sigma-Aldrich); RNA purity was assessed using A260/A280 ratio between 
1.8 and 2.1, respectively.  
cDNA synthesis was performed by converting the total RNA (2 µg) into cDNA using SuperScript II 
Reverse Transcriptase (Thermo-Fisher Scientific). Mater mix was prepared by mixing 2 × RT buffer 
(10 µl) and 20 × enzyme mix (1 µl), and the mix was added to RNA samples (2 µg), followed by 
the addition of Oligo-dT primers to initiate cDNA synthesis, and to prevent labeling of the rRNA 
and tRNA.   
2.16.3 Primers   
Both forward and reverse primer sequences used in this thesis were designed for specificity using 
the Primer-BLAST software (Basic Local Alignment Search Tool) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The primers used in this thesis are listed below (Table 
4). 




Table 5: Target genes, forward primers, and reverse primers used for qPCR analysis. 
Target Forward Primer Reverse Primer 
18S 5′-ATGGCCGTTCTTAGTTGGTG-3′ 5′-CGCTGAGCCAGTCAGTGTAG-3′ 
IL-6 5′-GAAAGCAGCAAAGAGGCACT-3′ 5′-TTTCACCAGGCAAGTCTCCT-3′ 
IL-12 5′-AACTTGCAGCTGAAGCCATT-3′ 5′-GACCTGAACGCAGAATGTCA-3′ 







IFN-α 5′-TTT CTC CTG CCT GAA GGA CAG-3′ 5′-GCT CAT GAT TTCTGC TCT GAC 
A-3′ 
IFN-β 5′-AAA GAA GCA GCA ATT TTC AGC-3′ 5′-CCT TGG CCT TCAGGT AAT GCA-
3′ 
p21 5′-TGGAGACTCTCAGGGTCGAAA-3′ 5′-CGGCGTTTGGAGTGGTAGAA-3′ 
p27 5′-CCGGTGGACCACGAAGAGT-3′ 5′-GCTCGCCTCTTCCATGTCTC-3′ 
 
2.16.4 Gene Expression Analysis  
The qRT-PCR was performed using the Light Cycler System (Applied Biosciences) to measure the 
mRNA expression levels of various targeted genes (Table 4). Each qRT-PCR reaction was 
conducted in triplicates, containing Power SYBR Green MasterMix (5 µl) (Applied Biosciences), 
forward and reverse primers (75 nM) and cDNA (500 ng), making up to total volume of 10 µl/well. 
The samples were incubated at 50°C and 95°C for 2 and 10 min, respectively, followed by 
amplification of the template for 40 cycles (15 seconds each cycle at 95°C and 1 min at 60°C). The 
specificity of the qRT-PCR was determined by melting-curve analysis. The gene expression of each 
target genes was normalized using the expression of human 18s rRNA (endogenous control).  The 
cycle threshold (Ct) mean value for each target gene was used to calculate the relative expression 
of each reaction using the Relative Quantification (RQ) value and formula: RQ = 2–∆∆Ct, which 
was compared with 18s relative expression.   
2.17 Luciferase Reporter Activity Assay 
MDCK cells (0.4 × 106) were cultured in complete DMEM supplemented with 10% FBS until about 
70–80% confluency. H1+N1 pseudotyped particles, harvested at 24 and 48 h, were used to carry 
out luciferase reporter activity using luciferase one-step assay kit (Thermo Scientific). Purified 




rfhSP-D (5 and 10 µg/ml) was used to examine its effect on the luciferase reporter activity; 
cells + H1+N1, and cells only acted as controls. Luciferase readings were measured using a 
GloMax 96 Microplate Luminometer (Promega). 
2.18 Multiplex Cytokine Array Analysis 
A549 cells (0.5 × 107) were incubated with IAV subtypes with or without rfhSP-D (20 µg/ml) in 
serum-free DMEM medium for 24h at 37°C under 5% (v/v) CO2. After incubation, the supernatant 
was collected in separate Eppendorf tubes for measuring the levels of secreted cytokines (TNF-
α, IL-6, IL-10, IL-1α, IFN-α, and IL-12p40), chemokine (eotaxin), and growth factors (GM-CSF and 
VEGF). The levels of secreted cytokines in the supernatants were measured using MagPixMilliplex 
kit (EMD Millipore). The assay buffer (25 µl), provided in the kit, was added to each well of a 96-
well plate, followed by addition of standard (25 µl), control (25 µl), or culture supernatant (25 µl) 
with IAV subtypes (in the presence or absence of rfhSP-D). Magnetic beads (25 µl) coupled to 
analytes were added to each corresponding well and incubated at 4°C for 18h. The wells were 
then washed with the assay buffer (25 µl) three times, and detection antibodies (25 µl) were 
incubated with the beads at RT for 1h. After washes with the assay buffer again (25 µl), 
Streptavidin–Phycoerythrin (25 µl) was added to the wells, followed by incubation at RT for 30 
mins. Following washes, sheath fluid (150 µl) was added to each well, and the readout was 
measured using the Luminex Magpix instrument. Assays were performed in triplicates.   
2.19 Cell Culture and Treatments for Breast Cancer Study  
Human breast cancer cell lines used in this study were selected based on their phenotypes, 
including triple-negative BT20 (ER-/PR-/HER2-) (ATCC-HTB19), triple-positive BT474 
(ER+/PR+/HER2+) (ATCC-HTB20) and HER2-postive SKBR3 (ER-/PR-/HER2+) (ATCC-HTB30). Each cell 
line was grown in complete RPMI medium (Sigma-Aldrich), supplemented with 10% v/v Fetal 
Bovine Serum (FBS), 100U/ml penicillin (Sigma-Aldrich), 2mM L-glutamine, 100μg/ml 
streptomycin (Sigma-Aldrich) and 1mM sodium pyruvate (Sigma-Aldrich) under 5% (v/v) CO2 at 
37°C until 85% confluency was achieved. Since all three cell lines were adherent, a required 
number of cells were detached using 2 × Trypsin-EDTA (0.5%) (Fisher Scientific) as described 




above. Cell number and viability were determined using Trypan Blue (0.4% w/v) and 
haematocytometer, as described above.  
2.20 rfhSP-D-HYA interaction   
For HYA (1500 kDa)-rfhSP-D interaction analysis, ELISA was performed as mentioned in section 
2.13. Briefly, a fixed concentration of HYA (1500 kDa; 20µg/ml) (provided by Prof. Ivan Donati, 
Department of Life Sciences, University of Trieste) diluted in CBC, pH 9.6 buffer was incubated 
overnight at 4°C. After blocking and washing, different amounts of rfhSP-D (20,10,5,2.5 or 1.25 
ug/ml) were added to corresponding wells and incubated at 37°C for 2h. In a parallel experiment, 
maltose-binding protein (MBP) (20,10,5,2.5 or 1.25 ug/ml) was used as a negative control. The 
unbound proteins were washed off using PBST three times. The binding between HYA-rfhSP-
D/MBP was probed using polyclonal anti-rabbit human SP-D antibody (1:5000) (MRC 
Immunochemistry Unit, Oxford) or rabbit anti-MBP polyclonal antibody (1:5000) (Thermo Fisher), 
and protein A-HRP secondary conjugate (1:5000) (Sigma-Aldrich).  
2.21 Fluorescence Microscopy  
BT20, BT474 and SKBR3 (0.5x105) breast cancer cell lines were grown on round coverslips (Sigma-
Aldrich) overnight under standard cell culture conditions in complete RPMI medium. The next 
day, the complete medium was removed, and the cells were washed gently with sterilized PBS 
twice, and incubated with rfhSP-D (10 or 20 µg/ml) in serum-free RPMI medium for different 
timepoints.    
2.21.1 rfhSP-D Binding to breast cancer cell lines    
After 1 h incubation of cells treated with rfhSP-D (10 µg/ml), unbound rfhSP-D was removed by 
washing the cells twice with PBS gently. The cells were then probed with primary antibodies- 
mouse anti-human SP-D or rabbit anti-human SP-D (MRC Immunochemistry Unit, Oxford) (1:200) 
for 1 h at RT. The cells were then washed twice with PBS ensuring the removal of excess antibody, 
and then incubated with secondary antibodies- anti-rabbit Alexa 488 conjugated with FITC 
(Thermo-Fisher) or anti-mouse conjugated with CY5 (Biogen) (1:500) and Hoechst (Thermo-
Fisher) (1:10,000) for 1 h at RT. After washing, cells were fixed with 4 % paraformaldehyde (PFA) 
(Fisher-Scientific) for 1 min at RT. After fixation, 5 µl of antifade (Citiflour) was added on top of 




the coverslips and the slides were viewed under the HF14 Leica DM4000 microscope for 
immunofluorescence analysis.  
2.21.2 Apoptosis Microscopy  
After treating the BT20, BT474 and SKBR3 (0.5x105) cells with rfhSP-D (20 µg/ml) for 24h, the 
coverslips were washed twice with 1× PBS carefully, and then incubated with FITC-Annexin V 
binding buffer containing FITC annexin (1:200) and PI (1:200) (Biolegend) for 15 min in dark at RT. 
After PBS wash three times, the coverslips were fixed with 4% PFA, followed by addition of 
antifade (5 µl) on top of the coverslips. The coverslips were then mounted on slides to view under 
a HF14 Leica DM4000 microscope. 
2.22 MTT Assay  
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma-Aldrich) assay was 
performed to measure the cell metabolic activity among un-treated and treated cells. In this 
assay, MTT dye enters the mitochondria, where it is reduced into an insoluble formazan product. 
The cells are then solubilized with an organic solvent, and the released solubilized formazan is 
measured spectrophotometrically. BT20, BT474 and SKBR3 cells (0.1x105) were seeded in 96 well 
plates in RPMI complete medium. Once 80% of cell confluency was obtained, the cells were 
incubated with a range of rfhSP-D concentration (5, 10, and 20 μg/ml) in serum free RPMI 
medium for 24h and 48h. Following washes, different concentrations of rfhSP-D (5, 10, and 20 
μg/ml) were added and incubated at 4°C for 6 hours. After removing the excess unbound rfhSP-
D, 10,000 breast cancer cells were added and incubated at 37°C for 24h. r Post treatment, the 
cells were incubated with 50 µg/µl MTT (5 mg/ml stock) per well for 4 h at 37°C. After 4 h of 
incubation, 75 µl of media was removed, leaving behind 25 µl per well, which was then mixed 
thoroughly with 50 µl of dimethyl sulfoxide (DMSO) and incubated for another 10 min at 37°C. 
The absorbance was read at 570 nm using an ELISA plate reader.  
2.23 Flow Cytometry   
BT20, BT474 and SKBR3 cells (0.4 × 106) were seeded in culture petri dishes (Nunc) using RPMI 
medium containing 10% FCS. Next day, the cells were washed twice with sterilized PBS and 
incubated with a varied concentration of rfhSP-D (5, 10, and 20 μg/ml), along with an untreated 




control in serum-free RPMI medium for 24h and 48h for apoptosis analysis. The cells were 
detached using 2 × Trypsin-EDTA (0.5%). Staurosporine (1μM/ml) was used as a positive control 
for apoptosis induction.  Apoptosis induction was also examined using the FL-SP-D (20 µg/ml) 
purified from BT474 cell culture medium.  After gentle washes with PBS, the cells were incubated 
with Alexa Fluor® 488 (1:200) (Sigma-Aldrich) and Hoechst (1:10,000) (Sigma-Aldrich) for 15 mins 
at RT in dark. Following washes with 1×PBS three times, apoptosis induction by rfhSP-D/FL-SP-
D/Staurosporine was measured using Novocyte Flow Cytometer. Compensation parameters 
were acquired using unstained, untreated FITC stained, and untreated PI-stained samples for all 
three cell lines.  
For solid phase studies, constant concentration of HYA (1500 kDa) (20 μg/ml) was coated in a 6 
well plates overnight at 4°C with and without rfhSP-D (20 μg/ml). After removing unbound HYA 
and rfhSP-D, the wells were washed with PBS, followed by addition of 0.4 × 106 cells to the 
HYA/rfhSP-D-coated wells and incubation at 37°C for 24h. For cell proliferation studies, the cells 
(0.4 × 106) were washed with PBS, probed with anti-mouse Ki-67 (Bio-Legend) diluted in 
permeabilization reagent of the FIX&PERM kit (Fisher Scientific), and incubated at RT for 30 
minutes. After PBS washes, the cells were incubated with goat anti-mouse-FITC conjugate (1:200) 
(Fisher Scientific) at RT in dark for 30 minutes. Cells (12,000) were acquired for each experiment 
and compensated before plotting the acquired data.  
2.24 Immunohistochemical analysis 
Breast cancer tissues and adjacent peritumoral mammary parenchymas used in this experiment 
were selected following ethical approval by the University Hospital of Palermo, Italy. The written 
consent for the use of subsequent tissue and blood specimens were signed and approved by the 
participants legally. The immunohistochemical experiments (Immunohistochemistry and Alcian 
blue staining) were performed by Dr Beatrice Belmonte (Tumor Immunology Unit, Human 
Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy).  
2.24.1 Immunohistochemistry (IHC) 
Luminal A, Luminal B, HER2+ and triple-negative breast cancer (TNBC) tissues were used, along 
with normal breast tissue as a control. Immunohistochemistry (IHC) technique was carried out 




using a polymer detection method. The selected breast cancer tissues were fixed using 10% (v/v) 
buffered formalin and 4 µm-thick tissue sections were deparaffinised and rehydrated. The 
antigen unmasking procedure was performed using Novocastra Epitope Retrieval Solutions, pH 
6 (EDTA-based) (Leica Biosystems) in a water bath for 30 min at 98°C. The tissue sections were 
then brought to RT, followed by gentle washes with PBS twice. The endogenous peroxidase was 
neutralized using 3% (v/v) H2O2, followed by Fc blocking (Novocastra, Leica Biosystems); the 
samples were then incubated at 4°C overnight with mouse anti-human SP-D monoclonal 
antibody (1:800) (Abcam). The staining was assessed via polymer detection kit (Novocastra, Leica 
Biosystems) and AEC (3-amino-9-ethylcarbazole) (Dako, Denmark) substrate chromogen. The 
slides were counterstained with Harris Hematoxylin (Novocastra, Leica Biosystems), and the 
prepared tissue sections were viewed under the Axio Scope A1 optical microscope (Zeiss). 
Axiocam 503 color digital camera (Zeiss) was used to collect microphotographs and analysed 
using the Zen2 software. 
2.24.2 Alcian Blue Staining 
The presence of HYA in the breast cancer tissue sections were detected using alcian blue staining. 
Deparaffinised and rehydrated tissue sections were incubated in 1 % Alcian blue (Dako) (diluted 
in 3 % v/v acetic acid, pH 2.5) at RT for 30 min. After incubation, the tissue sections were gently 
washed under running water for 10 mins and the sections were dehydrated in progressively 
increasing percentages of ethanol (80, 90 and 100 %). The mounted slides were then viewed 
under a Leica DM 3000 optical microscope; and images were collected using a Leica DFC320 
digital camera (Leica Microsystems, Wetzlar, Germany). 
2.25 Adhesion Assay 
BT20, BT474 and SKBR3 cells (0.5 × 105) were seeded in T75 culture flask and grown in complete 
RPMI medium overnight at 37°C under 5% (v/v) CO2. The following day, the complete medium 
was removed, the cells were gently washed with PBS, and labelled with FAST DiI fluorescent dye 
(Molecular Probes, Invitrogen). The stained cells (resuspended in serum free RPMI medium) were 
then allowed to adhere to 96 microtiter wells pre-coated with 20 μg/ml of HYA, rfhSP-D and BSA 
(negative control). The cell adhesion was measured after 35 mins of incubation at 37°C under 
standard cell culture conditions. The wells were washed with PBS twice to remove the non-




adhered cells, and the remaining cells were lysed using lysis buffer containing 10 mM Tris–HCl, 
pH 7.4 + 0.1% (v/v) SDS. The plate was read at 544nm using Infinite200 (TECAN), and the data 
were expressed as percentage adhesion with reference to a standard curve established using an 
increasing number of FAST DiI stained cells. 
2.26 mRNA Transcript Analysis of Cell Cycle Inhibitors  
BT20, BT474, or SKBR3 cells (0.5 x 107) were grown in RPMI containing 10% FCS until 85% cell 
confluency was reached. Cells (0.3 x 107) were added on to pre-coated 6-well plate with HYA 
(20 µg/ml), HYA+rfhSP-D (20 µg/ml), and rfhSP-D (20 µg/ml) and incubated at 37°C for 24h. The 
treated cell pellet was frozen at −80°C for RNA extraction later. The, RNA and cDNAs were 
prepared as mentioned in section 2.16. p21/p27 mRNA levels were performed via qRT-PCR (as 
described in section 2.16.4) using the primers listed in table 5.  
2.27 Intracellular Signaling Analysis  
Signaling pathways in rfhSP-D treated breast cancer cells in the presence of HA were analysed 
using the ‘PathScan Intracellular Signaling Array Kit (Cell Signaling Technology). BT20, BT474 and 
SKBR3 cells (0.5 × 106) were seeded in a 6-well plate in serum-free RPMI medium. Following 
washes with PBS, cells (resuspended in serum free RPMI medium), cells were left to adhere to 
pre-coated plates with HYA and rfhSP-D (20 μg/ml) for 25 min at 37°C under 5% (v/v) CO2. The 
medium was discarded, and the unbound cells were washed with cold PBS, followed by cell lysis 
using ice-cold lysis buffer containing a cocktail of protease inhibitors (Roche Diagnostics). The 
wells were then incubated with array diluent blocking buffer (100 µ/well) at RT for 15 mins on 
the multi-well gasket. After incubation, the array blocking buffer was decanted, and the cell lysate 
(75 µl) (0.8 mg/ml) was added to each corresponding well, followed by incubation at RT for 2h 
on an orbital shaker. The contents in the wells were then discarded and washed with 1x Array 
Wash Buffer (100 µl) three times (5 mins each wash). Biotinylated detection cocktail antibody 
(100 µl/well) was added to the wells, and incubated at RT for 1 h, followed by probing with 
Streptavidin-conjugated DyLight 680 (100 µl/well) for 30 mins. The fluorescence readout was 
measured using the LI-COR Biosciences Infrared Odyssey imaging system (Millennium science) 
and collected data was processed by the software Image studio 5.0. 




2.28 Statistical Analysis 
The graphs included in this thesis were generated using the GraphPad Prism 6.0 software, a one-
way ANOVA test was carried out for statistical significance analysis. Significant values were 
considered based on *p < 0.05, **p < 0.01, and ***p < 0.001, between untreated and treated 

























Chapter 3  
 



















3.1 Abstract  
Human surfactant protein D (SP-D) can modulate host response against pathogens via a diverse 
range of mechanisms. The direct interaction between influenza A virus (IAV) and SP-D has been 
shown to result in virus neutralization and enhanced phagocytosis. Anti-viral role of SP-D during 
IAV infection is well-documented; SP-D binds via its CRD region to carbohydrate pattern on 
hemagglutinin (HA) and neuraminidase (NA) of the IAV. SP-D- HA binding leads to direct inhibition 
of cellular infection via restriction of HA-sialic acid (SA) interaction. In this study, anti-IAV role of 
a recombinant fragment of human SP-D (rfhSP-D), composed of homotrimeric neck and CRD 
regions, has been examined. rfhSP-D bound both IAV subtypes (H1N1 and H3N2) in a dose- and 
calcium-dependent manner.  Far-western blotting analysis revealed that rfhSP-D binds to HA (~70 
kDa), NA (~60 kDa), and M1 (~25 kDa). rfhSP-D can modulate IAV entry, as evident from down-
regulation of matrix protein 1 (M1) in A549 cells infected with IAV subtypes, pH1N1 and H3N2 at 
2h rfhSP-D treatment. In addition, IAV-induced mRNA levels of IFN-α, IFN-β, TNF-α, IL-6, and 
RANTES were reduced following rfhSP-D treatment for both pH1N1 and H3N2, particularly at 2h 
post-infection of A549 cell line. rfhSP-D was also found to interfere with IAV infection of MDCK 
cells through HA binding and reduce luciferase reported activity in MDCK cells transfected with 
H1+N1 pseudotyped lentiviral particles. ~30% reduction in luciferase activity was seen with rfhSP-
D (10 µg/ml) treatment, suggestive of an entry inhibitory role of rfhSP-D against IAV infectivity. 
Furthermore, rfhSP-D treatment also led to suppression of crucial pro-inflammatory cytokines 
and chemokines levels, as revealed by the multiplex cytokine array analysis. In the case of pH1N1 
subtype, rfhSP-D treatment resulted in suppressed levels of IFN-α, TNF-α, IL-12 (p40), IL-10, GM-
CSF, eotaxin and VEGF at 24h post-treatment. However, down-regulation of IL-12 (p40), IL-10, 
eotaxin and VEGF was not so evident in the case of H3N2 infected A549 cells, with the exception 
IFN-α, TNF-α, and GM-CSF. These data demonstrate that the anti-IAV effect of rfhSP-D and its 
immunomodulatory effect on host cells can depend on an IAV-subtype-specific manner.        
 
 





The immune system is composed of innate and adaptive immunity, consisting of effector 
mechanisms that contribute to host defense against a variety of pathogens. The initial primary 
response to an infection in a host is the trigger of its innate immune system. To distinguish self 
from non-self, the innate immune cells recognize pathogen associated molecular patterns 
(PAMS) via its pattern recognition receptors (PRRs) such as C-type lectin receptors (CLRs) and toll-
like receptors (TLRs). Collectins are soluble multimeric lectins, representing an important group 
of Ca2+-dependent soluble PRRs detected in the pulmonary surfactant and several mucosal 
surfaces (Nayak et al., 2012). Collectins are involved in the first line of defense against several 
pathogens via binding and interacting with specific glycoconjugates and lipid moieties found on 
the surface of microorganisms (Van Iwaarden et al., 1994, Murugaiah et al., 2020b).   
In vivo and in vitro studies have demonstrated the immunomodulatory roles of human SP-D 
against pathogens. SP-D is composed of a cysteine-linked N-terminal region, a triple-helical 
collagen region, an α-helical neck region, and the C-terminal carbohydrate recognition domains 
(CRDs) or C-type lectin domain (Kishore et al., 2006). SP-D is present in pulmonary, as well as non-
pulmonary, epithelia, but primarily synthesized by Clara cells and alveolar type II (Kishore et al., 
2006). SP-D can induce numerous protective functions against including agglutination, 
opsonization, neutralization and enhanced phagocytosis (Kishore et al., 2006). SP-D is also 
involved in controlling pulmonary inflammation, and thus, linking innate immunity with adaptive 
via modulation of maturation of dendritic cell and helper T cells polarization (Madan et al., 1997b, 
Nayak et al., 2012).  
Direct interaction between SP-D and various viruses often results in viral neutralization and 
phagocytosis induction in vitro (Hartshorn et al., 1994, Hartshorn et al., 2000). Anti-viral activity 
of human SP-D during Influenza A Virus (IAV) infection have been reported, where SP-D can bind 
HA and NA, and inhibit hemagglutination at initial stages of the infection (Hillaire et al., 2013). 
IAV is an enveloped RNA virus, it encodes two surface glycoproteins, nucleocapsid protein, an ion 
channel protein, structural scaffolding protein, two non-structural proteins, a tripartite 
polymerase complex, and three non-essential proteins (Roberts et al., 2015). IAV is subtyped 
based on HA and NA glycoproteins, and both glycoproteins are involved in viral replication and 




pathogenicity (Mitnaul et al., 2000). IAV binding to target host cells is mediated by the globular 
head region of HA to SA receptors found on the surface of a host cell (Skehel and Wiley, 2000, 
Wilson and Cox, 1990). Subtypes of IAV have been suggested to bind α (2–6) linkage of SA 
receptors in humans (Glaser et al., 2005). It is reported that SA and its linkage are important for 
the initiation of IAV infection of both epithelial and immune cells. Thus, SA receptor binding 
inhibition or enzymatic switching of SA-mediated linkages can result in cell resistant or alter 
susceptibility to IAV infection. Subsequently, SA present on cell surfaces is considered as an 
imperative essential receptor and determinant of IAV tropism, contributing to immune response 
trigger as well as to viral pathogenesis. 
It is crucial to study the molecular mechanisms of host defense against viruses, including IAV to 
produce novel anti-IAV therapies. SP-D-HA binding interaction results in direct inhibition of 
cellular viral infection by preventing HA-SA receptor binding (Hartshorn et al., 2008). Interaction 
of SP-D with HA-mediated glycosylation sites has been reported, and SP-D has been identified as 
a β-type inhibitor of IAV. This interaction is Ca2+-dependent, thus, SP-D binding to NA can also 
inhibits the release of progeny viral particles from infected host cells (Tecle et al., 2007, Hartshorn 
et al., 2000). Furthermore, recombinant full-length porcine SP-D is involved in anti-viral activity 
against different subtypes of IAV by similar mechanisms, more than human SP-D due to 
differences in their structural domains, such as additional loop in its CRD region, an additional 
cysteine in the collagen domain and, an additional glycosylation site (Hillaire et al., 2014).  
In this study, a well-characterized recombinant homotrimeric fragment of human SP-D 
comprising neck and CRD region (rfhSP-D) was used to examine its ability to act as an entry 
inhibitor of IAV using pseudotyped viral particles, and modulation of subsequent immunological 








3.3 Results  
3.3.1 Expression and Purification of a Recombinant Fragment of Human SP-D (rfhSP-D)  
Recombinant expression of human SP-D and has been previously reported in E.coli BL21 (λDE3) 
pLysS under bacteriophage T7 promoter (Singh et al., 2003), containing the pUK-D1 construct 
(compromising eight Gly-X-Y repeats, the neck and CRD regions). The transformants expressed a 
~20 kDa protein following IPTG induction, compared to the un-induced cells (Figure 15). The over-
expressed insoluble rfhSP-D from inclusion bodies was refolded by the method of denaturation 
and renaturation. The soluble rfhSP-D fractions were purified using maltose-agarose column and 
appeared as a single band on 15% SDS-PAGE (v/v) under reducing condition (Figure 15). The 
purified peak fractions of rfhSP-D were loaded onto to the Pierce™ High-Capacity Endotoxin 
Removal Resin (Qiagen) column to remove LPS and the endotoxin levels were found to be 
0.5 pg/µg of rfhSP-D (Figure 16). The immunoreactivity of affinity purified rfhSP-D was analysed 
and confirmed via western blotting, using anti- SP-D polyclonal antibody that was raised against 
native human SP-D (Figure 17). 
3.3.2 Affinity Purified rfhSP-D Binds to IAV Subtypes  
The ability of microtiter-coated rfhSP-D to bind pH1N1 and H3N2 IAV subtypes was determined 
using direct binding ELISA (Figure 17). rfhSP-D bound both pH1N1 andH3N2 in a calcium and 
dose-dependent manner. VSV-G pseudotyped lentivirus was used as a negative control RNA 
virus, which did not show any binding with all rfhSP-D concentrations tested. The ability of rfhSP-
D to interfere with IAV binding in vitro was then assessed via cell binding assay using A549 cells 
(Figure 18). A549 cells were challenged with purified pH1N1 or H3N2, pre-incubated with a varied 
concentration of rfhSP-D. Increased IAV binding in the presence of rfhSP-D was observed at the 
concentration of 10 μg/ml for both IAV subtypes, and the binding was found to occur in a dose-
calcium dependent manner. MBP was used as a negative control; no significant binding was 
observed.



















Figure 15: Expression and Purification of a Recombinant form of Human Surfactant Protein D (rfhSP-D). 
(A) Expression of rhSP-D under bacteriophage T7 promoter, expressed as ~20kDa insoluble protein. Different colonies that were tested 
for rfhSP-D expression following IPTG induction (Lanes 2-3). (B) Eluted fractions (lanes 1-3) were passed through a maltose agarose 
column appeared as a single band at ~20kDa. (C) Immunoreactivity of affinity purified rfhSP-D was examined via wester blotting; lane 
1: BSA as negative control and lane 2: purified rfhSP-D.   
  



















Figure 16: Expression and Purification of a Recombinant form of Human Surfactant Protein D (rfhSP-D). 
The endotoxins trigger Factor C proteolytic activity found in limulus amebocyte lysate (LAL), which is photometrically measured using 
chromogenic substrate 405 nm. A standard curve is generated using 4 E. coli endotoxin standards, which were plated in parallel to the 
test (rfhSP-D) sample. Using standard curve, where 1 EU/ml is equivalent to 0.1ng endotoxin/ml, the endotoxin levels of purified rfhSP-
D were found to be ~0.5 pg/µg. 








Figure 17: ELISA to show rfhSP-D binding to (A) pH1N1 and (B) H3N2 IAV subtypes. 
96-microtiter wells were coated with varied concentrations of rfhSP-D (5, 2.5, 1.25, and 0.625 µg/ml). 20 µl of concentrated pH1N1 or 
H3N2 virus (1.36 × 106 pfu/ml) was diluted in PBS (200 µl) + 5 mM CaCl2 and 10 µl of diluted virus was added to all the wells and 
incubated at 37°C for 2h.  The wells were then probed with either monoclonal anti-influenza virus H1 or polyclonal anti-influenza virus 
H3 antibody (1:5000). VSV-G pseudotyped lentivirus was used as a negative RNA virus control. The data were plotted as mean of three 
independent experiments done in triplicates ± SEM. 
 







Figure 18: Cell-binding assay to show binding of (A) pH1N1 and (B) H3N2 IAV subtypes pre-incubated with rfhSP-D to A549 cells. 
96-microtiter wells were coated with A549 cells (1 × 105 cells/ml) and incubated overnight at 37°C under standard cell culture 
conditions. Different concentrations of pre-incubated rfhSP-D (10, 5, 2.5, or 1.25 µg/ml) with pH1N1 and H3N2 virus were added to 
the corresponding wells and incubated for 2h at room temperature. Following fixation with 4% paraformaldehyde solution, 
monoclonal anti-influenza virus H1, or polyclonal anti-influenza virus H3 were added to corresponding well. Pre-incubated maltose-
binding protein (MBP) (10, 5, 2.5, or 1.25 µg/ml) with pH1N1 and H3N2 virus was used as a negative control protein. The data were 
expressed as mean of three independent experiments done in triplicates ± SEM.




3.3.3 rfhSP-D Interacts with HA and Restricts IAV Replication in A549 Cells 
Human SP-D binding to the glycosylation site of HA1 domain on IAV is well documented 
(Hartshorn et al., 2000). Binding of rfhSP-D (10 µg/ml) to HA (~70 kDa) and M1 (~27 kDa) of 
pH1N1 and H3N2 IAV subtypes was established using far western-blotting (Figure 19). A direct 
binding ELISA was also performed to examine the ability of rfhSP-D (5, 10 and 20 µg/ml) to bind 
purified recombinant HA protein of IAV (Figure 19). rfhSP-D interacted with HA dose- and – 
calcium dependently; no significant binding was seen with VSV-G pseudotyped particles.  
In view of rfhSP-D binding to key IAV proteins, an infection assay was carried out to assess the 
impact of this interaction on IAV viral infectivity and replication. rfhSP-D interaction with key 
proteins of IAV may suppress cellular viral infection, i.e. by inhibiting HA interaction with SA 
containing receptors, and HA-induced fusion to endosomes. rfhSP-D-HA interaction may appear 
to be another dimension at which rfhSP-D may inhibit target cell infection, thus, intracellular 
replication. The mechanism of direct inhibition of IAV infectivity by purified rfhSP-D (10 µg/ml) 
protein was thus investigated via infection assay (Figure 20). An up-regulation of M1 mRNA 
expression at 2 and 6h was seen in A549 cells infected with pH1N1 or H3N2 (Figure 20). However, 
A549 cells infected with IAV subtypes pre-incubated with rfhSP-D showed down regulation of M1 
expression compared to A549 cells challenged with pH1N1 or H3N2 virus alone. M1 
downregulation due to rfhSP-D preincubation was found to be more effective in the case of 
pH1N1 when compared to H3N2 subtype; a −8 log10 fold downregulation was seen at 2 h rfhSP-
D preincubation. This suppressive effect by rfhSP-D was validated using western-blotting (19); a 
lower level of M1 expression was detected in rfhSP-D treated sample following post 6h 
incubation, compared to untreated samples (A549 cells + virus). In addition, titration assay was 
also performed to establish the anti-IAV effect of rfhSP-D (Figure 21). Nearly 40% virus titer 
reduction was observed with rfhSP-D (10 µg/ml) treated cells compared to untreated samples, 
suggestive of rfhSP-D’s ability to act as an entry inhibitory of IAV infection. However, differential 
inhibitory effects of rfhSP-D on IAV subtypes may reflect on the glycosylation of IAV 
glycoproteins, including HA or NA, implying a significant correlation between HA-glycan binding 
and susceptibility of IAV subtypes to inhibition by rfhSP-D that involve specific binding sites on 
IAV glycoproteins.    









Figure 19: Far-western blot analysis to show binding of rfhSP-D to purified (A) pH1N1 and (B) H3N2 subtypes of IAV. 
Concentrated virus (10 μl) (1.36 × 106 pfu/ml) was first run on the 12% (v/v) SDS-PAGE, and then transferred onto a nitrocellulose 
membrane, followed by incubation with rfhSP-D (5 µg). The membrane was probed with anti-rabbit SP-D polyclonal antibodies in PBS 
(1:1000). (A&B) rfhSP-D bound to hemagglutinin (HA) (~70 kDa) and matrix protein 1 (~M1) (27 kDa) in the case of both pH1N1 and 
H3N2 IAV subtypes. (C) ELISA to show the rfhSP-D binding to purified recombinant HA (5, 10, and 20 μg/ml). VSV-G was used as a 
negative control protein. The data were plotted as mean of three independent experiments carried out in triplicates ± SEM. 
Significance was determined using the unpaired one-way ANOVA test (***p < 0.0001) (n = 3). 
  








Figure 20: rfhSP-D suppress replication of (A) pH1N1 and (B) H3N2 in target human A549 cells. 
(A&B) Expression of M1 in pH1N1 and H3N2 subtypes of IAV after infection of A549 cells at 2 and 6 h. A549 cells (0.4 × 106 cells/ml) 
were incubated either with pre-incubated pH1N1 and H3N2 with or without purified rfhSP-D (10 µg). Cell pellets harvested at 2 and 
6 h were subjected to qRT-PCR to analyze the M1 expression of IAV. Infection was measured via qRT-PCR using M1 primers and 18S 
(an endogenous control). Data shown are normalized to M1 levels at 2 h untreated control (cells + virus). Significance was determined 
using the unpaired one-way ANOVA test (**p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3). (C) Western blotting to shown 
expression of M1 in untreated (cells + virus) and treated (cells + virus + 10 µg/ml rfhSP-D) following 6 h incubation. A549 cells (1 × 105 
cells/ml) were incubated either with pre-incubated pH1N1 and H3N2 with or without purified rfhSP-D (10 µg). Cell pellets were 
harvested, sonicated, and the proteins separated on 12% (v/v) transferred on to nitrocellulose membrane, blocked with 5% milk and 
probed with anti-mouse M1 antibody for 1 h followed by anti-rabbit conjugated with HRP for 1 h before developing colour with DAB.  
 






Figure 21: Titration assay to show the anti-IAV activity of rfhSP-D (10 µg/ml), using both pH1N1 (A) and H3N2 (A) IAV subtypes. 
A549 cells (0.4 × 106 cells/ml) were infected with pH1N1/H3N2 (MOI 1) for 24 h. Then, the supernatants were harvested, and viral titer 
measured using a TCID50 assay. rfhSP-D (10 µg/ml) treatment reduced viral titer by approximately 40%, suggesting that rfhSP-D acts 
as an entry inhibitor of IAV subtypes tested. 
 




3.3.4 rfhSP-D Triggers an Anti-inflammatory Response in A549 cells Following Viral Challenge 
The mRNA expression of pro-inflammatory cytokines and chemokines following rfhSP-D 
(10 µg/ml) treatment was determined via qRT-PCR analysis. The relative mRNA expression levels 
of pro-inflammatory cytokines, TNF-α and IL-6, by H3N2 strain were upregulated at 6 h post 
treatment, which were brought down slightly by rfhSP-D treatment at 2 h (Figure 22 & 23). 
However, TNF-α and IL-6 mRNA levels were found to be downregulated in pH1N1-infected A549 
cells considerably by rfhSP-D at 2 h, which gradually recovered by 6 h (Figure 21 & 22).  By 
contrast, reduced mRNA level of IL-12 was observed in both pH1N1/H3N2 challenged A549 cells 
incubated with rfhSP-D, suggesting a likely Th1 response reduction and suppression of IFN-γ 
production by CD4+ T cells. RANTES (1 log10 fold) levels were also suppressed by rfhSP-D at 2 h 
treatment in the case of pH1N1. However, in the case of H3N2 infected cells, RANTES levels were 
also downregulated by 0.5-fold (log10) at 2 h following rfhSP-D treatment when compared to 
untreated sample (cells + virus). Furthermore, rfhSP-D treatment also led to suppression of type 
1 interferons, IFN-α and IFN-β, at 2 and 6h post-treatment (Figure 23). Suppressive effects by 
rfhSP-D on type 1 INF levels is an indication of rfhSP-D ability to reduce the rate of viral replication 
and infectivity, thereby, downregulating the levels of INF produced by the innate immune cells 
as a first line of defense.   
3.3.5 Differential Ability of rfhSP-D to Downregulate Pro-inflammatory Cytokines and 
Chemokines 
A multiplex cytokine array was performed to assess secretion of cytokines, chemokines, and 
growth factors using supernatants of the IAV challenged and rfhSP-D treated A549 cells 24 h post 
rfhSP-D treatment. A dramatic suppression of some of the key pro-inflammatory cytokines and 
chemokines were seen with rfhSP-D (10 µg/ml) treatment when compared to virus infected A549 
cells. In the case of pH1N1, rfhSP-D treatment led to downregulation of IFN-α, TNF-α, IL-10, IL-12 
(p40), GM-CSF, VEGF, and eotaxin at 24 h (figure 25 & 26). However, these suppressive effects 
on IL-10, eotaxin, VEGF, and IL-12 (p40) were not observed in H3N2 subtype, with the exception 
of IFN-α, TNF-α, and GM-CSF. These data seem to suggest that the anti-IAV effect of SP-D and its 
immunomodulatory effect on host cells can depend on an IAV-subtype-specific manner.       
















Figure 22: mRNA expression profile of A549 cells challenged with pre-incubated pH1N1 with rfhSP-D (10 µg/ml) in both untreated 
(cells + virus) and treated samples (cells + virus + rfhSP-D). 
mRNA transcript expression levels of cytokines and chemokine were measured using qRT-PCR and the data were normalized using 18S 
rRNA expression as a control. The relative expression (RQ) was calculated by using cells only time point as the calibrator. RQ = 2−ΔΔCt 
was used to calculate the RQ value. Assays were conducted in triplicates and error bars represents ± SEM. Significance was determined 
using the unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3). 
 
















Figure 23: mRNA expression profile of A549 cells challenged with pre-incubated H3N2 with rfhSP-D (10 µg/ml) in both untreated 
(cells + virus) and treated samples (cells + virus + rfhSP-D). 
mRNA transcript expression levels of cytokines and chemokine were measured using qRT-PCR and the data were normalized using 18S 
rRNA expression as a control. The relative expression (RQ) was calculated by using cells only time point as the calibrator. RQ = 2−ΔΔCt 
was used to calculate the RQ value. Assays were conducted in triplicates and error bars represents ± SEM. Significance was determined 
using the unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3). 






Figure 24: mRNA expression profile of A549 cells challenged with pre-incubated H3N2 with 
rfhSP-D (10 µg/ml) in both untreated (cells + virus) and treated samples (cells + virus + rfhSP-
D). 
mRNA transcript expression levels of type I interferon (IFN) subtypes were measured using qRT-
PCR and the data were normalized using 18S rRNA expression as a control. The relative 
expression (RQ) was calculated by using cells only time point as the calibrator. RQ = 2−ΔΔCt was 
used to calculate the RQ value. Assays were conducted in triplicates and error bars 
represents ± SEM. Significance was determined using the unpaired one-way ANOVA test 
(*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3).




















Figure 25: Multiplex cytokine array analysis of culture supernatants that were collected at 24 h time point. 
A549 (1 × 106) cells were infected with pH1N1 IAV subtype, followed by rfhSP-D (10 µg/ml). The levels of cytokines levels (TNF-α, IL-6, 
IL-10, IL-1α, IFN-α, and IL-12p40), chemokine (eotaxin), and growth factors (GM-CSF and VEGF) were measured using a commercially 
available MagPix Milliplex kit (EMD Millipore). Experimental assays were performed in triplicates and error bars represent ± SEM 
(n = 3); significance was determined using unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001). 



















Figure 26: Multiplex cytokine array analysis of culture supernatants that were collected at 24 h time point. 
A549 (1 × 106) cells were infected with H3N2 IAV subtype, followed by rfhSP-D (10 µg/ml). The levels of cytokines levels (TNF-α, IL-6, 
IL-10, IL-1α, IFN-α, and IL-12p40), chemokine (eotaxin), and growth factors (GM-CSF and VEGF) were measured using a commercially 
available MagPix Milliplex kit (EMD Millipore). Experimental assays were performed in triplicates and error bars represent ± SEM 
(n = 3); significance was determined using unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.




3.3.6 rfhSP-D Acts as an Entry Inhibitor of IAV Infection  
In this study, H1+N1 pseudotyped lentiviral particles were generated as a safe strategy to 
determine the involvement of IAV glycoproteins in the recognition and neutralization of IAV by 
rfhSP-D. Generation of H1+N1 pseudotypes was carried out by co-transfecting HEK293T cells with 
plasmid composed of the coding sequence of the indicated H1+N1, psPAX2, and pHIV-Luciferase 
backbone via calcium phosphate transfection method. Post-transfection, H1+N1 pseudotyped 
particles and cell lysates were harvested from the culture supernatant at 24 and 48h, and 
analysed via western blotting; the HA expression was determined using anti-H1 monoclonal 
antibody (Figure 27). HA expression was evident ~70 kDa, confirming the success of pseudotyped 
production. Furthermore, rfhSP-D bound to HA at ~70 kDa, as evident from far western-blotting 
analysis (Figure 27), suggesting the rfhSP-D-HA binding is crucial for suppression of infectivity of 
IAV. In addition, purified H1+N1 pseudotyped particles were used to transfect MDCK cells to 
determine the luciferase reporter assay with and without rfhSP-D (5 and 10 µg/ml). Increased 
levels of luciferase reporter activity were measured at 24h post transfection compared to 48h 
(Figure 28). Approximately, rfhSP-D (10 µg/ml) treatment led to approximately 30% reduction in 
the luciferase reporter activity when compared to cells only challenged with H1+N1 pseudotyped 

































Figure 27: Analysis of purified H1+N1 pseudotyped lentiviral particles. 
(A) Western blotting to show the expression of hemagglutinin (HA) glycoprotein of IAV in purified 
H1+N1 pseudotyped lentiviral particles and cell lysate harvested at 24 and 48 h post-transfection. 
The presence of HA was identified at ~70 kDa. (B) Far western blotting to show binding of rfhSP-
D to purified H1+N1 pseudotyped lentiviral particles and cell lysate at 24 and 48 h. HA was evident 
at ~70 kDa when probed with rfhSP-D antibody. 








Figure 28: rfhSP-D Binds to H1+N1 Pseudotyped Lentivirus and Reduces Luciferase Reporter Activity. 
(A) Luciferase reporter activity of purified H1+N1 pseudotyped lentiviral particles harvested at 24 and 48 h, and (B) Luciferase reporter 
activity of rfhSP-D treated MDCK cells transfected with these lentiviral particles. Significance was determined using the unpaired one-
way ANOVA test (*p < 0.05 and ****p < 0.0001) (n = 3).




3.4 Discussion  
The immune system has evolved several defense mechanisms to overcome IAV-mediated 
respiratory tract infections for suppressing their replication and infectivity. IAV infection is 
responsible for up to half a million mortality rates worldwide, and higher morbidity outcome (five 
million cases per year) (Clayville, 2011). It is fundamentally crucial to study the molecular 
mechanisms of host’s first line of defense in order to develop effective anti-IAV therapies. The 
primary targets for IAV are airway and alveolar epithelial cells, which bind to sialic acid receptor, 
and result in alveolar epithelial damage (Shin et al., 2020, Denney and Ho, 2018). Human SP-D is 
primarily detected in the alveolar space of the lungs and synthesized by Clara cells (Crouch et al., 
2009) and alveolar type-II cells (Kishore et al., 2006). SP-D has been reported have a wide range 
of anti-viral role against IAV (Ng et al., 2012), including neutralization, agglutination, opsonization 
and clearance of virions. Interaction of SP-D with HA or NA glycoproteins of IAV has been shown 
to result in suppression of viral attachment and entry into the host cells (Yang et al., 2013). 
However, inhibition of IAV infection by SP-D and its subsequent immune response is not fully 
studied. Therefore, this study was aimed at investigating the ability of rfhSP-D to act as an entry 
inhibitor of IAV infection and modulate immunological responses in vitro.  
Using pH1N1 and H3N2 IAV subtypes, this study demonstrates that viral entry inhibition by rfhSP-
D is not limited to specific IAV subtypes. rfhSP-D interaction with IAV viral proteins was 
established via protein-to-protein studies using ELISA, cell-binding assay, and far western 
blotting.  As evident from the ELISA, the maximum binding of rfhSP-D to pH1N1 and H3N2 
subtypes was observed at the concentration of 5 µg/ml. rfhSP-D also bound to purified 
recombinant HA in a concentration- and calcium- dependent manner. Furthermore, far-western 
blotting analysis revealed that rfhSP-D bound pH1N1 or H3N2 via HA (~70 kDa) in addition to 
recognizing M1 (~25 kDa). It is well known that N-linked oligosaccharides found on IAV 
glycoproteins (HA or NA) can be recognised by the CRD of SP-D. Therefore, rfhSP-D is likely to 
suppress IAV infection by inhibiting HA-SA containing receptor interactions.  A reverse genetic 
method has been developed to analyze the role of the N-glycosylation site on the H1 head in 
regulating SP-D sensitivity in vivo and in vitro (Tate et al., 2011b). Asn144 is a crucial determinant 
of sensitivity to mouse bronchoalveolar lavage (BAL), a rich source of SP-D (Tate et al., 2011a), 




and hence, virulence in mice. However, Asn144 deletion from HA of Brazil-H1N1 (A/Brazil/11/78) 
strain can reduce sensitivity to mouse BAL and can lead to enhanced virulence in mice (Tate et 
al., 2011b) . Furthermore, simultaneous deletion of addition of Asn144 or Asn104 from Brazil HA 
led to significant changes in sensitivity to mouse BAL as well as virulence compared to loss of 
either residue/site alone (Tate et al., 2011b). These studies indicate that simultaneous SP-D 
binding to multiple glycans on HA of IAV strains is likely to enhance the overall binding affinity 
and thereby antiviral activity.  
The immune response of A549 lung epithelial cells following IAV challenge with and without 
rfhSP-D was examined using qRT-PCR. Using qPCR and multiple cytokine arrays, the ability of 
rfhSP-D to modulate viral replication and inflammatory immune response after IAV challenge was 
examined. We measured M1 mRNA expression levels between rfhSP-D treated and untreated 
A549 cells challenged with IAV subtypes. In the case of pH1N1, rfhSP-D suppressed M1 mRNA 
expression at 2h, while showed reduced viral M1 expression at 6h in the case of H3N2. 
Suppression of M1 expression levels were also evident using western blotting; rfhSP-D treated 
cells showed lowered M1 expression when compared to untreated cells at 6h incubation. Thus, 
rfhSP-D treatment also caused reduced viral replication as evident from titration assay, 
suggesting that rfhSP-D acted as an entry inhibitor against IAV subtypes tested. HA is suggested 
to undergo N-linked glycosylation, leading to modulation of antigenicity, fusion, receptor binding 
specificity, and IAV-mediated immune responses. Therefore, SP-D could play anti-IAV role via 
binding to glycans found on viral HA. Studies have reported that mutations flanking the CRD 
region of human SP-D can confer anti-viral effects for pandemic IAV (Nikolaidis et al., 2014). 
Many studies have shown that there is a direct and indirect relationship between cytokine levels 
and viral replication (Mogensen and Paludan, 2001). The primary targets for IAV is the lung 
epithelial cells, and after the initial exposure, progeny virus particles can proliferate and infect 
surrounding cells, including alveolar macrophages (Chen et al., 2018b). Therefore, the acute 
inflammatory response is induced by the activation of pro-inflammatory cytokines and 
chemokines (Betakova et al., 2017, Oslund and Baumgarth, 2011, Tisoncik et al., 2012), where 
increased levels can cause a dramatic cytokine storm. Altered levels of IFNs, TNFs, interleukins 
and chemokines have been reported in patients infected with IAV (Liu et al., 2019, Ramos and 




Fernandez-Sesma, 2015). Higher IFN levels in the early stages of IAV infection can cause 
irreversible lung damage in mice infected with H5N1 (Tisoncik et al., 2012, Hu et al., 2012).  
However, IFN signaling may also be crucial in preventing the spread of H5N1 (Zeng et al., 2007, 
Alibek and Liu, 2006). TNFs are crucial soluble factors in the cytokine storm during IAV infection. 
The survival rate of H5N1-infected mice lacking TNF receptors and H5N1-infected mice treated 
with anti-TNF-α antibody was unchanged compared with healthy controls (Peiris et al., 2009). In 
addition, IL-1 and IL-6 are the crucial pro-inflammatory cytokines produced by the host cells 
following IAV infection. IL-1 expression is observed in the early stage of IAV infection, followed 
by an upregulation of IL-6 levels (Tisoncik et al., 2012). H5N1 infected mice lacking IL-6 receptors 
have shown poor survival, indicating the protective effect of IL-6 pathway in the cytokine storm 
(Tisoncik et al., 2012). These data suggest that cytokine storm could also lead to the destruction 
of the vascular barrier, causing tissue edema, capillary leakage, and multiple organ failure 
(Tisoncik et al., 2012). However, there is no report of a specific singular mechanism when it comes 
to inducing a cytokine storm caused by influenza virus strains. 
In this study, altered levels of pro-inflammatory cytokines were observed in pH1N1 and H3N2 
challenged A549 cells with and without rfhSP-D. Up-regulation of TNF-α and IL-6 was observed 
in H3N2 infected cells, compared to pH1N1 challenged cells. However, rfhSP-D treatment caused 
suppression of TNF-α and IL-6 levels at 2 h. IL-12 mRNA levels were also considerably reduced by 
rfhSP-D treatment in the case of both IAV subtypes, suggesting the likely suppression of Th1 
immune response. RANTES mRNA transcript levels were downregulated (log101 fold) following 
rfhSP-D treatment at 2 h when compared to pH1N1-infected cells only. Conversely, H3N2 
infected cells treated with rfhSP-D seemed to have reduced RANTES levels (log101 fold). 
Furthermore, rfhSP-D treatment also caused suppression of IFN-α and IFN-β levels at 2 and 6 h. 
Enriched mRNA levels of IFN-α and IFN-β were observed in untreated sample (cells + virus), which 
was three-fold (log10 fold) suppressed following rfhSP-D treatment at 6 h. This indicates that 
when the cells are infected with IAV subtypes, A549 cells will produce higher levels of IFN-α and 
IFN-β to eliminate viral particles. Since the addition of rfhSP-D can inhibit viral replication, lower 
levels of INF are detected. In addition, the expression of certain key pro-inflammatory cytokines, 
chemokines and other soluble factors was significantly down-regulated following rfhSP-D 




treatment, as evident from cytokine array analysis. Through rfhSP-D treatment, the 
downregulation of various humoral factors can also promote the prevention of life-threatening 
secondary bacterial infections caused by virus-mediated abnormal immune regulation.  
Targeting entry of viruses into host cells is an emerging method for developing antiviral 
treatments, because in the early stages of the virus cycle, virus reproduction can be restricted or 
prevented, thereby minimizing the drug resistance of the released viral particles. In this study, 
lentiviral pseudotyped particles were generated as a safe alternative model that mimics the 
structure and surface of IAV to determine whether rfhSP-D can act as an entry inhibitor in cells 
transduced with pseudotyped IAV particles (limited to one replicative cycle). H1+N1 pseudotyped 
particles were analysed and validated via SDS-PAGE and western botting. HA expression in H1+N1 
pseudotyped particles was assessed by western blotting using monoclonal anti-H1 antibody. 
Incubation of H1+N1 pseudotyped lentiviral particles with rfhSP-D was found to facilitate its 
binding to HA that evident at 70 kDA in the far western blot. Luciferase reporter activity assay 
was performed to validate the entry inhibitory role of rfhSP-D. rfhSP-D treatment caused 30% 
reduction in luciferase reporter activity in MDCK cells transduced with H1+N1 pseudotyped 
particles. Therefore, this indicates the ability of rfhSP-D to inhibit viral infection by binding to the 
HA found on the infected MDCK cells. 
In conclusion, M1 suppression, downregulation of pro-inflammatory cytokines/chemokines, and 
reduced levels of luciferase reporter activity following rfhSP-D treatment highlight the potential 
of rfhSP-D as cell entry inhibitor against IAV subtypes tested in this study. 
 
 
































4.1 Abstract  
Breast cancer is a heterogeneous disease; its four molecular subtypes exhibit distinct molecular 
and immunological signatures. Breast tumours vary according to the circulating levels of 
oestrogen, progesterone receptors and HER2 over-expression. Protective effects of SP-D (as well 
as rfhSP-D) has been reported against lung adenocarcinoma, pancreatic and prostate cancer cell 
lines, and primary explants. Here, the effects of the recombinant form of human SP-D (rfhSP-D) 
on a range of breast cancer lines in terms of cell viability reduction, apoptosis induction, and 
signaling pathways were investigated. rfhSP-D (5 μg/ml) was able to bind to BT20, BT474 and 
SKBR3 breast cancer cell lines regardless of their phenotypes. The cell viability of HER2 over-
expressing and triple-positive breast cancer cell lines (SKBR3: ~68%; BT474: ~61%), were reduced 
following culture in the presence of immobilized rfhSP-D (20 μg/ml) at 24h; no significant effect 
was seen in triple-negative cell line (BT20). Cleaved caspase 3 (~17kDa) and 9 (~37kDa) were also 
detected in rfhSP-D treated BT474 and SKBR3 cells, suggesting involvement of intrinsic apoptosis 
pathway. Furthermore, rfhSP-D treatment upregulated p53 phosphorylation at Ser15, and p21 
and p27 expression levels, indicating the possibility of cdc2-cyclin B1 reduction leading to G2/M 















4.2 Introduction   
The immune surveillance of transformed cells remains one of the targeted areas of research for 
designing and developing therapeutic approaches (Swann et al. 2007; Kim et al. 2007). Studies 
using in vivo and in vitro tumour models have reported the involvement of effector immune cells, 
soluble factors, and signaling cascades in anti-cancer immune responses. However, both innate 
and adaptive immunity can also help in the progression of transformed cells by inducing 
immunosuppression, promoting angiogenesis and metastasis of cancer cells (Palucka and 
Coussens, 2016, Vesely et al., 2011).  
Lung surfactants (SP-A, SP-B, and SP-D) has been used as a biomarker for cancer studies. 
Expression levels of SP-A in cancer cells has been shown to be associated with patient prognosis 
(Mitsuhashi et al., 2013), especially in carcinoma originating from type II pneumocytes. Deletion 
of SP-A gene (SFTPA1) in non-small cell lung cancer cells has also been shown to be significantly 
correlated with tumour progression (Mitsuhashi et al., 2013, Jiang et al., 2005). 
Recently, studies have reported interaction of SP-D with a range of cancer cells (leukemia, lung, 
pancreatic and prostate). rfhSP-D treatment resulted in the suppression of tumour progression, 
invasion, EMT and induction of enhanced apoptosis, suggesting inhibition of cell proliferation 
(Kaur et al., 2018a, Kaur et al., 2018b, Kumar et al., 2019, Thakur et al., 2019, Mahajan et al., 
2014, Hasegawa et al., 2015). These studies therefore suggest that SP-D has an immune 
surveillance role against cancer cells. In this context, the current study was aimed at examining 
the role of rfhSP-D in breast cancer, which contributes to nearly 60% mortality rate in lower-
income nations (Sun et al., 2017, Ferlay et al., 2010). In this study, the possible protective effects 
of rfhSP-D in triple-negative (ER−/PR−/HER2−), triple-positive (ER+/PR+/HER2+), and HER2+-









4.3 Results  
4.3.1 rfhSP-D Binds Breast Cancer Cell lines and Reduces Cell Viability 
Breast cancer cell lines, BT20, BT474 and SKBR3, bound rfhSP-D (10 μg/ml) following 1h 
incubation at 4°C and revealed membrane localization (Figure 29). The nucleus of the cell was 
stained with Hoechst dye, while localization of the bound rfhSP-D on the cell membrane was 
detected using green FITC fluorescence. All rfhSP-D treated breast cancer cell lines showed a 
similar ‘cluster’ like binding pattern on the cell membrane. No FITC was detected in the untreated 
controls, when probed with both primary and secondary antibodies for each cell line, suggesting 
that the rfhSP-D binding observed in the treated sample was protein-specific.  
The quantitative analysis of cell viability in rfhSP-D treated and untreated cells was carried out 
using MTT assay at 24h and 48h time point (Figure 30). The cells were incubated with a varied 
concentration of rfhSP-D (5, 10, and 20 μg/ml) in serum free RPMI medium, along with an 
untreated control, where no protein was added. The cell viability of HER2 over-expressing and 
triple positive breast cancer cell lines (SKBR3: ~40%; BT474: ~30%) were reduced following 
solution phase rfhSP-D (20 μg/ml) treatment at 24h in a dose dependent manner, whereas no 
significant effect was seen in triple negative cell line (BT20) (Figure 30).  In the case of FL-SP-D, 
the reduction on cell viability was concentration dependent, where maximum reduction was seen 
with 20 μg/ml for both SKBR3 and BT474 cell lines, while BT20 had no effect as seen. However, 
no significant difference was seen at all concentration of rfhSP-D treatment for 48h in all the cell 
lines investigated in this study (Data not shown). 






Figure 29: rfhSP-D (10 μg/ml) binding to triple negative (BT20), triple positive (BT474) and HER2+-overexpressing (SKBR3) breast 
cancer cell lines using fluorescence microscopy. 
The cell nucleus was stained with Hoechst (1:10,000), and both untreated (cells only) and rfhSP-D-treated cells were probed with 
polyclonal anti-human SP-D/FITC antibody (1:200). Membrane localization of the bound proteins was only detected in the rfhSP-D-
treated cells, while no FITC was detected in the untreated control (cells only).
































Figure 30: Cell viability reduction by rfhSP-D in breast cancer cell lines via MTT assay. 
Cells (0.1x105) were treated with varied concentration of rfhSP-D (5, 10, 20 µg/ml) (A) and human 
full-length SP-D (hFL-SP-D) (B), followed by incubation for 24h at 37°C under standard cell culture 
conditions. Assays were done in triplicates ± SEM and the significance were established using the 
unpaired one-way ANOVA test (*p < 0.05 and **p < 0.01) (n = 3). The statistical analysis was 
performed between cells only and rfhSP-D-treated breast cancer cells.
 
 






























































4.3.2 Apoptosis Induction by rfhSP-D in Breast cancer cell lines 
The quantitative and qualitative analysis of apoptosis induction by rfhSP-D was performed using 
flow cytometry and immunofluorescence microscopy, respectively. A significant proportion of 
breast cancer cells treated with rfhSP-D induced apoptosis at 24h of post treatment as revealed 
by FACS analysis (Figure 31 & 32). rfhSP-D (20 μg/ml) in solution was effective in inducing the 
maximum apoptosis at 24h; SKBR3 (~34%), BT474 (~27%), while the treatment had no significant 
effect on BT20 cell line in terms of cell death at all the protein concentrations tested. However, 
both BT474 and SKBR3 cell lines became more susceptible to apoptosis induction following 
immobilized rfhSP-D (20 μg/ml) compared to rfhSP-D in solution (Figure 31 & 32). An increased 
apoptosis was seen in SKBR3 (~68%), and BT474 (~61%), while immobilized rfhSP-D had no effect 
on BT20 cell line. These data suggest that immobilized rfhSP-D is more effective apoptosis inducer 
than solution-phase, probably due to the way rfhSP-D protein molecules are presented in an 
array platform, exposing their CRD regions to interact with putative cell receptors. However, 
solution-phase protein molecules are free floating molecules which may possibly have 
competitive binding with their receptors. 
For both BT47 and SKBR3 cell lines, approximately around 56% cells were both stained with FITC 
and PI positive, suggesting that annexin V/FITC was able to bind to phosphatidylserine (PS) found 
on the surface of cells undergoing apoptosis. However, the higher percentage of cells stained for 
PI alone was found in BT474 cell line when compared to SKBR3 cell line, suggesting that these 
cells were either at the late stage of apoptosis or undergoing necrosis. The percentage of viable 
cells in the untreated (cells only) sample was significantly higher as compared to rfhSP-D treated 
sample: BT474 (~92%), and SKBR3 (~96%). This suggested that apoptosis induction was a protein 
(rfhSP-D)-specific effect, where the integrity of the cell membrane was intact in untreated cells, 
and hence, the cells were still viable, blocking the translocation of PS from inner cell membrane 
to outer plasma membrane, and preventing the PS - Annexin V interaction. Staurosporine (1 
μM/ml) was used as a potent apoptosis inducer; Staurosporine-treated BT20, BT474, and SKBR3 
showed ~70% of apoptosis induction at 24 h (Figure 31 & 32).  




Fluorescence microscopic analysis of apoptosis induction by rfhSP-D in BT474 and SKBR3 cell lines 
revealed a positive staining for cell membrane integrity marker, Annexin V (conjugated to FITC), 
and disoriented cell membrane morphology (Figure 33). PI positive staining was seen only in 
rfhSP-D treated BT474 and SKBR3 cells compared to untreated controls. However, no positive 
staining of Annexin V or PI was detected in BT20 treated cells as well as untreated control. 
4.3.3 Apoptosis induction in BT474 and SKBR3 by rfhSP-D via Intrinsic Pathway 
Since rfhSP-D induced apoptosis in BT474 and SKBR3 breast cancer cell lines, further studies were 
performed to examine the likely apoptotic pathways that may be activated due to rfhSP-D 
treatment. Since apoptosis can be initiated via intrinsic or extrinsic pathways, expression of 
caspases was examined in breast cancer cell lines treated with rfhSP-D (20 μg/ml) via western 
blotting (Figure 34). Cleavage of caspase 9 (~37 kDa) and 3 (~17 kDa) (Figure 34) was observed in 
rfhSP-D-treated BT474 and SKBR3 cells at 12h, suggestive of a possible involvement of intrinsic 
apoptotic pathway. However, cleavage of caspase 3 and 9 was not detected in untreated controls 
(cells only) and in BT20 cells. Additionally, cleaved caspase 8 was also tested to determine the 
trigger of extrinsic pathway, but there was no difference observed between untreated controls 
and rfhSP-D treated cells (data not shown).     














Figure 31: Flow cytometric analysis of apoptosis induction in triple negative (BT20), triple positive (BT474) and HER2+-
overexpressing (SKBR3) breast cancer cell lines treated with immobilized rfhSP-D and human full-length SP-D (hFL-SP-D) (20 
μg/ml) for 24 h. 
For both Annexin V/FITC and DNA/PI staining, 12,000 cells were acquired and plotted. A significant difference was detected among 
rfhSP-D/hFL-SP-D-treated and untreated (cells only) samples, as evident by the shift in the fluorescence intensity. The data were 
expressed as the mean of three independent experiments (n = 3) done in triplicates ± SEM. Statistical significance was performed using 
the unpaired one-way ANOVA test (**p < 0.01 and ****p < 0.0001). The percentage of apoptosis induction was calculated by 
normalizing the rfhSP-D/hFL-SP-D-treated cells with their untreated (cells only) counterparts. 












Figure 32: Flow cytometric analysis of apoptosis induction in triple negative (BT20), triple positive (BT474) and HER2+-
overexpressing (SKBR3) breast cancer cell lines treated with solution-phase rfhSP-D and human full-length SP-D (hFL-SP-D) (20 
μg/ml) for 24 h. 
For both Annexin V/FITC and DNA/PI staining, 12,000 cells were acquired and plotted. A significant difference was detected among 
rfhSP-D/hFL-SP-D-treated and untreated (cells only) samples, as evident by the shift in the fluorescence intensity. The data were 
expressed as the mean of three independent experiments (n = 3) done in triplicates ± SEM. Statistical significance was performed using 
the unpaired one-way ANOVA test (**p < 0.01 and ****p < 0.0001). The percentage of apoptosis induction was calculated by 
normalizing the rfhSP-D/hFL-SP-D-treated cells with their untreated (cells only) counterparts. 






Figure 33: Fluorescence microscopy analysis of rfhSP-D-mediated apoptosis induction in breast cancer cells for 24 h, using an 
Annexin V with a propidium iodide (PI) staining kit. 
The nucleus of the cells was stained with Hoechst (1:10,000), and the cell membrane was stained positively with Annexin V and PI 
(1:200) in rfhSP-D-treated cell lines, suggesting that cells treated triggered apoptosis at 24 h, where PS translocated to the outer 
plasma membrane was able to bind Annexin V due to loss of membrane integrity and PI stain was taken, which stained the DNA of 
apoptotic cells. No Annexin V/PI staining was detected in untreated (cells only) control.  
 
















Figure 34: Activation of caspases in triple positive (BT474) and HER2+-overexpressing (SKBR3) breast cancer cell lines following 
rfhSP-D treatment at 12 h. 
Western blot analysis showed cleaved caspase 3 at 17kDa (A) and cleaved caspase 9 at 37kDa (B) in the rfhSP-D-treated cells for 24 h, 
suggesting induction of the intrinsic pathway. 





4.3.4 rfhSP-D Induced Up-regulation of Cell Cycle Inhibitors and p53-dependent Apoptosis 
mechanism. 
p53 is a transcription factor, known to be involved in the regulation of oncogenic responses 
including DNA damage, cell cycle arrest, and apoptosis induction. Thus, the levels of activated 
p53 in rfhSP-D-treated breast cancer cells were determined using the PathScan Intracellular 
Signaling Array Kit (Figure 36). rfhSP-D (20 μg/ml) treated SKBR3 cells showed increased levels of 
p53 phosphorylation at Ser15 (Figure 36). However, downregulation was observed in BT20 cells 
following rfhSP-D treatment, suggesting up-regulation of p53 may also have contributed to p53-
dependent apoptosis induction by rfhSP-D in SKBR3 cells. In addition, rfhSP-D treatment also 
caused upregulation of p21 and p27 transcript levels in BT474 and SKBR3 cell lines (Figure 35) at 
12h. This may indicate the possibility of cdc2-cyclin B1 reduction, leading to G2/M cell cycle 
arrest. In contrast, no significance differences were observed in terms of p21 and p27 mRNA 
levels in rfhSP-D treated BT20 cells. 

















Figure 35: rfhSP-D treatment caused upregulation of p21 (A) and p27 (B) cell cycle inhibitors in triple positive (BT474) and HER2+-
overexpressing (SKBR3) breast cancer cell lines. 
BT20, BT474, and SKBR3 (0.4 × 106) cells were seeded in a pre-coated plate with rfhSP-D (20 µg/ml). The treated cancer cells were 
lysed and pelleted down. The pelleted cells were subjected to RNA extraction, followed by cDNA synthesis and qPCR. The comparative 
quantification method was carried out to calculate the efficiencies of each targeted gene for each individual PCR. The takeoff results 
obtained with p21/p27 primers were normalized with TBP (housekeeping gene) primers. Assays was conducted in triplicates, and error 
bars represent ± SEM. Unpaired one-way ANOVA test was performed to measure the significance; *p < 0.05 and **p < 0.01 (n = 3). 
The statistical analysis was performed between untreated (cells only) and rfhSP-D-treated breast cancer cells. 
 



















Figure 36: Intracellular signaling to show p53 phosphorylation (at Ser15) in rfhSP-D-treated triple negative (BT20) (A) and HER2+-
overexpressing (SKBR3) (B) breast cancer cell lines. 
The phosphorylation status of p53 was evaluated using total cell lysates with a PathScan Antibody Array Kit (Cell Signaling). Data were 
generated from at least three independent experiments and presented as mean ± SD. Unpaired one-way ANOVA test was performed 
to measure the significance: *p < 0.05, and ***p < 0.001 (n = 3). The statistical analysis was performed between untreated (cells only) 
and rfhSP-D-treated breast cancer cells.




4.4 Discussion  
In this study, it was found that rfhSP-D binds to all breast cancer cell lines tested regardless of 
their phenotypes: BT20 (ER−/PR−/HER2−), BT474 (ER+/PR+/HER2+), and SKBR3 (ER−/PR−/HER2+). 
However, the putative receptor or the ligand rfhSP-D is binding to on the breast cancer cell 
surface, is not yet known. Recently, the interaction between the CRD region of human SP-D and 
the N-glycan of EGFR has been reported, which leads to down-regulation of EGF signal 
transduction in human lung adenocarcinoma cells (Hasegawa et al., 2015). In addition, SP-D's 
ability to trigger TNF-α produced in human CCR2+ monocytes by interacting with the receptor 
OSCAR has been reported (Barrow et al., 2015). rfhSP-D treatment reduced cell viability of BT474 
and SKBR3 cell lines and induced apoptosis at 24 h. Cell viability assay was carried out using varied 
concentrations of rfhSP-D (5, 10, and 20 μg/ml) and different time points (12, 24, and 48 h); rfhSP-
D was only effective in inducing the optimal cell viability reduction and apoptosis at the 
concentration of 20 μg/ml at 24 h. A significant percentage reduction in viable cells was observed 
in rfhSP-D-treated BT474 and SKBR3 cells compared to untreated control (cells only) sample, as 
evident from the MTT assay. However, in terms of cell viability, rfhSP-D has had no effect on triple 
negative (BT20) cell line.   
The significant increase in the number of Annexin V-/PI-positive breast cancer cells observed by 
flow cytometry and fluorescence microscopy demonstrated the ability of rfhSP-D to induce 
apoptosis in SKBR3 and BT474 cell lines within 24 hours. The cell surface of healthy cells is 
composed of lipids distributed asymmetrically on the inner and outer surfaces of the plasma 
membrane. PS is one of these lipids, which is confined to the inner surface of the plasma 
membrane and therefore only exposed to the cytoplasm of the cell. However, when stress factors 
trigger cell apoptosis, the lipid asymmetry disappears, and PS shifts to the outer leaflet of the 
plasma membrane (Porter and Janicke, 1999). Annexin V (36kDa) is a calcium-binding 
intracellular protein that binds to PS, and Annexin V can also stain cells that undergo necrosis 
due to membrane rupture, which allows Annexin V to enter the entire plasma membrane. 
Immobilised rfhSP-D induced apoptosis in SKBR3 (~68%) and BT474 (~61%), while no effect was 
observed on BT20 cell line.  In the two cell lines, approximately 56% cells were stained with FITC 
as well as PI, suggesting that annexin V/FITC was able to bind to PS found on the surface of cells 




undergoing apoptosis. However, the BT474 showed higher percentage of PI alone stained cells 
when compared to SKBR3 cell line, indicating that these cells were at the late stage of apoptosis. 
However, no significant difference in terms of cell viability reduction and apoptosis induction was 
observed at all concentration of rfhSP-D treatment for 48h in all the cell lines investigated in this 
study. Lack of apoptosis induction at 48h seems to imply that the rest of viable cells (~30%) which 
are not affected by rfhSP-D treatment at 24h are probably recovering.  
Western blot analysis of BT474 and SKBR3 breast cancer cells treated with rfhSP-D showed that 
caspase 9 and 3 were cleaved after 12 h of rfhSP-D treatment. Caspase is a well-known cysteine 
aspartic protease, which plays a vital role in apoptosis. Caspase 9 is triggered by cellular stress 
(such as DNA damage) by binding to the apoptotic protease activator 1 (Apaf-1). Apaf-
1/procaspase 9 triggers executor cysteine proteases 3 and 7 in turn (Julien and Wells, 2017). 
Caspase 3 is an essential apoptotic executor, triggered by the proteolytic enzyme cleavage at 
Asp175, which leads to inactivation of Poly (ADP-ribose) polymerase (PARP) (Walsh et al., 2008, 
Porter and Janicke, 1999). Our findings indicate that the apoptosis induction in SKBR3 and BT474 
cell lines by rfhSP-D may occur through the intrinsic apoptotic pathway (Elmore, 2007). Recently, 
the indispensable role of rfhSP-D in innate immune surveillance against prostate cancer has been 
reported. It has been shown that rfhSP-D-mediated apoptosis occurs through two different 
mitochondrial pathways (Thakur et al., 2019).  
To further understand the mechanism of apoptosis induced by rfhSP-D treatment, the signal 
pathways that may be related to tumor proliferation and cell death were analyzed. rfhSP-D 
treatment leads to increased phosphorylation of p53 (at Ser15) in BT474 and SKBR3 cell lines, 
which may be mediated by oxidative stress caused by rfhSP-D (Kaur et al., 2018a, Janssen et al., 
2008). The up-regulation of p53 in BT474 and SKBR3 cell lines treated with rfhSP-D leads to down-
regulation of the pAkt pathway, leading to increased levels of Bad and Bax, which triggers the 
release of cytochrome c, caspase 9 cleavage and apoptosis induction. Furthermore, elevated 
expression levels of phosphorylated p53 and p21/p27 cause inactivation of the cyclin B–cdc2 
complex, which is essential for regulating the transition of G2/M cell cycle, leading to DNA repair 
or induction of apoptosis (Kaur et al., 2018a). The apoptosis mediated by rfhSP-D may be due to 




the expression of HER2 on BT474 and SKBR3 cells. The absence of HER2 expression seems to be 
the likely cause of BT20 cell being resistant to rfhSP-D-induced apoptosis. Whether HER2 is 
involved in mediating rfhSP-D-induced apoptosis is under investigation. In addition, previous 
studies have reported the interaction of SP-D with HMGA1, CD14, CD91-calreticulin complex, 
SIRPα and EGFR (Janssen et al., 2008, Thakur et al., 2019, Mahajan et al., 2013, Hasegawa et al., 
2015). The SP-D interaction with these key molecules appear to be part of the possible 
mechanism/receptor that rfhSP-D may mediate its apoptotic effects on breast cancer cells. As 
demonstrated in previous studies, the CRD region of SP-D can interact with pattern recognition 
receptors TLR-2, TLR-4 (Ohya et al., 2006), and CD14 (Augusto et al., 2003), which may inactivate 
and suppress the pro-inflammatory and pro-survival downstream signaling on breast cancer cells. 
However, further research is essential to understand the involvement of CRD region of SP-D and 
its possible interaction partners involved in inducing the downstream mechanisms leading to 
induction of apoptosis.  
In conclusion, rfhSP-D treatment can induce apoptosis in BT474 and SKBR3 cell lines involving 
intrinsic apoptotic pathways, but it has no effect on the triple-negative BT20 cell line. Most 
conventional anti-cancer therapies only target actively proliferating tumour cells. New strategies 
involving immune surveillance molecules like rfhSP-D can potentially target signaling cascades to 
















Chapter 5   
 
Hyaluronic Acid Modulates the Pro-apoptotic Effects of rfhSP-D on Breast 
















5.1 Abstract  
The oncogenesis and progression of tumour including metastasis is profoundly dictate by tumour 
microenvironment including a range of extracellular matrix components (e.g., hyaluronic acid; 
HYA) and infiltrating immune cells (e.g., tumour-associated macrophages; TAMs). Having 
established a likely role of SP-D in innate immune surveillance against breast cancer, we sought 
to investigate if SP-D itself is present in the breast cancer tissues and if yes, what are the likely 
sources for its production. In addition, we wanted to know if the TME factors especially HYA can 
modulate the pro-apoptotic effects of rfhSP-D. In this study, the effect of a recombinant fragment 
of human SP-D (rfhSP-D) on a range of breast cancer lines was examined in the presence of HYA. 
Breast cancer is classified into four molecular subtypes characterized by varied expressions of 
estrogen (ER), progesterone (PR), and epidermal growth factor (EGF) receptors (HER2). As 
established in the previous chapter, rfhSP-D treatment triggered apoptosis induction in HER2-
overexpressing (SKBR3) and triple-positive (BT474) breast cancer cell lines [but not in the triple-
negative cell line (BT20)] at 24 h. Upregulation of p21/p27 cell cycle inhibitors and p53 
phosphorylation (Ser15) was also evident in rfhSP-D-treated BT474 and SKBR3 cell lines, 
suggestive of G2/M cell cycle arrest. rfhSP-D-treated BT474 and SKBR3 cells also showed cleaved 
caspases 9 and 3, indicating an involvement of the intrinsic apoptosis pathway. However, rfhSP-
D-induced apoptosis was nullified in the presence of hyaluronic acid (HYA). rfhSP-D bound to 
solid-phase HYA and promoted cell proliferation of BT474 and SKBR3 cell lines. Decreased 
transcriptional levels of p53 was observed in rfhSP-D-treated SKBR3 cells in the presence of HYA 
compared to cells treated with rfhSP-D only. Thus, HYA seems to negate the anti-tumorigenic 










5.2 Introduction   
Breast cancer is correlated with an increased mortality rate due to angiogenesis, metastasis, and 
resistance to conventional chemotherapy (Al-Mahmood et al., 2018). Furthermore, the 
development, progression and metastasis of breast cancer appears to be impacted by innate 
immune molecules and associated inflammatory mediators in the tumour microenvironment (Al-
Mahmood et al., 2018, Qu et al., 2018). 
While acting as a bridge between innate and adaptive immunity, human SP-Dis known for its 
activity in immune surveillance and immunomodulation in infection, allergy, and cancer (Kishore 
et al., 2006, Hasegawa et al., 2015, Kaur et al., 2018a, Kaur et al., 2018b, Kumar et al., 2019, 
Thakur et al., 2019, Mahajan et al., 2013). A recombinant fragment of SP-D (rfhSP-D) composed 
of homotrimeric neck region and CRD was reported to induce apoptosis several cancers in p53-
dependent manner (Mahajan et al., 2013, Thakur et al., 2019, Kaur et al., 2018a). Furthermore, 
rfhSP-D treatment was also effective in inducing apoptosis in primary tumour cells isolated from 
patients with metastatic prostate cancer (Thakur et al., 2019).These studies therefore suggest 
that rfhSP-D has an immune surveillance role against cancer cells.  
During the breast tumorigenesis, the tumor cells appear to interact with surrounding stroma to 
create a tumor microenvironment, supporting the growth, survival, and invasion of tumour cells. 
The extracellular matrix (ECM) is an important constituent of the niche, composed of several 
proteoglycans and glycosaminoglycans, which offer structural basis for tissue organization. This 
contributes to progression of malignant tumour formation, cell survival, proliferation and 
invasion via angiogenesis and metastasis (Heldin et al., 2013, Bernert et al., 2011). Hyaluronic 
acid (HYA), a polymeric non-sulfated glycosaminoglycan, and the most abundant component of 
the ECM plays an essential role in inflammation, angiogenesis, and cancer progression (Bernert 
et al., 2011). Several studies have reported that HYA participates in the regulation of breast tumor 
cell migration and invasion in vitro and tumor progression in vivo (Tolg et al., 2006, Bourguignon 
et al., 2009). Abnormal levels of HYA in the initial and late stage of ductal breast carcinoma in 
situ (DCIS) microenvironment appears to correlate with tumour stage progression and migration 
(Corte et al., 2010). 




Pro-tumorigenic effects of HYA and its altered expression levels in breast tumors and possible 
mechanisms through which HYA might induce proliferation of tumour cells are areas of great 
interest.  As HYA and SP-D are overexpressed in several carcinomas, targeting both HYA and SP-
D is clinically relevant to inhibit HYA-mediated intracellular signaling that promotes tumour cell 
progression and invasion. Therefore, this study was aimed at examining the interaction between 
HYA and rfhSP-D and its implication on the cell adhesion and proliferation of triple-negative, 





















5.3 Results  
5.3.1 Expression of Human SP-D in Breast cancer tissues 
The expression of human SP-D was analyzed in eight cases of invasive ductal carcinoma using 
immunohistochemistry (IHC) technique (Figure 37). The study involved two cases for each 
molecular phenotypes of breast cancer (luminal A, luminal B, triple negative and Her2-Neu), 
which are based on the expression of the ER, PR, and the Her2-Neu status. The molecular 
phenotypes reflect the neoplastic heterogeneity of breast cancer, and can also vary in gene 
expressions, clinical and morphological features, treatment responses and outcome (Turashvili 
and Brogi, 2017). This study was aimed to analyze the presence of human SP-D distribution in all 
molecular phenotypes of breast cancer and to dissect its relevant biological role in neoplastic 
progression, thus, determine potential prognostic markers of mammary carcinoma. IHC analysis 
revealed heterogeneous inter-tumor and intra-tumor expressions of SP-D within the molecular 
subtypes mentioned above. IHC staining for SP-D expression showed a cytoplasmic expression in 
both the healthy peritumoral mammary parenchyma and neoplastic tissues, as previously 
demonstrated (Mangogna et al., 2018). Furthermore, SP-D distribution was also evident in 
cytoplasmic labelling and highlighted enriched SP-D expression in the neoplastic subclones of 
luminal A type and the ductal epithelium of peritumoral mammary parenchyma. However, a 
lower SP-D expression was evident in triple-negative breast cancer (TBNC) (Figure 37). A 
heterogeneous SP-D expression was also observed in luminal B and HER2 groups. 
5.3.2 Expression of HYA in Breast Cancer Tissues 
Serial sections for the HYA localization within the tumor microenvironment was examined 
following histochemical analysis of breast cancer and normal healthy tissue specimens. Presence 
of acid mucins was revealed by Alcian blue staining, containing sialic acid and HYA (Zugibe, 1970, 
Pearse, 1968, Conn, 1953) in the tumour stroma. Alcian blue staining highlighted a very faint HYA 
and sialic acid distribution in the peritumoral mammary parenchyma in all the molecular classes 
of breast cancer tested. In the luminal B and HER2 groups, a higher heterogeneous expression of 
HYA was also evident (Figure 38). Thus, a stronger staining for Alcian blue staining was evident 




where a lower SP-D expression was detected, indicating that a modification of ECM might be 















Figure 37: Presence of human SP-D and hyaluronic acid (HYA) in different histotypes of 
neoplastic breast and normal ductal mammary epithelium. 
Detection of SP-D and HYA expression was detected by immunohistochemical (IHC) staining. SP-
D was highly expressed by the ductal epithelium of peritumoral mammary parenchyma and the 
neoplastic sub-clones of luminal A type. Reduced SP-D expression was evident in triple-negative 
breast cancer (TBNC). AEC (red) chromogen was used to visualize the binding of anti-human SP-
D antibodies. Histochemical staining with Alcian Blue underlined distribution of HYA in normal 
and breast cancer tissue sections; in particular, the staining was greatly visible in tumor-
associated stroma.  
 





















Figure 38: Immunohistochemical and histochemical analysis of SP-D (A–F) and HYA (G–L) 
expression in Luminal-B and Her2+/ER-/PR- breast carcinoma. 
A higher variability of SP-D and HYA distribution was seen within the same isotype. There is a 
slight inverse correlation between expression of SP-D and HYA. AEC (red) chromogen was used 
to visualize the binding of anti-human SP-D antibodies, whereas histochemical staining with 
Alcian Blue highlighted HYA presence.




5.3.3 rfhSP-D Binds to High Molecular Weight HYA (1500 kDa) and Promotes Breast Cancer 
Cell Adhesion 
The confirmation of HYA and SP-D distribution in breast cancer tissues prompted to examine 
whether rfhSP-D binds to HYA and can modulate the nature of the interaction between rfhSP-D 
and breast cancer cells. rfhSP-D bound to solid-phase HYA (1,500 kDa) in a dose-dependent 
manner (Figure 39). Furthermore, interaction of breast cancer cells with immobilized rfhSP-D (20 
μg/ml) or HYA (20 μg/ml)-bound rfhSP-D was established using cell adhesion assay (Figure 40). 
All three breast cancer cell lines, including BT20, BT474, and SKBR3 were able to adhere to 
immobilized rfhSP-D, HYA, and to HYA-bound rfhSP-D. Immobilised rfhSP-D alone showed a 
higher cell adhesion in BT20 cell line when compared to immobilized HYA alone or HYA-bound 
rfhSP-D. However, there was no significant cell adhesion observed with immobilised rfhSP-D, HYA 
or HYA-bound rfhSP-D in BT474 or SKBR3 cell lines (Figure 40). 
5.3.4 HYA Modulates Pro-apoptotic Effects of rfhSP-D in Breast Cancer Cell Lines    
The interaction between rfhSP-D and HYA, and its implication on breast cancer cells were 
investigated via flow cytometry (Figure 41). Pre-coated HYA, HYA + rfhSP-D, and rfhSP-D-only 
wells were incubated with breast cancer cells, along with untreated control (cells only with no 
HYA +/-rfhSP-D), and the cells were subjected to Annexin V/FITC staining after 24h incubation. 
Flow cytometry analysis for the quantification of apoptosis revealed that HYA addition to rfhSP-
D treated cells reduced apoptosis by ~45%. Additionally, proliferation assay was also performed 
to determine whether rfhSP-D together with HYA induced a proliferative response in the breast 
cancer cell lines. Therefore, the HYA + rfhSP-D treated breast cancer cells, along with untreated 
control, were stained with mouse anti-Ki-67 antibody to measure the percentage of proliferation. 
rfhSP-D (20 μg/ml)-treated SKBR3 cells incubated with HYA (20 μg/ml) resulted in ~30% cell 
proliferation (Figure 42), suggesting that addition of HYA negated pro-apoptotic effects of rfhSP-
D against breast cancer cell lines. In the case of BT474 cell line, approximately ~47% of 
proliferative cells were seen following rfhSP-D treatment, while HYA + rfhSP-D-treated BT474 
cells showed ~95% of proliferative cells stained with Ki-67 antibody. BT474 cells treated with HYA 
only showed ~88% of Ki-67-positive cells, while ~66% of proliferative cells were quantified in HYA-




treated SKBR3 cells. However, in the case of BT20 cell line, the cell proliferation was not 
significantly affected by either HYA or rfhSP-D treatment, suggesting that these cells continue to 
proliferate and grow unhindered.  The % of cell proliferation were compared to untreated 












Figure 39: Interaction of rfhSP-D with hyaluronic acid (HYA). 
Constant concentration of 1500kDa HYA (20ug/ml) coated in ELISA plates and incubated with 
decreasing concentration of rfhSP-D (20,10,5,2.5 or 1.25 ug/ml) at 37°C. In a parallel experiment, 
maltose-binding protein (MBP) (20,10,5,2.5 or 1.25 ug/ml) was used as a negative control 
protein. Following washes, the bound HYA-rfhSP-D/MBP interaction was detected using anti-
rabbit SP-D polyclonal antibody (1:5000) or rabbit anti-MBP polyclonal antibody (1:5000) 
(Thermo Fisher). The reaction was developed using TMB substrate and the reading was read at 
450 nm and the data were expressed as mean of three independent experiments done in 
triplicates ± SEM. Significance was determined using unpaired one-way ANOVA test 
(***p < 0.001).









Figure 40: The effects of rfhSP-D on triple negative (BT20), triple positive (BT474) and HER2+-overexpressing (SKBR3) breast cancer 
lines adhesion. 
FAST DiI fluorescent dye-labelled cells allowed to adhere to wells pre-coated with HYA, rfhSP-D, HYA+ rfhSP-D, and BSA (negative 
control). The cell adhesion was measured after 35 minutes of incubation at 37°C under 5% CO2. The data is expressed as adhesion 
percentage with reference to a standard curve established using an increasing number of FAST DiI -labeled cells. The data is expressed 
as the mean of three independent experiments (n = 3) done in triplicates ± SEM. Statistical significance was determined using the 
unpaired one-way ANOVA test (**p < 0.01). The statistical analysis was carried out between rfhSP-D and HYA + rfhSP-D -treated breast 


















Figure 41: Induction of apoptosis induction in triple negative (BT20), triple positive (BT474) and HER2+-overexpressing (SKBR3) 
breast cancer lines following HYA (20 µg/ml) challenge in the presence and absence of rfhSP-D (20 µg/ml). 
The data were expressed as the mean of three independent experiments (n = 3). A significant difference was seen among rfhSP-D 
treated and untreated samples, as made evident by the shift in the fluorescence intensity. Staurosporine (1 μM/ml) was used as a 
positive control, a known inducer of apoptosis. The data were generated from three independent experiments (n = 3) and expressed 
as mean ± SD (*p < 0.1, **p < 0.01, and ****p < 0.0001). Untreated sample (cells only) was used as a negative control and data shown 

















Figure 42: Proliferative effects of rfhSP-D treatment on triple negative (BT20), triple positive (BT474) and HER2+-overexpressing 
(SKBR3) breast cancer lines. 
BT20, BT474 and SKBR3 cells were seeded in wells pre-coated with rfhSP-D, HYA + rfhSP-D, and HYA. Proliferative cell percentage was 
assessed by staining the cells with mouse anti-human KI-67 antibody, and KI-67-stained cells were measured via flow cytometry. The 
data were generated from three independent experiments (n = 3) and expressed as mean ± SD (*p < 0.1, **p < 0.01, and ****p < 
0.0001). The statistical analysis was carried out between rfhSP-D and HYA + rfhSP-D-treated breast cancer cells. 
 




5.3.5 Secretion of SP-D by Breast Cancer Cell Lines 
Given the distribution of SP-D in the breast cancer tissues, further studies were carried out to 
purify SP-D from the culture supernatants of the breast cancer cells on the assumption that 
breast cancer cells may also be a possible source of SP-D distribution in the tumor 
microenvironment. The presence of SP-D in culture medium from the breast cancer cell lines was 
confirmed and analyzed via western blotting (Figure 43). Culture medium collected from BT20, 
BT474, and SKBR3 cell lines were passed through a maltose Sepharose column, and the EDTA-
eluted fractions (5 µg/ml) were validated via western blotting; full-length SP-D (FL-SP-D) was 
detected at ~43kDa only for BT474 supernatant. Both BT20 and SKBR3 cell lines did not secrete 
any FL-SP-D. Furthermore, secreted FL-SP-D by BT474 was tested for its ability to induce 
apoptosis in these cell lines (Figure 43). However, the culture supernatant-purified FL-SP-D (20 
µg/ml) was not able to trigger apoptosis in BT474, as well as in BT20 and SKBR3 cell lines (Figure 
43).  
5.3.6 Down-regulation of p53 by HYA addition in rfhSP-D-treated Breast Cancer Cell Lines 
To further understand the mechanism of apoptosis inhibition mediated by HYA addition in rfhSP-
D-treated breast cancer cell lines, the status of p53 and cell cycle inhibitors was analyzed. Down-
regulation of phosphorylated p53, p21, p27 as well as caspase 3 was detected in HYA + rfhSP-D-
treated BT474 and SKBR3 cells (Figure 44 & 46). There were no significant differences found in 
terms of p21 and p27 mRNA expression levels in the case of BT20 between HYA + rfhSP-D and 
rfhSP-D-treated BT20 cells. Down-regulation of these key mediators may possibly suggest the 
resistance of the breast cancer cells to apoptosis in the presence of HYA. 
















Figure 43: Secretion of full-length human SP-D were detected in culture medium from triple positive (BT474) breast cancer cell 
line. 
The levels were confirmed and analyzed via western blotting (A). The collected culture medium from BT20, BT474, and SKBR3 cell lines 
was passed through a maltose Agarose column, and the eluted fractions (5 µg/well) were validated via western blotting; full-length 
SP-D (FL-SP-D) was detected at ~43 kDa only from BT474 culture medium. Secreted FL-SP-D by BT474 was examined for its ability to 
induce apoptosis (B). No effect of secreted full-length SP-D (20 µg/ml) was observed in terms of cell viability and induction of apoptosis. 
FL-SP-D purified from human lung lavage (hFL-SP-D) (20 µg/ml) and rfhSP-D (20 µg/ml) was also used in the sample experiment, along 
with Staurosporine (1μM/ml) as a positive control of apoptosis induction. Unpaired one-way ANOVA test was performed to measure 
the significance: *p < 0.05, and ***p < 0.001 (n = 3).  The statistical analysis was performed between untreated (cells only) and protein-
treated breast cancer cells. 







Figure 44: rfhSP-D treatment caused upregulation of p21 and p27 cell cycle inhibitors in triple positive (BT474) and HER2+-
overexpressing (SKBR3) breast cancer cell lines. 
BT20, BT474, and SKBR3 (0.4 × 106) cells were seeded in a pre-coated plate with HYA + rfhSP-D or rfhSP-D alone. The treated cancer 
cells were lysed and pelleted down. The pelleted cells were subjected to RNA extraction, followed by cDNA synthesis and qPCR. The 
comparative quantification method was carried out to calculate the efficiencies of each targeted gene for each individual PCR. The 
takeoff results obtained with p21/p27 primers were normalized with TBP (housekeeping gene) primers. Assays was conducted in 
triplicates, and error bars represent ± SEM. Unpaired one-way ANOVA test was performed to measure the significance; *p < 0.05 and 
**p < 0.01 (n = 3). The statistical analysis was performed between rfhSP-D and HYA+ rfhSP-D-treated breast cancer cells. 


















Figure 45: Intracellular signaling to show p53 phosphorylation (at Ser15) in rfhSP-D-treated triple negative (BT20) (A) and HER2+-
overexpressing (SKBR3) (B) breast cancer cell lines. 
The phosphorylation status of p53 was evaluated using total cell lysates with a PathScan Antibody Array Kit (Cell Signaling). Data were 
generated from at least three independent experiments and presented as mean ± SD. Unpaired one-way ANOVA test was performed 
to measure the significance: *p < 0.05 and ***p < 0.001 (n = 3). The statistical analysis was performed between rfhSP-D and HYA+ 


































































5.4 Discussion  
During the development of breast tumors, tumor cells interact with the surrounding matrix to 
form a tumor microenvironment (TME), thereby supporting the growth, survival, and invasion of 
cancer cells. ECM is an important constituent of the TME, leading to the progression of the 
formation and spread of malignant tumors. ECM is composed of a variety of proteoglycans and 
glycosaminoglycans, helping cell survival, proliferation, invasion, angiogenesis, and immune cell 
infiltration (Heldin et al., 2013, Bernert et al., 2011). HYA, an abundant component of ECM, is 
synthesized as a large linear anionic polymer on the cell surface. The role of HYA in inflammation-
mediated breast cancer has been established (Soria and Ben-Baruch, 2008, Ponting et al., 1992) 
as well as its ability  to modify tumor cell migration and invasion (Li et al., 2007). Compared with 
normal breast epithelial tissue, HYA synthesis and accumulation have been detected in aggressive 
breast cancer cells (Li et al., 2007). Furthermore, cancer cells overexpressing HYA synthase 2 have 
been reported to enhance angiogenesis and stromal cell recruitment, indicating that enhanced 
HYA levels in the tumor stroma support breast carcinoma (Bernert et al., 2011). To understand 
the inherent mechanisms of the pro-tumor effect of an increased HYA expression in breast 
tumors and its consequence on tumor proliferation via its receptors, including CD44, are likely to 
influence future therapeutic strategies. This study involved studying rfhSP-D-HYA interaction and 
its effect on the adhesion and proliferation of BT20, BT474 and SKBR3 breast cancer cells.  
Direct binding ELISA showed that rfhSP-D bound HYA in a dose-dependent manner. The ability of 
breast cancer cells to interact with HYA-bound rfhSP-D was examined by cell adhesion assay. 
Compared with rfhSP-D combined with HYA or HYA alone, a clear cell adhesion binding pattern 
was observed with rfhSP-D alone. This may be due to the interaction of rfhSP-D-treated breast 
cancer cells with apoptotis-related receptors. Apoptosis and proliferation experiments were also 
performed to study the effect of HYA-bound rfhSP-D. Compared with rfhSP-D alone, SKBR3 cells 
seeded on HYA-bound rfhSP-D showed increased cell proliferation (1.7-fold). For BT474 cells 
treated with rfhSP-D, the addition of HYA resulted in a two-fold increase in proliferating cells. 
However, in the presence of rfhSP-D combined with HYA, the percentage of proliferating cells 
was not significantly different from the percentage of HYA alone or untreated SKBR3 and BT474 
cells. Therefore, these findings indicate that the pro-apoptotic effect of rfhSP-D is negated by the 




addition of HYA. However, no significant difference in the proliferation of BT20 cells was seen 
among all the conditions, indicating that these cells continued to grow and were not affected by 
rfhSP-D treatment alone or in combination with HYA. The addition of HYA may also regulate the 
interaction between rfhSP-D-treated cells and pro-apoptotic signaling pathways, thereby limiting 
the possibility of apoptosis induction. Therefore, the addition of HYA can promote cell 
proliferation by interacting with the proliferation signal cascades (e.g. PI3K-Akt and Ras-ERK) 
(Misra et al., 2015). Even though breast cancer tissues express SP-D, the distribution of HYA in 
the breast tumor microenvironment seems to provide a self-protective layer, thereby negating 
the anti-tumor effects of SP-D since rfhSP-D treated BT474 and SKBR3 cells undergo apoptosis, 
and the addition of HYA to rfhSP-D can enhance cell proliferation. Thus, breast cancer cells are 
likely to use HYA in their tumor microenvironment as an escape mechanism from SP-D (rfhSP-D) 
mediated apoptosis induction.  
To further understand the mechanism of rfhSP-D mediated apoptosis, the possible signal 
pathways related to tumor adhesion and proliferation were analyzed. Decreased levels of 
caspase 3 and p53 were detected in HYA + rfhSP-D-treated BT474 and SKBR3 cells, which may 
indicate that cells became resistant to rfhSP-D-mediated apoptosis by the addition of HYA. 
Additionally, down-regulation of p21 and p27 was detected in HYA + rfhSP-D-treated BT474 and 
SKBR3 cells. Although p21 triggering is p53-dependent in certain events (such as DNA damage), 
in some cases the expression of p21 is independent of the state of p53, for example in normal 
tissue development and differentiation (Shamloo and Usluer, 2019, Zilfou and Lowe, 2009). p21 
can lead to tumor evolution for tumor growth by slowing the accumulation of DNA damage. It 
has been suggested that the induction of p21 expression is required to promote tumor cell 
motility and tumorigenesis (Kreis et al., 2019, Shamloo and Usluer, 2019). Due to the controversy 
over the role of p21, because of its cytoplasmic location, it can be considered as an oncoprotein 
and/or tumor suppressor gene. The dual role of p21 as an oncogenic or tumor suppressor protein 
makes it difficult to understand the mechanism of p53–p21-triggered apoptosis induction or 
development of cancer progression (Shamloo and Usluer, 2019, Abbas and Dutta, 2009). 
In conclusion, the participation of rfhSP-D and its related pro-apoptotic properties in cancer 
models may be a new type of therapeutic agent targeting multiple cells signaling pathways, 




including tumor cell survival factors, transcription factors, protein kinases and pro-apoptotic 
gene markers. The mechanism by which rfhSP-D induces apoptosis and inhibits tumor cell 
proliferation is tumor-specific, due to its different effects on cell types and the expression of 
possible putative receptors. The interaction between HYA + rfhSP-D and cell receptors on a wide 
range of cancer, including breast cancer is currently under investigation. Furthermore, it is 
significant to note that full-length SP-D purified from BT474 culture medium was not able to 
trigger apoptosis in any of the three breast cancer cell lines tested in this study. The possible 
reasons could be that the cancer cells could produce a dysfunctional protein owing to protein 
misfolding, altered oligomerization and or mutations. The roles of SP-D in the cancer biology is 
complex and is strongly dependent on the TME composition. SP-D and HYA are overexpressed in 
breast and other cancers. Targeting HYA and SP-D is clinically relevant for the inhibition of HYA-
























Chapter 6  
 

















This thesis provides the evidence that human SP-D has an immune surveillance role against IAV 
infection and breast cancer. Having generated biologically active rfhSP-D, this study considered 
it imperative to examine some of the protective effects of rfhSP-D against different subtypes of 
IAV (pH1N1 and H3N2) (Chapter 3) and phenotypes of breast cancer (BT20, BT474 and SKBR3) 
(Chapter 4 and 5). Previous studies have reported that the direct interaction of IAV with human 
SP-D resulted in virus neutralization and enhanced phagocytosis (Hartshorn et al., 1994, 
Hartshorn et al., 1993). In this study, it was clear the that the ability of rfhSP-D to act as an entry 
inhibitor against IAV infection was not limited to a specific IAV-subtype. The important aspect of 
host–pathogen interaction arising out of chapter 3 is the ability of rfhSP-D to bind HA and M1 IAV 
proteins, thus, suppressing replication in both pH1N1 and H3N2 subtypes. In addition, rfhSP-D-
treated A549 cells infected with pH1N1 and H3N2 subtypes showed downregulation of mRNA 
transcript levels of TNF-α, IFN-α, IFN-β, IL-6, and RANTES, particularly during the initial stage of 
IAV infection. Furthermore, rfhSP-D treatment was found to reduce luciferase reporter activity 
of MDCK cells transfected with H1+N1 pseudotyped lentiviral particles, indicative of an entry 
inhibitory role of rfhSP-D against infectivity of IAV. Following rfhSP-D treatment, a dramatic 
suppression of key pro-inflammatory cytokines and chemokines levels was also evident in IAV 
challenged A549 cells. These data appear to highlight that the extent of immunomodulatory 
effects of SP-D on host cells can differ depending on IAV subtype.  Since full-length human SP-D 
as well as rfhSP-D clearly interact with the IAV glycoproteins, thus acting as an entry inhibitor, it 
would be worth examining the possible amino acid residues involved in rfhSP-D- HA/NA binding. 
This can be performed by in silico docking analysis and confirmed using site-directed 
mutagenesis.    
Chapter 4 reveals that rfhSP-D can interfere with breast cancer cell lines with the exception of 
the triple-negative (ER-/PR-/HER2-); triple-positive (ER+/PR+/HER2+) and HER2+ overexpressing 
breast cancer cell lines are susceptible to rfhSP-D induced apoptosis although rfhSP-D bound 
triple negative- BT20, triple-positive BT474 and HER2+-positive SKBR3 breast cancer cell lines 
equally well. Upregulation of cell cycle inhibitors (p21/p27) and p53 phosphorylation (Ser15) was 
also evident in rfhSP-D-treated BT474 and SKBR3 cell lines, which signified cell cycle arrest at 
G2/M checkpoints. Exogenous rfhSP-D treatment also caused cleavage of caspase 9 and 3 in triple 




positive and HER2+-overexpressing breast cancer cell lines, highlighting the involvement of 
intrinsic apoptosis pathway. Additionally, interaction between SP-D and HYA, abundant 
component of the ECM, which plays a crucial role in inflammation, angiogenesis, and cancer 
progression has been reported (Chapter 5). Interaction of breast cancer cells with HYA can sustain 
growth and promote malignant progression of tumour cells. rfhSP-D bound to HYA in a calcium 
and dose-dependent manner and a greater cell adhesion binding pattern was seen with rfhSP-D 
alone compared to HYA alone or HYA-bound-rfhSP-D treated breast cancer cells. HYA-bound-
rfhSP-D-treated SKBR3 and BT474 cells showed an increased cell proliferation, when compared 
to rfhSP-D alone treated SKBR3/BT474 cells. Therefore, these findings indicate that pro-apoptotic 
activity of rfhSP-D are modulated by HYA -in rfhSP-D treated triple positive and HER2+-
overexpressing breast cancer cell lines. However, following rfhSP-D treatment, the cell 
proliferation was not affected in triple negative cell line among all the conditions, suggestive of 
continuous growth of these cells. Expression of human SP-D was also evident in breast cancer 
tissues with varying phenotypes and HYA distribution within the breast tumour 
microenvironment appears to provide a self-protective coat, thus, modulating the anti-
tumorigenic effects of SP-D.  
Since triple positive and HER2+-overexpressing breast cancer cell lines, treated with rfhSP-D 
undergo apoptosis, and HYA addition to rfhSP-D enhances cell proliferation, this suggest that 
breast cancer cells can use HYA as an escape mechanism from rfhSP-D-triggered apoptosis 
induction. Transfecting BT2O cell line with WT HER2+ plasmid to examine if HER2+ WT transfected 
BT20 cell line undergo apoptosis induction by rfhSP-D will be one way to prove that rfhSP-D 
susceptibility is due to HER2 expression on BT474 and SKBR3 cells; a lack of it seems to increase 
BT20 cells resistant to rfhSP-D effect. If HER2 is implicated in mediating rfhSP-D induced 
apoptosis, examining the molecular mechanism of downstream signaling pathways including 
MAPK and/or PI3K/AKT/mTOR pathways will be crucial to validate the hypothesis. Furthermore, 
RNA-sequencing will be an ideal method to investigate other pathways implicated in the 
treatment of breast cancer with rfhSP-D. The data generated from RNA-sequencing should be 
validated by qRT-PCR and western blotting, and generation of cellular knockout models for the 
implicated pathways. Furthermore, using rfhSP-D combined with commercially available anti-




breast cancer drug such as trastuzumab (Herceptin™) would also be a logical way to study if 
rfhSP-D can act as an adjuvant therapy in murine models.  
Although, these in vitro studies in this thesis provided the first evidence of anti-tumour properties 
of rfhSP-D against breast cancer cell lines, respectively, further validation in vivo (i.e. using animal 
models) will be the next logical step. Studies have involved several animal models of breast 
cancer to study the molecular mechanisms involved in the development of breast tumorigenesis 
in vivo. Given the genetic complexity that is associated with the progression of each breast cancer 
subtypes, mouse models have become a potent tool for cancer research, and those can be 
subclassified into xenograft models, chemically, virally, or ionizing radiation (IR)-triggered models 
and genetically engineered mice (GEMs) including  transgenics and knockouts (Hanahan et al., 
2007, Wagner, 2004). The use of xenograft models is primarily based on the transplantation of 
human breast cancer cell lines into immunocompromised mice. Cancer cells in the xenograft 
models show the development of tumor growth, but do not metastasize (Zhang et al., 2013a) as 
is the case for luminal B (BT474) and triple negative (MDA-MB-231/ MDA-MB-435) (Goetz et al., 
2017, Dai et al., 2017) cell lines. Furthermore, luminal A (MCF7 and T47D) and triple negative 
(MDA-MB-231, MDA-MB-435, and SUM1315) cell lines have been used to create breast cancer 
models of spontaneous metastasis through orthotopic injection (Iorns et al., 2012, Holliday and 
Speirs, 2011). Thus, the use of metastatic cell-derived xenografts (CDX) transplantation models 
in which breast cancer cells (MDA-MB-231 and SUM149) are injected into the tail vein of mouse 
are suitable for observing experimental metastasis and invasion (Gomez-Cuadrado et al., 2017). 
Experiments to examine the effect of rfhSP-D in xenografts models would initially require 
estimation of the lethal dose (LD50), effective dose (ED50) and the half-life of rfhSP-D. These 
results would help determine the means of administration for rfhSP-D in murine models. Taken 
together, the use of xenografts models will be useful for studying tumor development, as well as 
validating the tumor markers, and signaling pathways involved. This can aid in the evaluation of 
anti-cancer drug development involving rfhSP-D for breast cancer.  
Therapeutic approaches targeting HYA synthesis, or HYA-receptor interaction would be a crucial 
measure for cancer treatment. Inhibition of HYA synthesis in breast cancer cells by 4-MU 
suppresses proliferation and migration in vitro and metastatic lesions of bone in vivo (Nagy et al., 




2015, Bohrer et al., 2014, Saito et al., 2013, Urakawa et al., 2012). Furthermore, the use of 4-MU 
treatment has also been shown to inhibit intracellular and cell surface HYA (Urakawa et al., 2012) 
and suppress Akt phosphorylation (Urakawa et al., 2012). In addition, bacteriophage 
hyaluronidase can prevent growth, migration, and invasion of breast cancer cells (Lee et al., 
2010). The use of recombinant human hyaluronidase (rHUPH20) has been reported to improve 
the outcome of drug delivery of antibody-based trastuzumab targeted therapy in HER2+ 
overexpressing breast cancer (Shpilberg and Jackisch, 2013). Other studies also suggest that 
degradation of HYA using by pegvor-hyaluronidase (PVHA) can remodel the TME in a murine 
model of breast cancer, thus, increasing the uptake of anti-Programmed Death-Ligand 1 (PD-L1) 
therapeutic antibody (Clift et al., 2019). PVHA treatment demonstrated a dramatic effectiveness 
of anti-PD-L1 antibody in reducing the breast tumor growth (Clift et al., 2019). Such pre-
treatments against HYA can enhance the follow-up treatment with rfhSP-D in murine models.  
Time is ripe for taking the knowledge about the involvement of rfhSP-D and its associated anti-
viral or anti-tumour effects forward to the development as a novel therapeutic approach to 
target multiple cellular signaling pathways. The mechanisms which enable rfhSP-D to trigger anti-
viral effect or apoptosis induction/inhibition of tumor cell proliferation are viral/tumor specific 
due to the differential effects and variation on the cell types and presence of putative receptors. 
Our preliminary data shows that rfhSP-D binds CD44 as well; CD44 is identified as a receptor for 
HYA, and CD44 signaling plays a critical role in breast cancer cell survival and proliferation. 
Investigating how rfhSP-D and HYA interaction affects the CD44 downstream signaling pathways 
will be the next logical step. There is a clear therapeutic potential of rfhSP-D against IAV 
strains/cancer where increased glycosylation leads to evasion of antibody susceptibility but 
increased susceptibility against soluble pattern recognition receptors (PRRs) such as SP-D. As a 
HA and NA-based inhibitor against IAV infection, rfhSP-D may be a viable therapeutic agent that 
may be administered as an inhalation formulation to control IAV infection.  Having established 
the specific nature of interactions between rfhSP-D and IAV/breast cancer, we can hope to 
examine in future host response in the murine models of infection/cancer using wild type, and 
SP-D knock-out mice.
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Complement protein C1q is the first recognition subcomponent of the complement 
classical pathway that plays a vital role in the clearance of immune complexes, 
pathogens, and apoptotic cells. C1q also has a homeostatic role involving immune 
and non-immune cells; these functions not necessarily involve complement activation. 
Recently, C1q has been shown to be expressed locally in the microenvironment 
of a range of human malignant tumors, where it can promote cancer cell adhesion, 
migration, and proliferation, without involving complement activation. C1q has been 
shown to be present in the ascitic fluid formed during ovarian cancers. In this study, 
we have examined the effects of human C1q and its globular domain on an ovarian 
cancer cell line, SKOV3. We show that C1q and the recombinant globular head modules 
induce apoptosis in SKOV3 cells in a time-dependent manner. C1q expression was 
not detectable in the SKOV3 cells. Exogenous treatment with C1q and globular head 
modules at the concentration of 10 µg/ml induced apoptosis in approximately 55% cells, 
as revealed by immunofluorescence microscopy and FACS. The qPCR and caspase 
analysis suggested that C1q and globular head modules activated tumor necrosis factor 
(TNF)-α and upregulated Fas. The genes of mammalian target of rapamycin (mTOR), 
RICTOR, and RAPTOR survival pathways, which are often overexpressed in majority 
of the cancers, were significantly downregulated within few hours of the treatment of 
SKOV3 cells with C1q and globular head modules. In conclusion, C1q, via its globular 
domain, induced apoptosis in an ovarian cancer cell line SKOV3 via TNF-α induced 
apoptosis pathway involving upregulation of Bax and Fas. This study highlights a 
potentially protective role of C1q in certain cancers.
Keywords: complement, c1q, ovarian cancer, apoptosis, TnF, mTOr
inTrODUcTiOn
C1q is the first subcomponent of the C1 complex that recognizes the IgG- or IgM-containing 
immune complexes and initiates the complement classical pathway. It can bind to various self- and 
non-self ligands and bring about a range of homeostatic functions including clearance of pathogens 
and apoptotic cells (1). Human C1q molecule is composed of 18 polypeptide chains (6A, 6B, and 6C). 
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Each C1q chain has a short N-terminal region, a triple-helical 
collagen region, and a C-terminal globular (gC1q) domain (1, 2). 
Recently, a wide range of immunomodulatory functions of C1q 
have become evident that are independent of its involvement in 
the complement activation (3, 4); these include modulation of 
dendritic cell functions (5), cancer progression (6), and neuronal 
synapse pruning (7).
Ovarian cancer is the sixth most frequently diagnosed cancer 
among women worldwide and has the highest mortality rate 
than any other female reproductive system-associated cancer. 
Approximately 70% of the ovarian cancers are diagnosed at an 
advanced stage III or IV, with nearly 85% expected mortality 
(8). The intraperitoneally ascitic fluid (AF) formed during ovar-
ian cancer has been shown to have high levels of complement 
components such as C3a and soluble C5b–9, which form the 
membrane attack complex, suggesting potential for the activation 
of complement in vivo. However, complement activation appears 
to be dampened due to the expression of membrane regulators 
such as CD46, CD55, and CD59 on the ovarian cancer cells, ren-
dering complement system as an inefficient immune surveillance 
mechanism. The malignant ovarian tumor cells isolated from AF 
have been shown to have C1q and C2 deposited on the surface, 
which were rendered susceptible to complement-mediated kill-
ing by AF in the presence of anti-CD59-neutralizing antibody 
(9). In a recent study, the presence of C1q has been shown in 
the stroma and vascular endothelium of a number of human 
malignant tumors, including lung adenocarcinoma, melanoma, 
colon adenocarcinoma, breast adenocarcinoma, and pancreatic 
carcinoma (6). This has raised a tumor growth-fostering role for 
locally synthesized C1q via promotion of adhesion, migration, 
and proliferation.
The importance of complement in cancer immunotherapy 
has acquired great interest recently. A broad array of cell surface 
tumor-associated antigens that are overexpressed, mutated, or 
partially expressed, as compared to normal tissues, have offered 
various antibody targets in different cancers (10). A number of 
these anti-cancer antibodies work via receptor or checkpoint 
blockade or as an agonist, apoptosis induction, immune-medi-
ated cytotoxicity either via complement or antibody, and T cell 
function regulation. In addition, therapeutic antibodies targeting 
growth factors and their receptors such as epidermal growth fac-
tor receptor, insulin-like growth factor 1 receptor, tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand receptors, and 
receptor activator nuclear factor-κB ligand (RANKL) have also 
been exploited for cancer treatment (11).
In this study, we sought to investigate the complement-
independent effects of exogenous C1q and recombinant forms 
of globular head modules on an ovarian cancer cell line, SKOV3.
MaTerials anD MeThODs
cell culture and Treatments
A human ovarian clear cell adenocarcinoma cell line, SKOV3 
(ATCC, Rockville, MD, USA) was used as an in vitro model for 
epithelial ovarian cancer. Cells were cultured in DMEM-F12 
media containing 10% v/v fetal calf serum, 2mM l-glutamine, 
and penicillin (100  U/ml)/streptomycin (100  µg/ml) (Thermo 
Fisher). Cells were grown at 37°C under 5% v/v CO2 until 80–90% 
confluency was reached.
Purification of human c1q
Human C1q was purified as published earlier (12). Briefly, freshly 
thawed human plasma was made 5  mM EDTA, centrifuged at 
5,000 × g for 10 min, and any aggregated lipids were removed 
using Whatmann filter paper (GE Healthcare, UK). The plasma 
was then incubated with non-immune IgG-Sepharose (GE 
Healthcare, UK) for 2 h at room temperature. C1q bound IgG-
Sepharose was washed extensively with 10 mM HEPES, 140 mM 
NaCl, 0.5 mM EDTA, and pH 7.0 before eluting C1q with CAPS 
(N-cyclohexyl-3-aminopropanesulfonic acid) buffer (100  mM 
CAPS, 1 M NaCl, 0.5 mM EDTA, pH 11). The eluted C1q frac-
tions were then passed through a HiTrap Protein G column 
(GE Healthcare, UK) to remove IgG contaminants, followed by 
dialysis against 0.1 M HEPES buffer, pH 7.5.
recombinant expression and 
Purification of gha, ghB, and ghc 
Modules of human c1q
The recombinant forms of the globular head regions of human 
C1q A (ghA), B (ghB), and C (ghC) chains were expressed 
as fusions to Escherichia coli maltose-binding protein (MBP) 
and purified, as reported previously (13). Expression constructs 
pKBM-A, pKBM-B, and pKBM-C were transformed into E. coli 
BL21 (Invitrogen) cells in the presence of ampicillin (100 µg/ml). 
The primary bacterial culture was grown overnight by inoculat-
ing a single colony in 25 ml of Luria-Bertani medium contain-
ing ampicillin. The bacterial culture was then grown in a 1  L 
batch until OD600 0.6 and then induced with 0.4 mM isopropyl 
β-d-thiogalactoside (IPTG) (Sigma-Aldrich, UK) for 3  h at 
37°C on a shaker and centrifuged (5,000  ×  g, 4°C, 15  min). 
Subsequently, the cell pellet for each fusion protein was lysed 
in 50 ml lysis buffer (20  mM Tris–HCl, pH 8.0, 0.5  M NaCl, 
0.2% v/v Tween 20, 1  mM EGTA pH 7.5, 1  mM EDTA pH 
7.5, and 5% v/v glycerol) containing lysozyme (100  µg/ml, 
Sigma-Aldrich, UK) and 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF; Sigma-Aldrich, UK) at 4°C for 30 min. The resultant cell 
suspension was sonicated at 60 Hz for 30 s with an interval of 
2 min each (12 cycles) and centrifuged (16,000 × g for 30 min). 
The supernatant was diluted 5-fold with buffer I (20 mM Tris–
HCl, pH 8.0, 100 mM NaCl, 0.2% v/v Tween 20, 1 mM EDTA 
pH  7.5, and 5% v/v glycerol) and passed through an amylose 
resin column (50  ml; New England Biolabs). The column was 
then washed extensively with buffer I (150  ml), followed by 
buffer II (250  ml of buffer I without Tween 20) before eluting 
1 ml fractions of fusion proteins with 100 ml buffer II containing 
10  mM maltose. The peak fractions were then passed through 
Pierce™ High Capacity Endotoxin Removal Resin (Qiagen) 
to remove lipopolysaccharide. Endotoxin levels in the purified 
protein samples were analyzed using the QCL-1000 Limulus 
amebocyte lysate system (Lonza). The assay was linear over a 
range of 0.1–1.0 EU/ml (10 EU =  1 ng of endotoxin), and the 
amount of endotoxin levels was <4  pg/μg of the recombinant 
proteins.
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Fluorescence Microscopy
SKOV3 cells (0.5 × 105) were grown on coverslips and incubated 
with human C1q, ghA, ghB, or ghC (10 µg/ml) in a serum-free 
DMEM-F12 medium for 1 h for analyzing cell binding, 24 h for 
apoptosis induction, and 15 h for mammalian target of rapamycin 
(mTOR) activation analysis. For binding analysis, the coverslips 
were washed three times with PBS and then incubated with rabbit 
anti-human C1q polyclonal antibody (MRC Immunochemistry 
Unit, Oxford, 1:200) for C1q and rabbit anti-MBP polyclonal 
antibody (Thermo Fisher) for MBP fusions of the globular head 
modules. Coverslips were washed three times with PBS, and 
then incubated with Alexa Fluor® 488 (1:500, Thermo Fisher) 
and Hoechst (1:10,000, Thermo Fisher) for immunofluorescence 
analysis. Apoptosis was analyzed via immunofluorescence using 
a FITC-Annexin V apoptosis detection kit with propidium 
iodide (PI) (Biolegend). After 24 h incubation with proteins, the 
coverslips were then incubated with Annexin V-binding buffer 
containing FITC Annexin V (1:200) and PI (1:200) for 15 min 
and washed twice with PBS before mounting on the slides to 
visualize under a HF14 Leica DM4000 microscope. For mTOR 
analysis, following the 15-h incubation with proteins, the cov-
erslips were washed three times with PBS. The cells were fixed 
and permeabilized using ice-cold 100% methanol at −20°C for 
10  min, followed by 1  h incubation with rabbit anti-human 
mTOR (1:500, Sigma), and then 1 h incubation with Alexa Fluor® 
488 (rabbit anti-human 1:500, Thermo Fisher) and Hoechst 
(1:10,000, Thermo Fisher) for immunofluorescence analysis. In 
order to detect caspase 3 activation, the protein-treated SKOV3 
cells were fixed and permeabilized using ice-cold 100% methanol 
at −20°C for 10 min, followed by 1 h incubation with rabbit anti-
human cleaved caspase 3 (1:500, Cell Signaling), and then 1 h 
incubation with secondary antibody (anti-rabbit) probed with 
CY3 (1:500, Thermo Fisher) and Hoechst (1:10,000, Thermo 
Fisher) for immunofluorescence analysis.
Dye exclusion assay
SKOV3 cells (0.1 × 106) were grown in a 12-well plate and incu-
bated with C1q, ghA, ghB, ghC, or MBP (10 µg/ml) along with an 
untreated control in serum-free DMEM-F12 for 24 h. Cells were 
detached using 5 mM EDTA, pH 8.0 and centrifuged at 1,200 × g 
for 5 min. The cell pellet was re-suspended in 1 ml DMEM-F12, 
and 10  µl of cell suspension was stained with 10  µl of Trypan 
blue (60%; Sigma-Aldrich, UK) for cell counting using hemocy-
tometer. The viable cells, i.e., unstained cells, were counted in 5 
different optical fields with a threshold value of 200 cells per field.
MTT assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (Thermo Fisher) assay was performed by incubating 
SKOV3 cells (0.1 × 105) in a 96-well microtiter plate with C1q, 
ghA, ghB, ghC, or MBP (10 µg/ml each) and an untreated control 
in serum-free DMEM-F12 medium for 24 h, followed by incuba-
tion with 50 µg/µl MTT (5 mg/ml stock) per well for 4 h at 37°C. 
Majority of the media was removed leaving behind 25 µl per well, 
which was mixed thoroughly with 50  µl of dimethyl sulfoxide 
(DMSO) and incubated for another 10 min at 37°C. The absorb-
ance was read at 570 nm using a plate reader.
Flow cytometry
SKOV3 cells (0.1 × 107) were incubated with C1q, ghA, ghB, or 
ghC (10  µg/ml), along with an untreated control, in a six-well 
plate for 24 h, followed by cell detachment using 5 mM EDTA 
and centrifugation at 1,200  ×  g for 5  min. FITC Annexin V 
apoptosis detection kit with PI (Biolegend) was used, as per the 
manufacturer’s instructions. Compensation parameters were 
acquired using unstained, untreated FITC stained, and untreated 
PI stained SKOV3 cells. SKOV3 cells (0.1 × 104) were acquired for 
each experiment and compensated before plotting the acquired 
data. For protein-binding analysis, SKOV3 cells (0.5  ×  106) 
were incubated with C1q, ghA, ghB, and ghC (10  µg/ml) and 
BSA-treated cells as a negative control. Cells were incubated at 
4°C for 1 h, followed by 1 h incubation with rabbit anti-human 
C1q polyclonal antibody (1:200) for C1q and rabbit anti-MBP 
(Thermo Fisher, 1:200) for globular head modules treated cells 
as well as their respective BSA-treated controls. The cells were 
then incubated with Alexa Fluor® 488 (1:1,000, Thermo Fisher) 
for 1 h and cells were washed with PBS three times between each 
step. Compensation parameters were acquired using unstained, 
untreated Alexa Fluor® 488-stained SKOV3 cells. SKOV3 cells 
(0.1 × 104) were acquired using Novocyte Flow Cytometer for each 
experiment and compensated before plotting the acquired data.
Western Blot
SKOV3 cells (0.1 ×  107) were plated in a six-well plate (Nunc) 
and incubated with C1q, ghA, ghB, or ghC (10 µg/ml), along with 
an untreated control in serum-free DMEM-F12 medium for 12 
and 24 h. The cells were lysed within the wells using lysis buffer 
(50 mM Tris–HCL, pH 7.5, 10% v/v glycerol, and 150 mM NaCl) 
over ice for 10 min, before being gently transferred to a pre-cooled 
microcentrifuge tube, and centrifuged for 15 min at 13,000 × g at 
4°C. The cell lysate was mixed with the treatment buffer (50 mM 
Tris pH 6.8, 2% β-merceptoethanol, 2% SDS, 0.1% bromophenol 
blue, and 10% glycerol) in order to run on SDS-PAGE (12% w/v) 
for 90 min at 120 V. The SDS-PAGE separated proteins were then 
electrophoretically transferred onto a nitrocellulose membrane 
(Sigma) using transfer buffer (25 mM Tris, 190 mM glycine, and 
20% methanol, pH 8.3) for 2 h at 320 mA, followed by blocking 
with 5% w/v dried milk powder (Sigma) in 100-ml PBS at room 
temperature for 2  h on a rotatory shaker. The membrane was 
washed with PBST (PBS + 0.05% Tween 20) three times, 10 min 
each, and incubated with primary anti-human C1q (polyclonal 
antibody), anti-caspase 9, anti-caspase 3, or anti-cleaved caspase 
3 antibodies (1:1000 Cell Signaling Technology) at 4°C overnight. 
The membrane was washed with PBST (three times, 10 min each) 
before incubating with secondary anti-rabbit IgG HRP-conjugate 
(1:1,000; Promega) for 1 h at room temperature. The bands were 
visualized using enhanced chemiluminescence (Thermo Fisher) 
in the Biorad ChemiDoc MP imaging system, or using 3,3-diam-
inobenzidine (DAB) substrate kit (Thermo Fisher).
Quantitative rT-Pcr
SKOV3 cells (0.5  ×  106) were incubated with C1q, ghA, ghB, 
or ghC (10 µg/ml) for various time points, and the centrifuged 
cell pellets were stored at −80°C. GenElute Mammalian Total 
RNA Purification Kit (Sigma-Aldrich, UK) was used, as per 
TaBle 1 | Target genes and terminal primers used in the qPcr analysis.




Mammalian target of rapamycin (mTOR) 5′-TGCCAACTATCTTCGGAACC-3′ 5′-GCTCGCTTCACCTCAAATTC-3′
RICTOR 5′-GGAAGCCTGTTGATGGTGAT-3′ 5′-GGCAGCCTGTTTTATGGTGT-3′
RAPTOR 5′-ACTGATGGAGTCCGAAATGC-3′ 5′-TCATCCGATCCTTCATCCTC-3′
Tumor necrosis factor (TNF)-α 5′-GTATCGCCAGGAATTGTTGC-3′ 5′-AGCCCATGTTGTAGCAAACC-3′
NF-κB 5′-TGAGGTACAGGCCCTCTGAT-3′ 5′-GTATTTCAACCACAGATGGCACT-3′
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the manufacturer’s instructions, to extract total RNA, followed 
by treatment with DNase I (Sigma-Aldrich, UK) to remove any 
DNA contaminants. The concentration and purity of total RNA 
were determined by measuring the absorbance at 260  nm and 
260:280  nm ratio, respectively, using NanoDrop 2000/2000c 
(Thermo Fisher Scientific). Total RNA (2 µg) was used to syn-
thesize cDNA using High Capacity RNA to cDNA Kit (Applied 
Biosystems).
Forward and reverse primer sequences (Table  1) were 
designed using the web-based Basic Local Alignment Search Tool 
and Primer-BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The 
qPCR reactions were performed to measure the mRNA expres-
sion level of various target genes. Each reaction was conducted in 
triplicates and consisted of 5 µl Power SYBR Green MasterMix 
(Applied Biosystems), 75 nM of forward and reverse primers, and 
500 ng cDNA, making up to a 10 µl final volume per well. Relative 
mRNA expression was determined by qPCR using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Samples were 
initially incubated at 50°C and 95°C for 2 and 10 min, respectively, 
followed by amplification of the template for 40 cycles (each cycle 
involved 15 s at 95°C and 1 min at 60°C). The gene expression 
was normalized using the expression of human 18S rRNA as an 
endogenous control. The cycle threshold (Ct) mean value for each 
target gene was used to calculate the relative expression using 
the relative quantification (RQ) value and formula: RQ = 2−ΔΔCt, 
which was compared with the relative expression of 18S.
statistical analysis
GraphPad Prism 6.0 was used to make graphs, and the statistical 
analysis was carried out using an unpaired one-way ANOVA 
test. Significant values were considered based on *p  <  0.05, 
*p  <  0.01, and ***p  <  0.001 between treated and untreated 
conditions. Error bars show the SD or SEM, as indicated in the 
figure legends.
resUlTs
human c1q and recombinant globular 
head Modules Bind sKOV3
The qualitative binding analysis of C1q and recombinant form of 
individual globular head (ghA, ghB, and ghC) modules (10 µg/ml) 
to SKOV3 cells using immunofluorescence microscopy revealed 
the membrane localization of these proteins following 1 h incu-
bation at 4°C (Figure  1A). The nucleus, stained with Hoechst, 
showed a blue fluorescence (Figure  1A, panel A). The bound 
proteins localized on the cell membrane via green fluorescence; 
all the four proteins showed similar binding pattern (Figure 1A, 
panels B and D). FACS analysis revealed similar binding pattern, 
consistent with the observations made under the immunofluo-
rescence microscopy. SKOV3 cells, treated with C1q and globular 
head modules, were over 90% positive in the FITC positive 
quadrant, as compared to the control protein, BSA (Figure 1B).
c1q and recombinant globular head 
Modules reduce cellular Viability via 
induction of apoptosis in sKOV3 cells
C1q and globular head modules (at 10 µg/ml concentration) were 
incubated with SKOV3 cells for 24 h. Trypan blue dye exclusion 
(Figure 2A) revealed a significant decrease in the cell viability fol-
lowing incubation with C1q (~50%), ghA (~50%), ghB (~40%), 
and ghC (~55%). MTT assay also confirmed the above mentioned 
observations (Figure 2B). Furthermore, the qualitative apoptosis 
analysis was performed using immunofluorescence microscopy. 
A significant proportion of SKOV3 cells, when treated with C1q 
proteins (10 µg/ml) for 24 h, stained positive for cell membrane 
integrity marker, Annexin V (conjugated to FITC), which binds 
to phosphatidylserine (PS) of the membrane of cells undergoing 
apoptosis (Figure  3, panel B). The nucleus was stained using 
Hoechst, which showed blue fluorescence (Figure 3, panel A). No 
FITC fluorescence was detected in the untreated cells, suggesting 
that the integrity of the cell membrane was intact, and hence, the 
cells were still viable (Figure 3).
FACS analysis revealed that the treatment of SKOV3 cells 
with C1q (10 µg/ml) for 24 h yielded approximately 58% (C1q, 
quadrant Q2-2; Figure 4) cells positive for both FITC (Annexin V 
marker) and PI (stains DNA) quadrant, significantly higher than 
1.42% untreated control cells (UT, quadrant Q2-2; Figure  4), 
which represented a cell population undergoing late apoptosis. 
In addition, 16% of cells stained positive for FITC only (C1q, 
quadrant Q2-4; Figure 4), which represented an early apoptotic 
cell population.
Similar trends were also observed when SKOV3 cells were 
treated with ghA, ghB, and ghC; approximately 50% (ghA and 
ghC) and 40% (ghB) of cells had undergone apoptosis after 
24 h treatment as seen in quadrant Q2-2 (ghA, ghB, and ghC in 
Figure 4). Approximately, 15–20% of early apoptotic cells stained 
positive for FITC alone (quadrant Q2-4; Figure  4) following 
treatment with each globular head module. In the untreated cells, 
approximately 90% of the cell population was both FITC and PI 
negative (UT, quadrant Q2-3; Figure 4). A shift in the florescence 
FigUre 1 | (a) Binding of human C1q and recombinant globular head modules, ghA, ghB, and ghC (10 µg/ml; 1 h incubation) to SKOV3 cells using 
immunofluorescence microscopy. Panel A shows the nucleus of the cells stained with Hoechst. Panel B shows the cells probed with anti-C1q (C1q) and anti-
maltose-binding protein (MBP) (globular heads) polyclonal antibodies, followed by anti-rabbit IgG labeled with FITC; the bound proteins are visible on the cell 
membrane (panels C and D). (B) Flow cytometric analysis to show binding of human C1q and ghA, ghB, and ghC (10 µg/ml) to SKOV3 cells after 1 h incubation. 
Panel a shows the number of cells probed with anti-C1q (C1q) and anti-MBP (globular heads) antibodies followed by anti-rabbit IgG labeled with FITC, as compared 
to the untreated cells. Panel b shows the shift in the fluorescent intensity from untreated to treated cells.
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FigUre 3 | analysis of apoptosis using immunofluorescence 
microscopy in sKOV3 cells treated with human c1q, gha, ghB, and 
ghc (10 µg/ml) and an untreated control after 24 h. Panel A shows the 
nucleus stained with Hoechst. Panel B shows the cell membrane integrity 
marker FITC Annexin V, which binds to PS of the cell membrane of cells 
undergoing apoptosis. No FITC was detected in the untreated SKOV3 cells.
FigUre 2 | sKOV3 cell viability assay via Trypan blue exclusion (a) 
and MTT (B) following treatment with human c1q, gha, ghB, ghc, and 
maltose-binding protein (MBP) (10 μg/ml)and untreated control for 
24 h (±seM, of three independent experiments). Cell numbers were 
reduced by approximately 50% in the treated as compared to untreated and 
MBP controls. Significance was established using the unpaired one-way 
ANOVA test (*p < 0.05, *p < 0.01, and ***p < 0.001) (n = 6).
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intensity in the treated SKOV3 cells, as compared to the untreated 
cells, further confirmed these observations (Figure 4).
c1q and individual globular head Modules 
Upregulate TnF-α Transcripts by sKOV3 
cells with concomitant Upregulation of 
nF-κB
The mRNA expression level of pro-inflammatory cytokine, 
TNF-α, was significantly upregulated at 12 h following C1q (log10 
1.2-fold) and globular head modules; ghA (log10 0.4-fold), ghB 
(log10 1-fold), and ghC (log10 0.7-fold) treatment in comparison 
to an untreated control, as determined by qPCR (Figure  5A). 
NF-κB was also significantly upregulated (log10 0.7-fold) at 12 h, 
as anticipated, consistent with TNF-α upregulation (Figure 5B). 
Both TNF-α (not shown) and NF-κB mRNA expressions were 
downregulated by 24 h (Figure 5C), which could be attributed 
to the late apoptosis stage. In addition, TNF-α transcriptional 
upregulation occurred at an earlier time point for ghA, i.e., at 6 h 
as compared to the other treated samples (data not shown). These 
results prompted us to further investigate the mRNA expression 
of pro-apoptotic makers of intrinsic (Bax) and extrinsic (Fas) 
apoptosis pathways.
c1q Upregulates expression of Pro-
apoptotic Bax and Fas in sKOV3 cells
C1q- and globular head module-mediated apoptosis was further 
investigated by analyzing the expression of pro-apoptotic genes, 
Bax and Fas, via qPCR. Fas was transcriptionally upregulated in 
the C1q (log10 0.4-fold) treated SKOV3 cells, most significantly 
at 12 and 24 h relative to the untreated control cells (Figure 6A). 
The globular head module-treated cells showed minimal mRNA 
expression levels at 12 h (data not shown) and significant upreg-
ulation of Fas at 24 h (log10 0.4-fold) (Figure 6B). Similar trend 
of minimal mRNA expression at 12 h (data not shown) and sig-
nificant upregulation at 24 h (Figure 6C) were observed for Bax 
mRNA expression in case of ghA, ghB, or ghC. The activation 
of apoptotic pathway causes the loss of cell membrane integrity, 
which was previously observed in the immunofluorescence 
FigUre 4 | The quantitative analysis of apoptosis using Facs. SKOV3 cells, treated with C1q and globular head modules for 24 h, yielded approximately 50% 
(C1q, ghA, ghB, and ghC quadrant Q2-2) cells positive for both FITC and PI, significantly higher than 1.42% untreated control cells (untreated, quadrant Q2-2). 
Approximately 20% cells stained positive for FITC only (C1q, ghA, ghB, and ghC quadrant Q2-4).
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microscopy at 24 h, consistent with the upregulation of mRNA 
expression of these genes. To further validate these results, the 
activation of Caspase 3 was investigated via western blot.
c1q and the globular head Modules 
activate caspase 3 in sKOV3 cells
Apoptotic markers, caspase 3 and cleaved caspase 3, were detected 
in the SKOV3 cells, treated with C1q and globular head modules, 
in comparison with the untreated cells. The cleaved caspase 3 was 
detected at 17 kDa after 24 h of C1q, ghA, and ghB treatment in 
the western blot (Figure 7B). A reduction in the abundance of the 
full length at 32 kDa was seen after 24 h in comparison to 12 h 
(Figure 7A) β-actin (45 kDa) was used as a loading control for 
12 h and 24 h (Figure 7C). In addition, the activation of caspase 
3 was also seen by immunofluorescence in parallel to apoptosis 
staining for Annexin V-FITC at 24 h following treatment with 
C1q or globular head modules. Activated caspase 3 was clearly 
visible in the cytoplasm probed with Cy3, suggesting that the 
SKOV3 cells were in the early stages of apoptosis as the membrane 
was stained positively for Annexin V-FITC, in comparison to the 
control where no staining was detected (Figure 7D). The cleaved 
caspase 3 in the ghC treatment sample could not be detected 
via western blot; however, activated caspase 3 was detected via 
immunofluorescence.
c1q, gha, ghB, and ghc Downregulate 
Prosurvival Factors such as ricTOr, 
mTOr, and raPTOr
In addition to the apoptosis markers, we also investigated the 
expression of mTOR signaling pathways since it is frequently 
detected in ovarian cancers (14). The mRNA expressions of 
mTOR, RICTOR, and RAPTOR (Figure 8A) were significantly 
downregulated (~log10 0.5-fold) at 6  h, thereby suggesting that 
the effects of C1q and globular head modules can compromise 
mTOR signaling within the first few hours of the treatment. 
Additionally, the presence of mTOR was detected abundantly in 
the cytoplasm (green) of the untreated cells, compared to SKOV3 
cells treated with C1q and globular heads at 15 h time point via 
immunofluorescence microscopy (Figure 8B).
DiscUssiOn
We report here, for the first time, that exogenous treatment with 
human C1q and recombinant globular head modules ghA, ghB, 
FigUre 6 | relative quantification comparisons of Fas (a) and Bax 
(B,c) mrna expression in sKOV3 cells treated with c1q, gha, ghB, 
and ghc (10 µg/ml). Fas expression was upregulated (~log10 0.5-fold) at 
12 h (C1q only) and 24 h (both for C1q and globular head modules). Bax 
expression was upregulated (~log10 0.5-fold) at 24 h. Significance was 
determined using the unpaired one-way ANOVA test (*p < 0.05, *p < 0.01, 
and ***p < 0.001) (n = 3).
FigUre 5 | relative quantification comparisons of TnF-α (a) and 
nF-κB (B,c) mrna expression in sKOV3 cells treated with c1q, gha, 
ghB, and ghc. The transcriptional expressions of both TNF-α and NF-κB 
were upregulated (log10 0.5- to 1-fold) after 12 h treatment and NF-κB at 24 h 
was downregulated. Significance was ascertained using the unpaired 
one-way ANOVA test (*p < 0.05, *p < 0.01, and ***p < 0.001) (n = 3).
8
Kaur et al. C1q and Ovarian Cancer
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 599
and ghC caused apoptosis in an ovarian cancer cell line, SKOV3. 
This was evident from a significant increase in the number of 
Annexin V-positive cells that were examined via immunofluores-
cence microscopy and FACS, presence of cleaved caspase 9 (data 
not shown) and 3 via western blot, and transcriptional upregula-
tion of pro-apoptotic markers, such as TNF-α, Bax, and Fas as 
illustrated in Figure 9. Based on these observations, it appears 
likely that C1q and individual globular head modules can induce 
apoptosis in SKOV3 cells via TNF-α-induced apoptosis pathway. 
However, other pathways could potentially be involved.
FigUre 7 | caspase activation in sKOV3 cells following treatment with c1q and globular head modules. (a) Western blot analysis of full-length/total 
caspase 3 at 32 kDa after 12 and 24 h of the treatment with C1q, ghA, ghB, ghC, and untreated. (B) The cleaved caspase 3 was observed at 17 kDa after 24 h of 
treatment with C1q, ghA, ghB, ghC, and untreated (c) Western blot analysis for β-actin as a loading control for 12 h and 24 h at 45 kDa. (D) The activation of 
caspase 3 was also shown by immunofluorescence microscopy at 24 h in parallel with apoptosis staining for Annexin V-FITC, where activated caspase 3 was clearly 
visible in the cytoplasm probed with CY3 at 24 h.
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During early apoptosis, the integrity of the cell membrane 
is lost and phosphatidylserine (PS) is exposed for Annexin V 
binding (21). A significant number of SKOV3 cells were stained 
positive for Annexin V, when examined under immunofluores-
cence microscope, suggesting that the cell membrane integrity 
was no longer intact as Annexin V labeled with FITC was able 
to bind to PS, which is usually present on the intracellular leaflet 
of the healthy cells. However, it is translocated to the outer 
leaflet during apoptosis. Hence, it provided the first evidence that 
SKOV3 cells were undergoing apoptosis following the treatment 
with C1q or globular heads for 24  h (Figure  3). Trypan blue 
exclusion (Figure 2A) and MTT assays (Figure 2B), as well as 
FACS analysis (Figure 4) of treated SKOV3 cells, validated C1q-
induced apoptosis of SKOV3 cells. Thus, we investigated if the 
levels of pro-apoptosis factors such as Fas and Bax were altered 
following C1q treatment of SKOV3 cells. This subsequently led 
us to examine the TNF-induced apoptosis pathway.
Tumor necrosis factor-α is a prototypical member of pro-
inflammatory cytokine family that performs various roles in 
inflammation and cell death (22). Members of the TNF family 
are associated with a wide range of immune processes and play 
an important role in cancer immune surveillance For example, 
TNF-α can mediate apoptosis selectively in tumor cells via 
death receptors involving TRAIL/FasL ligands (23). Following 
treatment of SKOV3 cells with C1q or globular head modules, 
the gene expression of TNF-α was upregulated at 6 h (C1q) and 
12  h (C1q, ghA, ghB, and ghC; Figure  5A), which underwent 
apoptosis by 24 h. Interaction of TNF-α with its receptor TNFR1 
can cause upregulation of NF-κB, as was the case in our study 
(Figure  5B). Fas mRNA upregulation is observed, as expected 
(Figure  6A), suggesting that Fas, a receptor for FasL and a 
member of TNF receptor family, mediated apoptosis crosstalk. 
Intriguingly, Bax, a marker of dysfunctional mitochondria, was 
also seen to be transcriptionally upregulated (Figure  6B). Bax 
FigUre 8 | (a) relative quantification comparisons of mammalian target of rapamycin (mTOr) (a), raPTOr (b), and ricTOr (c) mrna expression in 
sKOV3 cells treated with c1q, gha, ghB, and ghc (10 µg/ml) at 6 h. Significance was obtained using the unpaired one-way ANOVA test (*p < 0.05, *p < 0.01, 
and ***p < 0.001) (n = 3). (B) Immunofluorescence microscopy to show the presence of mTOR detected abundantly in the cytoplasm (green) of the untreated cells, 
compared to SKOV3 cells treated with C1q and globular heads at 15 h time point.
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FigUre 9 | illustration of the likely apoptosis pathway in action following c1q binding to sKOV3 cells. Exogenous treatment of SKOV3 cells with C1q and 
individual globular head modules can induce upregulation of TNF-α and Fas. TNF-α stimulation triggers two parallel, but contrasting, pathways: the pro-apoptotic 
caspase (15) and the anti-apoptotic NFκB-IκB inhibitor of apoptosis proteins (IAP) pathway (16). The cell survival or death, however, depends upon interactions 
among the components of these two pathways as well as other factors such as mitochondrial dysfunction (15, 16). TNF-α can bind to TNF type I receptor (TNFR1), 
which is then internalized to first form a complex with TNFR1-associated DEATH domain, receptor-interacting protein 1 (RIP1), TNF receptor-associated factor 2 
(TRAF2), and cellular inhibitor of apoptosis protein-1 (c-IAP1) (complex I), triggering the upregulation of nuclear factor-κB (NF-κB). A second complex (complex II) is 
later formed when complex I bind to Fas-associated protein with death domain (FADD), which is recruited upon activation of Fas (15, 17). Complex II subsequently 
causes downstream activation of apoptosis signal by activating caspase cascade, resulting in the cleavage of initiator caspase 8 and effector caspase 3 leading to 
apoptosis (15, 17–19). However, NF-κB upregulation may intersect apoptotic pathway as it can promote the induction of various cellular apoptosis inhibitors such as 
TRAF1, TRAF2, cIAP-1, c-IAP-2, and X-linked inhibitor of apoptosis protein (XIAP) (15, 20).
acts as a signal for the release of apoptogenic factors such as 
cytochrome c, Smac (second mitochondria-derived activator of 
caspase)/DIABLO (direct inhibitor of apoptosis protein-binding 
protein), apoptosis-inducing factor, Omi/HtrA2, or endonuclease 
G from the mitochondria. Release of Smac/DIABLO and Omi/
HtrA2 into cytosol has been shown to promote caspase activation 
by antagonizing the IAPs, which are formed following the NF-κB 
upregulation (16). This suggests that Bax upregulation in our 
study may have negated the effects of NF-κB signaling pathway 
to cause inhibition of apoptosis. In addition, Bax can also trigger 
caspase activation by forming a cytochrome c/apoptotic protease 
activating factor 1/caspase 9-complex, which can further cause 
cleavage of caspase 3, or by proceeding via caspase-independent 
death effectors (16, 24–26).
SKOV3 cell line has previously been reported to have a dys-
functional apoptosome, which causes the activation of caspase 9, 
to some extent, to further cleave caspase 3 (27). This is supported 
by our results since activation of caspase 9 was observed (data not 
shown), which was unable to activate caspase 3, suggesting that 
cleaved caspase 3 (Figure 7B) could not have arisen exclusively 
due to mitochondrial pathway and validated a crosstalk between 
intrinsic and extrinsic pathways. This observation appears to sug-
gest that C1q-induced apoptosis in SKOV3 cells had taken place, 
primarily via the extrinsic pathway.
Ovarian cancer cells, including SKOV3 cancer cell line, 
exhibit constitutive activation of Akt/mTOR survival pathway, 
thus protecting the cancer cells from apoptosis (28). mTOR, 
a serine–threonine kinase, upon activation by Akt, forms 
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Surfactant protein D (SP-D) is a soluble C-type lectin, belonging to the collectin 
(collagen-containing calcium-dependent lectin) family, which acts as an innate immune 
pattern recognition molecule in the lungs at other mucosal surfaces. Immune regulation 
and surfactant homeostasis are salient functions of SP-D. SP-D can bind to a range of 
viral, bacterial, and fungal pathogens and trigger clearance mechanisms. SP-D binds 
to gp120, the envelope protein expressed on HIV-1, through its C-type lectin or car-
bohydrate recognition domain. This is of importance since SP-D is secreted by human 
mucosal epithelial cells and is present in the female reproductive tract, including vagina. 
Another C-type lectin, dendritic cell (DC)-specific intercellular adhesion molecule-3-grab-
bing non-integrin (DC-SIGN), present on the surface of the DCs, also binds to HIV-1 
gp120 and facilitates viral transfer to the lymphoid tissues. DCs are also present at the 
site of HIV-1 entry, embedded in vaginal or rectal mucosa. In the present study, we 
report a direct protein–protein interaction between recombinant forms of SP-D (rfhSP-D) 
and DC-SIGN via their C-type lectin domains. Both SP-D and DC-SIGN competed for 
binding to immobilized HIV-1 gp120. Pre-incubation of human embryonic kidney cells 
expressing surface DC-SIGN with rfhSP-D significantly inhibited the HIV-1 transfer to 
activated peripheral blood mononuclear cells. In silico analysis revealed that SP-D and 
gp120 may occupy same sites on DC-SIGN, which may explain the reduced transfer of 
HIV-1. In summary, we demonstrate, for the first time, that DC-SIGN is a novel binding 
partner of SP-D, and this interaction can modulate HIV-1 capture and transfer to CD4+ 
T cells. In addition, the present study also reveals a novel and distinct mechanism of host 
defense by SP-D against HIV-1.
Keywords: surfactant protein D, Dc-sign, hiV-1 infection, protein–protein interactions, gp120
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inTrODUcTiOn
Surfactant protein D (SP-D) is a collagen-containing C-type lec-
tin, belonging to the collectin family (1). The primary structure 
of human SP-D is composed of three subunits of polypeptide 
chains; each subunit consists of a short N-terminal region, a 
triple-helical collagen-like region, an α-helical coiled-coil neck 
region, and a calcium-dependent highly conserved C-type lectin 
or carbohydrate recognition domain (CRD) at the C-terminus 
(2, 3). The primary structure can get cross-linked via the cysteine-
containing N-terminal region to give rise to a cruciform structure, 
which can undergo further multimerization to yield a fuzzy ball, 
where the CRD regions are facing toward the exterior. SP-D, via 
its homotrimeric CRD region, is known to interact with a wide 
range of viral, bacterial, and fungal pathogens and bring about 
clearance mechanisms that involve aggregation or agglutina-
tion, opsonization, enhanced phagocytosis, and super-oxidative 
burst (3, 4). Primarily found in the lungs as a part of pulmonary 
surfactant, SP-D has been localized at a range of extrapulmonary 
sites as a part of mucosal defense system (5).
SP-D is present throughout the female genital tract, with likely 
involvement in the prevention of uterine infections (6). Epithelial 
linings of vagina, cervix, uterus, fallopian tubes, and ovaries are 
positively immunostained for SP-D (7). SP-D has been shown to 
bind to different strains of HIV-1 (BaL and IIIB) at pH 7.4 (physi-
ological) and 5.0 similar to the pH found in the female urogenital 
tract (8). Glycoprotein gp120, a highly conserved mannosylated 
oligosaccharide present on the envelope of HIV-1 virion, plays an 
important role in the viral entry and facilitates viral replication 
by activating the NF-κB pathway. SP-D has been shown to bind 
gp120 of various strains of HIV-1 and prevent HIV-1 interaction 
with CD4 receptor on T cells, thereby inhibiting viral entry and 
replication (9, 10).
Another pattern recognition immune regulatory molecule, 
DC-SIGN/CD209, a type-II transmembrane protein of 44  kDa 
present on dendritic cell (DC) surface (11), plays a major role in 
mediating DC adhesion, migration, inflammation, and activation 
of T cell. DC-SIGN can serve as a route of immune escape for 
pathogens and tumors (12) and is a known receptor for many 
viruses, including HIV-1 and HIV-2. DC-SIGN is expressed by 
both mature and immature DCs in lymphoid tissues (11, 13), but 
not on follicular DCs, plasmacytoid DCs or CD1a+ Langerhans 
cells (14), monocytes, T cells, B cells, thymocytes, and CD34+ bone 
marrow cells. It is also expressed by polarized (M2) macrophages 
that infiltrate tumors (15), and on antigen-presenting cells such as 
macrophages, and in chorionic villi of placenta (16). Cells express-
ing DC-SIGN are located in T cell area of lymph nodes, tonsils, 
and spleen and dermal DCs in skin (CD14+ macrophages) (17). 
DC-SIGN expressing cells are seen in mucosal tissue of rectum 
(18) (with high antigen-presenting capacities), cervix, and uterus, 
in hepatic sinusoid and lymphatic sinus (19, 20).
HIV-1 virus, when exposed to genital and anal mucosal tis-
sues, binds to DC-SIGN on tissue embedded DCs (21, 22) and 
gets transmitted to CD4+ T  cells, activating adaptive immune 
response (23, 24). DC-SIGN facilitates HIV-1 transmission 
in both cis and trans fashion (25). Expression of DC-SIGN is 
regulated by IL-4 during monocyte–DC differentiation pathway, 
along with GM-CSF (26). TGF-β and IFNs are known to be 
inhibitors of DC-SIGN expression, and, thus, indirectly regulate 
HIV-1 transmission (26).
The interaction between HIV-1 and DC-SIGN takes place in 
the mucosal tract where SP-D is present. Since both SP-D and 
DC-SIGN can bind gp120, we set out to examine if interplay 
between these proteins can modulate DC-SIGN-mediated viral 
transfer of HIV-1. This view was further substantiated by obser-
vations that SP-D levels are increased in the broncho-alveolar 
fluid of HIV-1 patients (27); and recombinant forms of SP-D 
(rfhSP-D) can bind to gp120 of HIV-1, acting as a potent inhibitor 
of viral infection in vitro via inhibition of the interaction between 
CD4 and gp120 (10). In this study, we show, using recombinant 
forms of tetrameric and monomeric forms of DC-SIGN and its 
homolog, DC-SIGNR, that there is a protein–protein interaction 
between the two C-type lectins via CRD regions. They compete 
for binding to HIV-1 gp120, and thus, SP-D suppresses DC-SIGN 
mediated transfer of HIV-1 to CD4+ cells.
MaTerials anD MeThODs
recombinant expression and Purification 
of soluble Forms of Tetrameric and 
Monomeric Dc-sign and Dc-signr
E. coli strain BL21 (λDE3) (Invitrogen, UK) was transformed with 
pT5T plasmid encoding DC-SIGN and DC-SIGNR sequences 
(inserted at the BamHI restriction site into plasmid construct) 
with and without multimerizing neck region. In the presence of 
neck region, the bacterial cells expressed tetrameric DC-SIGN 
and DC-SIGNR; without the neck region, the corresponding con-
structs produced monomeric forms of DC-SIGN and DC-SIGNR 
(28). E. coli strain BL21 (λDE3) cells containing ampicillin (50 µg/
ml) (Sigma-Aldrich) resistant plasmids [except in the case of 
DC-SIGNR monomer expressing construct that was kanamycin 
(50 µg/ml) (Sigma-Aldrich) resistant] were subcultured overnight 
at 37°C. One liter LB medium containing ampicillin or kanamy-
cin was inoculated with 10 ml of overnight bacterial culture and 
grown at 37°C until the OD600 reached 0.7, and then induced with 
0.5  mM isopropyl β-d-1-thiogalactopyranoside (IPTG). After 
3 h, the bacterial cells were centrifuged at 13,800 × g for 15 min 
to collect the bacterial pellet. Protein expression was analyzed via 
12% SDS-PAGE.
The cell pellet was treated with 22 ml of lysis buffer, containing 
100 mM Tris, pH 7.5, 0.5 M NaCl, lysozyme (50 µg/ml), 2.5 mM 
EDTA, pH 8.0, and 0.5  mM phenylmethylsulfonyl fluoride 
(PMSF), and left to stir for 1 h at 4°C. Cells were then sonicated 
for 10 cycles, each cycle of 30 sec with 2 min interval. The soni-
cated cell suspension was spun at 10,000 × g for 15 min at 4°C. The 
inclusion bodies, present in the pellet, were solubilized in 20 ml of 
6 M urea, 10 mM Tris–HCl, pH 7.0, and 0.01% β-mercaptoethanol 
(β-ME) by rotating on a shaker for 1 h at 4°C. The mixture was 
then centrifuged at 13,000 × g for 30 min at 4°C and the superna-
tant was drop-wise diluted fivefold with loading buffer containing 
25 mM Tris–HCl, pH 7.8, 1 M NaCl, and 2.5 mM CaCl2 with gentle 
stirring. This was then dialyzed against 2 l of loading buffer with 
three buffer changes every 3 h. Following further centrifugation 
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at 13,000 × g for 15 min at 4°C, the supernatant was loaded onto 
a Mannan agarose column (5 ml; Sigma) pre-equilibrated with 
the loading buffer. The column was washed with five bed volumes 
of the loading buffer and the bound protein was eluted in 1 ml 
fractions using the elution buffer containing 25 mM Tris–HCl, 
pH 7.8, 1 M NaCl, and 2.5 mM EDTA. The absorbance was read 
at 280 nm and the peak fractions were frozen at −20. Purity of 
protein was analyzed by 15% w/v SDS-PAGE.
expression and Purification of rfhsP-D
E. coli BL21 (λDE3) pLysS containing plasmid pUK-D1 (con-
taining cDNA sequences for 8 Gly–X–Y repeats, neck, and CRD 
region of human SP-D) was cultured in ampicillin (100  µg/
ml) (Sigma-Aldrich) and chloramphenicol (50  µg/ml) (Sigma-
Aldrich) at 37°C overnight. Expression and purification was car-
ried out as described earlier (29, 30). Bacterial cells were grown 
until the OD600 reached 0.6 to 0.8, then induced with 0.4 mM IPTG 
and allowed to grow for an additional three hours. Cells were then 
pelleted via centrifugation and was re-suspended in 50 ml of lysis 
buffer (50 mM Tris–HCl, pH 7.5, 200 mM NaCl, 5 mM EDTA 
with freshly added 0.1 mM PMSF, and 100 µg/ml lysozyme) at 
4°C for 1 h. The cell lysate was then sonicated at 4 kHz for 30 s 
with 2 min interval for 15 cycles. The sonicate was centrifuged 
at 13,800 × g for 15 min at 4°C to collect the rfhSP-D-rich pel-
let containing inclusion bodies. 25  ml of solubilization buffer 
(50  mM Tris–HCl, pH 7.5, 100  mM NaCl, 5  mM EDTA, 6  M 
urea) was used to re-suspend the pellet, and incubated at 4°C for 
1 h. The dialysate was then centrifuged at 13,800 × g, at 4°C for 
15 min, and the supernatant was dialyzed against solubilization 
buffer containing 4 M urea and 10 mM β-ME for 2 h at 4°C. The 
dialysis buffer was serially changed to solubilization buffer con-
taining 2, 1, and 0 M urea at 4°C, 2 h each. Final dialysis was done 
in solubilization buffer containing 5 mM CaCl2 for 3 h to com-
pletely remove any traces of urea. The dialysate was centrifuged at 
13,800 × g, 4°C for 15 min and the clear supernatant containing 
rfhSP-D was affinity-purified using maltosyl-agarose column 
(Sigma-Aldrich). The bound protein was eluted with solubiliza-
tion buffer containing 10 mM EDTA, pH 7.5. Endotoxin levels 
were removed by passing the purified protein fractions through 
Polymyxin B column (Detoxi-Gel, Peirce & Warriner, UK) and 
the levels were measured using the Limulus Amebocyte Lysate 
Assay (BioWhitaker, UK). The endotoxin level was found to be 
<5 pg/μg rfhSP-D.
sDs-Page and Far Western Blot analysis
DC-SIGN and DC-SIGNR proteins were separated on a 12% 
(w/v) SDS-PAGE under reducing conditions. After electro-
phoresis, the polyacrylamide gels were stained with Coomassie 
Brilliant Blue. For the far western blotting, proteins were electro-
transferred onto polyvinylidene difluoride (PVDF) membrane 
(Sigma) and blocked with 5% w/v milk in PBS. The membrane 
bound proteins were probed with rfhSP-D (5 μg/ml) for 2 h, 
followed by addition of anti-SP-D (1:1,000) (Medical Research 
Council Immunochemistry Unit, Oxford) polyclonal antibod-
ies. The blot was then probed with Protein A-HRP Conjugate 
(1:1,000) (Sigma), followed by color development with diamin-
obenzidine as a substrate (Sigma-Aldrich, UK).
elisa
Microtitre wells were coated with DC-SIGN and DC-SIGNR 
proteins in carbonate/bicarbonate buffer, pH 9.6 in decreasing 
double dilutions (5–0.625 µg/well) in duplicates and left overnight 
at 4°C. The microtiter wells were blocked with 2% w/v BSA in 
PBS for 2 h at 37°C. The wells were then washed three times with 
PBS + 0.05% v/v Tween 20 and incubated with a constant concen-
tration (2.5 µg) of rfhSP-D in 20 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 5 mM CaCl2 or 5 mM EDTA at 37°C for 1 h, followed by 
1 h at 4°C. Following PBS + Tween 20 wash, the bound rfhSP-D 
was detected using anti-SP-D (1:5,000) polyclonal antibody and 
Protein A-HRP conjugate (1:5,000). Color was developed using 
o-Phenylenediamine (OPD) as a substrate and absorbance was 
measured at 490 nm.
competitive elisa
The ability of rfhSP-D to compete with and DC-SIGN for binding 
to HIV-1 gp120 (Abcam; ab167715) gp120 was analyzed by com-
petitive ELISA. Gp120 was coated at 250  ng/well in duplicates 
and left overnight at 4°C. Wells were blocked with 2% BSA in 
PBS for 2  h at 37°C. The wells were washed three times with 
PBS + 0.05% v/v Tween 20. A constant concentration of DC-SIGN 
tetramer (5 μg/ml) and decreasing concentrations of rfhSP-D 
(5 −  0.625 μg/well) in calcium buffer were added to the wells, 
which were subsequently probed with anti-DC-SIGN (1:5000) 
polyclonal antibodies. Following washes, the wells were incubated 
with Protein HRP conjugate (1:1,000). Color was developed using 
OPD as a substrate.
Fluorescence Microscopy
Human embryonic kidney cells 293 (HEK 293), transfected 
with DC-SIGN construct (DC–HEK) (31), were grown and 
maintained in DMEM (Life technologies, UK) containing 10% 
v/v fetal calf serum, 2 mM l-glutamine, penicillin (100 U/ml)/
streptomycin (100  µg/ml) (Thermo Fisher), and blasticidin 
(5 µg/ml) (Gibco). HEK 293 cells were grown and maintained in 
DMEM (Life technologies) containing 10% FBS. Both cell lines 
were grown under standard conditions (37°C, 5% v/v CO2) until 
80–90% confluency was reached. HEK 293 and DC–HEK cells 
(0.5 × 105) were grown on the coverslips in a 24-well plate (Nunc) 
overnight to perform three different sets of immunofluorescence 
experiments; DC-SIGN expression (primary antibody: rabbit 
anti-DC-SIGN, 1:500 and secondary antibody: anti-rabbit/CY3, 
1:500, Thermo Fisher), rfhSP-D (10 µg/ml) binding to DC-SIGN 
(primary antibody: monoclonal anti-SP-D, 1:500 and second-
ary antibody: anti-mouse conjugated/CY5, 1:500, Abcam) and 
co-localization of DC-SIGN and rfhSP-D (primary antibodies: 
anti-DC-SIGN polyclonal and anti-SP-D monoclonal, 1:500 
and secondary antibodies: anti-rabbit/CY3 and anti-mouse/
FITC, 1:500) on the cell surface of DC–HEK cells. HEK 293 cells 
were used as a control for all experiments and DC–HEK cells 
were incubated with secondary antibody alone as an additional 
control. Hoechst (1:10,000, Thermo Fisher) was used to stain the 
nucleus for all the staining experiments. The cells were incubated 
for 1 h with primary antibody followed by 1 h incubation with 
secondary antibodies as described earlier with three times 
FigUre 1 | SDS-PAGE analysis of purified recombinant forms of DC-SIGN, DC-SIGNR, and recombinant forms of SP-D (rfhSP-D). (a) 12% SDS-PAGE of 
affinity-purified tetrameric and monomeric forms of DC-SIGN and DC-SIGNR under reduced conditions. (B) 12% v/v SDS-PAGE of affinity-purified rfhSP-D.
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phosphate-buffered saline (PBS, Thermo Fisher) washes between 
each step. For rfhSP-D binding with DC-SIGN analysis, the 
rfhSP-D was incubated with the cells for 1 h at 4°C. The cells were 
fixed with 4% paraformaldehyde (Sigma) before mounting on the 
coverslips to visualize under a HF14 Leica DM4000 microscope.
Viral Transfer assay
Pooled human peripheral blood mononuclear cells (PBMCs) 
(HiMedia Laboratories, India) were stimulated in RPMI 
1640 medium (Sigma-Aldrich) containing 10% v/v FBS, 1% 
Penicillin–Streptomycin and 5 µg/ml phytohemaglutinin (PHA) 
and 10 U/ml of rhIL-2 (Gibco) for 24 h. PHA/IL-2 was washed 
off and activated PBMCs were cultured further in complete 
RPMI medium. For the experiment, DC–HEK cells were grown 
in a 12-well tissue culture plate until 80% confluence in complete 
DMEM/F12 (Sigma-Aldrich, USA) containing 10% FBS (Gibco) 
and blasticidin. Indicated concentrations of rfhSP-D containing 
5  mM CaCl2 was added to each well and incubated for 2  h to 
allow binding to DC-SIGN. The wells without rfhSP-D were used 
as controls. Excess protein was removed, and cells were chal-
lenged for 1 h with 5 ng/ml p24 of HIV-1 SF-162 strain (kindly 
provided by Dr. Jay Levy, AIDS Program, National Institutes of 
Health, USA). 5 mM EDTA was added along with the virus in 
EDTA controls. Unbound virus was washed off and DC–HEK 
cells were cocultured with PHA/IL-2 activated PBMCs for 24 h 
to facilitate transfer. PBMCs along with the medium were then 
FigUre 2 | Direct binding ELISA showing interaction between recombinant forms of SP-D (rfhSP-D) and DC-SIGN/DC-SIGNR. DC-SIGN tetramer (a), DC-SIGNR 
tetramer (B), DC-SIGN monomer (c), and DC-SIGNR monomer (D) were coated at decreasing double dilutions from 5 to 0.625 µg/well and then probed with 
2.5 µg of rfhSP-D in either in calcium or EDTA buffer. The binding was detected using anti-human surfactant protein D polyclonal antibodies (1:5,000 dilutions).  
The data represent mean and SD values of at least five experiments.
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separated (siphoned off) from the DC–HEK monolayer and were 
transferred to fresh plates. They were cultured further in RPMI 
1640 medium containing 10% FBS for 7  days, and viral titers 
were determined in supernatants on day 4 and 7 using HIV-1 p24 
antigen ELISA kit (XpressBio Life Science Products, Frederick, 
MD, USA).
Molecular Modeling and Bioinformatics
The crystal structures of trimeric human lung SP-D (PDB ID: 
1PW9), CD4 bound to HIV-1 envelope glycoprotein gp120 
(PDB ID:1GC1) and homo 10-mer DC-SIGN complexed with 
sugars (PDB ID:1K9I) were retrieved from Protein Data Bank. 
The tetrameric form of non-glycosylated DC-SIGN was used for 
docking studies as this structure was found to bind to rfhSP-D 
in  vitro experiments. DC-SIGN tetramer was docked to CD4 
already bound to HIV-1 envelope glycoprotein gp120 (PDB ID: 
1GC1) using Patch Dock server with default parameters.
The CRD-mediated protein–protein interaction between 
trimeric SP-D and tetrameric DC-SIGN, as observed in this study 
was further examined by docking these two molecules using 
ZDOCK algorithm of Discovery Studio (Accelrys Inc.). The best 
pose of these two molecules was subsequently docked into gp120 
using Patch Dock server. The shortlisted poses from PatchDock 
and ZDOCK were further refined using Fire Dock and RDOCK, 
respectively.
resUlTs
rfhsP-D and Dc-sign can interact with 
each Other via Their c-Type lectin 
Domains
Structurally, DC-SIGN is composed of an extracellular domain 
(ECD) which exists as a tetramer, stabilized by an N-terminal 
α-helical neck region, followed by a CRD. DC-SIGN and 
DC-SIGNR comprising of the entire ECD (tetramer) (Figure 1A) 
and the CRD region alone (monomer) (Figure 1A) were expressed 
in E. coli and affinity-purified on Mannose-agarose (28). The 
CRD regions of DC-SIGN and SIGNR bound mannose weakly 
as majority of the proteins appeared in the flow through. The ECD 
domains of both DC-SIGN and DC-SIGNR bound to mannose 
with much greater affinity in the presence of Ca2+ and eluted 
with EDTA. A recombinant form of human SP-D, containing 8 
Gly–X–Y repeats of the collagen, neck, and CRD regions were 
expressed and purified as homotrimeric molecules, as described 
earlier (29, 30) (Figure 1B). Tetrameric and monomeric forms 
of DC-SIGN and DC-SIGNR were checked for their respective 
interactions with rfhSP-D via ELISA (Figure 2), which showed a 
calcium- and dose-dependent interaction between the two lectins; 
tetrameric forms bound rfhSP-D better than the monomers. This 
was confirmed by a far western blot (Figure 3A), which revealed 
that rfhSP-D was able to bind to DC-SIGN and DC-SIGNR 
FigUre 4 | Competitive inhibition ELISA to show that recombinant form of 
SP-D (rfhSP-D) inhibits DC-SIGN binding to immobilized HIV-1 gp120. HIV-1 
gp120 trimer (250 ng per well) was first coated to which 5–0.625 µg/well of 
rfhSP-D and a constant concentration (5 µg/well) of DC-SIGN tetramer were 
added. Bound DC-SIGN tetramer was detected by anti-DC-SIGN polyclonal 
antibodies. Protein A-HRP conjugate (1:1,000) was used to detect the 
antibodies bound and color was developed using o-Phenylenediamine. 0 in 
the graph represents the control where only PBS was used instead of gp120, 
and the experiments were repeated three times.
FigUre 3 | Far western blot to detect binding of recombinant forms of SP-D 
(rfhSP-D) to PVDF bound DC-SIGN and DC-SIGNR. (a) Tetrameric and 
monomeric variants of DC-SIGN and DC-SIGNR were run on a SDS-PAGE 
and were transferred to a PVDF membrane followed by incubation with  
5 µg/ml rfhSP-D and then probed with anti-SP-D polyclonal antibody.  
(B) Docked structure of trimeric surfactant protein D (SP-D) (yellow cartoon) 
and tetrameric DC-SIGN (blue cartoon). The two molecules interact via their 
carbohydrate recognition domains.
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proteins immobilized on PVDF membrane. The CRD-mediated 
protein–protein interaction between trimeric SP-D and tetrameric 
DC-SIGN was further studied by docking these two molecules. 
The docked pose showed that the two molecules likely interact 
via their CRD regions (Figure 3B).
rfhsP-D:Dc-sign interaction leads to 
competition for Binding to hiV-1 gp120
To examine if rfhSP-D can inhibit the binding of DC-SIGN to 
gp120, we carried out a competitive ELISA. As expected, both 
rfhSP-D and DC-SIGN tetramer bound gp120 in a dose- and 
calcium-dependent manner (data not shown) (32). In order to 
assess a likely interference by rfhSP-D in DC-SIGN: gp120 inter-
action, a constant concentration of DC-SIGN tetramer was used 
against different concentrations of rfhSP-D and added to solid-
phase gp120 (Figure 4). With increasing concentration, rfhSP-D 
was able to inhibit DC-SIGN-gp120 interaction, suggesting that 
the binding sites on these two C-type lectins for gp120 may be 
overlapping.
rfhsP-D co-localizes with Dc-sign on 
the surface of Transfected heK 293 cells
Human embryonic kidney cells transfected with DC-SIGN 
construct (DC–HEK cells) were shown to express DC-SIGN 
via immunofluorescence microscopy. The DC-SIGN expres-
sion seen on the cell surface on DC–HEK cells was evenly dis-
tributed, as compared to HEK 293 cells, which were used as a 
control, using anti-DC-SIGN polyclonal antibody (Figure 5A). 
DC–HEK cells, incubated with secondary antibody alone, did 
not show any expression (Figure  5A). rfhSP-D binding was 
visible on the cell surface of DC–HEK cells, whereas rfhSP-
D binding could not be detected in either HEK 293 cells or 
DC–HEK cells incubated with secondary antibody alone as 
controls (Figure 5B). rfhSP-D and DC-SIGN co-localized on 
the HEK cell surface transfected with DC-SIGN construct 
(Figure 5C).
rfhsP-D inhibits Dc-sign-Mediated Viral 
Transfer to PBMcs in a Dose-Dependent 
Manner
To understand whether interaction between rfhSP-D and 
DC-SIGN impacted upon DC-SIGN-mediated HIV-1 transfer 
to T  cells, we performed a coculture assay using DC–HEK 
cells and mitogen-activated PBMCs. Presence of rfhSP-D led 
to a significantly (p < 0.005) reduced HIV-1 p24 levels in day 
4 and day 7 PBMC culture supernatants in a dose-dependent 
manner (Figure 6). This suggested that, in presence of rfhSP-D, 
the viral uptake by DC–HEK was significantly inhibited result-
ing in reduced transfer and replication of HIV-1 in PBMC 
cultures. It is likely that rfhSP-D may have occupied sites on 
both DC-SIGN as well as HIV-1 gp120 that resulted in reduced 
FigUre 5 | Continued
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FigUre 5 | Immunofluorescence microscopy to show recombinant forms of SP-D (rfhSP-D) binding to DC-SIGN on the surface of the human embryonic kidney 
(HEK) cells transfected with DC-SIGN construct (DC–HEK cells). (a) DC–HEK cells incubated with anti-rabbit/CY3 did not show DC-SIGN expression (control). 
DC–HEK and HEK cells incubated with anti-DC-SIGN followed by anti-rabbit conjugated with CY3 showed the DC-SIGN expression in DC–HEK cells only and not 
HEK cells. Hoechst was used to stain the nucleus. (B) Analysis of rfhSP-D binding to DC-SIGN on the DC–HEK cells via immunofluorescence. DC–HEK cells 
incubated with anti-SP-D for 1 h and then probed with anti-mouse/CY5 did not show binding. DC–HEK cells incubated with rfhSP-D (5 µg/ml) for 1 h, followed by 
anti-SP-D for 1 h and then anti-mouse/CY5 showed the binding on the cell surface. (c) DC-SIGN expression and rfhSP-D binding co-localization analysis via 
immunofluorescence microscopy. DC–HEK cells incubated with secondary antibodies only (anti-mouse/FITC and anti-rabbit/FITC) for 1 h did not show 
immunofluorescence. DC–HEK and HEK cells incubated with rfhSP-D for 1 h prior to incubation anti-SP-D monoclonal and anti-DC-SIGN polyclonal for 1 h followed 
by anti-mouse/FITC and anti-rabbit/CY3 for 1 h showed co-localization for rfhSP-D binding and DC–HEK expression.
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DC-SIGN interaction with HIV-1 gp120. EDTA significantly 
inhibited DC–HEK-mediated viral transfer, as reported previ-
ously (33).
Bioinformatics analysis revealed That 
hiV-1 gp120 and rfhsP-D May Occupy the 
same site on the crDs of Dc-sign
To support our hypothesis that DC-SIGN once bound to rfhSP-D 
may not interact with gp120, we performed in silico analyses. The 
best-docked pose of rfhSP-D and DC-SIGN was subsequently 
docked to gp120 using Patch Dock server. The shortlisted poses 
from Patch Dock and ZDOCK were further refined using Fire 
Dock and RDOCK, respectively. Two poses appear to suggest 
that HIV-1 gp120 and rfhSP-D possibly occupy the same site 
on the CRD of DC-SIGN (Figure  7). Thus, in the presence of 
rfhSP-D, it is likely that interaction of DC-SIGN with gp120 could 
be inhibited. To validate our bioinformatics strategy, we evalu-
ated the known interaction of gp120 with DC-SIGN followed by 
docking with CD4. DC-SIGN binds to gp120 at a site distant 
from its CD4 binding site, and hence, DC-SIGN-bound HIV-1 
possibly interacts with CD4 for viral transmission (Figure 8). The 
global energy of these docked complexes has also been presented 
(Table 1).
DiscUssiOn
In this study, we report, for the first time, an interaction of 
DC-SIGN and SP-D, two C-type lectins and pattern recognition 
receptors; both proteins are known to bind to HIV-1 gp120. We 
demonstrate that this interaction involves their CRD domains, 
which is relevant in inhibiting DC-SIGN-mediated HIV-1 
trans-infection of CD4+ T cells. Interaction of HIV-1 gp120 with 
DC-SIGN not only increases the affinity of gp120 for CD4 (34) 
but also leads to a productive infection via reactivation of provirus 
involving NF-κB pathway (35, 36). This interaction also results 
in downregulation of Nef-induced release of IL-6 (37) and leads 
to Ask-1-dependent activation leading to induction of apoptosis 
of human DCs (38). Simultaneous binding of rfhSP-D to both 
FigUre 7 | Two poses suggesting that HIV-1 gp120 and recombinant forms 
of SP-D possibly occupy the same site on carbohydrate recognition domain of 
DC-SIGN. Docked structures of surfactant protein D trimer (yellow cartoon 
and calcium ions as red spheres) complexed with DC-SIGN tetramer (blue 
cartoon and calcium ions as green spheres) and HIV-1 envelope glycoprotein, 
gp120 (cyan cartoon). The sugars present in gp120 are shown as sticks. The 
calcium ions of DC-SIGN are represented as green spheres. (a) Rank no. 1. 
(B) Rank no. 2.
FigUre 6 | DC-SIGN-mediated HIV-1 transfer assay. DC–HEK cells were 
grown in a 12-well plate until 80% confluence. 20, 10, and 1 µg/ml of 
recombinant forms of SP-D (rfhSP-D) concentrations were added to the cells 
and incubated for 2 h for binding. Unbound protein was removed and cells 
were challenged with 2.5 ng/ml p24 of HIV-1 (SF-162 strain) for 1 h (to bind 
to DC-SIGN). After 1 h, unbound virus was washed off and cells were 
cocultured with phytohemaglutinin-activated peripheral blood mononuclear 
cells (PBMCs) for 24 h. This allows the DC-SIGN captured virus to be 
transferred to CD4+ cells, where virus will multiply. PBMCs were separated 
from the monolayer and cultured separately for 4 days to determine viral titer.
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gp120 and DC-SIGN, thus, may result in blockade of DC-SIGN-
mediated viral transmission and inhibition of replication.
Structure–function studies have revealed that the CRD 
region of DC-SIGN is the specific ligand-binding site that is 
reliant on the neck region within the extracellular domain 
(ECD) (39). This notion was validated in our binding ELISA 
type assays when we used the tetrameric forms of DC-SIGN 
and DC-SIGNR (comprising of the ECD and CRD region) as 
well as the monomeric forms, which only consist of the CRD 
region. The binding studies involving rfhSP-D highlighted that 
multimeric forms of DC-SIGN and DC-SIGNR bind better, not 
surprisingly, due to multivalent nature of interactions. Since 
DC-SIGN promotes HIV-1 infection, we examined if rfhSP-D 
by virtue to its ability to bind gp120 as well as DC-SIGN can 
potentially interfere with HIV-1 (40–42). We also included 
DC-SIGNR (DC-SIGN-Related), a homolog of DC-SIGN, in 
our study. DC-SIGNR, expressed on endothelium including 
liver sinusoidal, lymph node sinuses, and placental capillary, 
can also bind gp120 to facilitate HIV-1 viral infection (43).
The current study provides the first evidence that DC-SIGN is 
a novel immune receptor or adaptor for the CRD region of SP-D, 
modulating the HIV-1 infection. Interaction of gp120 and rfhSP-
D is calcium dependent as reported earlier (8–10). Tetrameric 
DC-SIGN also efficiently binds gp120 in a dose-dependent 
manner, which is not significantly inhibited in presence of sugars 
similar to previous reports (28, 44). The recombinant rfhSP-D 
has been shown to inhibit the gp120-CD4 interaction (10) while, 
DC-SIGN-bound trimeric gp140 interacts with CD4 more avidly 
(34). In vitro competitive assays and the bioinformatics analysis 
confirmed that rfhSP-D and DC-SIGN compete for gp120. The 
reduced p24 levels confirmed that rfhSP-D significantly inhibits 
the DC-SIGN mediated viral transfer.
The rfhSP-D molecule (a recombinant fragment of human 
SP-D comprising homotrimeric C-type lectins), with part of 
collagen region, α-helical coiled-coil neck, and CRD region, has 
been extensively studied via in vitro, in vivo, and ex vivo experi-
ments. In a number of studies, rfhSP-D has worked at par with 
full-length SP-D, as evident from its ability to be therapeutic in 
murine models of allergic bronchopulmonary aspergillosis (45, 
46), invasive pulmonary aspergillosis (45), and dust mite allergy 
(47). It can also induce apoptosis in activated eosinophils (29, 
48) and PBMCs (49). Thus, rfhSP-D is an excellent well-tested 
therapeutically active molecule.
Mannose-binding lectin, another serum collectin, is also 
known to inhibit DC-SIGN-mediated trans-infection of HIV-1 
T cells (50) whereas SP-A and SP-D facilitate this transfer (8, 
51). Madsen et  al. incubated SP-D-HIV-1 complexes with 
immature monocyte-derived DCs and demonstrated increased 
viral uptake and transfer from DCs to PM-1 cells. However, 
the assay system employed in the two studies (Madsen and 
ours) significantly differed, thus the observed variation in 
the results. Further studies in appropriate animal models will 
TaBle 1 | Energy for docked complexes of DC-SIGN and gp120 bound to CD4 
refined using FireDock.
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FigUre 8 | Known interaction of gp120 with DC-SIGN followed by docking with CD4. Selected docked poses of tetrameric DC-SIGN (blue cartoon) and HIV-1 
envelope glycoprotein gp120 (cyan cartoon) bound to CD4 (pink cartoon). The sugars present in gp120 are shown as sticks. (a) Rank no. 1. (B) Rank no. 2. (c) Rank 
no. 3. (D) Rank no. 4.
help to determine the overall effects of SP-D and DC-SIGN 
binding during virus infections. Our findings have revealed 
a new phenomenon in SP-D-mediated viral transfer through 
DCs as rfhSP-D occupies similar sites as gp120 on DC-SIGN. 
Hence, pre-incubation of rfhSP-D may have occupied gp120-
binding site on DC-SIGN (displacement of gp120 via ELISA 
and in  silico analysis), resulting in poor uptake. This must 
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Mycobacterium tuberculosis can proficiently enter macrophages and diminish comple-
ment activation on its cell surface. Within macrophages, the mycobacterium can sup-
press macrophage apoptosis and survive within the intracellular environment. Previously, 
we have shown that complement regulatory proteins such as factor H may interfere with 
pathogen–macrophage interactions during tuberculosis infection. In this study, we show 
that Mycobacterium bovis BCG binds properdin, an upregulator of the complement 
alternative pathway. TSR4+5, a recombinant form of thrombospondin repeats 4 and 
5 of human properdin expressed in tandem, which is an inhibitor of the alternative 
pathway, was also able to bind to M. bovis BCG. Properdin and TSR4+5 were found 
to inhibit uptake of M. bovis BCG by THP-1 macrophage cells in a dose-dependent 
manner. Quantitative real-time PCR revealed elevated pro-inflammatory responses 
(TNF-α, IL-1β, and IL-6) in the presence of properdin or TSR4+5, which gradually 
decreased over 6 h. Correspondingly, anti-inflammatory responses (IL-10 and TGF-β) 
showed suppressed levels of expression in the presence of properdin, which gradually 
increased over 6 h. Multiplex cytokine array analysis also revealed that properdin and 
TSR4+5 significantly enhanced the pro-inflammatory response (TNF-α, IL-1β, and 
IL-1α) at 24 h, which declined at 48 h, whereas the anti-inflammatory response (IL-10) 
was suppressed. Our results suggest that properdin may interfere with mycobacterial 
entry into macrophages via TSR4 and TSR5, particularly during the initial stages of 
infection, thus affecting the extracellular survival of the pathogen. This study offers novel 
insights into the non-complement related functions of properdin during host–pathogen 
interactions in tuberculosis.
Keywords: complement, cytokine, properdin, macrophage, Mycobacterium tuberculosis, Mycobacterium bovis 
Bcg, phagocytosis, thrombospondin repeats
inTrODUcTiOn
Properdin is an upregulator of the alternative pathway of complement activation. In one of the three 
pathways of the complement system, the alternative pathway, the activation of the major complement 
opsonin, C3, is driven by a complex serine protease, C3bBb, also called the C3 convertase, which 
is bound to the surface of the complement-activating target. To form C3bBb, factor B associates 
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with C3b in the presence of Mg2+ and factor D, a serine protease, 
which cleaves factor B into Bb and Ba fragments producing a 
C3 convertase C3bBb (1). This complex, which has a half-life of 
90 s, is stabilized by the binding of properdin, which increases 
the half-life by 5- to 10-fold (2). Furthermore, C3b molecules are 
generated by C3bBb and deposited near to the surface-bound 
convertase leading to the opsonization of the target and forma-
tion of C5 convertase, producing C5a and C5b, leading on to the 
lytic pathway and cell lysis (3).
The monomer of human properdin (53 kDa) has a flexible rod-
like structure with a length of 26 nm and a diameter of 2.5 nm, 
composed of seven thrombospondin type I repeats (TSR). Each 
TSR is of about 60 amino acids, typically containing six con-
served cysteine residues: these occur in TSR1–TSR6 (4–6), but 
the N-terminal domain, TSR0, is truncated. TSR4 is crucial for 
binding to C3bBb and TSR5 for binding to C3bBb, suggesting 
that both TSRs may be important for stabilizing the C3 convertase 
complex (5). Recently, TSR4+5, expressed as a double domain, 
has been shown to bind to properdin ligands such as C3b and 
inhibit the alternative complement pathway (7). These studies 
demonstrate the important role that these TSRs may play in the 
alternative pathway and in their interaction with pathogens.
Properdin circulates in plasma at a concentration of about 
4–25  µg/ml existing as cyclic oligomers, dimer, trimer, and 
tetramer in a ratio of 26:54:20 (4). The dissociation and reas-
sociation of properdin upon denaturation–renaturation cycles 
stimulated by guanidine or low pH indicates properdin ratio 
stability in solution (8). The interaction between properdin 
monomers involves the N-terminal end of one monomer and 
the C-terminal end of another (9). Properdin can also bind to 
microbial surfaces of several pathogens, including Neisseria 
gonorrhoeae (10), Salmonella typhimurium lipopolysac-
charide (LPS), Neisseria meningitidis lipooligosaccharide (11), 
and Chlamydia pneumoniae (12). Binding of properdin to 
microbial surfaces results in the recruitment of fluid phase 
C3b, inducing assembly of C3 convertase C3bBb and causing 
further deposition of C3b on the pathogen surface (13–15), 
subsequently generating a C5 convertase, MAC formation, 
and cell lysis. At 10 µg/ml, recombinant properdin enhanced 
complement deposition on N. meningitidis and S. pneumoniae 
and dramatically enhanced serum lysis of these bacteria, and 
in the mouse model, significantly reduced bacteremia and 
increased survival rates (16).
Although Mycobacterium tuberculosis and its close-relative 
Mycobacterium bovis have significant interaction with com-
ponents of the innate immune system, e.g., toll-like receptors, 
complement, surfactant proteins SP-A and SP-D (17), the initial 
stages of tuberculosis pathogenesis remain poorly understood. 
Many bacteria have evolved mechanisms to evade immune 
responses: by inhibiting complement activation by proteolytic 
cleavage of complement proteins, having their own complement 
inhibitors (18), or binding complement regulatory proteins like 
factor H (15, 19).
Mycobacterium tuberculosis is a highly specialized intra-
cellular pathogen and may exploit complement proteins to 
enhance its uptake by macrophages. Although it has been 
shown that M. tuberculosis can activate all three pathways of 
the complement system (20, 21), it is unclear how the patho-
gen uses complement proteins in tuberculosis pathogenesis. 
M. tuber culosis has been shown to bind to complement receptors 
(CR) CR1, CR3, and CR4 and gain entry into macrophages (22–24). 
There is also evidence that enhanced phagocytosis of M. tuber-
culosis by human alveolar and monocyte-derived macrophages 
results from C3 opsonization (24). The ability of M. tuberculosis to 
bind to CR3 non-opsonically has also been shown which may be 
important for bacterial invasion when complement is sparse, for 
example, in the lung (25). Properdin has recently been considered 
as a pattern recognition receptor (PRR) on its own, i.e., binding 
to recognition patterns without need for prior deposition of C3b 
or C3bBb (26–28). Therefore, we investigated the role of proper-
din in tuberculosis pathogenesis, by using the model organism 
M. bovis BCG.
Here, we show, for the first time, that properdin and recombi-
nant form of TSR4+5 expressed as a two-module protein binds to 
M. bovis BCG, demonstrating its role as a soluble PRR. Properdin 
and TSR4+5 were found to inhibit the uptake of M. bovis BCG 
by macrophages during phagocytosis, altering the pro- and anti-
inflammatory cytokine response, and thus, possibly shaping the 
adaptive immune response in tuberculosis pathogenesis.
MaTerials anD MeThODs
Purification of native Properdin
The affinity columns, IgG Sepharose and anti-properdin mono-
clonal antibody Sepharose, were prepared as described previously 
(7). The IgG-Sepharose column was prepared from human 
non-immune IgG (~26  mg IgG/ml of Sepharose) coupled to 
CNBr-activated Sepharose (GE Healthcare, UK). For preparation 
of the anti-human properdin column, CNBr-activated Sepharose 
(GE Healthcare Life Sciences, UK) was used to couple to anti-
properdin mouse monoclonal antibody (2 mg/ml). One liter of 
human plasma (TCS Biosciences) containing 5 mM EDTA was 
filtered through Whatman filter paper before applying to IgG 
Sepharose to deplete C1q (which would otherwise have bound 
to the IgG on the anti-properdin Sepharose). The column was 
washed with three bed volume of HEPES buffer (10 mM HEPES, 
140  mM NaCl, 0.5  mM EDTA, and pH 7.4). Plasma was then 
applied to the monoclonal anti-properdin column and washed 
with the same HEPES buffer. Bound properdin was eluted with 
3 M MgCl2 and the peak fractions were dialyzed against HEPES 
buffer overnight at 4°C. Contaminants were further removed by 
applying the pooled protein fractions to a HiTrap Q FF-Sepharose 
(GE Healthcare) ion-exchange column, followed by washing the 
column with three bed volumes of 50  mM Tris–HCl, pH 7.5, 
50 mM NaCl, and 5 mM EDTA. Properdin did not bind to the Q 
Sepharose column and appeared in the flow-through free from 
contaminants as demonstrated by SDS-PAGE.
For the size exclusion chromatography analysis, 50 µl of the 
proteins at the concentrations varying from 0.3 mg/mL to 1.0 mg/
mL were applied to a TSKgel G2000SWXL, 5 µm, 7.8 × 300 mm 
column (Tosoh Bioscience). The column was equilibrated with 
buffer containing 50 mM sodium phosphate, pH7.0 and 300 mM 
NaCl at the flow rate 0.3 ml/min using SCL-10Avp HPLC system 
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(Shimadzu). The absorbance was detected at 230 and 280 nm. The 
Bio-Rad Gel Filtration Standard (Cat # 151-1901) were used for 
the protein molecular weight calibration of the column.
expression and Purification of Tsr4+5
The recombinant maltose-binding protein (MBP) fusion pro-
teins MBP-TSR4+5, MBP-TSR4, or MBP-TSR5 were expressed 
in Escherichia coli as described previously (7, 29). The E. coli 
BL21 bacterial cells (Life Technologies) were grown in 1 L of 
Luria–Bertani medium with 100 µg/ml ampicillin, shaking at 
37°C until an optical density at 600  nm (OD600) of between 
0.6 and 0.8 was reached. Protein expression was then induced 
in the bacterial cell culture with 0.4  mM isopropyl β-d-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3 h shaking 
at 37°C. The cells were then pelleted at 4,500  rpm, 4°C for 
10 min, lysed using 50 ml lysis buffer [20 mM Tris–HCl, pH 
8.0, 0.5  M NaCl, 1  mM EDTA, 0.25% v/v Tween 20, 5% v/v 
glycerol, 100  µg/ml lysozyme (Sigma-Aldrich), and 0.1  mM 
phenylmethanesulfonyl fluoride (Sigma-Aldrich)], and incu-
bated for 1 h at 4°C on a rotary shaker. The cell lysate was then 
sonicated using a Soniprep 150 (MSE, London, UK) at 60 Hz for 
30 s with an interval of 2 min (12 cycles) and then centrifuged 
at 13,000 rpm for 15 min at 4°C. The supernatant was diluted 
five-fold with buffer A (20  mM Tris–HCl, pH 8.0, 100  mM 
NaCl, 1  mM EDTA, and 0.25% v/v Tween 20) and passed 
through an amylose resin column (25 ml bed) (New England 
Biolabs) that was equilibrated in buffer A. The affinity column 
was washed with buffer A without Tween 20 and with 1 M NaCl, 
20 mM Tris–HCl, pH 8.0, 1 mM EDTA, followed by buffer B 
(20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA). The 
MBP-TSR4+5 fusion protein was eluted with 100 ml of buffer 
B containing 10 mM maltose (Sigma-Aldrich) (affinity elution 
buffer). Trace contaminants were further removed by applying 
the fusion protein to a DEAE Sepharose column. Thus, the affin-
ity purified fusion protein in affinity elution buffer was applied 
to the ion-exchange (5 ml bed) column and washed with three 
column volumes of low salt buffer containing 50 mM Tris–HCl, 
pH 7.5, 100 mM NaCl, 5 mM EDTA, at pH 7.5. After extensive 
washing with low salt buffer, the fusion protein eluted at 0.2 M 
NaCl using a NaCl gradient (50 mM to 1 M). The peak elutions 
were then passed through Pierce™ High Capacity Endotoxin 
Removal Resin (Qiagen) to remove LPS. Endotoxin levels were 
determined using the QCL-1000 Limulus amebocyte lysate 
system (Lonza), and the assay was linear over a range of 0.1–1.0 
EU/ml (10 EU = 1 ng of endotoxin). The endotoxin levels were 
less than 4 pg/µg of the MBP-TSR4+5.
Mycobacterial cell culture
Mycobacterium bovis BCG (Pasteur strain) were grown in liquid 
culture using Middlebrook 7H9 media (Sigma-Aldrich), sup-
plemented with 0.2% (v/v) glycerol, 0.05% (v/v) Tween-80, and 
10% (v/v) albumin dextrose catalase (ADC) (BD BBL, Becton 
Dickinson). Green fluorescent protein (GFP)-expressing M. bovis 
BCG (Danish Strain 1331) containing the pGFPHYG2 plasmid 
was a kind gift from B. Robertson, Imperial College, London, UK. 
GFP-M. bovis BCG was grown in the above conditions/media but 
with the addition of 50 µg/ml of hygromycin to maintain the plas-
mid. Cultures were incubated at 37°C with agitation (~120 rpm) 
for 7–10  days until the bacteria had reached the exponential 
growth phase at OD600nm = 0.60–1.00.
assay of human Properdin and  
Tsr4+5 Binding to Mycobacteria
Mycobacterium bovis BCG, harvested and washed in PBS, was 
adjusted to a concentration of 1.25 × 109 cells/ml in PBS (OD600 = 1 
equates to approximately 1 × 109 cell/ml). Then 200 µl of bacterial 
suspension was dispensed into individual microtiter wells of a 
96-well plate (Maxisorp™, NUNC). Plates were incubated at 
4°C overnight and washed with buffer 1 [10 mM HEPES pH 7.5, 
140  mM NaCl, 0.5  mM EDTA, and 100  µg/ml hen ovalbumin 
(Sigma-Aldrich)]. Wells were blocked for 2 h at 37°C with buffer 
1 + 10% (w/v) Marvel Dried Milk powder.
Human properdin (up to 50 µg/ml) or TSR4+5 (up to 30 µg/ml) 
were added, in two-fold serial dilutions (100 µl/well) in buffer 1 
and incubated for 2 h at 37°C. Individual TSR4 and TSR5 pro-
teins, MBP and BSA were used as negative controls. Microtiter 
wells were washed three times with buffer 1. Mouse anti-
properdin monoclonal antibody (1.19  mg/ml) diluted 1/2,500 
in buffer 1 (29) was added to the wells containing properdin. 
Mouse anti-MBP monoclonal antibody (Sigma-Aldrich) was 
added to wells containing TSR4+5, TSR4 and TSR5, diluted 
1/5,000 in buffer 1, and incubated for 1 h at 37°C. For the BSA 
negative control, mouse anti-BSA monoclonal antibody (Sigma-
Aldrich) was used (1/5,000 dilution). Plates were washed an 
additional three times in buffer 1 and then incubated with goat 
anti-mouse IgG-horseradish peroxidase conjugate (Sigma-
Aldrich), diluted 1/5,000 in buffer 1. The substrate p-nitrophenol 
phosphate (Sigma-Aldrich) was then added to each well, and the 
plates read at 405 nm.
Fluorescence Microscopy for  
Tsr4+5 Binding to Mycobacteria
Mycobacterium bovis BCG bacteria (approximately 106 cells) 
were spotted on poly-l-lysine coated microscope slides (Sigma-
Aldrich) and incubated at 37°C for cells to adhere. After washing 
three times with PBS, bacterial cells were then fixed with 4% 
paraformaldehyde for 5 min. Slides were washed three times with 
PBS and then incubated at 37°C for 1 h with 0, 1, or 10 μg/ml of 
TSR4+5, or 10 µg/ml of BSA (negative control) in buffer 1. Slides 
were washed three times with PBS, and then the primary mono-
clonal antibody (mouse anti-MBP) added at 1/500 dilution and 
incubated for 1 h at room temperature. After washing three times 
with PBS, goat anti-mouse conjugated with AlexaFluor488 (1/500 
dilution) was added as the secondary antibody and incubated for 
1 h at room temperature. Slides were then washed three times 
with PBS and mounted with antifade (Citifluor AF3) PBS solu-
tion and viewed using a LeicaDM4000 Fluorescence microscope. 
Images were processed using Image J.1
1 http://imagej.nih.gov/ij.
TaBle 1 | Primers used for quantitative real-time PCR.
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Phagocytosis assay
THP-1 macrophage cells were cultured in RPMI-1640 (Gibco) 
(RPMI) containing 10% (v/v) fetal bovine serum (FBS) (Sigma-
Aldrich), 2 mM l-glutamine (Sigma-Aldrich), 100 U/ml penicil-
lin (Sigma-Aldrich), 100  µg/ml streptomycin (Sigma-Aldrich), 
and 1 mM sodium pyruvate (Sigma-Aldrich) and left to grow in 
5% CO2 at 37°C for approximately 3 days before passaging. Cells 
were resuspended in RPMI and adjusted to 1 × 106 cells/well (in 
1.8 ml) in a 24-well plate. To induce adherence onto the wells, 
THP-1 cells were treated with 50 ng/ml of phorbol 12-myristate 
13-acetate (PMA) (Sigma-Aldrich) into RPMI-1640 without FBS, 
penicillin or streptomycin and left to settle for at least 30  min 
before adding 200 µl of bacterial culture (1 × 109 bacteria/ml).
M. bovis BCG bacteria were pelleted at mid-exponential 
phase, at an OD600nm = 0.6–1.0 by centrifugation at 1,000 × g for 
10 min at 4°C. The mycobacterial pellet was resuspended in the 
buffer 1. This mycobacterial culture was then separated into dif-
ferent microfuge tubes and treated with varying concentrations 
of properdin (2 or 20  µg/ml) or MBP-TSR4+5 (1 or 5 µg/ml). 
Control samples were left untreated, and all were incubated for 2 h 
at 37°C for binding to occur. The mycobacterial suspension was 
washed once in growth medium before resuspending in RPMI 
medium without FBS, penicillin, or streptomycin. 200 µl of the 
mycobacterial suspension was added to each well of THP-1 cells. 
Mycobacterial concentration was adjusted to give approximate 
multiplicity of infection (MOI) ratio of 10:1.
Plates were gently swirled and incubated at 37°C, 5% CO2 
for up to 48 h to allow mycobacterial uptake. THP-1 cells were 
sampled at 15, 30, and 45 min and 1, 2, and 6 h. Supernatants were 
collected after 24 and 48 h of incubation for multiplex analysis. 
Plates were washed three times with PBS to remove extracellular 
bacteria. THP-1 cells were then lifted by adding 1 ml of 0.25% 
trypsin to the wells and incubated for 10 min at 37°C, 5% CO2. 
THP-1 cells were collected by centrifugation at 1,000  ×  g for 
10 min at 4°C.
To recover and count the ingested mycobacteria, THP-1 cells 
were lysed by resuspending the cell pellets in 1 ml of sterile water, 
followed by a series of vortex mixing for 10 min at room tempera-
ture. 24-well plates containing 2 ml Middlebrook 7H10 agar with 
10% Oleic Acid+ADC (OADC) (BD, BBL, Becton Dickinson) 
were prepared. Four serial 1/10 dilutions were made, and 10 µl of 
the concentrated mycobacterial suspension and diluted suspen-
sion from each time point was spotted onto the 7H10 agar wells. 
The 24-well plates were secured with parafilm and wrapped in 
aluminum foil, inverted and incubated at 37°C for 10–14 days. 
Wells were photographed, and the colony-forming unit (CFU) 
count determined. The same procedure was used to quantify the 
initial input number of bacteria incubated with THP-1 cells.
Fluorescence Microscopy  
for Phagocytosis assay
THP-1 cells were cultured as described above and seeded at 
1 × 105 cells per 13 mm coverslip and differentiated with PMA 
as described above. GFP-expressing M. bovis BCG was incubated 
with 0, 1, 10 µg/ml of TSR4+5 for 2 h at 37°C in buffer 1. Cells 
were also incubated with 10 µg/ml of BSA as a negative control. 
Cells were washed twice in PBS and then resuspended in plain 
RPMI media. 1 × 106 GFP-M. bovis BCG was added to the THP-1 
cells (MOI of 10:1) and incubated for phagocytosis for 2 h at 37°C. 
THP-1 cells were then washed three times in PBS to remove 
extracellular bacteria and then fixed in 4% paraformaldehyde 
for 5 min. After washing three times in PBS, THP-1 cells were 
incubated with 2 µg/ml of AlexaFluor546-conjugated wheat germ 
agglutinin (Invitrogen) to reveal the plasma membrane. Cells 
were then washed three times and mounted using Vectashield 
antifade with DAPI (Vector Labs) to reveal nucleus. Slides were 
observed under a Leica DM4000 fluorescence microscope at 40× 
magnification. Images were processed using Image J (see text 
footnote 1).
Quantitative real-Time Pcr (qPcr) 
analysis of mrna expression of cytokines
THP-1 cell pellets were collected from each time point as described 
above. RNA extraction was performed using the GenElute 
Mammalian Total RNA Purification Kit (Sigma-Aldrich) accord-
ing to the manufacturer’s protocol. Samples were then treated 
with DNase I (Sigma-Aldrich) to remove any contaminating 
DNA according to the manufacturer’s protocol. The amount of 
RNA was measured using the NanoDrop 2000/2000c spectro-
photometer (Thermo Fisher Scientific) at 260 nm, and the ratio of 
absorbance at 260 and 280 nm was used to assess the purity of the 
RNA. Complementary DNA (cDNA) was synthesized using High 
Capacity RNA to cDNA Kit (Applied Biosystems, UK) according 
to the manufacturer’s protocol. Primer sequences (Table 1) were 
designed and analyzed for specificity using the nucleotide Basic 
Local Alignment Search Tool and Primer-BLAST.2
PCR was performed on all cDNA samples to assess the 
quality of the cDNA. The qPCR assays were performed for the 
expression of pro- and anti-inflammatory cytokines. The qPCR 
reaction consisted of 5 µl Power SYBR Green MasterMix (Applied 
Biosystems), 75 nM of forward and reverse primer, 500 ng tem-
plate cDNA in a 10 µl final reaction volume. qPCR was performed 
in a 7900HT Fast Real-Time PCR System (Applied Biosystems). 
The initial steps were 2  min incubation at 50°C followed by 
10 min incubation at 95°C, the template was then amplified for 
40 cycles under these conditions: 15  s incubation at 95°C and 
1  min incubation at 60°C. Samples were normalized using the 
expression of human 18S rRNA. Data were analyzed using the 
relative quantification (RQ) Manager Version 1.2.1 (Applied 
Biosystems). Cycle threshold (Ct) values for each cytokine target 
2 http://blast.ncbi.nlm.nih.gov/Blast.cgi.
FigUre 1 | Purified human properdin and recombinant maltose-binding protein (MBP)-thrombospondin repeats (TSR) 4+5. (a) Properdin was purified from human 
plasma. Filtered plasma was applied to a non-immune IgG-Sepharose column, then to a mouse monoclonal anti-properdin Sepharose column; properdin was 
eluted with 3 M MgCl2. The eluted samples were dialyzed against HEPES buffer (10 mM HEPES, 140 mM NaCl, 0.5 mM EDTA, pH 7.4) overnight at 4°C. 
Contaminants were removed by applying the protein to a Q Sepharose column, and the product appears as a single band on SDS-PAGE and western blot at about 
55 kDa. (B) MBP-TSR4+5 was purified via an amylose resin column, and the purified fusion protein also appears on SDS-PAGE as a band of about 55 kDa.
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gene were calculated, and the relative expression of each cytokine 
target gene was calculated using the RQ value, using the formula: 
RQ = 2−ΔΔCt for each cytokine target gene, and comparing relative 
expression with that of the 18S rRNA constitutive gene product. 
Assays were conducted twice in triplicate.
Multiplex analysis
Supernatants were collected from the phagocytosis assay at 24 
and 48  h to determine the levels of secreted cytokines (IL-6, 
IL-10, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, 
IL-17A, IL-9, and TNF-β), chemokines (MCP-3, MDC, Eotaxin, 
Fractalkine, GRO, IL-8, IP-10, MCP-1, and MIP-1α), growth fac-
tors (IL-2, EGF, FGF-2, G-CSF, GM-CSF, IL-3, IL-4, IL-5, IL-7, and 
VEGF), and other related ligands and receptors (IFN-α2, IFN-ϒ, 
FLT-3L, IL-1RA, and sCD40L). MagPix Milliplex kit (EMD 
Millipore) was used to measure immune response following the 
manufacturer’s protocol. 25 µl of assay buffer was added to each 
well of a 96-well plate, followed by the addition of 25 µl of standard, 
controls or supernatants of cells treated with M. bovis BCG in the 
presence or absence of properdin and MBP-TSR4+5. 25 µl of mag-
netic beads coupled to analytes of interest was added in each well 
and incubated for 18 h at 4°C. The 96-well plate was washed with 
the assay buffer, and 25 µl of detection antibodies was incubated 
with the beads for 1 h at room temperature. 25 µl of streptavidin– 
phycoerythrin was then added to each well and incubated for 
30 min at room temperature with shaking at 750 rpm. Following 
a washing step, 150 µl of sheath fluid was added to each well, and 
the plate was read using the Luminex Magpix instrument. Assays 
were conducted in duplicate.
statistical analysis
Analysis of data for statistical significance was conducted using 
GraphPad Prism 6 for Windows (GraphPad Software, Inc.). 
Statistical analyses were made using two-way ANOVA for mRNA 
expression data and a one-way ANOVA for the multiplex data. 
p Values < 0.05 were considered statistically significant, unless 
otherwise stated (non-significant).
resUlTs
human Properdin and Tsr4+5  
Bind to Mycobacteria
Human properdin was purified from human plasma. SDS-PAGE, 
followed by western blotting using antihuman properdin poly-
clonal antibodies, showed a distinct band at 55 kDa (Figure 1A), 
which was the expected molecular weight of the glycosylated 
monomer. The two biologically active modules of properdin 
TSR4 and TSR5 were expressed together in tandem as previously 
described, fused to MBP (7), and is also shown on an SDS-PAGE 
gel, which has a molecular weight of 55 kDa (Figure 1B). Using 
gel filtration chromatography, we found that human properdin 
eluted as a mixture of monomer, dimer and trimer; a negligible 
amount probably formed aggregates. Nearly 60% of MBP-TSR4+5 
appeared as a monomer while nearly 40% was found to migrate as 
a dimer (data not shown).
The binding of properdin to M. bovis BCG was observed to 
be in a dose-dependent manner; BSA was used as a negative 
control that showed almost no binding (Figure  2A). TSR4+5 
binding was also observed to be in a dose-dependent manner. 
MBP was used as a negative control (Figure 2B). The two binding 
curves cannot be compared quantitatively, as different detection 
antibodies were used. Because the MBP-TSR4+5 recombinant 
protein and properdin monomer have about the same molecular 
weight, 5 µg of TSR4+5 corresponds in molar terms to about 5 µg 
of properdin monomer (Figures 1A,B). The binding of a mixture 
of the two separately expressed TSR4, and TSR5 is much lower 
than that of the combined expressed TSR4+5 (Figure 2B). For 
this comparison, the same detection antibody was used. These 
results suggest that both TSR4 and TSR5 modules contribute 
to the interaction with M. bovis BCG, and that TSR4+5 binds 
FigUre 2 | Human properdin binds mycobacteria via thrombospondin 
repeats (TSR) 4+5. (a) Properdin binding to mycobacteria; BSA was used as 
a negative control protein. (B) Comparison between TSR4+5 and individual 
TSR4 and TSR5 binding to mycobacteria; maltose-binding protein (MBP) as 
negative control. Assays were conducted in 10 mM HEPES, 140 mM NaCl, 
0.5 mM CaCl2 + 0.5 mM MgCl2, 100 µg/ml hen ovalbumin, and pH 7.5. 
Serial dilutions of properdin were incubated in mycobacteria coated wells 
followed by incubation with mouse anti-properdin monoclonal antibody and 
mouse anti-BSA monoclonal antibody, respectively; serial dilutions of 
TSR4+5, TSR4 or TSR5 were incubated in another set of mycobacteria 
coated wells followed by incubation with mouse anti-MBP monoclonal 
antibody. Anti-mouse IgG conjugated with alkaline phosphatase and 
substrate p-nitrophenol phosphate were incubated in both sets of wells, and 
the color was measured at 405 nm using a plate reader. Assay was 
conducted in quadruplicate. Error bars represent SD. (c) Differential direct 
binding of 0, 1, and 10 µg/ml of TSR4+5 to Mycobacterium bovis BCG. 
10 µg/ml of BSA was used as a negative control. Cells were incubated for 
2 h with either TSR4+5 or BSA. Cells were washed, fixed, and stained with 
mouse anti-MBP monoclonal antibody followed by goat anti-mouse 
1gG-conjugated with AlexaFluor488. Images are shown as single sections 
taken using a Leica DM4000 microscope; bar scale 10 µm.
FigUre 2 | Continued
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with similar characteristics to that of whole properdin on 
M. bovis BCG surface. These results were further confirmed using 
microscopy where TSR4+5 specifically bound to M. bovis BCG in 
a dose-dependent manner (Figure 2C).
Properdin inhibits Uptake of M. bovis  
Bcg by ThP-1 cells
Properdin inhibited the uptake of M. bovis BCG by THP-1 
cells. At a concentration of 20 µg/ml, uptake of  M. bovis BCG 
was significantly reduced by properdin (Figure  3A). TSR4+5 
was also able to substantially inhibit uptake of M. bovis  
BCG by THP-1 cells (Figure  3B). The effect of properdin and 
TSR4+5 on the phagocytosis of M. bovis BCG was dose depend-
ent. The input number of M. bovis BCG was about 7.8 × 106 CFU/
ml, which was the total number of bacteria added to THP-1 
cells. Without properdin or TSR4+5, 5.0  ×  106  CFU/ml of M. 
bovis BCG was phagocytosed which was approximately 66% 
efficiency of phagocytosis compared with the input number. 
At the highest concentration tested, properdin showed an 
inhibition of uptake of approximately 60% compared with 
M. bovis BCG with no properdin (Figure  3A). For TSR4+5, 
the effect on M. bovis BCG was slightly lower at approxi-
mately 40% inhibition (Figure  3B). These results were also 
confirmed by microscopy, with TSR4+5 having a suppres-
sive effect on the uptake of GFP-expressing M. bovis BCG 
by THP-1 cells (Figure  3C). PMA stimulation was used to 
induce differentiation of THP-1 cells before incubation with 
M. bovis BCG. PMA has been shown to activate protein kinase 
C and increase cell adherence and expression of surface mark-
ers associated with macrophage differentiation (30). These data 
show that (i) properdin has an anti-opsonic effect on M. bovis 
BCG, inhibiting phagocytosis; and (ii) TSR4+5 modules play a 
major role in this interaction of M. bovis BCG and macrophages. 
These observations demonstrate, for the first time, a novel, 
non-complement-related role for properdin in host–pathogen 
interactions in tuberculosis.
Properdin induces a Pro-inflammatory 
response During the early Phase of 
Phagocytosis of M. bovis Bcg by  
ThP-1 cells
The effect of properdin on the inflammatory response during the 
phagocytosis of M. bovis BCG was measured. The gene expres-
sion of key pro- and anti-inflammatory cytokines in tuberculosis 
was determined using quantitative real-time PCR. Our data 
showed that properdin significantly enhanced the upregulation of 
pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 from THP-1 
cells challenged by M. bovis BCG (Figure 4A), particularly at the 
FigUre 3 | Continued
FigUre 3 | Effect of properdin and thrombospondin repeats (TSR) 4+5 on 
the phagocytosis of Mycobacterium bovis BCG by THP-1 cells. (a) M. bovis 
BCG was treated with properdin at concentrations of 0, 2, and 20 µg/ml or 
with (B) TSR4+5 at concentrations 0, 1, and 5 µg/ml. The mycobacteria 
were incubated with macrophage for 2 h. After THP-1 cell lysis, surviving 
internalized M. bovis BCG were measured by plating lysates on 7H10 media 
to obtain colony-forming units (CFUs). The input value is the starting number 
of M. bovis BCG added to the THP-1 cells, before phagocytosis. A one-way 
ANOVA test was performed on the data to determine significant differences 
in CFU count by properdin or TSR4+5. All comparisons were significant 
(p < 0.05), unless where shown (ns, not significant, p > 0.05). Samples were 
analyzed in triplicate. (c) Differential uptake of GFP-M. bovis BCG by THP-1 
macrophages after treatment with 0, 1, and 10 µg/ml of TSR4+5, or 10 µg/
ml of BSA, used as a negative control. Cells were incubated for 2 h. Cells 
were then washed, fixed, and stained with AlexaFluor546-conjugated wheat 
germ agglutinin to reveal the plasma membrane (red), and the nucleus was 
stained with DAPI (blue). Images are shown as single sections, taken using a 
Leica DM4000 microscope; bar scale 10 µm.
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anti-inflammatory cytokines measured from THP-1 cells (IL-10 
and TGF-β) were shown to be downregulated in the presence of 
properdin, when challenged by M. bovis BCG (Figure 4B). IL-12 
also appeared to be downregulated (Figure  4A). Properdin, 
therefore, appears to play an important role in pro-inflammatory 
cytokine production by macrophages infected by M. bovis BCG, 
which may have significant implications in shaping the adaptive 
immune response during M. tuberculosis infection.
Cytokine gene expression by THP-1 cells infected with M. bovis 
BCG were also studied in the presence of TSR4+5, which 
revealed that TSR4+5 also has a significant effect on the pro- 
inflammatory response. TNF-α was upregulated (Figure  5A), 
while IL-10 was found to be downregulated (Figure  5B), dur-
ing the first hour of phagocytosis. IL-12 was also shown to be 
significantly downregulated (Figure 5A). These data mirror the 
observations for properdin, and hence, validate the importance 
of TSR4+5 in the binding of properdin to M. bovis BCG and in 
its modulation of the inflammatory response. These data are also 
similar to recent published observations of another complement 
regulatory protein, factor H (19), thus offering potentially novel 
insights into the involvement of these proteins in host–pathogen 
interactions in tuberculosis.
Multiplex analysis of cytokine secretion
The inflammatory response during the phagocytosis of M. bovis 
BCG by THP-1 cells was further determined by measuring the 
secretion of cytokines, chemokines, and other growth factors 
using the Multiplex analysis of supernatants collected at 24 
and 48  h post phagocytosis (Figures  6A–D). The secretion 
of pro-inflammatory cytokines TNF-α, IL-1β, and IL-1α was 
significantly enhanced by treatment with properdin or TSR4+5 
at the 24 h time point (Figure 6A). The enhancement of these 
pro-inflammatory cytokines can be critical for controlling 
mycobacterial infection, particularly in the formation of the 
granuloma. However, by 48  h, there was a decrease in the 
production of pro-inflammatory cytokines (IL-6, IL-12p40, 
IL-12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, and IL-9) in the 
presence of properdin- and TSR4+5-treated M. bovis BCG 
(Figure  6A). Properdin and TSR4+5 also downregulated the 
initial stage of uptake (within the first hour of phagocytosis), 
which decreased gradually toward the later stages of phagocy-
tosis. The increase in TNF-α transcript was particularly striking 
as TNF-α is well known for activating macrophages for killing of 
intracellular mycobacteria. In addition, TNF-α is a key media-
tor in the early stages of granuloma formation. By contrast, the 
FigUre 4 | Temporal mRNA expression profile of cytokines produced by THP-1 cells incubated with different concentrations of properdin and Mycobacterium bovis 
BCG. (a) Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and IL-12; (B) anti-inflammatory cytokines: TGF-β and IL-10. The expression of each cytokine was 
measured using qPCR, and the relative expression [relative quantification (RQ)] calculated by normalizing the data using human 18S rRNA expression as a control. 
The RQ value was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted twice in triplicates. Error bars represent SD. A two-way ANOVA test was 
performed on the data to determine significant differences in expression of cytokine production by properdin. All comparisons were significant (p < 0.05), unless 
where shown (ns, not significant, p > 0.05).
8
Al-Mozaini et al. Interaction of Human Properdin With M. bovis BCG
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 533
anti-inflammatory response such as IL-10 after 24 and 48 h of 
phagocytosis, although this was less pronounced for IL-12 at 
48  h (Figure  6A). These observations again mirror the initial 
responses observed in cytokine gene expression of during the 
first few hours of phagocytosis, in the presence of properdin or 
TSR4+5 (Figures 5A,B). The effect of properdin and TSR4+5 
also led to marked downregulation of a number of growth 
factors MCP-3 (24 h), MDC, Eotaxin, Fractalkine (24 h), GRO 
FigUre 5 | Temporal mRNA expression profile of cytokines produced by THP-1 cells incubated with different concentrations of thrombospondin repeats (TSR) 4+5 
and Mycobacterium bovis BCG. (a) Pro-inflammatory cytokines: TNF-α and IL-12; (B) anti-inflammatory cytokine: IL-10. The expression of each cytokine was 
measured using qPCR, and the relative expression [relative quantification (RQ)] calculated by normalizing the data using human 18S rRNA expression as a control. 
The RQ value was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted twice in triplicates. Error bars represent SD. A two-way ANOVA test was 
performed on the data to determine significant differences in expression of cytokine production by TSR4+5. All comparisons were significant (p < 0.05), unless 
where shown (ns, not significant, p > 0.05).
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(24  h), IP-10, MCP-1, MIP-1, VEGF, G-CSF (48  h), GM-CSF 
(48 h), and VEGF (24 h) (Figures 6B,C). Additional ligands and 
receptors (IFN-α2, IFN-γ, FLT-3L, IL-1RA, and sCD40L) did 
not show any significant changes (Figure 6D).
DiscUssiOn
We have previously shown that a complement regulatory protein, 
factor H, can bind to M. bovis BCG and inhibit its uptake by 
THP-1 macrophages (19). Factor H can also enhance the pro-
inflammatory response during this host–pathogen interaction 
(19). This study highlighted a novel complement-independent 
property of factor H as an anti-opsonin and in the modulation of 
the inflammatory response against a pathogen. With the goal of 
further elucidating the role of complement control proteins in the 
early stages of mycobacterial infection, this study looked at the 
role of properdin, an upregulator of the alternative complement 
pathway. Properdin and thrombospondin repeat (TSR) modules 
TSR4+5 were shown to bind to M. bovis BCG and inhibit bacterial 
uptake by THP-1 cells, augmenting the inflammatory response. 
These observations are similar to what has been observed previ-
ously with factor H (19), which is intriguing, since properdin and 
factor H have opposing effects on the regulation of complement 
activation (3). These findings were also consistent with previous 
reports, which have demonstrated that properdin deficient mice 
have a reduced M1 (IL-1β) and increased M2 (arginase-1, MCP-
1, IL-10) profile, crucial for the tumor microenvironment (31). 
This suggests that the production of IL-1β and reduction in IL-10 
mediated by properdin may be required for protection against M. 
tuberculosis in the initial phase of infection.
The functions of properdin have been extensively investigated 
within the remit of the complement alternative pathway, and 
FigUre 6 | Continued
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FigUre 6 | Multiplex cytokine analysis of supernatants collected at 24 and 48 h phagocytosis of Mycobacterium bovis BCG by THP-1 cells incubated with or 
without properdin and thrombospondin repeats (TSR) 4+5. The supernatants were collected from phagocytosis assay of M. bovis BCG in the presence or absence 
of properdin and TSR4+5 at 24 and 48 h time point. The levels of cytokine production were measured for (a) (IL-6, IL-10, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, 
IL-13, IL-15, IL-17A, IL-9, and TNF-β), (B) chemokines (MCP-3, MDC, Eotaxin, Fractalkine, GRO, IL-8, IP-10, MCP-1, and MIP-1α), (c) growth factors (IL-9, IL-2, 
EGF, FGF-2, G-CSF, GM-CSF, IL-3, IL-4, IL-5, IL-7, and VEGF), and (D) related ligands and receptors (IFN-α2, IFN-γ, FLT-3L, IL-1RA, and sCD40L) using multiplex 
analysis. Error bars represent SD. A one-way ANOVA test was performed on the data to determine significant differences in expression of cytokine production by 
properdin or TSR4+5. All comparisons were significant (p < 0.05), unless where shown (ns, not significant, p > 0.05). Supernatants were analyzed in duplicate.
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its involvement with pathogens has largely been characterized 
as complement dependent. In this study, we aimed to look at 
the complement-independent interaction of properdin with 
mycobacteria (i.e., effects in the absence of other complement 
proteins), with a view to examining its possible role in the patho-
genesis of tuberculosis. The role of complement in tuberculosis 
has been examined, but little is understood about the role of 
the individual complement proteins in tuberculosis infection, 
especially complement control proteins. Properdin has been 
shown to play a role in a number of pathogenic infections 
such as those by C. pneumoniae, in which properdin promotes 
complement C3b deposition and opsonization (12). A recent 
study also demonstrated that a low dose of properdin, which 
is highly polymerized, is able to protect against N. meningitidis 
and Streptococcus pneumoniae, by assembling the alternative 
complement pathway (16). The central premise in these recent 
studies is that properdin is an upregulator of the complement 
alternative pathway, and thus, when in contact with pathogens, 
the alternative pathway is triggered and stabilized by properdin.
Properdin has also been shown to enhance the uptake of apop-
totic T cells by dendritic cells (DCs) and macrophages, thus pro-
moting phagocytosis (27). Properdin may also bind to the DNA 
found to be exposed on apoptotic and necrotic cells, suggesting 
that this may also be a crucial site for alternative pathway activation 
(32). There is recent evidence to suggest that properdin, locally 
produced by tolerogenic DCs, binds to necrotic cells, confirming 
its role a pattern recognition molecule of the innate immunity. In 
addition, properdin is also involved in the interaction of DC and 
T cell responses. Interestingly, silencing of properdin by treating 
DCs with siRNA in the presence/absence of IFN-γ reduced the 
proliferation of allogenic T  cells (33). Properdin binds to early 
apoptotic cells via sulfated GAGs, resulting in C3b deposition and 
uptake by phagocytes. Activation of neutrophils drives the deposi-
tion of properdin, which binds apoptotic T cells. Since properdin 
has been shown to bind apoptotic cells via GAGs (27) or DNA, 
it remains unclear what other ligands and receptors are involved 
in properdin–apoptotic cell interaction. It is likely that properdin 
as a soluble factor is acting as an adaptor molecule. Furthermore, 
properdin also binds to NKp46 expressed on natural killer cells, 
innate lymphoid cells (ILC)1 and ILC3. This study demonstrated 
that the control of meningococcal infection was dependent on 
NKp46 and group 1 ILCs, further elucidating the role of properdin 
as an independent pattern recognition molecule (34).
In our study, we show that purified native properdin and 
TSR4+5 bind to M. bovis BCG in a dose-dependent manner, 
suggesting that the binding of properdin to M. bovis BCG may 
be via TSR4+5. The physiological concentration of properdin in 
serum is about 25 µg/ml (35). We also demonstrate that coating of 
M. bovis BCG with properdin inhibits the uptake of the bacterium 
by THP-1 cells; however, only about 60% inhibition was achieved 
at the highest dose of native properdin. TSR4+5 was also able to 
mirror the effects of properdin, in inhibiting the uptake of M. 
bovis BCG by macrophages by up to 40%.
The recruitment of properdin by mycobacteria may be particu-
larly crucial in the initial stages of tuberculosis infection, when 
after inhalation, the first host cell M. tuberculosis encounters is 
the alveolar macrophage.
In the lungs, mycobacteria are phagocytosed by alveolar 
macro phages, which are unable to completely eliminate them, 
and so produce crucial chemoattractants (36), which recruit 
inflammatory cells such as neutrophils, macrophages, γδ-T cells, 
and natural killer cells that stimulate inflammation and tissue 
remodeling (36–38). Our findings may be indicative of the 
early inflammatory processes in  vivo, involved in granuloma 
formation, which are nodular-type lesions that cordon-off M. 
tuberculosis infection, and provide an environment for the bacilli 
to persist and survive as a latent infection. TNF-α and IFN-γ are 
involved in recruitment of cells in the granuloma (39, 40). Thus, 
properdin may play a role in granuloma formation by promoting 
pro-inflammatory cytokines. Inflammatory balance is essential 
particularly of Th2/Th1 cytokines, which are required to maintain 
a protective granuloma (41). This is determined by the balance 
in IFN-γ/TNF-α versus IL-4/IL-10/TGF-β within the granuloma. 
Properdin and TSR4+5 may be implicated in maintaining this 
balance. It is not known whether complement proteins reside in 
the granuloma; however, during infection, complement proteins 
may be produced locally at sites of infection. Properdin may be 
secreted by neutrophils, monocytes and T cells locally at the site 
of infection (3). Thus, innate immune molecules residing in or 
being recruited at sites of infection may play a role in the balance 
of Th1/Th2, which may cause granuloma necrosis and replication 
of M. tuberculosis (41–43).
TNF-α was dramatically increased in the first 24 h of phago-
cytosis in the presence of properdin and TSR4+5, compared 
to non-treated mycobacteria. TNF-α plays a major role in 
granuloma formation and our results suggest that properdin may 
have a role in potentiating the pro-inflammatory response that 
results in granuloma formation. These observations are further 
strengthened by the concurrent increase in IL-1α levels over 24 h 
which have been shown to be key in macrophage proliferation 
and maturation during granuloma formation (44).
During phagocytosis, pro- and anti-inflammatory 
cytokines were produced by THP-1 cells when treated with 
properdin or TSR4+5. In the initial stages of infection by 
M. bovis BCG, pretreated with properdin, during phagocytosis, 
the expression of TNF-α was significantly enhanced. Other pro-
inflammatory responses that were also elevated in the presence of 
properdin at initial stages of infection are IL-1β and IL-6. IL-1β is 
a mediator of inflammation and is required for host resistance to 
M. tuberculosis infection (45). IL-6 is a biomarker for tuberculo-
sis, as increased levels are observed in patients with tuberculosis 
(46) that is required for a T cell response against M. tuberculosis 
infection (47, 48). Conversely, IL-10, IL-12, and TGF-β were 
downregulated by properdin, thus suppressing the anti-inflam-
matory response. The downregulation of IL-12 by properdin 
in vivo may suppress the Th1 response. TSR4+5 was also able to 
mimic the cytokine response like properdin, suggesting that the 
modules responsible for the major part of the interaction with 
M. bovis BCG may be TSR4+5.
Macrophages play a significant role in the innate immune 
response to pathogens and so are also crucial for an adaptive 
immune response (49). However, M. tuberculosis can evade the 
innate immune defense, inhibiting phagosome maturation (36), 
resisting anti-microbial agents damaging the bacterial cell wall 
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and facilitating replication within the host and escaping early 
immune recognition. Thus, these pathogens interfere with the 
early immune response and the induction of pro-inflammatory 
cytokines (49).
IL-10 and TGF-β suppression by properdin may enhance the 
clearance of mycobacteria by the host during the early stages of 
M. tuberculosis infection. After phagocystosis of M. tuberculosis, 
IL-10 has been shown to block phagolysosome maturation  and 
antigen presentation by macrophages, thus aiding the survival of 
the pathogen (50, 51). Furthermore, IL-10 can inhibit the gen-
eration of reactive oxygen and nitrogen intermediates in IFN-γ 
activated macrophages, which are required for intracellular kill-
ing (52, 53). The enhanced levels of IL-10 and TGF-β in the lungs 
of active tuberculosis patients demonstrate a weakened immune 
response to M. tuberculosis, and hence, a role in the pathogenesis 
and disease progression (54, 55). VEGF was also found to be at 
a significantly higher level in tuberculosis patients with extrapul-
monary tuberculosis (EPTB) than those with pulmonary disease 
(56). In our study, properdin and TSR4+5 seems to result in a 
marked elevation of VEGF after 48 h. Since our data also shows 
that mycobacteria have a reduced phagocytosis by macrophages, 
the resulting extracellular bacteria may be encouraged by VEGF 
to disseminate. The beneficial effect of properdin may be to 
inhibit the mechanisms involved in evasion and, thus, facilitate a 
protective response against mycobacterial infection.
The downregulation of IL-12 by properdin or TSR4+5 may 
be due to the reduced phagocytosis of M. bovis BCG, thus, 
downregulating the Th1 response. This may be necessary for the 
Th1/Th2 homeostasis in the protective granuloma (41, 57, 58). 
Both IL-10 and TGF-β levels were supressed, whilst TNF-α was 
elevated during the first 24 h after phagocytosis.
Although M. bovis BCG shares 99% genome homology to M. 
tuberculosis, there are some genetic differences which lead to its 
avirulence. The major difference between M. bovis BCG and M. 
tuberculosis is the large genomic deletion RD1, which causes the 
loss of various virulent genes coding for proteins such as ESAT-6, 
CFP-10 and also a bacterial secretion system (59, 60). Therefore 
the findings in our study will need to be validated using virulent 
strains of M. tuberculosis.
Properdin deficiency renders the host susceptible to a range 
of bacterial infections, especially Neisseria species. Three types 
of properdin deficiency have been reported: type I (absence of 
the properdin protein), type 2 (low level of properdin about 1–10% 
found in the serum), and type 3 deficiency (normal levels of 
protein being produced, but functionally defective). The most 
commonly reported deficiency is the type I properdin deficiency 
that exhibits fulminant infections. The incidence of tuberculosis 
has not been reported in properdin deficient subjects, possibly 
due to the majority of studies being in Scandinavia or west-
ern Europe, in populations where there is a low incidence of 
tuberculosis.
The data in this study suggest that properdin, via TSR4+5, 
may help in the clearance of mycobacterial infection by circum-
venting pathogen immune evasion strategies by upregulating 
the pro-inflammatory response. Properdin may also promote 
the formation and maintenance of the protective granuloma. 
The data in this study give further insights into the involve-
ment of complement regulatory proteins in shaping the cellular 
immune response against mycobacteria in a complement 
activation-independent manner. Further studies are needed 
to fully characterize the nature and extent of involvement of 
properdin in tuberculosis pathogenesis, particularly in the early 
stages of infection.
The complement-independent interaction between human 
properdin and mycobacteria is a novel observation, which is 
independent of C3b deposition and aggregation of properdin 
(61). This is consistent with our recent study where we have 
shown that properdin can recognize chemical patterns on 
nanoparticles via TSR4+5 and modulate immune response 
by THP-1 cells (26) without involving complement activa-
tion/deposition. In conclusion, properdin may be involved 
in modulating host-pathogen interactions in tuberculosis. 
However, further studies are needed on pathogenic M. 
tuberculosis and in vivo, to understand the precise role of 
this complement regulatory protein in pathogenesis, which 
may give new insights into therapies against this formidable 
disease.
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Human surfactant protein D (SP-D) is a potent innate immune molecule, which is emerg-
ing as a key molecule in the recognition and clearance of altered and non-self targets. 
Previous studies have shown that a recombinant fragment of human SP-D (rfhSP-D) 
induced apoptosis via p53-mediated apoptosis pathway in an eosinophilic leukemic cell 
line, AML14.3D10. Here, we report the ability of rfhSP-D to induce apoptosis via TNF-α/ 
Fas-mediated pathway regardless of the p53 status in human pancreatic adenocarci-
noma using Panc-1 (p53mt), MiaPaCa-2 (p53mt), and Capan-2 (p53wt) cell lines. Treatment 
of these cell lines with rfhSP-D for 24 h caused growth arrest in G1 cell cycle phase 
and triggered transcriptional upregulation of pro-apoptotic factors such as TNF-α and 
NF-κB. Translocation of NF-κB from the cytoplasm into the nucleus of pancreatic cancer 
cell lines was observed via immunofluorescence microscopy following treatment with 
rfhSP-D as compared to the untreated cells. The rfhSP-D treatment caused upregula-
tion of pro-apoptotic marker Fas, as analyzed via qPCR and western blot, which then 
triggered caspase cascade, as evident from cleavage of caspase 8 and 3 analyzed via 
western blot at 48 h. The cell number following the rfhSP-D treatment was reduced in the 
order of Panc-1 (~67%) > MiaPaCa-2 (~60%) > Capan-2 (~35%). This study appears to 
suggest that rfhSP-D can potentially be used to therapeutically target pancreatic cancer 
cells irrespective of their p53 phenotype.
Keywords: pancreatic cancer, innate immunity, surfactant protein D, apoptosis, immune surveillance
inTrODUcTiOn
Human surfactant protein D (SP-D), a member of soluble C-type lectin family called Collectins, 
plays a vital role in linking the innate and adaptive immunity to protect against infection, allergy, and 
inflammation (1). Although its homeostatic role in lungs has been widely studied, its specific func-
tions at extra-pulmonary tissues such as kidney, human trachea, brain, testis, heart, prostate, kidneys, 
and pancreas are poorly understood (1–3). SP-D deficiency in animal models has been shown to 
be associated with considerable pathophysiological consequences (4–6). SP-D gene knockout mice 
showed chronic inflammation and fibrosis due to accumulation of surfactant phospholipids in the 
lungs, monocytes infiltration, and activation of pro-inflammatory alveolar macrophages (5, 6). The 
absence of SP-D in children makes them more susceptible to frequent pneumonia as compared to 
Table 1 | Target genes and terminal primers used in the qPCR analysis.
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SP-D sufficient children (7). SFTPD (SP-D gene) polymorphisms 
increase the susceptibility to chronic and infectious lung diseases 
(8), pneumococcal lung disease (9), emphysema (10), tuberculo-
sis (11, 12), Crohn’s disease, and ulcerative colitis (12).
SP-D has been shown to be a potent innate immune molecule 
at pulmonary as well as extra-pulmonary mucosal surfaces 
by virtue of its ability to control inflammatory response and 
helper T cell polarization (3). The first clue came via a murine 
model of allergic hypersensitivity, when therapeutic treat-
ment with a recombinant fragment of human SP-D (rfhSP-D) 
lowered peripheral and pulmonary eosinophilia, in addition 
to specific IgE levels and Th2 cytokines in the spleen (13, 
14). It turned out that rfhSP-D selectively induced apoptosis 
in sensitized eosinophils derived from allergic patients (15). 
Using an eosinophilic cell line, AML14.3D10 (a model cell line 
for leukemia), it was established, via proteomics analysis, that 
apoptosis induction by rfhSP-D involved upregulation of p53 
(16, 17). Another crucial study by Pandit et al. (18) revealed 
that rfhSP-D was able to induce apoptosis in activated human 
PBMCs, but not in resting, non-activated PBMCs. These stud-
ies, for the first time, raised the possibility that SP-D can have 
a function of immune surveillance against activated self and 
perhaps altered self. Recently, human lung adenocarcinoma 
cells (A549 cell line), when exogenously treated with SP-D, 
showed suppressed epidermal growth factor (EGF) signaling 
by reducing the EGF binding to EGFR, which subsequently 
reduced the cell proliferation, invasion, and migration of 
cancer cells (19).
Here, we set out to examine a possible pro-apoptotic role of 
SP-D in pancreatic cancer. Pancreatic cancer is the fourth leading 
cause of cancer-related mortality in the western world (20, 21) 
and its 5-year survival rate is ~5% (22). The poor prognosis 
has been attributed to the silent nature of the tumor in early 
stages, aggressive phenotype, surgical complications, and lack 
of targeted efficacious therapies (23). In this study, we show that 
rfhSP-D, composed of 8 Gly-X-Y repeats, homotrimeric neck and 
carbohydrate recognition domains (CRDs) (1), induces cell 
growth arrest in G1 phase and subsequent apoptosis in human 
pancreatic adenocarcinoma cells using Panc-1, MiaPaCa-2, and 
Capan-2 cell lines. The apoptosis induction appears to involve 
TNF-α, NF-κB, and Fas axis, revealing a p53 independent route 
of apoptosis induction in the p53 mutated Panc-1 and MiaPaCa-2 
cell lines and p53-dependent apoptosis in p53 wild type Capan-2 
cell line by rfhSP-D.
MaTerials anD MeThODs
cell culture and Treatments
Human pancreatic cancer cells lines, Panc-1 (CRL-1469), 
MiaPaCa-2 (CRL-1420), and Capan-2 (HTB-80), were obtained 
from ATCC and used as an in vitro model in this study. All cell 
lines were cultured at 37°C under 5% v/v CO2 using DMEM-F12 
media (Thermo Fisher) containing 10% v/v fetal calf serum with 
2  mM l-glutamine, and penicillin (100  U/ml)/streptomycin 
(100  µg/ml) (Thermo Fisher) until 80–90% confluency was 
reached.
expression and Purification of rfhsP-D
Plasmid pUK-D1 (containing cDNA sequences for 8 Gly-X-Y 
repeats, neck, and CRD region of human SP-D), transformed 
into Escherichia coli BL21 (λDE3) pLysS (Invitrogen), was used 
to express rfhSP-D, as described earlier (15, 16). The expression 
cassette included a short stretch of eight N-terminal Gly–X–Y 
triplets with substitution of S for P in position 2 (residue 180), 
followed by the α-helical coiled-coil neck region (residues 203–235) 
and the globular CRD region (residues 236–355). Endotoxin 
levels were determined using the QCL-1000 Limulus amebocyte 
lysate system (Lonza) and the assay was found to be linear over 
a range of 0.1–1.0  EU/ml (10  EU  =  1  ng of endotoxin). The 
amount of endotoxin levels were <4 pg/μg of the rfhSP-D. Full 
length native SP-D (FL-SP-D) was purified form lung washings of 
alveolar proteinosis patients using methods previously described 
by Strong et al. (24).
Fluorescence Microscopy
All cell lines used in this study (Panc-1, MiaPaCa-2, and Capan-2) 
were grown on coverslips using 0.5 × 105 cells overnight. Next day, 
cells were washed three times with PBS before being incubated 
with rfhSP-D (20 µg/ml) in a serum-free DMEM-F12 medium. 
For rfhSP-D and FL-SP-D binding analysis, the coverslips were 
incubated for 1 h with mouse anti-human SP-D (rfhSP-D) and rab-
bit anti-human SP-D (FL-SP-D) (MRC Immunochemistry Unit, 
Oxford; 1:200), followed by goat anti-mouse IgG H&L (Cy5) and 
Goat anti-Rabbit IgG H&L Alexa Fluor 488 (1:500; Abcam), 
respectively, and Hoechst (1:10,000; Thermo Fisher) for fluores-
cence microscopy analysis. For apoptosis analysis via fluorescence 
microscopy using an FITC annexin V apoptosis detection kit with 
propidium iodide (PI) (BioLegend), the cells were incubated with 
rfhSP-D (20 µg/ml) for 48 h. After 48 h, the cells were incubated 
with annexin V binding buffer containing FITC annexin V (1:200), 
PI (1:200), and Hoechst (1:10,000) for 15 min, and washed twice 
with PBS before mounting on the slides to visualize under a HF14 
Leica DM4000 microscope.
Flow cytometry
Cell lines were plated in a 6-well plate (0.1 × 107) and incubated 
with rfhSP-D (20  µg/ml), FL-SP-D (10 and 20  µg/ml), and an 
FigUre 1 | (a) Fluorescence microscopy showing binding of rfhSP-D and (b) FL-SP-D (10 µg/ml; 1 h incubation) to Panc-1, MiaPaCa-2, and Capan-2 cells. The 
nucleus of the cells was stained with Hoechst. Cells were probed with mouse anti-human SP-D/CY5 (rfhSP-D) and rabbit anti-human/FITC (FL-SP-D); the bound 
proteins are visible on the cell membrane in the treated cells. No CY5 or FITC fluorescence was detected in the untreated control cells.
3
Kaur et al. Immune Surveillance by SP-D in Pancreatic Cancer
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1126
untreated control, for 24 and 48 h, followed by cell detachment 
using 5  mM EDTA, pH 8, and centrifugation at 1,200  ×  g for 
5 min. For cell cycle analysis, the cells were fixed in 70% v/v etha-
nol for 30 min at 4°C, followed by PBS wash twice at 850 × g. The 
cells were then treated with ribonuclease (100 µg/ml) to ensure 
DNA staining without RNA contamination before staining with 
PI (50 µg/ml). 10,000 cells were then acquired for both treated 
and untreated samples and the PI histograms were plotted using 
the set markers within the analysis program of Novocyte Flow 
Cytometer. For apoptosis analysis via FACS, FITC annexin V 
apoptosis detection kit with PI (BioLegend) was used, as per 
manufacturer’s instructions. Compensation parameters were 




bromide) (Thermo Fisher) assay was performed by incubating 
pancreatic cancer cells (0.1 × 105) in a 96-well microtiter plate 
with rfhSP-D, FL-SP-D (10 and 20  µg/ml), and an untreated 
control in serum-free DMEM-F12 medium for 48  h, followed 
by incubation with 50 µg/µl MTT (5 mg/ml stock) per well for 
4 h at 37°C. Majority of the media was removed leaving behind 
25 µl per well, which was mixed thoroughly with 50 µl of dimethyl 
FigUre 2 | Cell cycle analysis following 24 h treatment of pancreatic cancer cell lines with rfhSP-D. Propidium iodide (PI) was used to stain DNA. PI histograms 
were plotted using set markers within the analysis program of Novocyte Flow cytometer. The rfhSP-D treated pancreatic cancer cells show arrest in G1 phase in the 
case of Panc-1 (G1 phase: 68%; S phase: 13%; G2 phase: 11%) and MiaPaCa-2 (G1 phase: ~50%; S phase: 17%; G2 phase: 10%) cell line at 24 h, whereas 
untreated Panc-1 cells (G1 phase: 3%; S phase: 42%; G2 phase: 32%) and MiaPaCa-2 cells (G1 phase: 2%; S phase: 32%; G2 phase: 33%) progressed to the 
next cell cycle phases.
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sulfoxide and incubated for another 10 min at 37°C. The absorb-
ance was read at 570 nm using a plate reader.
Western blot
Cell lines (0.1 × 107 cells) were seeded in a 6-well plate (Nunc) and 
incubated with rfhSP-D (20 µg/ml), together with an untreated 
control, in a serum-free DMEM-F12 medium. The cells were 
lysed within the wells using treatment buffer (50 mM Tris-HCl 
pH 6.8, 2% v/v β-mercaptoethanol, 2% v/v SDS, 0.1% w/v 
bromophenol blue, and 10% v/v glycerol) and transferred to 
pre-cooled microcentrifuge tubes followed by sonication for 
15 s. The samples were heated at 100°C for 10 min and subjected 
to SDS-PAGE (12% w/v) for 90 min at 120 V. The SDS-PAGE 
separated proteins were then electrophoretically transferred 
onto a nitrocellulose membrane (Thermo Fisher) using an 
iBLOT (Thermo Fisher). The membrane was then blocked 
using 5% w/v dried milk powder (Sigma) in 100 ml PBS for 2 h 
on a rotatory shaker at room temperature. The membrane was 
incubated with rabbit anti-human caspase primary antibodies 
(anti-cleaved caspase 3; anti-cleaved caspase 8; Cell Signaling) 
at 4°C overnight, followed by incubation with secondary Goat 
anti-rabbit IgG HRP-conjugate (1:1,000; Promega) for 1  h 
at room temperature. The membrane was washed with PBST 
(PBS +  0.05% Tween 20) three times, 10  min each time. The 
color was developed using 3,3′-diaminobenzidine substrate kit 
(Thermo Fisher).
Quantitative rT-Pcr
Panc-1, MiaPaCa-2, and Capan-2 cells were incubated with and 
without rfhSP-D (20 µg/ml) for various time points. The cell pellet 
FigUre 3 | Continued
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FigUre 3 | (a) Fluorescence microscopy to analyze apoptosis in pancreatic cancer cell lines following treatment with rfhSP-D. Cells were treated with rfhSP-D for 
48 h and apoptosis was analyzed using an annexin V/propidium iodide (PI) staining kit. The cell membrane was positively stained for annexin V and the DNA staining 
is visible in the treated cells indicating that the cells underwent apoptosis turning the membrane inside out, thus making phosphatidylserine available for annexin V 
binding; due to the porous membrane, PI was taken in which stained the DNA of apoptotic cells. No such staining was seen in the untreated cells. The nucleus was 
stained with Hoechst for both treated and untreated cells. (b,c) Quantitative analysis of apoptosis using Flow Cytometer. Cells were treated with rfhSP-D or 
FL-SP-D for 48 h and apoptosis was analyzed using annexin V with PI kit. 10,000 cells were acquired and plotted for both annexin V/FITC and DNA/PI staining, 
which showed a shift in the fluorescence intensity of both FITC and PI between treated and untreated cells. Approximately 67% of Panc-1 cells, ~60% MiaPaCa-2 
cells, and ~35% Capan-2 cells underwent apoptosis following rfhSP-D treatment and ~25% Panc-1 and MiaPaCa-2 cells following FL-SP-D treatment as compared 
to untreated cells. No significant difference was seen in Capan-2 cells following FL-SP-D treatment. (D,e) MTT assay to assess cell viability following treatment with 
rfhSP-D and FL-SP-D (10 and 20 µg/ml) and untreated for 48 h (±SEM, of three independent experiments). Cell numbers were reduced by approximately 70% in 
the rfhSP-D-treated Panc-1, 60% in MiaPaCa-2, and 45% in Capan-2 cells, as compared to untreated cells. Cell numbers were reduced by approximately 25% in 
the Panc-1 and MiaPaCa-2 and less than 10% in Capan-2 cells treated with FL-SP-D as compared to untreated cells. Significance was established using the 
unpaired two-way ANOVA test (**p < 0.01, ****p < 0.0001, ns: non-significant) (n = 3).
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for each time-point was centrifuged and stored at −80°C. RNA 
was extracted using GenElute Mammalian Total RNA Purification 
Kit (Sigma-Aldrich, UK), as per manufacturer’s instructions, 
followed by treatment with DNase I (Sigma-Aldrich, UK). The 
absorbance at 260 and 260:280 nm ratio was used to determine 
the concentration and purity of total RNA, respectively, using 
NanoDrop 2000/2000c (Thermo-Fisher Scientific). Total RNA 
(2 µg) was used for cDNA synthesis using High Capacity RNA to 
cDNA Kit (Applied Biosystems). The forward and reverse primers 
used in this study were designed using the web based Basic Local 
Alignment Search Tool and Primer-BLAST (http://blast.ncbi.
nlm.nih.gov/Blast.cgi) are given in Table 1.
Relative mRNA expression was determined by qPCR reac-
tions performed in triplicates consisting of 10 µl final volume per 
well [5 µl Power SYBR Green MasterMix (Applied Biosystems), 
75 nM of forward and reverse primers, and 500 ng cDNA], using 
the 7900HT Fast Real-Time PCR System (Applied Biosystems). 
Samples were initially incubated at 50°C (2 min) and 95°C (10 min), 
followed by 40 cycles (each cycle for 15 s at 95°C and 1 min at 
60°C) for amplification of the template. Human 18S rRNA, an 
endogenous control, was used to normalize the gene expression. 
Relative quantification (RQ) value and formula: RQ = 2−ΔΔCt was 
used to calculate the relative expression of each target.
statistical analysis
Graphs were made and statistically analyzed using Graphpad 
Prism 6.0 by applying an unpaired two-way ANOVA test. 
Significance of values is based on *p  <  0.05, **p  <  0.01, 
***p  <  0.001, ****p  <  0.0001 between treated and untreated 
samples. Error bars represent the SD or SEM, as indicated in the 
figure legends.
resUlTs
rfhsP-D binds to a range of Pancreatic 
cell lines
The fluorescence microscopy analysis of rfhSP-D and FL-SP-D 
binding to Panc-1, MiaPaCa-2, and Capan-2 cells revealed its 
membrane localization following 1 h incubation at 4°C (Figure 1). 
The rfhSP-D probed with mouse anti-human SP-D-CY5 anti-
body and FL-SP-D probed with rabbit anti-human SP-D-FITC 
appeared evenly bound in clusters on the cell membrane, along 
with nucleus stained positively with Hoechst. All cell lines showed 
a similar rfhSP-D and FL-SP-D binding pattern. No CY5 or FITC 
fluorescence was detected in the untreated controls, probed with 
primary and secondary antibodies, for each cell line, suggesting 
the rfhSP-D and FL-SP-D binding observed in the treated cell 
lines was protein-specific.
rfhsP-D induces cell cycle arrest in  
g1 Phase in Panc-1 and MiaPaca-2
Panc-1, MiaPaCa-2, and Capan-2 cell lines were individually 
treated with rfhSP-D for 24 h to assess whether rfhSP-D induced 
growth arrest. DNA binding dye, PI, was used to analyze the cell 
cycle for both treated and untreated cells via DNA quantitation. 
rfhSP-D induced inhibition of DNA synthesis in treated Panc-1 
(68%) and MiaPaCa-2 (50%) in comp arison to untreated Panc-1 
(3%) and MiaPaCa-2 (2%) cells, respectively, as the cells were 
arrested in G1 phase (Figure 2). DNA synthesis was unaffected 
in the untreated cells for both cell lines since Panc-1 (43%) and 
MiaPaCa-2 (31%) were seen in S phase and Panc-1 (32%) and 
MiaPaCa-2 (33%) in the G2 phase of cell cycle. The growth arrest 
was, however, not seen in Capan-2 cell line following the rfhSP-
D treatment (data not shown). Growth arrest at 24 h following 
rfhSP-D treatment prompted the determination of cell fate at a 
later time point; therefore, all cell lines were analyzed for likely 
apoptosis at 48 h.
rfhsP-D induces apoptosis induction  
in Pancreatic cancer cells by 48 h
The qualitative apoptosis analysis of Panc-1, MiaPaCa-2, and 
Capan-2 treated with FL-SP-D or rfhSP-D for 48 h using immuno-
fluorescence microscopy (Figure 3A) showed that the cell mem-
brane was disoriented and the PI bound to DNA in the treated 
cells as compared to untreated cells, where no florescence was 
detected, indicating that cells were undergoing apoptosis at 48 h.
The flow cytometry analysis to quantify apoptosis showed 
significant reduction in the viable cell percentage of Panc-1, 
MiaPaCa-2, and Capan-2. The rfhSP-D induced apoptosis in 
~67% of Panc-1 cells at 48 h, out of which, ~57% Panc-1 cells 
were both FITC and PI positive and ~7% were FITC alone posi-
tive, suggesting annexin V/FITC binding to phosphatidylserine, 
a cell membrane phospholipid, which is externalized during early 
apoptotic stage and the passage of PI, a DNA stain, through the 
porous cell membrane into the nucleus in order to intercalate the 
DNA. Approximately, 10% cells were PI alone positive, which 
FigUre 4 | Cleavage of caspase 3 (a) and 8 (b) in pancreatic cancer cell lines following rfhSP-D treatment. Pancreatic cancer cell lines were analyzed for caspase 
8 and 3 activation via western blot using anti-rabbit cleaved caspase 3 and 8 (1:1,000) at 4°C overnight, followed by incubation with secondary anti-rabbit IgG 
HRP-conjugate (1:1,000) for 1 h at room temperature. The membrane was washed with PBST (PBS + 0.05% Tween 20) three times, 10 min each between each 
step. The bands were developed using 3,3′-diaminobenzidine substrate kit. The cleaved caspase 3 and 8 were detected only in the rfhSP-D treated samples of all 
cell lines, whereas no bands appeared in the untreated cell samples. Full-length caspase 8 bands are visible around 43 kDa. (c) Anti-GAPDH was used as a loading 
control.
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suggested that these cells were either dead or in late apoptotic 
stage. The percentage of viable cells, i.e., unstained, in the 
untreated sample was significantly higher (70%) as compared 
to treated (26%) (Figure 3B). The rfhSP-D induced apoptosis in 
MiaPaCa-2 was ~60%. However, rfhSP-D induced apoptosis in 
Capan-2 (~35%) cell line, which was not as much as in Panc-1 and 
MiaPaCa-2 cell lines (Figure 3B). The treatment with FL-SP-D 
(20 µg/ml) for 48 h induced apoptosis in approximately 25% of 
Panc-1 and MiaPaCa-2 cell lines, and less than 10% in Capan-2 cell 
line. No significant difference was seen with FL-SP-D (10 µg/ml) 
FigUre 5 | Relative quantification (RQ) of Fas mRNA expression in Panc-1, MiaPaCa-2, and Capan-2 cell lines treated with rfhSP-D (20 µg/ml) for 12 and 24 h.  
(a) Fas expression was upregulated in the treated samples at 12 and 24 h as compared to untreated cells. Significance was determined using the unpaired two-way 
ANOVA test (****p < 0.0001) (n = 3). (b) Fas expression via western blot analysis in pancreatic cell lines treated with rfhSP-D for 24 h using rabbit anti-human Fas 
(1:1,000) at 4°C overnight, followed by incubation with secondary anti-rabbit IgG HRP-conjugate (1:1,000) for 1 h at room temperature. The bands were developed 
using diaminobenzidine substrate kit. Fas expression at ~50 kDa was upregulated in the treated samples at 24 h for all cells as compared to untreated. Anti-GAPDH 
used as a loading control.
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treatment for 48 h in all the cell lines investigated in this study 
(Figure 3C).
The cell viability analysis via MTT assay following rfhSP-D 
treatment showed ~60% decrease in the cell viability of Panc-1 
and MiaPaCa-2 and 45% in Capan-2 as compared to untreated 
(Figure 3D) and BSA (10 and 20 µg/ml; data not shown) con-
trols. The cell viability analysis via MTT assay following FL-SP-D 
treatment also showed consistent reduction as seen in flow 
cytometer analysis (Figure 3E). Apoptosis was further confirmed 
by analyzing the activation of caspase to determine the pathway 
involved.
rfhsP-D activates cleavage of  
caspase 8 and 3
Western blot analysis revealed that caspase 8 and 3 were cleaved 
in all the cell lines following treatment with rfhSP-D for 48 h 
(Figure  4). The cleavage of caspase 3, however, was not seen 
in the untreated cells and faint bands appeared for caspase 8 in 
FigUre 6 | Relative quantification (RQ) of p53 mRNA expression in Capan-2 
cell line treated with rfhSP-D (20 µg/ml) for 2, 6, and 12 h. p53 expression 
was significantly upregulated in the rfhSP-D-treated samples at 2, 6, and 
12 h as compared to the untreated. Significance was determined using the 
unpaired two-way ANOVA test (****p < 0.0001) (n = 3).
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the untreated cells (Figure 4), which further confirmed that cell 
death occurred via apoptosis. Interestingly, although Capan-2 
cell line appeared unaffected in terms of cell cycle arrest at 24 h; 
yet, the cleaved bands for caspase 8 and 3 were seen in Capan-2 
treated cells too, which suggested that rfhSP-D can affect the 
cancer cells via multiple pathways. Caspase 9 was tested as a 
marker for intrinsic apoptosis pathway; however, no difference 
was noted between treated and untreated cells (data not shown). 
Therefore, gene expressions were assessed for pro-apoptotic 
genes such as Bax, an intrinsic pathway marker, and Fas, an 
extrinsic pathway marker, to further determine the apoptotic 
pathway.
rfhsP-D Upregulates the expression  
of Pro-apoptotic Marker, Fas
Human pancreatic cancer cells often escape apoptosis by down-
regulating apoptosis stimulators such as FasL/FasR (25), or 
pro-apoptotic proteins such as Bax (26). These pro-apoptotic 
genes, Bax and Fas, for time-points ranging from 2 to 24 h in 
all the cell lines, were analyzed. Bax was unaffected following 
the treatment with rfhSP-D in Panc-1 and MiaPaCa-2 cell lines 
at all time-points (data not shown), which, in addition to unaf-
fected caspase 9, suggested that intrinsic pathway may not have 
been involved in causing the cell death in these cell lines. Fas 
expression was unaffected at earlier time-points up to 6 h (data 
not shown); however, it was upregulated at 12 and 24 h in Panc-1 
(log10 ~0.5), MiaPaCa-2 (log10 ~1), and Capan-2 (log10 ~1) cell 
lines (Figure 5A), which indicated that apoptosis induction by 
rfhSP-D is likely to take place via the extrinsic pathway. Western 
blot analysis also showed upregulation of Fas at the protein 
level in rfhSP-D treated cells as compared to untreated cells 
(Figure 5B). Since TNF-α and NF-κB are crucial factors in the 
apoptotic pathway and they can regulate Fas expression (27), the 
effect of rfhSP-D on the gene expression of TNF-α and NF-κB 
as well as translocation of NF-κB from the cytoplasm to nucleus 
was investigated.
rfhsP-D Upregulates p53 expression  
in capan-2 cell line
The p53 transcript levels were measured by qPCR following the 
treatment with rfhSP-D at 2, 6, and 12 h in Capan-2 cells and com-
pared with the p53 levels in untreated cells for each time-point. 
Interestingly, the levels of p53 were upregulated, most significantly 
at 12  h, which suggested that p53 may also have contributed 
to the apoptosis in Capan-2 cells (Figure 6).
rfhsP-D Upregulates the expression of 
TnF-α and causes nuclear Translocation 
of nF-κb
Following treatment with rfhSP-D, the analysis of TNF-α mRNA 
expression levels showed a significant upregulation in Panc-1 
(log10 ~0.5), MiaPaCa-2 (log10 ~1), and Capan-2 (log10 ~1) at 12 
and 24 h; however, no difference was observed at earlier time-
points. Similar transcriptional upregulation was noted for NF-κB 
for Panc-1 (log10 ~0.4), MiaPaCa-2 (log10 ~0.8), and Capan-2 
(log10 ~0.6) at 12 and 24  h (Figure  7A). Immunofluorescence 
microscopy of Panc-1, MiaPaCa-2, and Capan-2 cell lines showed 
that NF-κB was translocated to the nucleus at 24 h, which was not 
seen in the untreated cells (Figure 7B). This further confirmed 
that NF-κB could play a key role in deciding the apoptotic fate 
of the pancreatic cancer cells following the rfhSP-D treatment.
rfhsP-D Downregulates the survival 
Pathway, mTOr
The mTOR is often deregulated in the pancreatic cancer (28) and its 
activation is associated with poor prognosis (29). Upon treatment 
with rfhSP-D, mRNA expression of mTOR was downregulated 
in Panc-1 and MiaPaCa-2 cell line at 12 h (Figure 8A), however, 
no difference was seen in Capan-2 (data not shown). In addi-
tion, immunofluorescence analysis revealed that in comparison 
to the untreated cells, a significant decrease in the cytoplasmic 
levels and an increased accumulation of mTOR in the nucleus 
of MiaPaCa-2 cells was evident (Figure 8B), where it has been 
shown to be present in its inactive form (30).
DiscUssiOn
In this study, we show that a recombinant fragment of human 
sur factant protein D (rfhSP-D) induces apoptosis in a range of 
pancreatic cancer cell lines. We show that rfhSP-D induces apop-
tosis regardless of p53 status using two p53 mutated, aggressive 
cell lines, Panc-1 (derived from head of the pancreas), MiaPaCa-2 
(derived from the body and tail of the pancreas), and a p53 wild 
type, non-aggressive cell line, Capan-2 (derived from head of the 
pancreas) (31).
Following the treatment with rfhSP-D, Panc-1 and 
MiaPaCa-2 cells were arrested in G1 phase at 24  h, whereas 
untreated cells progressed to S and G2 phase. In addition, 
upregulation of Fas, an apoptosis stimulator, and pro-apoptotic 
TNF-α (and associated transcription factor, NF-κB) at 24 h was 
consistent with the cleavage of caspase 8 and 3 at 48 h. These 
findings indicated that cell death is likely to occur via TNF-α/
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FigUre 7 | Continued
Fas-mediated apoptosis pathway (32–34). The cell viability 
after 48  h of rfhSP-D treatment was reduced in the order 
of Panc-1  >  MiaPaCa-2  >  Capan-2, which coincided with 
the approximate growth arrested percentage of Panc-1 and 
MiaPaCa-2 at 24 h. Although Capan-2 cells were not arrested 
in the cell cycle, yet they underwent apoptosis at 48 h, which 
may be attributed to their increased sensitivity to Fas-mediated 
apoptosis as compared to other two cell lines (25) and upregu-
lation of p53 transcripts following the treatment with rfhSP-D, 
as reported previously (16). Treatment with FL-SP-D induced 
apoptosis in approximately 25% of Panc-1 and MiaPaCa-2, 
com pared to Panc-1 (~67%) > MiaPaCa-2 (~60%) > Capan-2 
(~35) by rfhSP-D. This quantitative difference is likely to be 
due to difference in the molar ration of the two proteins at the 
same concentration.
Fas is a type I membrane protein that belongs to TNF super-
family (35, 36) that undergoes trimerization upon binding to its 
physiological ligand, FasL, to form a Fas-associated death domain 
protein (FADD) via its cytoplasmic domain (37, 38). It then acti-
vates downstream caspase cascade, which subsequently causes 
cleavage of caspase 3 as the terminal molecular event during 
apoptosis (39, 40). When the Panc-1, MiaPaCa-2, and Capan-2 
cell lines were treated with rfhSP-D, Fas remained unaffected up 
to 12 h. Upregulation of Fas transcripts as well as protein was seen 
at 24 h, indicating that TNF-α (41) and NF-κB (33) might also 
be affected since they are well known to tightly regulate the Fas-
mediated apoptosis pathway. TNF-α, another member of TNF 
superfamily, acts via TNFR2 to increase the susceptibility of the 
target cells to Fas-mediated death; in addition, it stimulates the 
downstream NF-κB signaling (42) by recruitment and activation 
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FigUre 7 | Relative quantification (RQ) comparisons of TNF-α (a) and NF-κB (b) mRNA expression in Panc-1, MiaPaCa-2, and Capan-2 cell lines treated with 
rfhSP-D (20 µg/ml) for 12 and 24 h. The transcriptional expressions of both TNF-α and NF-κB were upregulated in the treated samples at 12 and 24 h as compared 
to untreated. Significance was determined using the unpaired two-way ANOVA test (*p < 0.05, ***p < 0.001, ****p < 0.0001) (n = 3). (c) Immunofluorescence 
microscopy to determine the translocation of NF-κB into nucleus following rfhSP-D treatment. Anti-NF-κB stained positively in the nucleus of treated cells as 
compared to untreated in all cell lines at 24 h.
of inhibitor of IκB kinases (IKK), which in turn enables its trans-
location to the nucleus where transcription of NF-κB-dependent 
genes such as Fas occurs (33, 43).
In this study, transcriptional levels of both NF-κB and TNF-α 
were upregulated at the same time-point as Fas, which was largely 
anticipated (33). In addition, the immunofluorescence microscopy 
revealed NF-κB translocation to nucleus at 24 h in the rfhSP-D-
treated cells as compared to the untreated counterpart, which 
suggested that TNF-α induced canonical NF-κB pathway (44). 
NF-κB can regulate both pro- as well as anti-apoptotic genes, 
depending upon its canonical or non-canonical signaling (43, 44). 
Interestingly, canonical NF-κB has been shown to bind directly to 
the Fas promoter to facilitate cell death via Fas-mediated pathway 
(33). NF-κB plays an important role in deciding the cell fate as 
its canonical activation acts a transcription factor of Fas, which 
upon stimulation induces apoptosis signaling (32, 33). How ever, 
SP-D has been shown to regulate steady-state NF-κB activation in 
alveolar macrophages of SP-D deficient mice (45). Interestingly, 
SP-D has also been shown to trigger TNF-α production in human 
CCR2+ inflammatory monocytes (46). These studies present an 
interesting central role of SP-D and their interdependent regula-
tion, which could be important in deciding the cell viability/apop-
tosis. Moreover, cleaved caspase 8 and 3 were seen at 48 h, whereas 
intrinsic apoptosis markers such as caspase 9 and Bax remained 
unaffected (27), in all rfhSP-D-treated pancreatic cancer cell lines 
as compared to untreated cells, which further confirmed the cell 
death via Fas-mediated pathway alone. In addition, mTOR pathway 
was downregulated following the treatment with rfhSP-D, which is 
crucial for cell survival and proliferation, and thus, to protect the 
cancer cells from apoptosis (47). These findings are also supported 
by studies such as targeting mTOR pathway using rapamycin 
(48), or its regulating component RICTOR knockdown (49), sig-
nificantly reduces the pancreatic cancer cell growth. Interestingly, 
immunofluorescence microscopy showed that rfhSP-D causes 
nuclear accumulation of mTOR in the treated cells, which may have 
a transcriptional role. However, the nuclear versions do not form 
an intact mTORC1 required for regulatory signaling pathways (30).
rfhSP-D bound all the pancreatic cell lines tested in this study: 
Panc-1, MiaPaCa-2, and Capan-2 (Figure  1A). However, the 
putative SP-D receptor or the ligand on the pancreatic cancer cell 
surface is not yet known. Recently, an interaction between the 
CRD region of human SP-D and N-glycans of EGFR has been 
reported which led to downregulated EGF signaling in human 
lung adenocarcinoma, A549 cell line cells (19).
In conclusion, rfhSP-D upregulates pro-apoptotic factors such 
as TNF-α, NF-κB, and Fas to activate caspase cascade to induce 
apoptosis in pancreatic cancer cell lines, which needs further 
exploration in orthotropic murine models. Majority of the 
conven tional anti-cancer therapies only target the rapidly prolif-
erating cancer cells, therefore, new strategies involving immune 
molecules such as rfhSP-D that target the signaling pathways to 
reduce the cell growth merit further investigation as these would 
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FigUre 8 | rfhSP-D downregulated the survival pathway, mTOR. (a) rfhSP-D treatment of Panc-1 and MiaPaCa-2 cells downregulated the mRNA expression of 
mTOR (****p < 0.0001). (b) Immunofluorescence microscopy showed reduced cytoplasmic levels of mTOR following treatment as compared to the untreated. 
Nuclear accumulation is clearly visible in the rfhSP-D treated cells.
not only help eliminate the tumor but could also influence recur-
rence or migratory capacity of the tumor cells.
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Surfactant protein D (SP-D) is expressed in the mucosal secretion of the lung and con-
tributes to the innate host defense against a variety of pathogens, including influenza A 
virus (IAV). SP-D can inhibit hemagglutination and infectivity of IAV, in addition to reducing 
neuraminidase (NA) activity via its carbohydrate recognition domain (CRD) binding to 
carbohydrate patterns (N-linked mannosylated) on NA and hemagglutinin (HA) of IAV. 
Here, we demonstrate that a recombinant fragment of human SP-D (rfhSP-D), containing 
homotrimeric neck and CRD regions, acts as an entry inhibitor of IAV and downregu-
lates M1 expression considerably in A549 cells challenged with IAV of H1N1 and H3N2 
subtypes at 2 h treatment. In addition, rfhSP-D downregulated mRNA levels of TNF-α, 
IFN-α, IFN-β, IL-6, and RANTES, particularly during the initial stage of IAV infection of 
A549 cell line. rfhSP-D also interfered with IAV infection of Madin Darby canine kidney 
(MDCK) cells through HA binding. Furthermore, rfhSP-D was found to reduce luciferase 
reporter activity in MDCK cells transduced with H1+N1 pseudotyped lentiviral particles, 
where 50% of reduction was observed with 10 µg/ml rfhSP-D, suggestive of a critical role 
of rfhSP-D as an entry inhibitor against IAV infectivity. Multiplex cytokine array revealed 
that rfhSP-D treatment of IAV challenged A549 cells led to a dramatic suppression of key 
pro-inflammatory cytokines and chemokines. In the case of pH1N1, TNF-α, IFN-α, IL-10, 
IL-12 (p40), VEGF, GM-CSF, and eotaxin were considerably suppressed by rfhSP-D 
treatment at 24 h. However, these suppressive effects on IL-10, VEGF, eotaxin and IL-12 
(p40) were not so evident in the case of H3N2 subtype, with the exception of TNF-α, 
IFN-α, and GM-CSF. These data seem to suggest that the extent of immunomodulatory 
effect of SP-D on host cells can vary considerably in a IAV subtype-specific manner. 
Thus, rfhSP-D treatment can downregulate pro-inflammatory milieu encouraged by IAV 
that otherwise causes aberrant inflammatory cell recruitment leading to cell death and 
lung damage.
Keywords: innate immunity, influenza a virus, surfactant protein D, pseudotyped lentiviral particles, inflammation
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IAV–SA receptor interaction, virus particles are internalized 
via clathrin, resulting in clathrin-mediated endocytosis, or via 
caveolin/clathrin-independent mechanism (14, 15). Thus, acidic 
environment triggers M2 ion channel and transfers protons and 
potassium into the interior portion of the virion to dissociate M1 
protein from the ribonucleoprotein (RNP) (16). Acidification 
also initiates HA-mediated conformational changes, which leads 
to viral fusion and RNPs release into the cytoplasm, resulting in 
viral transcription and replication. It is, therefore, suggested that 
SA and its linkage are crucial for the initiation of IAV infection of 
both epithelial and immune cells. Thus, inhibition of SA receptor 
binding or enzymatic switching of SA-mediated linkages can 
confer cell resistance, and/or alter susceptibility to IAV infection. 
Hence, cell surface SA is considered as an important primary 
receptor and determinant of IAV tropism, contributing to induc-
tion of immune responses as well as to viral pathogenesis.
It is crucial to understand the molecular mechanisms of host 
defense against IAV in order to design novel anti-IAV strategies. 
SP-D binding to HA leads to a direct inhibition of cellular infec-
tion by preventing HA–SA receptor interaction (4). SP-D has 
been shown to bind HA-mediated glycosylation sites, identified as 
β-type inhibitor of IAV. This interaction is calcium dependent, and 
binding of SP-D to NA inhibits the release of progeny virions from 
infected cells (17, 18). It has been reported that recombinant full-
length porcine SP-D has a potent antiviral activity against a wide 
range of IAV by similar mechanisms, more than human SP-D due 
to structural differences, such as an additional loop in its CRD, an 
additional glycosylation site, and an additional cysteine in the col-
lagen domain (19). In this study, we have used a well-characterized 
recombinant homotrimeric fragment of human SP-D comprising 
neck and CRD region (rfhSP-D), and examined its ability to act 
as an entry inhibitor of IAV and pseudotyped viral particles, and 




The A/England/2009 (pH1N1) and the A/HK/99 (H3N2) strains 
were gifted by Wendy Barclay from the Imperial College, London 
and Leo Poon from the University of Hong Kong, respectively. 
The plasmids used to produce the H1+N1 pseudotyped lentiviral 
particles were obtained from Addgene. The pHIV-Luciferase 
plasmid was a gift from Bryan Welm (Addgene plasmid # 21375); 
psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260); 
and Vesicular Stomatitis Virus (VSV-G) was offered by Bob 
Weinberg (Addgene plasmid #8454). Monoclonal Anti-Influenza 
Virus H1 HA, A/California/04/2009 (H1N1)pdm09, Clone 5C12 
(produced in  vitro), NR-42019 and Polyclonal Anti-Influenza 
Virus H3 HA, A/Hong Kong/1/1968 (H3N2) (antiserum, Goat), 
NR-3118 were obtained from BEI Resources, NIAID, NIH, USA.
cell culture
Adenocarcinomic human alveolar basal epithelial cells (A549), 
Madin Darby Canine Kidney (MDCK), and human embryonic 
kidney (HEK) 293T cell lines were cultured in Dulbecco’s Modified 
inTrODUcTiOn
The innate immune system is composed of both cellular and 
humoral players to encounter invading pathogens. It is also an 
important component in the initiation and modulation of the 
adaptive immunity. To distinguish self from non-self, the innate 
immune system has evolved to recognize pathogen-associated 
molecular patterns through a number of pattern recognition 
receptors, including toll like receptors and C-type lectin receptors. 
Collectins are collagenous lectins, representing a crucial group 
of calcium-dependent pattern recognition molecules present in 
pulmonary secretions and mammalian serum (1). They play a 
crucial role in the first line of defense against a diverse range of 
pathogens by interacting with specific glycoconjugates and lipid 
moieties present on the surface of microorganisms. A significant 
number of in vitro and in vivo studies have focused on the immu-
nomodulatory functions of a lung collectin, human surfactant 
protein D (SP-D). SP-D is primarily organized into four regions: 
a cysteine-linked N-terminal region involved in multimerization, 
a triple-helical collagen region composed of Gly-X-Y repeats, an 
α-helical, coiled-coil trimerizing neck region, and the C-terminal 
carbohydrate recognition domains (CRDs) or C-type lectin 
domain (2). Human SP-D is primarily synthesized by alveolar type 
II and Clara cells, in addition to being present in several extra-
pulmonary tissues. SP-D triggers a range of anti-microbial defense 
mechanisms, including agglutination/aggregation, phagocytosis, 
and direct growth inhibition (1). SP-D is also capable of control-
ling pulmonary inflammation including allergy and asthma, and 
thus, linking innate with adaptive immunity via modulation of 
dendritic cell maturation, and polarization of helper T cells (1).
The direct nature of interaction between SP-D and Influenza 
A Virus (IAV) has been reported (3, 4), which often results in 
virus neutralization and enhanced phagocytosis (5, 6). Anti-viral 
roles of SP-D during IAV infection have been well-documented, 
principally by Hartshorn group. IAV is an enveloped RNA virus 
and a member of Orthomyxoviridae family that possesses eight 
single-stranded RNA segments with negative orientation. These 
RNA segments can encode up to 13 viral proteins, including 
two surface glycoproteins, an ion channel protein, nucleocapsid 
protein, structural scaffolding protein, a tripartite polymerase 
complex, two non-structural proteins, and three non-essential 
proteins (7). IAV is subtyped based on their surface glycoproteins, 
such as hemagglutinin (HA) and neuraminidase (NA); to date, 
there are 19 HA and 9 NA protein subtypes that have been well 
established. Both HA and NA play an important role in the host 
range, viral replication, and pathogenicity (8). Among the three 
genera of influenza viruses reported, infection by IAV is the 
most common and severe in humans, swine, and avian species. 
It is also known to cause pandemic infections, being diverse in 
host specificity. IAV is considered as a major human respiratory 
pathogen following 1918 H1N1 influenza pandemic (Spanish Flu) 
(9), which is believed to have resulted in the zoonotic transmission 
of an avian virus to a human host and has rapidly dispersed (10).
Binding of IAV to target cells is mediated via the globular head 
of HA to sialic acid (SA) receptors present on the host cell surface 
(11, 12). IAV subtypes have adapted to human preferentially via 
binding with α (2–6) linkage of SA receptors (13). Following 
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Eagle’s Medium (DMEM) (Sigma-Aldrich), supplemented with 
10% v/v fetal bovine serum (FBS), 2 mM l-glutamine, 100 U/ml 
penicillin (Sigma-Aldrich), 100  µg/ml streptomycin (Sigma-
Aldrich) and 1 mM sodium pyruvate (Sigma-Aldrich), and left 
to grow at 37°C in the presence of 5% v/v CO2 for approximately 
3  days before passaging. Since these cells were adherent, they 
were detached using 2× Trypsin-EDTA (0.5%) (Fisher Scientific) 
for 10 min at 37°C. Cells were then centrifuged at 1,200 rpm for 
5 min, followed by re-suspension in complete DMEM with FBS, 
penicillin, and streptomycin, as described above. To determine 
the cell count and viability, an equal volume of the cell suspen-
sion and Trypan Blue (0.4% w/v) (Fisher Scientific) solution were 
vortexed, followed by cell count using a hemocytometer with 
Neubauer rulings (Sigma-Aldrich). Cells were then re-suspended 
in complete DMEM for further use.
Purification of iaV subtypes
MDCK cells at 80–90% confluency were washed with sterile 
PBS twice before infection. Diluted pH1N1 (2 × 104) or H3N2 
(3.3  ×  104) (600  µl/flask) was transferred to the flask contain-
ing 20 ml of complete DMEM, and incubated at 37°C for 1 h. 
Unbound viruses were removed by washing three times with ster-
ile PBS. 25 ml of infection medium [DMEM with 1% penicillin/
streptomycin, 0.3% bovine serum albumin (BSA), and 1 µg/ml of 
l-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK)—
Trypsin] (Sigma-Aldrich) were added to the flasks, and incubated 
at 37°C for 3 days. The virus particles were then harvested via 
centrifugation of the infection medium at 3,000 × g at 4°C for 
15 min. The supernatant obtained was centrifuged at 10,000 × g 
for 30 min at 4°C. 26 ml of supernatant was added slowly to 
new ultra-clear centrifuge tubes containing 30% w/v sucrose 
(8  ml/tube) (Sigma-Aldrich), and centrifuged at 25,000  ×  g at 
4°C for 90 min. The upper phase of the medium and the sucrose 
phase were carefully removed; IAV particles at the bottom were 
re-suspended in 100 µl of sterile PBS. Virus suspension (15 µl) 
was subsequently analyzed by SDS-PAGE and ELISA.
Tissue culture infectious Dose  
50% (TciD50) assay
Purified pH1N1 or H3N2 virus stocks were prepared with a starting 
dilution of 10−2 in DMEM and 146 µl of the diluted virus was 
added to all wells; uninfected MDCK cells were used as a control. 
46  µl of pH1N1 or H3N2 was then serially diluted (1/2log10  
up to 10−7) and incubated at 37°C for 1 h in a microtiter plate. 
1 × 105 MDCK cells, earlier trypsinised and re-suspended in 2× 
infection medium, were added to each well and incubated for 
3 days at 37°C under 5% v/v CO2 until cytopathic effect (CPE) was 
observed. After 5 days, each well was observed under microscope, 
and the number of wells that were positive and negative for CPE 
at each dilution was recorded.
expression and Purification of a 
recombinant Fragment of human sP-D 
containing neck and crD regions
A recombinant fragment of human SP-D (rfhSP-D) was 
expressed under bacteriophage T7 promoter in Escherichia coli 
BL21 (λDE3) pLysS (Invitrogen), transformed with plasmid 
pUK-D1 containing cDNA sequences for the 8 Gly-X-Y repeats, 
neck and CRD regions of human SP-D, as described previously 
(20). Briefly, a primary inoculum of 25 ml bacterial culture was 
inoculated into 500  ml of LB containing 100  µg/ml ampicillin 
and 34  µg/ml chloramphenicol (Sigma-Aldrich), grown to 
OD600 of 0.6, and then induced with 0.5  mM isopropyl β-d-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3  h. The 
bacterial cell pellet was re-suspended in lysis buffer (50  mM 
Tris–HCl pH7.5, 200  mM NaCl, 5  mM EDTA pH 8, 0.1% v/v 
Triton X-100, 0.1 mM phenyl-methyl-sulfonyl fluoride, 50 µg/ml 
lysozyme) and sonicated (five cycles, 30 s each). The sonicate was 
harvested at 12,000  ×  g for 30  min, followed by solubilization 
of inclusion bodies in refolding buffer (50  mM Tris–HCl pH 
7.5, 100 mM NaCl, 10 mM 2-Mercaptoethanol) containing 8 M 
urea. The solubilized fraction was then dialyzed stepwise against 
refolding buffer containing 4  M, 2  M, 1  M, and no urea. The 
clear dialysate was loaded onto a maltose agarose column (5 ml; 
Sigma-Aldrich) and the bound rfhSP-D was eluted using 50 mM 
Tris–HCl, pH 7.5, 100 mM NaCl, and 10 mM EDTA. The eluted 
fractions were then passed through PierceTM High Capacity 
Endotoxin Removal Resin (Qiagen) to remove endotoxin. The 
endotoxin levels were measured via QCL-1000 Limulus amebo-
cyte lysate system (Lonza), and found to be <5 pg/µg of rfhSP-D.
Direct Binding elisa
Maxisorp 96-well microtiter plates were coated with rfhSP-D 
(5, 2.5, 1.25, and 0.625 µg/well) in carbonate-bicarbonate buffer 
(CBC), pH 9.6, and incubated overnight at 4°C. After remov-
ing the CBC buffer, microtiter wells were washed with PBS 
three times, blocked with 2% w/v BSA in PBS for 2 h at 37°C, 
and then washed three times with PBST (PBS +  0.05% Tween 
20). 20 µl of concentrated pH1N1, H3N2 virus (1.36 × 106 pfu/
ml), or purified recombinant HA (2.5  µg/ml) was diluted in 
200  µl of PBS, 10  µl of diluted virus was added to each well, 
and incubated at room temperature (RT) for 2 h in buffer con-
taining 5  mM CaCl2. VSV-G pseudotyped lentivirus was used 
as a negative control. The microtiter wells were washed with 
PBST three times and the binding was probed with primary 
antibody: monoclonal anti-influenza virus H1 (BEI-Resources) 
and polyclonal anti-influenza virus H3 (BEI-Resources) antibody 
(1:5,000 dilution in PBS) for 1 h at 37°C. The wells were washed 
again with PBST and incubated with anti-mouse IgG-Horseradish 
peroxidase (HRP)-conjugate (1:5,000) (Fisher Scientific) and 
Protein A-HRP-conjugate (Fisher Scientific) in PBS (100 µl/well), 
respectively, for 1  h at 37°C. Color was developed using 3,3′, 
5,5′-Tetramethylbenzidine (TMB) substrate (Sigma-Aldrich). The 
reaction was stopped using 2 N H2SO4 and the absorbance was 
read at 450  nm using iMark™ microplate absorbance reader 
(Bio-Rad).
Far Western Blotting
rfhSP-D (5  µg) or 10  µl of concentrated pH1N1/H3N2 
(1.36  ×  106  pfu/ml) were run separately on a 12% (w/v) SDS-
PAGE, and then electrophoretically transferred onto a nitrocel-
lulose membrane (320 mA for 2 h) in 1× transfer buffer (25 mM 
Tris–HCl pH 7.5, 190 mM glycine, and 20% methanol), followed 
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by blocking overnight in 5% w/v dried milk powder in PBS 
(Sigma-Aldrich) at 4°C on a rotatory shaker. The membrane was 
then washed with PBST three times, 10 min each. For far western 
blotting, the nitrocellulose membrane was incubated with 5 µg/ml 
of rfhSP-D in PBS containing 5 mM CaCl2 for 1 h at RT and 1 h 
at 4°C. Following PBST wash, the membrane was incubated with 
primary antibodies, polyclonal rabbit anti-human SP-D, mono-
clonal anti-influenza virus H1 (BEI-Resources), or polyclonal 
anti-influenza virus H3 (BEI-Resources) in PBS (1:1,000) for 
1 h at RT. Following washing, the membrane was probed with 
secondary antibodies: protein-A-HRP-conjugate, or rabbit anti-
mouse IgG HRP conjugate (1:1,000) (Fisher Scientific) in PBS 
(100 µl/well) for 1 h at RT. After PBST wash, the blot was devel-
oped either using 3,3′-diaminobenzidine (DAB) or enhanced 
chemiluminescence substrate. For M1 detection, following 6  h 
incubation, both untreated (cells  +  virus) and treated samples 
(cells + virus + 10 µg/ml rfhSP-D) were run on the 12% (w/v) 
SDS-PAGE, and transferred onto a nitrocellulose membrane, as 
described above. The M1 expression was detected using anti-M1 
monoclonal antibody (BEI-Resources).
cell-Binding assay
A549 cells were seeded in microtiter wells using complete DMEM 
(1 ×  105 cells/well) and incubated overnight at 37°C. The wells 
were washed with PBS three times, and then rfhSP-D (10, 5, 2.5, 
and 1.25 µg/ml) was pre-incubated with pH1N1 or H3N2 virus 
(1.36 × 106 pfu/ml) diluted in 200 µl of PBS + 5 mM CaCl2; 10 µl of 
diluted virus was added to the corresponding wells, and incubated 
at RT for 2 h. Maltose-binding protein (MBP) was used as a nega-
tive control. The microtiter wells were then washed with PBS three 
times, and fixed with 4% paraformaldehyde (Fisher Scientific) for 
10 min at RT. The wells were washed again with PBS three times, 
and blocked with 2% w/v BSA in PBS for 2 h at 37°C. Monoclonal 
anti-influenza virus H1 (BEI-Resources) and polyclonal anti-
influenza virus H3 (BEI-Resources) in PBS (1:5,000) were added 
to each well and incubated for 1 h at 37°C. After washing with 
PBST three times, the corresponding wells were probed with goat 
anti-mouse IgG-HRP-conjugate (Thermo-Fisher), or Protein 
A-HRP conjugate (1:5,000) in PBS for 1 h at 37°C. The wells were 
washed again with PBST three times and the color was developed 
using TMB substrate. The reaction was stopped using 2 M H2SO4, 
followed by absorbance reading at 450 nm.
Titration assay
Maxisorp 96-well plates were coated with 0.01% collagen (Sigma-
Aldrich) and incubated at RT for 3 h. After removing the excess 
collagen, the wells were washed with PBS twice. 75,000 A549 cells 
were seeded and grown overnight at 37°C in the presence of 5% 
v/v CO2, until 75–80% confluency. Cells were washed with 1× PBS 
twice, pH1N1 or H3N2 virus (MOI of 1) diluted in pure DMEM 
with 10 µg/ml rfhSP-D was added to cells, respectively. The plates 
were incubated at 37°C for 1 h. The wells were then washed with 
PBS twice and 200 µl of infection medium was added to the cells, 
and incubated for 24 h at 37°C with 5% v/v CO2. The media of the 
infected cells in the presence or absence of rfhSP-D was collected 
and virus titer was estimated by TCID50.
infection assay Using ph1n1 and h3n2
A549 cells were cultured in complete DMEM with usual sup-
plements at 37°C in CO2 incubator until about 70–80% conflu-
ence. Cells, washed with PBS twice, trypsinised, and adjusted 
to 5 × 105 cells in 12-well plates (Fisher Scientific), were left to 
adhere overnight at 37°C in serum-free complete DMEM. Cells 
were washed in PBS before the addition of rfhSP-D (10 µg/well) 
in pure DMEM containing 5 mM CaCl2 with MOI 1 of pH1N1 
or H3N2 virus (1 h at RT and 1 h at 4°C). The pre-incubated 
virus and protein mix was then added onto the cells in a circular 
motion and incubated at 37°C for 1 h in DMEM only. Medium 
containing unabsorbed virus and rfhSP-D protein was removed, 
cells were washed with PBS twice, infection medium was added, 
and then left to incubate 2 and 6  h. The infected cells were 
detached by scrapping with a sterile cell scrapper, centrifuged at 
1,500 × g for 3 min, and frozen at −80°C until further analysis 
via qPCR.
real-Time Quantitative Pcr analysis
The infected A549 cells were lysed using a lysis solution (50 mM 
Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA pH 8, 0.1% v/v 
Triton X-100). Total RNA was extracted using RNase Mini Kit 
(Qiagen). Contaminating DNA was removed by DNase I treat-
ment, followed by heat-inactivation at 70°C of DNase I and 
RNase. A260 nm was used to quantify the amount of RNA using 
NanoDrop 2000/2000c (Sigma-Aldrich), and the RNA purity was 
assessed using A260/A280 ratio between 1.8 and 2.1. The isolated 
RNA was then converted into cDNA using SuperScript II Reverse 
Transcriptase (Thermo-Fisher Scientific). Oligo-dT primers were 
added to initiate cDNA synthesis and to avoid labeling of the 
rRNA and tRNA. cDNA was synthesized using high capacity 
RNA to cDNA Kit (Thermo-Fisher Scientific) using 1–2  µg of 
total RNA. Primer sequences were designed for specificity using 
the Primer-BLAST software (Basic Local Alignment Search 
Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Table  1). The 
qRT-PCR was performed using the Light Cycler system (Applied 
Biosciences). The amplification program used was at 95°C for 
5 min, followed by 45 cycles of 95°C for 10 s, 60°C for 10 s, and 
72°C for 10  s. The specificity of the assay was established by 
melting-curve analysis.
Multiplex cytokine array analysis
Supernatant from A549 cells, incubated with IAV with or without 
rfhSP-D for 24 h were collected for measuring secreted cytokines 
[TNF-α, IL-6, IL-10, IL-1α, interferon (IFN)-α, and IL-12p40], 
chemokine (eotaxin) and growth factors (GM-CSF and VEGF). 
The analytes were measured using MagPixMilliplex kit (EMD 
Millipore). 25  µl of assay buffer was added to each well of a 
96-well plate, followed by addition of 25 µl of standard, control, 
or supernatant from A549 cells infected with pH1N1 or H3N2 
(with or without rfhSP-D). 25 µl of magnetic beads, coupled to 
analytes, were added to each well, and incubated for 18 h at 4°C. 
The plate was washed with the assay buffer and 25 µl of detection 
antibodies were incubated with the beads for 1 h at RT. 25 µl of 
Streptavidin–Phycoerythrin was then added to each well and 
incubated for 30  min at RT. Following a washing step, 150  µl 
TaBle 1 | Target genes, forward primers, and reverse primers used for qPCR.

























IFN-α 5′-TTT CTC CTG CC 
T GAA GGA CAG-3′
5′-GCT CAT GAT TTC  
TGC TCT GAC A-3′
IFN-β 5′-AAA GAA GCA G 
CA ATT TTC AGC-3′
5′-CCT TGG CCT TCA 
GGT AAT GCA-3′
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of sheath fluid was added to each well and the plate was read 
using the Luminex Magpix instrument. Assays were conducted 
in duplicate.
Production of h1+n1 Pseudotyped 
lentiviral Particles
HEK293T  cells were co-transfected with 20  µg of pcDNA3.1-
swineH1-flag (H1 from swine H1N1 A/California/04/09) 
(Invitrogen), pcDNA3.1-swine N1-flag (N1 from swine H1N1 
A/California/04/09) (Invitrogen), pHIV-Luciferase backbone 
(Addgene), which carries a modified proviral HIV-1 genome with 
env deleted and designed to express the firefly luciferase reporter, 
and psPAX2 (Addgene). psPAX2 is a second-generation lentiviral 
packaging plasmid and can be used with second or third genera-
tion lentiviral vectors and envelope expressing plasmid. VSV-G 
lentivirus was produced in a similar way as described above, 
without H1+N1 plasmids. Supernatant containing the released 
H1+N1 pseudotyped and VSV-G lentiviral particles were har-
vested at 24 and 48 h and centrifuged at 5,000 × g for 10 min to 
remove any debris, and concentrated via ultra-centrifugation. The 
transfected HEK293T cells were lysed using lysis buffer (50 mM 
Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA, 0.1% v/v Triton 
X-100). The filtered supernatant and the cell lysate were analyzed 
via western blotting and luciferase reporter activity assay.
luciferase reporter activity assay
MDCK cells were cultured in supplemented DMEM as described 
earlier, until about 70–80% confluency. The harvested H1+N1 
pseudotyped particles at 24 and 48  h were used to perform 
luciferase reporter activity using luciferase one-step assay kit 
(Thermo Scientific). rfhSP-D (5 and 10  µg/ml) was used to 
determine its effect on the luciferase reporter activity; cells only, 
and cells  +  H1+N1 particles were used as controls. Readings 
were measured using a GloMax 96 Microplate Luminometer 
(Promega).
statistical analysis
Graphs were generated using GraphPad Prism 6.0 software and the 
statistical analysis was performed using a two-way ANOVA test. 
Significant values were considered based on *p < 0.1, **p < 0.05, 
***p  <  0.01, and ****p  <  0.001 between treated and untreated 
conditions. Error bars show the SD or SEM, as indicated in the 
figure legends.
resUlTs
rfhsP-D Binds Directly to iaV subtypes
Escherichia coli BL21 (λDE3) pLysS containing pUK-D1 construct 
(20) expressed a ~20  kDa protein following IPTG induction, 
compared to the un-induced bacterial cells (Figure  1A). The 
overexpressed insoluble rfhSP-D as inclusion bodies was refolded 
via denaturation and renaturation cycle. The soluble rfhSP-D frac-
tions were affinity purified using maltose–agarose column, which 
appeared as a single band on 12% SDS-PAGE (v/v) under reducing 
condition (Figure 1B). The immunoreactivity of purified rfhSP-
D was confirmed via western blotting using rabbit polyclonal 
anti-human SP-D antibody that was raised against native human 
SP-D purified from lung lavage of alveolar proteinosis patients 
(Figure 1C). The ability of pH1N1 and H3N2 subtypes to bind 
microtiter-coated rfhSP-D was examined via ELISA. As shown 
in Figure 2, rfhSP-D bound both IAV subtypes in a dose- and 
calcium-dependent manner. VSV-G pseudotyped lentivirus was 
used as a negative control RNA virus, where no significant binding 
was seen with all rfhSP-D concentrations tested. For cell-binding 
assay, A549 cells were challenged with purified pH1N1 or H3N2 
pre-incubated with a range of rfhSP-D concentrations (Figure 3). 
The maximum inhibition (50%) of cell binding was seen at 10 µg/
ml. MBP was used as a negative control protein.
rfhsP-D Binds to ha and restricts 
replication of iaV in a549 cells
Previous studies have shown that SP-D binds to the glycosylation 
site of HA1 domain on IAV (18). Far western blotting revealed 
that rfhSP-D bound to HA (70 kDa) and M1 (27 kDa) of pH1N1 
(Figure  4A) and H3N2 (Figure  4B) subtypes. As shown in 
Figure 4C, rfhSP-D was able to bind purified recombinant HA pro-
tein in a concentration-dependent manner. The binding of rfhSP-
D may inhibit cellular viral infection by restricting the interaction 
of HA with SA containing receptors, and HA-mediated fusion in 
endosomes. The interaction between rfhSP-D and HA appears to 
offer another dimension at which rfhSP-D may suppress target cell 
infection and intracellular replication. The mechanism of direct 
inhibition of IAV by rfhSP-D was thus investigated via infection 
assay. A549 cells infected with pH1N1 and H3N2 revealed an 
upregulation of M1 expression at 2 and 6 h time points (Figure 5). 
However, A549 cells, pre-treated with rfhSP-D showed down-
regulation of viral M1 expression when compared to untreated 
cells challenged with virus (Figure  5). The downregulation of 
M1 expression due to rfhSP-D pre-incubation was more effective 
in the case of pH1N1 compared to H3N2, where −8 log10 fold 
downregulation was seen at 2 h (Figure 5A). This was validated 
via western blotting, where a low M1 expression was detected 
FigUre 1 | SDS-PAGE (12% v/v) under reducing conditions showing expression and purification of a recombinant surfactant protein D (rfhSP-D). The neck  
and carbohydrate recognition domain regions were expressed in Escherichia coli BL21 (λDE3) pLysS. (a) Following induction with 0.5 mM IPTG, a ~20 kDa band 
appeared being overexpressed compared to uninduced sample. Following denaturation–renaturation cycle, the rfhSP-D was purified on an affinity column to 
homogeneity after elution with EDTA as fractions F1, F2 and F3 (B). A rabbit polyclonal antibody raised against full-length SP-D purified from human bronchoalveolar 
lavage (c) recognized the purified rfhSP-D, but not BSA that was used as a negative control protein.
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in rfhSP-D (10 µg/ml) treated sample following 6 h incubation, 
when compared to untreated samples (cells + virus) (Figure 5C). 
Furthermore, anti-IAV activity of rfhSP-D was confirmed via 
virus titration assay (Figures  5D,E). Approximately 40% titer 
reduction was seen in 10 µg rhfSP-D treated cells compared to 
untreated samples, suggesting the ability of rfhSP-D to act as an 
entry inhibitor. Differential inhibitory effects of rfhSP-D on IAV 
subtypes may reflect on the glycosylation of the HA protein of 
IAV, suggesting a correlation between HA-glycan attachment and 
susceptibility of IAV strains to inhibition by rfhSP-D that involves 
specific interaction sites on HA.
rfhsP-D Modulates Pro-inflammatory 
cytokine/chemokine immune responses 
Following Virus challenge to a549 cells
The qPCR analysis revealed that there was an upregulation of 
pro-inflammatory cytokines TNF-α and IL-6 by H3N2 strain, 
which were brought down slightly by rfhSP-D at 2 h (Figure 6A). 
However, both TNF-α and IL-6 in the case of pH1N1 were found 
to be downregulated considerably by rfhSP-D at 2  h, which 
gradually recovered by 6 h (Figure 6B). IL-6, which is crucial for the 
resolution of IAV infection, acts by inducing neutrophil medi-
ated viral clearance. An elevated level of IL-6 in lung and serum 
has been reported in patients infected with pH1N1 (21). TNF-α 
and IL-6 are the key contributors to IAV-mediated respiratory 
diseases and acute lung injury. By contrast, there was a broad 
level of downregulation of IL-12 in the case of both IAV subtypes 
incubated with rfhSP-D, suggesting a likely reduction of Th1 
response and suppression of IFN-γ production by CD4+ T cells. 
Suppressed transcript level of RANTES (1 log10 fold) by rfhSP-D 
was observed at 2 h treatment in the case of pH1N1. However, 
in the case of H3N2 strain, RANTES was downregulated by 0.5-
fold (log10) (Figure 6B) at 2 h following treatment with rfhSP-D 
compared to untreated A549 cells. Furthermore, suppression 
of IFN-α and IFN-β were also seen with rfhSP-D treatment 
at both 2 and 6 h time points (Figure 6C). Both of these type 
I IFN cytokines play a crucial anti-viral role against IAV, and 
FigUre 3 | Cell-binding assay to show binding of (a) pH1N1 and (B) H3N2 
pre-incubated with rfhSP-D to A549 cells. Microtiter wells were coated with 
A549 cells (1 × 105 cells/ml) and incubated overnight at 37°C. Varied 
concentrations of pre-incubated rfhSP-D (10, 5, 2.5, and 1.25 µg/ml) with 
pH1N1 and H3N2 virus were added to the corresponding wells, followed by 
incubation at room temperature for 1–2 h. After fixing the cells with 4% 
paraformaldehyde solution, monoclonal anti-influenza virus H1, or polyclonal 
anti-influenza virus H3 were added to corresponding well. Maltose-binding 
protein (MBP) was used as a negative control protein. The data were expressed 
as mean of three independent experiments done in triplicates ± SEM.
FigUre 2 | ELISA to show binding of rfhSP-D to (a) pH1N1 and (B) H3N2: 
microtiter wells were coated with different concentrations of rfhSP-D  
(5, 2.5, 1.25, and 0.625 µg/ml). 20 µl of concentrated pH1N1 or H3N2 virus 
(1.36 × 106 pfu/ml) was diluted in 200 µl of PBS + 5 mM CaCl2 and 10 µl of 
diluted virus was added to all the wells, and probed with either monoclonal 
anti-influenza virus H1 or polyclonal anti-influenza virus H3 antibody. VSV-G 
pseudotyped lentivirus was used as a negative RNA virus control. The data 
were expressed as mean of three independent experiments done in 
triplicates ± SEM.
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determine the rate of viral replication in the initial stages of 
infection. Suppression of type I IFN levels suggests the ability of 
rfhSP-D to reduce the rate of viral replication, thereby reducing 
the levels of INF produced by the innate immune system.
Multiplex cytokine array analysis reveals 
a Differential ability of rfhsP-D to 
Downregulate Pro-inflammatory 
cytokines and chemokines
To assess secretion of cytokines, chemokines, and growth factors 
over a period of 24 h post rfhSP-D treatment, a multiplex cytokine 
array was performed using supernatants of the IAV challenged 
and rfhSP-D treated A549 cells. rfhSP-D induced a dramatic 
suppression of some of the key pro-inflammatory cytokines 
and chemokines in the virus infected A549 cells. In the case of 
pH1N1, TNF-α, IFN-α, IL-10, IL-12 (p40), VEGF, GM-CSF, and 
eotaxin were considerably suppressed by rfhSP-D treatment at 
24 h (Figure 7A). However, these suppressive effects on IL-10, 
VEGF, eotaxin, and IL-12 (p40) were not so evident in the case 
of H3N2 subtype, with the exception of TNF-α, IFN-α, and 
GM-CSF (Figure 7). These data seem to suggest that the extent 
of immunomodulatory effect of rfhSP-D on host cells can vary 
considerably in a IAV subtype-specific manner.
rfhsP-D Binds to h1+n1 Pseudotyped 
lentivirus and reduces luciferase 
reporter activity
H1+N1 pseudotyped lentiviral particles were produced as a safe 
strategy to study the differential or combinatorial involvement of 
HA or NA viral glycoproteins in the recognition and neutraliza-
tion of IAV by rfhSP-D. The production of lentiviral particles 
pseudotyped with envelope proteins H1+N1 was carried out 
by co-transfecting HEK293T cells with plasmid containing the 
coding sequence of the indicated H1+N1, pHIV-Luciferase 
backbone, and psPAX2. Purified H1+N1 pseudotyped particles 
FigUre 4 | Far western blot analysis to show rfhSP-D binding to purified (a) pH1N1 and (B) H3N2: 10 μl of concentrated virus (1.36 × 106 pfu/ml) was first run on 
the SDS-PAGE under reducing conditions, and then transferred onto a nitrocellulose membrane and incubated with 5 µg of rfhSP-D. The membrane was probed 
with anti-rabbit SP-D polyclonal antibodies. rfhSP-D bound to HA (70 kDa) and M1 (27 kDa) in the case of both pH1N1 and H3N2 subtypes. (c) ELISA to show  
the binding of rfhSP-D to purified recombinant hemagglutinin (HA) (μg/ml). VSV-G was used as a negative control. The data were expressed as mean of three 
independent experiments carried out in triplicates ± SEM. Significance was determined using the unpaired one-way ANOVA test (***p < 0.0001) (n = 3).
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and cell lysate harvested at 24 and 48 h were analyzed via western 
blotting, and the expression level of HA was determined using 
anti-H1 monoclonal antibody (Figure  8A); HA was evident at 
70 kDa. Far western blotting revealed binding of rfhSP-D to HA at 
70 kDa (Figure 8B), suggesting that the binding of rfhSP-D to HA 
is crucial for the inhibition of viral infectivity. Purified H1+N1 
pseudotyped particles harvested at 24 and 48  h were used to 
transduce MDCK cells to measure the luciferase reporter activity 
assay. Higher levels of luciferase reporter activity were observed 
at 24 h when compared to 48 h post-transfection (Figure 8C). 
Thus, pseudotyped particles harvested at 24  h were used to 
transduce MDCK cells with or without rfhSP-D (5 and 10 µg/ml) 
(Figure  8D). Nearly 50% reduction in the luciferase reporter 
activity was observed with 10 µg/ml of rfhSP-D compared to cells 
challenged with H1+N1 pseudotyped particles. This suggested an 
entry inhibitory role of rfhSP-D against IAV.
DiscUssiOn
Respiratory tract infection caused by IAV is associated with up 
to half a million mortality rates worldwide and five million cases 
of morbidity per year. A new swine-origin H1N1 IAV, identified 
in April 2009, spread worldwide, and was officially declared 
pandemic in June 2009. There are concerns that H1N1 or H3N2 
viruses reassort with existing H5N1 virus using bird or pig as 
intermediate hosts, giving rise to more pathogenic IAV. Thus, it 
is important to understand molecular mechanisms of host’s first 
line of defense against IAV in order to design and develop novel 
and effective anti-IAV strategies. SP-D expressed at the mucosal 
sites including lungs plays an important role during IAV infec-
tion (22). SP-D has been shown to have a wide range of innate 
immune roles including neutralization, agglutination, opsoni-
zation and clearance of viruses including IAV. The binding ability 
of rfhSP-D to HIV-1 gp120 was reported, primarily in a dose- and 
calcium-dependent manner (23). Human SP-D has also been 
shown to bind IAV-HA and NA, resulting in the inhibition of 
viral attachment and entry into the host cells (24). However, the 
mechanism of direct inhibition of IAV and pseudotyped viral 
particles by SP-D and subsequent immune response is not fully 
explored.
Using two different IAV subtypes (pH1N1 and H3N2), we have 
shown that the entry inhibitory capability of rfhSP-D is not limited 
FigUre 5 | rfhSP-D restricts replication of (a) pH1N1 and (B) H3N2 in target human A549 cells. M1 expression of both pH1N1 and H3N2 influenza A virus (IAV) 
(MOI 1) after infection of A549 cells at differential time points at 2 and 6 h. A549 cells were incubated either with pre-incubated pH1N1 and H3N2 with (10 µg) or 
without purified rfhSP-D. Cell pellets were harvested at 2 and 6 h to analyze the M1 expression of IAV. Cells were lysed, and purified RNA extracted was converted 
into cDNA. Infection was measured via qRT-PCR using M1 primers and 18S was used as an endogenous control. Results shown are normalized to M1 levels at 2 h 
untreated. Significance was determined using the unpaired one-way ANOVA test (**p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3). (c) Western blotting to 
shown M1 expression in both untreated (cells + virus) and treated (cells + virus + 10 µg/ml rfhSP-D) following 6 h incubation. Titration assay to show the anti-IAV 
activity of rfhSP-D (10 µg/ml), using both pH1N1 (D) and H3N2 (e) subtypes. A549 cells were infected with pH1N1/H3N2 (MOI 1) for 24 h. Then, the supernatants 
were collected and virus titers measured using a TCID50 assay. Treatment with rfhSP-D reduced viral titers by approximately 40%, suggesting that rfhSP-D acts as 
an entry inhibitor.
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to a particular IAV subtype. To identify the interaction of rfhSP-D 
with IAV viral proteins, protein–protein interaction studies were 
carried out via ELISA, cell-binding assay, and far western blot. 
The ELISA (Figure 2) and cell-binding assay (Figure 3) revealed 
the maximal binding of rfhSP-D to both pH1N1 and H3N2 
IAV subtypes at 5  µg/ml, and the maximum inhibition of cell 
binding was seen at 10 µg/ml of rfhSP-D. Furthermore, rfhSP-D 
bound purified recombinant HA protein in a concentration- and 
calcium-dependent manner (Figure  4C). rfhSP-D bound HA 
(70 kDa) and M1 (25 kDa) (Figure 4). N-linked oligosaccharides 
FigUre 6 | Continued
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FigUre 6 | Differential mRNA expression profile of A549 cells challenged with pre-incubated (a) pH1N1, (B) H3N2 with rfhSP-D, and (c) expression levels of type I 
interferon (IFN) subtypes in both untreated and treated samples. The expression levels of cytokines and chemokine were measured using qRT-PCR and the data 
were normalized via 18S rRNA expression as a control. The relative expression (RQ) was calculated by using cells only time point as the calibrator. The RQ value 
was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted in triplicates and error bars represents ± SEM. Significance was determined using the 
unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3).
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found on the IAV envelope glycoproteins (HA and NA) are known 
to be recognized by the CRD region of SP-D. Thus, HA-exposed 
glycans differing in location and numbers between IAV subtypes 
may be responsible for this interaction. rfhSP-D is likely to inhibit 
IAV infection by preventing the HA interaction with SA contain-
ing receptors. A reverse genetic approach has been used to analyze 
the role of N-glycosylation sites on the head of H1 in modulating 
sensitivity to SP-D in vitro and in vivo (25). It was found that HA 
Asn-144 was a critical factor in sensitivity to SP-D (25).
We also examined the immune response of A549 lung epi-
thelial cells following IAV challenge in the presence or absence 
of rfhSP-D, which can impact upon cellular infection and viral 
replication. Therefore, the ability of rfhSP-D to modulate viral 
replication as well as inflammatory immune response following 
IAV challenge was examined via infection assay, qPCR, and mul-
tiplex cytokine array. The key aspect of host–pathogen interaction 
arising out of this study is the ability of rfhSP-D-bound pH1N1 
and H3N2 to undergo suppressed replication, as evident by the 
expression of M1 gene. M1 is a matrix protein of IAV that lies 
beneath the lipid layer and is the most abundant protein, which 
is essential for viral stability and integrity. Thus, it plays a critical 
role in the recruitment and assembly of viral sites, nuclear export 
of viral RNPs, and thus, establishing the host components for 
viral budding (26). rfhSP-D suppressed the expression of M1 in 
pH1N1 (Figure 5A) at 2 h, while downregulating at 6 h in the case 
of H3N2 (Figure 5B). In addition, a lowered M1 expression was 
detected via western blot in the rfhSP-D treated sample compared 
to untreated sample following 6 h incubation (Figure 5C). Viral 
replication was also reduced in the presence of rfhSP-D as evident 
in Figures 5D,E. This suggests that rfhSP-D could act as an entry 
inhibitor against the subtypes tested (pH1N1 and H3N2). It is 
known that HA undergoes N-linked glycosylation, leading to 
modulation of antigenicity, fusion activity, receptor-binding 
specificity, and immune evasion of IAV. Therefore, SP-D can play 
an important role in innate defense against IAV as entry inhibi-
tor by interfering with glycosylation sites and binding to glycans 
on the viral HA. It has been reported that the combinatorial 
substitutions of D325A/S+R343V in a trimeric neck and CRD 
fragment of human SP-D markedly increased anti-viral activity 
against pandemic IAV. This is because of the increased ability of 
the mutant to block the SA binding sites, aggregate the virus and 
reduce viral uptake (27).
Our qPCR data demonstrated an increased expression level 
of TNF-α and IL-6 in the case of H3N2 subtype (Figure  6B) 
FigUre 7 | Multiplex cytokine array analysis of supernatants that were collected at 24 h time point. A549 cells were infected with pH1N1 (a) and H3N2 (B), treated 
with 10 µg/ml of rfhSP-D. Cytokines (TNF-α, IL-6, IL-10, IL-1α, IFN-α, and IL-12p40), chemokine (eotaxin), and growth factors (GM-CSF and VEGF) were measured 
using a commercially available MagPix Milliplex kit (EMD Millipore). Assays were conducted in triplicates and error bars represent ± SEM (n = 3); significance was 
determined using unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001).
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compared to pH1N1. However, when pH1N1 was treated with 
rfhSP-D, TNF-α and IL-6 were suppressed at 2 h (Figure 6A), 
which recovered later (6 h). Elevated TNF-α and IL-6 levels can 
contribute to virus-mediated respiratory diseases or acute lung 
injury. IL-12 was considerably downregulated by rfhSP-D in 
the case of both IAV subtypes, suggesting the likely suppression 
of Th1 immune response. mRNA expression of RANTES was 
10-fold (log101 fold) downregulated in the presence of rfhSP-D 
at 2 h time point in pH1N1 compared to A549 cells challenged 
with IAV. However, cells, challenged with H3N2 and treated 
with rfhSP-D, were seen to have log10 one-fold downregulation 
of RANTES expression. In this study, we also report the ability 
of rfhSP-D (10 µg/ml) to downregulate both IFN-α and IFN-β 
expression (Figure 6C) at 2 and 6 h. Higher expression levels of 
IFN-α and IFN-β were detected in the untreated (cells + virus) 
sample, which was threefold (log10 fold) downregulated in the 
presence of rfhSP-D at 6 h. This suggests that when cells were incu-
bated with pH1N1/H3N3 (MOI 1), higher levels of both IFN-α 
and IFN-β were produced by A549 cells to clear the virions. Since 
addition of rfhSP-D caused inhibition of viral replication, lower 
levels of INF were detected. Recently, the E3 ubiquitin ligase, 
TRIM29, has been shown to be a negative regulator of type I IFN 
responses in the lungs post-IAV challenge in vivo. TRIM29 acts 
by inhibiting IFN-regulatory factors and signaling via NF-κB, 
leading to degradation of NF-κB essential modulator (28). 
Whether rfhSP-D works via similar mechanisms is worth further 
investigation using SP-D gene-deficient mice (29). In addition, 
cytokine array analysis using supernatants that were collected at 
13
Al-Ahdal et al. IAV Entry Inhibition by rfhSP-D
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1586
FigUre 8 | Continued
FigUre 8 | (a) Western blotting to show the expression of influenza A virus-hemagglutinin (HA) protein in purified H1+N1 pseudotyped lentiviral particles and  
cell lysate at 24 and 48 h. The presence of HA was identified at 70 kDa. (B) Far western blotting to show rfhSP-D binding in both purified H1+N1 pseudotyped 
lentiviral particles and cell lysate at 24 and 48 h. HA was evident at 70 kDa when probed with rfhSP-D. (c) Luciferase reporter activity of purified H1+N1 
pseudotyped lentiviral particles at 24 and 48 h, and (D) Luciferase reporter activity of rfhSP-D treated MDCK cells transduced with these lentiviral particles. 
Significance was determined using the unpaired one-way ANOVA test (*p < 0.05 and ****p < 0.0001) (n = 3).
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24 h showed considerable downregulation of some of the key pro-
inflammatory cytokines, chemokines, and other soluble factors in 
the presence of rfhSP-D. The downregulation of various humoral 
factors by rfhSP-D treatment could also facilitate the prevention 
of life-threatening secondary bacterial infections that may be 
caused by aberrant virus-mediated immune modulation.
In this study, we have produced the second-generation 
lentiviral vectors pseudotyped for H1+N1 of IAV. This system 
contains a single packaging plasmid (psPAX2) encoding genes 
including Gag, Pol, and Tat. pHIV-Luciferase was used as a lenti-
viral transfer plasmid, which is flanked with long terminal repeat 
(LTR) sequences, and designed to express the firefly luciferase 
reporter. Thus, pHIV-Luciferase is “replication incompetent” 
which contains an additional sequence deletion in the 3′ LTR 
leading to viral “self-inactivation” post-integration. This was 
selected as a safe alternative method to mimic the structure 
and surfaces of IAV, and to prove rfhSP-D as an entry inhibi-
tor in cells transduced with pseudotyped IAV particles that are 
restricted to only one replicative cycle. The lentiviral particles 
pseudotyped with H1+N1 were analyzed via SDS-PAGE and 
western blotting. Expression of HA in purified H1+N1 pseudo-
typed lentiviral particles from transfected HEK293T  cells was 
assessed by western blotting using anti-H1 monoclonal antibody 
(Figure 8A). H1+N1 pseudotyped lentiviral particles, purified 
via ultra-centrifugation,  were used to investigate the combinato-
rial or differential involvement of viral envelope glycoproteins in 
the recognition and neutralization of HA by rfhSP-D. Incubation 
of rfhSP-D with these H1+N1 pseudotyped lentiviral particles 
was found to facilitate its binding to HA that appeared at 70 kDA 
in the far western blot (Figure 8B). To validate the effectiveness 
of rfhSP-D as an entry inhibitor of IAV, luciferase reporter activ-
ity assay was performed. Nearly 50% luminescent signal was 
seen with 10 µg/ml of rfhSP-D when compared to MDCK cells 
challenged with H1+N1 pseudotyped lentiviral particles alone. 
This, therefore, suggested the ability of rfhSP-D to inhibit viral 
infectivity through binding to cell surface bound HA found on 
the infected MDCK cells.
In summary, suppression of M1 expression, pro-inflammatory 
cytokine response, as well as luciferase reporter activity in target 
A549 cells by rfhSP-D highlight its potential as a therapeutic 
molecule in an entry inhibitory role against IAV.
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A B S T R A C T
Hydrophilic lung surfactant proteins have emerged as key immunomodulators which are potent at the re-
cognition and clearance of pulmonary pathogens. Surfactant protein A (SP-A) is a surfactant-associated innate
immune molecule, which is known to interact with a variety of pathogens, and display anti-microbial effects. SP-
A, being a carbohydrate pattern recognition molecule, has a wide range of innate immune functions against
respiratory pathogens, including influenza A virus (IAV). Some pandemic pH1N1 strains resist neutralization by
SP-A due to differences in the N-glycosylation of viral hemagglutinin (HA). Here, we provide evidence, for the
first time, that a recombinant form of human SP-A (rfhSP-A), composed of α-helical neck and carbohydrate
recognition domains, can actually promote the IAV replication, as observed by an upregulation of M1 expression
in lung epithelial cell line, A549, when challenged with pH1N1 and H3N2 IAV subtypes. rfhSP-A (10 μg/ml)
bound neuraminidase (NA) (∼60 kDa), matrix protein 1 (M1) (∼25 kDa) and M2 (∼17 kDa) in a calcium de-
pendent manner, as revealed by far western blotting, and direct binding ELISA. However, human full length
native SP-A downregulated mRNA expression levels of M1 in A549 cells challenged with IAV subtypes.
Furthermore, qPCR analysis showed that transcriptional levels of TNF-α, IL-12, IL-6, IFN-α and RANTES were
enhanced following rfhSP-A treatment by both IAV subtypes at 6 h post-IAV infection of A549 lung epithelial
cells. In the case of full length SP-A treatment, mRNA expression levels of TNF-α and IL-6 were downregulated
during the mid-to-late stage of IAV infection of A549 cells. Multiplex cytokine/chemokine array revealed en-
hanced levels of both IL-6 and TNF-α due to rfhSP-A treatment in the case of both IAV subtypes tested, while no
significant effect was seen in the case of IL-12. Enhancement of IAV infection of pH1N1 and H3N2 subtypes by
truncated rfhSP-A, concomitant with infection inhibition by full-length SP-A, appears to suggest that a complete
SP-A molecule is required for protection against IAV. This is in contrast to a recombinant form of trimeric lectin
domains of human SP-D (rfhSP-D) that acts as an entry inhibitor of IAV.
1. Introduction
The initial response to an infection in a host is the activation of its
innate immune system. Understanding how innate immune mechan-
isms restrict the spread of respiratory infections is crucial to designing
therapeutic strategies. Influenza virus is a major infectious respiratory
pathogen, and remains a serious global health concern, resulting in up
to half a million deaths annually (WHO, 2018). There are four distinct
types of Influenza virus, cause infections in humans; influenza virus A
(IAV) represents the most common cause of significant health threat.
IAV is responsible for approximately 70% of all influenza related
deaths, and has caused highly pathogenic pandemics (WHO, 2009). IAV
is further classified into different subtypes, depending on the combi-
nation of their surface glycoproteins, hemagglutinin (HA) and neur-
aminidase (NA) (Bouvier and Palese, 2008). IAV exerts a greater se-
lective pressure on the host, with a complex pathogenesis, characterised
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T
by rapid viral replication and viral distribution within the lungs, while
evoking cellular and humoral immunity (Fukuyama and Kawaoka,
2011). Although IAV has evolved numerous molecular strategies to
avoid and escape the host’s immune response to promote its continuous
survival within the host, a range of immune responses could potentially
target any stage of IAV.
The pulmonary surfactant system is composed of abundant proteins
and lipids that lower the surface tension of the alveoli, and play im-
portant roles in innate immunity. Its hydrophilic proteins, also called
collectins, are soluble collagenous lectins that serve multiple anti-
microbial functions against influenza viruses by binding to oligo-
saccharide structures via conserved carbohydrate recognition domains
(CRDs) on the surface of viral particles (van de Wetering et al., 2004).
The interaction between IAV and collectins (found within the mam-
malian serum and pulmonary fluids) leads to anti-viral activity in vitro
(Reading et al., 1997). Bovine conglutinin and mannose binding lectin
(MBL) cause inhibition of IAV hemagglutination and neutralisation
(Hartley et al., 1992). Other collectins, including surfactant protein A
(SP-A) and SP-D, expressed in the lungs, mucosal and epithelial surfaces
in the body, are involved in a number of immune functions involving
neutralization, agglutination, opsonisation and clearance of pathogens.
SP-A is a collagenous calcium-dependent defense lectins, composed
of N-terminal domain rich in cysteine, collagen domain, an α-helical
coiled-coil neck, and a C-terminal carbohydrate recognition domain
(CRD) (Kishore et al., 2006; Nayak et al., 2012). The overall structure of
SP-A is made up six of these subunits, which look like a bouquet
(Kishore et al., 2006). The trimeric CRD region recognises pathogens by
engaging terminal monosaccharide residues or charged patterns on
microorganisms, serving as soluble pattern recognition receptors
(PRRs). Thus, collagen like region is crucial for the interaction with
immune cell-mediated receptors such as calreticulin-CD91 complex to
bring about removal of pathogens (Kishore et al., 2006; Gardai et al.,
2003).
Direct interaction between SP-A and various viruses results in viral
neutralisation and induction of phagocytosis in vitro. SP-A can interact
with glycoprotein 120 of HIV-1 and suppress infection of CD4+ T cells,
and enhance HIV-1 transfer via dendritic cells, serving as a dual mod-
ulator of HIV-1 infection (Gaiha et al., 2008). SP-A has also been shown
to interact with herpes simplex virus type 1 (HSV-1), and mediate
phagocytosis of HSV-1 by alveolar macrophages (van Iwaarden et al.,
1991). SP-A can bind to the F2 subunit of respiratory syncytial virus
(RSV) and neutralise its infectivity (Ghildyal et al., 1999). In the case of
IAV, SP-A can bind HA and NA, and inhibit haemagglutination at initial
stages. However, pH1N1 pandemic strains are not neutralised by SP-A
due to variations in the N-linked glycosylation of HA (Job et al., 2010).
We have recently shown a recombinant form of human surfactant
protein D, containing homotrimeric neck and CRD region (rfhSP-D),
binds HA and reduces M1 expression in A549 cells challenged with
pH1N1 and H3N2 strains (Al-Ahdal et al., 2018). In addition, mRNA
expression levels of TNF-α, IFN-α, IFN-β, IL-6 and RANTES were down-
regulated following rfhSP-D treatment. Furthermore, rfhSP-D also re-
duced MDCK cell transduction by H1 + N1 pseudotyped lentiviral
particles, suggesting a possible therapeutic potential against IAV in-
fection. In this regards, this study was aimed at investigating the pos-
sible role of a well-characterised recombinant truncated form of human
SP-A (rfhSP-A) made up of trimeric CRDs, using pH1N1 and H3N2 IAV
subtypes.
2. Method and materials
2.1. Virus and antibodies
A/England/2009 (pH1N1) and the A/HK/99 (H3N2) influenza A
subtypes were used for most experiments. Vesicular Stomatitis Virus
(VSV-G) was used as a control for ELISA. Monoclonal Anti-Influenza
Virus NA, A/California/04/2009 (pH1N1) pdm09, Clone 5C12
(produced in vitro), NR-42019 and A/Hong Kong/1/1968 (H3N2) (an-
tiserum, Goat), NR-3118 and anti-M1 monoclonal antibody were ob-
tained from BEI Resources, NIAID, NIH, USA. Monoclonal anti-influ-
enza A virus M2 protein was obtained from Abcam.
2.2. Cell culture
Most reagents were purchased from Sigma unless mentioned
otherwise. A549 and MDCK cell lines were cultured in complete DMEM
containing FBS (10%), L-glutamine (2 mM), penicillin (100 U/ml),
streptomycin (100 μg/ml) and sodium pyruvate (1 mM). Cells were
cultured at 37 °C in a CO2 incubator until they were 80% confluent.
Cells were trypsinised (0.5%; 10 min), spun at 1000 rpm for 7′, and
suspended in complete DMEM. Viable cells were counted via Trypan
Blue (0.4%).
2.3. Virus purification and infection titre determination
Purification and production of pH1N1 and H3N2 subtypes were
carried out as described earlier (Al-Ahdal et al., 2018). MDCK cells were
infected with pH1N1 (2 × 104) or H3N2 (3.3 × 104) by incubation at
37 °C for 1 h. Post infection, the viral particles were pelleted via
3000×g centrifugation at 4 °C for 10′. Supernatants containing virus
particles were then subjected to ultracentrifugation (25,000×g, 4 °C,
1 h 30′), followed by re-suspending virus in 100 μl of PBS. 15 μl of virus
stock was assessed via reduced SDS-PAGE and ELISA. Tissue culture
infectious dose (TCID50) assay was performed to determine the in-
fectious titre of the purified pH1N1 and H3N2 viral stocks, and to assess
its cytopathic effects (CPE) using MDCK cells, as reported recently (Al-
Ahdal et al., 2018). CPE effects of infected and non-infected cells were
microscopically examined at each viral dilution.
2.4. Production of rfhSP-A
DNA sequences coding for trimeric neck and CRD region were
cloned under T7 promoter and expressed in Escherichia coli BL21
(λDE3) pLysS using construct pUK-A1 (Karbani et al., 2014). E. coli cells
were grown in LB medium, containing 100 μg/ml ampicillin and 34 μg/
ml of chloramphenicol, at 37 °C until an OD600 reached 0.6. Following
induction with 0.5 mM isopropyl β-D-thiogalactoside (IPTG), the bac-
terial culture was left to grow further for another 3 h on a shaker at
37 °C. The bacterial cell culture was then centrifuged (4500 rpm, 4 °C,
10′) and the pellet was re-suspended in lysis buffer (0.05 M Tris−HCL
pH 7.5, 0.2 M NaCl, 0.005 M EDTA, 0.1% Triton X-100, 0.1 mM phe-
nylmethane sulfonyl fluoride (PMSF), 50 μg lysozyme) for 1 h at 4 °C.
The lysate was sonicated using a Soniprep 150 (MSE, London, UK) at
60 Hz for 30 s with an interval of 2 min (12 cycles), followed by cen-
trifugation at 12,000 rpm for 15 min. The inclusion bodies were dena-
tured fully in 50 ml of 0.5 M Tris−HCl, 0.1 M NaCl, pH7.5 and 8 M urea
for 1 h at 4 °C. The soluble fraction was dialysed against the same buffer
containing 4 M, 2 M, 1 M and no urea for 2 h at each urea concentration.
The refolded material was then extensively dialysed against affinity
buffer that contained 10 mM CaCl2 instead of 5 mM EDTA for 2 h. The
supernatant was loaded on a 5 ml of mannose-sepharose column, and
bound rfhSP-A was eluted with buffer with 10 mM EDTA. Purified
rfhSP-A was run on SDS-PAGE to assess its purity. LPS was removed
using Endotoxin Removal Resin. LPS level was determined using QCL-
1000 Limulus amebocyte lysate system (Lonza) and found to be ∼5 pg/
μg of rfhSP-A.
2.5. Extraction of full length native SP-A from human bronchoalveolar
lavage fluid
Human full-length native SP-A (FLSP-A) was purified as published
earlier (Strong et al., 1998). Bronchoalveolar lavage fluid (BAL) col-
lected from pulmonary alveolar proteinosis patients was made up with
A.A. Al-Qahtani, et al. Immunobiology 224 (2019) 408–418
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buffer I containing 20 mM Tris−HCl and 10 mM EDTA, pH 7.4, fol-
lowed by centrifugation at 10,000 × g. The centrifuged cell pellet was
extracted using buffer I with 6 M urea. The solubilised FLSP-A was
centrifuged again at 10,000 × g and the soluble fraction was dialysed
against 4, 2, and 1 M urea in buffer II (20 mM Tris−HCl, 100 mM NaCl,
and 5 mM EDTA, pH 7.4). The supernatant was again dialysed against
buffer II containing 15 mM CaCl2, and loaded onto maltose agarose
column, followed by elution with buffer II containing 10 mM EDTA.
2.6. SDS-PAGE
SDS-PAGE 12% (w/v) was performed to analyse and detect the
purity of purified rfhSP-A and FLSP-A. Purified proteins were diluted in
1:1 (v/v) ratio in 2× Laemmli sample buffer (10 ml) (Bio-Rad,
Hertfordshire) containing 1 M Tris−HCL (pH 6.8, 1 ml), 10% SDS
(4 ml), 100% Glycerol (2 ml), 1% Bromophonol blue, β-mercap-
toethanol (2.5 ml) and distilled water (d.H2O). The protein was then
denatured for 10 min at 95 °C before loading. Standard pre-stained
protein marker (Fisher Scientific) was also loaded to assess the size of
the purified rfhSP-A. The SDS-PAGE gel was stained overnight using
staining solution (1 g of Brilliant Blue, 50% v/v methanol, 10% acetic
acid and 40 ml of D.H2O). The stained gel was then de-stained using the
de-staining solution 40% (v/v) methanol, 10% (v/v) acetic acid until
the protein bands were visible.
2.7. Direct binding ELISA
FLSP-A, rfhSP-A, rfhSP-D and VSV-G (as a negative control protein)
(10, 5, 2.5, and 1.25 μg/well) were coated on microtitre wells of a
Maxisorp 96 well plate (Sigma-Aldrich) in carbonate/bicarbonate
buffer, pH 9.6 and incubated at 4 °C overnight. After washing with PBS
three times, the unoccupied sites on the wells were blocked with 2% w/
v BSA for 2 h at 37 °C, followed by washing with PBST (PBS + 0.05%
Tween 20). pH1N1/H3N2 virus (20 μl of 1.36 × 106 pfu/ml) was di-
luted 10 times using PBS, and 10 μl was incubated in the wells for 2 h at
RT. After washing, monoclonal anti-H1 and polyclonal anti-H3 (both
from BEI-Resources) in PBS (1:5000) were added to the appropriate
wells and incubated at 37 °C for 1 h, followed by 1 h incubation with
rabbit anti-mouse and protein A conjugated to HRP (1:5000), respec-
tively (Fisher Scientific). TMB was used as a substrate and the plate was
read at OD450.
2.8. Far western blotting
Purified pH1N1/H3N2 (1.36 × 106pfu/ml) was run on SDS-PAGE
and then separated proteins were transferred to a PVDF membrane
using transfer buffer (0.25 M Tris, 0.19 M glycine and 20% methanol).
After blocking the membrane with 5% w/v milk power in PBS at 4 °C
and washing with PBST, the membrane was probed with monoclonal
anti-NA, anti-M1 or anti-M2 (1:1000 dilutions) antibodies for 1 h at RT.
For far-western blotting, the membrane was incubated with 5 μg/ml of
rfhSP-A in 5 mM CaCl2 buffer overnight at 4 °C. Binding was probed
with rabbit anti-human SP-A polyclonal antibodies in PBS (1:1000) for
1 h at RT. Rabbit anti-mouse and Protein A conjugated to HRP (1:5000)
(Fisher Scientific) were used as respective conjugates/secondary probes
for monoclonal and polyclonal antibodies. The colour was developed
using DAB as a substrate and H2O2.
2.9. Cell-binding assay
A549 cells (10,000 cells per well) were seeded in complete DMEM
and incubated at 37 °C until 80% confluence was reached. After
washing with different concentration of purified rfhSP-A (1.25–10 μg/
ml) were pre-treated with pH1N1/H3N2 virus (1.36 × 106 pfu/ml).
10 μl of diluted virus stock was added to the appropriate wells, and
incubated for 2 h at RT. After fixing the wells with 4% v/v paraf-
ormaldehyde (Fisher Scientific) for 10′ at RT, the blocking step was
carried out using 2% w/v BSA. Anti-H1 and H3 antibodies and sec-
ondary probes were used, as described earlier, using TMB as a substrate.
2.10. Quantitative RT-PCR
rfhSP-A and FLSP-A (10 μg/ml) were added to A549 cells
(0.5 × 106) in DMEM + 5 mM CaCl2 with MOI 1 of H1N1/H3N2 virus
and pelleted at different time points. Total RNA was extracted from the
above-mentioned cells using GenElute Mammalian Total RNA
Purification Kit (Sigma-Aldrich, UK). Total RNA was treated with
DNase I (Sigma-Aldrich, UK) prior to assessing concentration and purity
of total RNA via reading at OD260 and OD260:OD280(NanoDrop 2000/
2000c; Thermo Fisher Scientific). 2 μg of RNA was converted into cDNA
using cDNA Kit (Applied Biosystems). qRT-PCR was performed using
the 7900 H T Fast Real-Time PCR System (Applied Biosciences). Each
reaction was carried out in triplicates and included 5 μl Power SYBR
Green MasterMix, 75 nM of FP and RP, and 500 ng cDNA. The ampli-
fication cycle involved 50 °C and 95 °C for 2′ and 10′, followed by 40
cycles of amplification. Human 18S rRNA was used to normalise gene
expression and as an endogenous control. A list of primers have been
provided in Table 1.
2.11. Multiplex cytokine array analysis
In order to measure the secreted cytokines and chemokines fol-
lowing rfhSP-A treatment, IAV treated A549 cells were incubated in the
presence or absence of rfhSP-A (10 μg/ml) for 24 h. Subsequently, su-
pernatants were collected for measuring IL-6, TNF-α, IL-8, IL12 (p40)
and MCP-1. The expression levels of various analytes were measured
using EMD Millipore multiplex kit. As per manufacture’s instruction,
25 μl assay buffer was added to microtiter wells, plus 25 μl standard,
control or supernatant of A549 cells. Magnetic beads (25 μl) linked-
analytes were added to each well and incubated at 4 °C for 18 h. After
assay buffer washing, detection antibodies (25 μl) were incubated with
beads at RT for 1 h. 25 μl of Streptavidin-Phycoerythrin was then added
to each well and incubated for 30 min. at RT. After another round of
washing, 150 μl of sheath fluid was added to each well and the plate
was read using the Luminex Magpix instrument.
Table 1
Target Genes, Forward and Reverse primers used for qPCR.







IFN-α 5’-TTT CTC CTG CCT GAA GGA CAG-3’ 5’-GCT CAT GAT TTC TGC TCT GAC A-3’
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2.12. Statistical analysis
GraphPad Prism 6.0 software was used to generate all the graphs.
Two-way ANOVA test was used to perform the statistical analysis, and
the significance values were considered between rfhSP-A treated and
untreated conditions based on *p < 0.1, **p < 0.05, ***p < 0.01, and
****p < 0.001. Error bars show the SD or SEM (figure legends).
3. Results
3.1. Interaction of affinity purified rfhSP-A and FLSP-A with pH1N1/H3N3
The affinity purified and LPS-free rfhSP-A appeared as a single band
at ∼18 kDa on 15% SDS-PAGE (v/v) under reducing condition (Fig. 1).
FLSP-A preparation appeared mostly as a ∼32 kDa monomer, with a
small proportion showing up as a non-reducible dimer of ∼64 kDa
(data not shown). The interaction of FLSP-A, rfhSP-A, and rfhSP-D with
pH1N1/H3N2 viral particles was determined using direct binding
ELISA. As shown in Fig. 2, FLSP-A, rfhSP-A and rfhSP-D bound IAV
subtypes in a dose and calcium-dependent manner. No significant
binding was observed with VSV-G pseudotyped lentivirus (negative
control RNA virus). Cell binding assay was also performed to assess the
interaction of rfhSP-A with A549 lung epithelial cells challenged with
pH1N1 and H3N2 (Fig. 3). Maximum cell binding was seen at 10 μg/ml
for both IAV subtypes, while a clear dose dependent binding was seen
with H3N2, compared to pH1N1.
3.2. rfhSP-A interaction with NA, M1, and M2 proteins of pH1N1 and
H3N2
Binding of rfhSP-A to NA (∼60 kDa), M1 (∼25 kDa) and M2
(∼17 kDa) of purified pH1N1 and H3N2 was established using far
western blotting (Fig. 4A). The ability of rfhSP-A to bind immobilised
purified recombinant NA was assessed using ELISA. As shown in
Fig. 4C, rfhSP-A interacted with NA dose- and calcium-dependently;
VSV-G-pseudotyped particles did not show significant binding. Poly-
merization of M1 is suggested to provide a crucial mechanism for the
elongation of filamentous IAV virions. In addition, rfhSP-A was also
found to bind matrix protein 2 (M2) migrating at ∼17 kDa, as evident
from western blotting (Fig. 4A). Binding of rfhSP-A to M2 protein may
suggest enhancement of viral replication by stabilising the viral bud-
ding site, enabling M2 polymerization leading to formation of fila-
mentous viral particles.
3.3. rfhSP-A promotes, while FLSP-A inhibits, infection of A549 cells by
IAV
Infection assay was performed to determine the ability of IAV to
infect A549 cells in the presence or absence of FLSP-A and rfhSP-A
(10 μg/ml). rfhSP-A treatment up-regulated M1 expression in infected
A549 cells when compared to untreated cells challenged only with virus
(Fig. 5). In the case of both IAV subtypes, rfhSP-A treatment upregu-
lated M1 expression at 2 and 6 h. The up-regulation of M1 expression
was more pronounced for H3N2 than pH1N1, where 7log10 fold up-
regulation was noted at 6 h (Fig. 5A). M1 is known to bind cytoplasmic
ends of HA and NA of IAV, allowing M1 association with lipid raft
membrane, and inducing change in its conformation and polymeriza-
tion at the site of virus budding (Gómez-Puertas et al., 2000). However,
FLSP-A caused downregulation of M1 expression at 2 h and 6 h in the
case of both IAV subtypes. The suppression of M1 following FLSP-A
treatment was more evident in the case of pH1N1 when compared to
H3N2, where -5 log10 fold reduction was seen at 6 h (Fig. 5B). This data
is using rfhSP-A is in contrast to a recent study using rfhSP-D, where -8
log10 fold downregulation of M1 expression was seen with pH1N1 at 2 h
(Al-Ahdal et al., 2018).
3.4. qRT-PCR analysis of modulation of immune responses by rfhSP-A on
A549 challenged with IAV subtypes
The mRNA levels of pro-inflammatory cytokines and chemokines
were determined via qPCR. The relative mRNA levels of TNF-α, IL-12,
Fig. 1. SDS-PAGE (15% w/v) analysis of affinity purified recombinant fragment
of Human Surfactant protein (rfhSP-A). pUK-A1 construct containing neck and
CRD region was expressed under T7 bacteriophage in Escherichia coli BL21
(λDE3) pLysS. Following IPTG induction, the expressed bacterial cells show
rfhSP-A overexpression at ∼18 kDa. The inclusion bodies were refolded and
affinity purified using a mannose-agarose column. Purified rfhSP-A appeared as
a homogenous band of ∼18 kDa.
Fig. 2. Binding of rfhSP-A to (A) pH1N1 and (B) H3N2 via ELISA. Microtiter
wells were coated with varied concentrations of FLSP-A, rfhSP-A and rfhSP-D
(10, 5, 2.5, and 1.25 μg/ml). 20 μl of concentrated pH1N1 or H3N2 virus
(1.36 × 106 pfu/ml) was diluted in 200 μl of PBS + 5 mM CaCl2 and 10 μl of the
diluted virus was added to all the wells, and probed with either monoclonal
anti-influenza virus H1 or polyclonal anti-influenza virus H3 antibody. VSV-G
pseudotyped lentivirus was used as a negative RNA virus control. The data were
expressed as mean of three independent experiments done in triplicates ± SEM.
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IFN-α, and RANTES were upregulated by both IAV strains, following
rfhSP-A treatment at 6 h time point. However, IL-6 was 2log10 fold
upregulated by pH1N1 at 6 h by rfhSP-A treatment (Fig. 6A), but no
significant change was obeserved with H3N2 strain at 6 h. Furthermore,
enhancement of IFN-α was also evident with rfhSP-A treatment at 2 h,
which gradually declined by 2log10 fold at 6 h (Fig. 7A). Upregulation
of type I interferon may suggest that rfhSP-A can enhance viral re-
plication, and thus, increase the levels of interferon type I response to
alert other immune cells to mobilise mechanisms towards viral clear-
ance. In the case of FLSP-A treatment, pro-inflammatory cytokines such
as TNF-α and IL-6 were downregulated at 6 h treatment for both pH1N1
and H3N2 (Fig. 6C & D). Enhanced level of IL-6 has been reported in
patients infected with pH1N1 (Paquette et al., 2012). IL-12 (-2 log10
fold) and RANTES (-6.5 log10 fold) were downregulated by FLSP-A
treatment in pH1N1 subtype (Fig. 6C), while this upregulation was seen
with H3N2 (Fig. 6D), suggesting the possible enhancement of Th1 im-
mune response. In the case of type I interferons, FLSP-A induced up-
regulation of INF-α at 6 h for both IAV strains.
3.5. Multiplex analysis of cytokine/chemokine array following rfhSP-A
treatment
Secretion of cytokines and chemokines, 24 h post rfhSP-A treatment,
was assessed using a multiplex cytokine/chemokine array. rfhSP-A
triggered enhancement of TNF-α, IL-6 and IL-8 in both IAV subtypes
(Fig. 8). However, no significant change in the level of MCP-1 was seen
with MCP-1 for both IAV subtypes. Increased IL-6 level has been linked
with the severity of IAV infection based on a study involving pH1N1-
infected mice (Paquette et al., 2012). Expression of TNF-α in lung
epithelial cells is suggested to be the key targets of IAV, and is im-
portant for controlling IAV in the host respiratory tract. TNF-α is in-
volved in recruiting monocytes, T and B lymphocytes to the site of in-
fection, suggesting its role in clearing the viral particles in the
respiratory tract prior to the induction of secondary immune response.
Therefore, up-regulation of TNF-α and IL-6 by rfhSP-A can serve as a
potential biomarker during IAV infection, similar to other diseases
(Damas et al., 1992; Theoharides et al., 2002).
4. Discussion
Influenza A virus (IAV) is a contagious respiratory virus, causing
substantial morbidity and mortality. Anders et al. first reported col-
lectins as beta inhibitors derived from bovine and mouse. The calcium
dependent mannose binding lectin (MBL) was shown to bind glycans
found on the globular region of HA, thus, inhibiting HA from binding to
sialic acid-decorated cell-surface receptors (Anders et al., 1990). Col-
lectins can orchestrate a number of anti-IAV mechanisms such as in-
hibition of HA and NA (Hartshorn et al., 1994, 2008; Al-Ahdal et al.,
2018), virus neutralisation, virus aggregation, IAV uptake by neu-
trophils, and viral opsonisation. SP-A is a calcium-dependent hydro-
philic C-type collectin, involved in pulmonary surfactant homeostasis
(Weaver and Whitsett, 1991), and reported to be a potent innate im-
mune molecule in the lungs. SP-A can bind various self and non-self-
ligands in a calcium- dependent manner, mostly via CRD region on the
target surface. Thus, recruitment and activation of immune cells occurs
via collagen domain for the clearance of microorganisms (Kishore et al.,
2006). SP-A can bind a diverse group of pathogens, acting as opsonins
leading to direct and indirect biological consequences (Crouch, 2000;
Lawson and Reid, 2000; Crouch and Wright, 2001). Specific interaction
of SP-A with a number of respiratory viruses has been reported, which
requires interaction with viral glycoproteins and complex oligo-
saccharides. Recently, we described a protective effect of rfhSP-D that
was able to inhibit entry of IAV into A549 cells challenged with pH1N1
and H3N2 subtypes (Al-Ahdal et al., 2018). Therefore, this study was
aimed at examining the direct interaction of a truncated recombinant
fragment of human SP-A (rfhSP-A) with IAV, and subsequent im-
munological consequences.
In this study, plasmid pUK-A1, containing cDNA sequences for neck
and CRD region of human SP-A (Karbani et al., 2014) was transformed
in Escherichia coli BL21 (λDE3) pLysS strain under T7 bacteriophage
promoter. rfhSP-A, recovered from inclusion bodies via denaturation-
renaturation cycles, was affinity purified on a mannose-agarose
column, which appeared as a ∼18 kDa band on a 15% SDS-PAGE gel
electrophoresis (Fig. 1). rfhSP-A eluted as a trimer on a gel filtration
column and was recognised by rabbit polyclonal and mouse monoclonal
antibodies raised against full length SP-A purified from lung lavage of
an alveolar proteinosis patient (data not shown). Affinity purified
rfhSP-A, made free from endotoxin, was then examined for its re-
spective interaction with IAV subtypes (pH1N1 and H3N2) via direct
ELISA (Fig. 2). The ability of rfhSP-A to bind IAV subtypes is consistent
with an earlier study using a recombinant form of truncated human SP-
D (rfhSP-D) composed of trimeric neck and CRD region (Al-Ahdal et al.,
2018).
Ten μg/ml of rfhSP-A bound best to both pH1N1 and H3N2 (Fig. 2).
The ability of rfhSP-A to bind IAV bound A549 cells was measured via
cell binding assay (Fig. 3). To understand whether interaction between
rfhSP-A and IAV subtypes led to specific interaction with IAV glyco-
proteins, far western blotting analysis was carried out (Fig. 4A). rfhSP-A
(10 μg/ml) bound to NA (∼60 kDa), M1 (∼25 kDa) and M2 (∼17 kDa)
of purified pH1N1 and H3N2 in a calcium-dependent manner. Fur-
thermore, in order to validate the binding interaction rfhSP-A and NA,
an ELISA was carried out using purified recombinant NA protein. As
Fig. 3. Cell-binding assay to show binding of (A) pH1N1 and (B) H3N2, pre-
incubated with rfhSP-A, to A549 cells. Microtiter wells were coated with A549
cells (1 × 105 cells/ml) and incubated overnight at 37 °C. Different con-
centrations of rfhSP-A (10, 5, 2.5, and 1.25 μg/ml), pre-incubated with pH1N1
and H3N2 virus were added to the corresponding wells, followed by incubation
at room temperature for 2 h. After fixing the cells with 4% paraformaldehyde,
monoclonal anti-influenza virus H1, or polyclonal anti-influenza virus H3 an-
tibodies were added to the corresponding wells. Maltose-binding protein (MBP)
was used as a negative control protein. The data were expressed as mean of
three independent experiments carried out in triplicates ± SEM.
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evident in Fig. 4B, rfhSP-A bound purified NA protein dose-depen-
dently. Previous studies have also suggested that full length SP-A can
bind to NA, and inhibit the release of viral particles from infected cells
(Tecle et al., 2007). Thus, N-linked oligosaccharides found on NA are
likely to be recognised by the CRD region of SP-A and SP-D (Tecle et al.,
2007).
The ability of rfhSP-A to modulate viral replication and host im-
mune response by IAV challenged A549 cells was also examined. IAV-
bound rfhSP-A was found to induce enhanced viral replication, based
on the expression levels of M1 gene. M1 is an abundant matrix protein
of IAV, which plays dual roles in virion assembly and infection
(Rossman and Lamb, 2011). Up-regulation of M1 expression was
brought about by rfhSP-A treatment in IAV challenged A549 cells,
compared to cells without rfhSP-A treatment but challenged with
pH1N1 or H3N2 only (Fig. 5). M1 upregulation, following rfhSP-A
treatment, was more pronounced in H3N2 infected cells compared to
pH1N1, where 7log10 fold upregulation was seen at 6 h (Fig. 5). How-
ever, A549 cells, pre-treated with FLSP-A, caused downregulation of M1
expression when compared to cells only challenged with IAV subtypes
(Fig. 5B). M1 downregulation by FLSP-A was found to be more effective
against pH1N1 subtype, when compared to H3N2, where -5 log10 fold
downregulation was evident at 6 h treatment (Fig. 5B). M1 can bind
cytoplasmic ends of HA and NA, polymerize and form the interior
structure of emerging viral particles (Rossman and Lamb, 2011). Ad-
ditionally, as evident from the far western blotting, rfhSP-A was also
able to bind Matrix protein 2 (M2) of IAV at ∼17 kDa (Fig. 4). HA
bound M1 serves as a docking site for the viral RNPs recruitment and
may mediate M2 recruitment to the site of viral budding (Rossman and
Lamb, 2011). M2 can stabilise the budding site, enabling polymeriza-
tion of the matrix protein, leading to formation of viral particles. Fur-
thermore, M2 has also been reported to change so as to facilitate release
of the progeny viral particles. Binding of rfhSP-A to NA/M1/M2, and
upregulation of M1 expression could explain the likely effect of rfhSP-A
as a facilitator of IAV replication of subtypes tested in this study.
mRNA expression of pro-inflammatory cytokines and chemokines
following rfhSP-A treatment was determined by qPCR, which showed
an upregulation of TNF-α, IL-12 and RANTES in the case of both IAV
subtypes at 6 h time point. However, an increased expression levels of
IL-6 (2log10 fold) (Fig. 6A) was seen only with pH1N1 at 6 h, while
H3N2 did not show any significant effect (Fig. 6B). In contrast,
Fig. 4. (A) Far western blot analysis to show
rfhSP-A binding to purified pH1N1 and H3N2.
10 μl of concentrated virus (1.36 × 106 pfu/
ml) was first run on the SDS-PAGE under re-
ducing conditions, transferred onto a ni-
trocellulose membrane, and incubated with
10 μg/ml of rfhSP-A. The membrane was
probed with rabbit anti-human SP-A poly-
clonal antibody. rfhSP-A bound to NA
(∼60 kDa), M1 (∼25 kDa) and M2 (∼17 kDa)
in the case of both pH1N1 and H3N2 subtypes.
The identity of SP-A bound IAV proteins was
validated using a separate blot that was di-
rectly probed with monoclonal anti-NA, M1
and M2 antibodies (B). (C) Direct ELISA to
show the ability of rfhSP-A to bind purified
recombinant neuraminidase (NA) of IAV. VSV-
G was used as a negative control protein,
where no significant binding was detected. The
data were expressed as mean of three in-
dependent experiments carried out in
triplicates ± SEM. Significance was de-
termined using the unpaired one-way ANOVA
test (***p < 0.0001)(n = 3.
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downregulation of TNF-α (-4.5 log10 fold) and IL-6 (-5 log10 fold) was
seen at 6 h following FLSP-A treatment (Fig. 6C & D). In the case of
pH1N1, FLSP-A also caused downregulation of IL-12 and RANTES
mRNA expression (Fig. 6C), while increased expression levels was ob-
served with H3N2 IAV subtype (Fig. 6D). Enhanced levels of TNF-α and
IL-6 have been reported during IAV infection, and it is also associated
with severe lung pathology and worse outcome in IAV infected patients
(La Gruta et al., 2007). However, these cytokines can also be protective
during seasonal influenza infection. Studies also report an increased
level of IL-6 in the lungs and serum of patients infected with influenza
virus, including the outbreak 2009 pH1N1 pandemic subtype (Kaiser
et al., 2001; Hagau et al., 2010a, 2010b). Therefore, increased levels of
IL-6 following rfhSP-A treatment may be associated with facilitation of
IAV infection.
Increased serum levels of TNF-α has been reported in most influenza
infected patients, particularly with pH1N1 subtype (Hagau et al.,
2010a, 2010b; Zúñiga et al., 2011; Bermejo-Martin et al., 2010;
Morales-García et al., 2012). In this study, when pH1N1 and H3N2
were treated with rfhSP-A, TNF-α expression levels were enhanced at
6 h (Fig. 6), suggesting the ability of rfhSP-A to increase viral infection.
Overexpression of TNF-α and IL-6 has been suggested as a hallmark of
viral infection (Mogensen and Paludan, 2001). Elevated levels of these
cytokines haven been observed in patients with both acute (Kaiser
et al., 2001) and severe (Heltzer et al., 2009) seasonal IAV infection.
Up-regulation of cytokine production upon H1N1 infection has been
reported as an important crucial player in the pathogenesis of IAV in-
fection. Thus, invasion of H1N1 strain into the lungs can trigger pro-
duction of pro-inflammatory cytokine profile, resulting in the devel-
opment of pneumonia.
rfhSP-A treatment caused increased levels of IL-12 by both pH1N1
and H3N2 in a time dependent manner (Fig. 6), suggesting the likely
enhancement of viral replication and Th1 immune response. RANTES
was down-regulated in the presence of rfhSP-A at 2 h, which recovered
by 2.5log10 fold later at 6 h time point in pH1N1 treated cells. However,
for H3N2, only 1log10 fold upregulation was seen following rfhSP-A
treatment in a time-dependent manner (Fig. 6B). Lower expression le-
vels of IFN-α was observed in the untreated sample, which was 3log10
fold up-regulated in the presence of rfhSP-A at 2 h (Fig. 7), suggesting
that rfhSP-A can enhance the rate of viral replication, and thus, thereby
enhance the levels of IFN produced by the innate immune cells in order
to clear viral particles from infected host.
In conclusion, a truncated recombinant form of human SP-A, rfhSP-
A, can promote pH1N1 and H3N2 subtypes of IAV instead of antici-
pated inhibition of infection. We have previously shown that its SP-D
counterpart acts as an entry inhibitor (Al-Ahdal et al., 2018), suggesting
that rfhSP-A may not have a therapeutic value. The effects of FLSP-A on
IAV challenged A549 cells is similar to the effect seen by rfhSP-D, where
downregulation of M1 and pro-inflammatory cytokines was seen with
FLSP-A treatment. The observed restriction of M1 replication following
FLSP-A treatment is likely to be due to the presence of collagen region,
which could shift the way SP-A acts on IAV infectivity involving its
putative receptor on the cell surface (Gardai et al., 2003). This study
highlights a fundamental difference in the structure-function relation-
ships between SP-A and SP-D. The literature is full of evidences where a
recombinant truncated form of human SP-D (rfhSP-D) containing tri-
meric neck and CRD regions behaves like full-length SP-D in vitro, in
vivo and ex vivo, including offering a protective effect against IAV
(Madan et al., 2010; Al-Ahdal et al., 2018). In the case of SP-A and IAV
interaction, it appears that only FLSP-A is capable of interfering with
IAV entry into the target cells, highlighting the importance of the col-
lagen domain and an intact SP-A molecule. It is also apparent that entry
inhibition is coupled with an anti-inflammatory response, as evident
from downregulation of TNF-α and IL-6. However, both FLSP-A as well
as rfhSP-A upregulate type I interferon (IFN-α) response, raising the
notion that FLSP-A creates an anti-inflammatory milieu during IAV
infection. How rfhSP-A on its own enhances IAV infection remains an
intriguing question. We are currently examining the mechanism of
enhanced infectivity that may involve topological alterations in M1 and
M2 proteins leading to an exaggerated budding.
Fig. 5. rfhSP-A treatment promotes infection
and replication (A), while suppression of M1
replication was seen with FLSP-A (B) of pH1N1
and (B) H3N2 in target human A549 cells. M1
mRNA expression of both pH1N1 and H3N2
influenza A virus (IAV) (MOI 1) after infection
of A549 cells at 2 and 6 h was measured. A549
cells were incubated with pH1N1 and H3N2,
pre-incubated with or without purified rfhSP-A
and FLSP-A (10 μg/ml). Cell pellets were har-
vested at 2 and 6 h to analyze the M1 expres-
sion of IAV. Cells were lysed, and purified RNA
extracted was converted into cDNA. Infection
was measured via qRT-PCR using M1 primers;
18S was used as an endogenous control.
Results shown are normalized to M1 levels at
2 h untreated. Significance was determined
using the unpaired one-way ANOVA test
(**p < 0.01, ***p < 0.001, and ****p <
0.0001) (n = 3). UT (un-treated sample), and
T (treated sample).
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Fig. 6. Differential mRNA expression profile of selected cytokines/chemokines produced by A549 cells challenged with pH1N1 and H3N2 pre-incubated with rfhSP-A
(A&B) and FLSP-A (C&D). The expression levels of selected cytokines and chemokine were measured using qRT-PCR and the data were normalized via 18S rRNA
expression as a control. The relative expression (RQ) was calculated by using cells only time point as the calibrator. The RQ value was calculated using the formula:
RQ = 2−ΔΔCt. Assays were conducted in triplicates and error bars represent ± SEM. Significance was determined using the unpaired one-way ANOVA test
(**p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3). UT (untreated sample), and T (treated sample).
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Fig. 6. (continued)
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Surfactant protein D (SP-D) is an important innate immune molecule that is involved in
clearing pathogens and regulating inflammation at pulmonary as well as extra-pulmonary
sites. Recent studies have established the role of SP-D as an innate immune surveillance
molecule against lung and pancreatic cancer, but little is known about its involvement in
signaling pathways it can potentially activate in ovarian cancer. We focused our study
on ovarian cancer by performing bioinformatics analysis (Oncomine) of datasets and
survival analysis (Kaplan-Meier plotter), followed by immunohistochemistry using ovarian
cancer tissue microarrays. SP-D mRNA was found to be expressed widely in different
types of ovarian cancer irrespective of stage or grade. These in silico data were further
validated by immunohistochemistry of clinical tissues. High transcriptional levels of SP-D
were associated with unfavorable prognosis (overall and progression-free survival). We
also detected SP-D protein in Circulating Tumor Cells of three ovarian cancer patients,
suggesting that SP-D can also be used as a potential biomarker. Previous studies have
shown that a recombinant fragment of human SP-D (rfhSP-D) induced apoptosis in
pancreatic cancer cells via Fas-mediated pathway. In this study, we report that treatment
of SKOV3 cells (an ovarian cancer cell line) with rfhSP-D led to a decrease in cell
motility and cell proliferation. This was followed by an inhibition of the mTOR pathway
activity, increase in caspase 3 cleavage, and induction of pro-apoptotic genes Fas and
TNF-α. These data, suggesting a likely protective role of rfhSP-D against ovarian cancer,
together with the observation that the ovarian cancer microenvironment overexperesses
SP-D leading to poor prognosis, seems to suggest that the tumor microenvironment
components manipulate the protective effect of SP-D in vivo.
Keywords: surfactant protein, SP-D, innate immunity, ovarian cancer, biomarker, circulating tumor cells
INTRODUCTION
Surfactant protein D (SP-D) is an innate immune molecule involved in clearing a range of
pathogens and apoptotic/necrotic cells at pulmonary as well as extra-pulmonary mucosal sites
(1, 2). SP-D interacts with infectious microbes using its C-type lectic domains and brings about
effector mechanisms via agglutination, enhanced phagocytosis and oxidative burst, and direct
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cytostatic properties (1); SP-D is also considered to be
involved in controlling allergic sensitization in the lungs (3)
where it exerts anti-lymphoproliferative effect following allergen
challenge (4). In mouse models of Aspergillus fumigatus-
induced allergic hypersensivity, immunopathological parameters
of type I and III hypersensitivity improved considerably
following therapeutic delivery of full-length human SP-D and
its recombinant fragment containing trimeric neck and lectin
domains (rfhSP-D) (5). SP-D can also induce apoptosis in
activated eosinophilic and T cells via p53 pathway (6–9). In
addition to several extrapulmonary sites, SP-D has also been
found in various parts of the reproductive tract, including the
ovaries (2, 10).
Emerging evidence seems to suggest that tumor cells are
affected by the inflammatory environment, which can influence
tumor proliferation and metastasis (11). Recent studies have
focused on lung cancer, as it is the primary production site of SP-
D where it plays a crucial role in surfactant and immunological
homeostasis. SP-D can downregulate the EGF pathway by
directly binding to EGFR and inhibit cell proliferation, invasion
and metastasis of the A549 lung cancer cell line (12). A clinical
study in 71 patients showed that low levels of SP-D were
associated with increased incidence of lung cancer and that
SP-D levels in bronchoalveolar lavage fluid could be used as
a biomarker (13). Moreover, single nucleotide polymorphisms
within the SP-D gene have been correlated with lung cancer,
pneumonia and emphysema (14, 15). In pancreatic cancer,
a recombinant fragment of human SP-D (rfhSP-D) induced
apoptosis in vitro via Fas-mediated pathway (16). Furthermore,
rfhSP-D inhibited TGF-β expression in a range of pancreatic
cancer cell lines, thereby reducing their invasive potential by
suppressing the Epithelial-to-Mesenchymal Transition (17).
In a recent study, it has been demonstrated that SP-D mRNA
is overexpressed in ovarian cancer and can be of a potential
prognostic value (18). Ovarian cancer affects over 65,500 women
every year in Europe alone, and within 5 years, nearly 70%
(42,716) of sufferers are predicted to die; it is the 6th leading cause
of death in women worldwide. Ovarian cancer is known as the
silent killer as it causes no symptoms in the early stages, so it
is difficult to detect. Even at its advanced stage, the symptoms
are very vague. Approximately, 70% of patients are diagnosed
at advanced stage III (where ovarian cancer has spread into the
upper part of the abdomen), or IV (where ovarian cancer cells
are outside the abdominal cavity), with nearly 85% expected
mortality. If ovarian cancer is diagnosed/detected early (Stage
I–in the ovary only), its treatment is much more successful
with the survival rates up to 90% (19, 20). In this study, we
carried out a bioinformatic analysis to ascertain the potential
prognostic role of SP-D in ovarian cancer. We also used a tissue
microarray to validate these data and circulating tumor cells
from ovarian cancer patients to measure/detect SP-D levels in
liquid biopsies.
Given its pro-apoptotic and anti-invasive potential in a few
in vitro cancer models, we hypothesized that rfhSP-D might be
a novel therapeutic agent in ovarian cancer. Thus, in this study,
we also investigated the effect of rfhSP-D on ovarian cancer
signaling, using the SKOV3 cell line as an in vitro model- with
emphasis to mTOR pathways. The mTOR pathway is a central
regulator of growth, proliferation, apoptosis and angiogenesis
providing balance between cellular resources. mTOR and one
of its substrates, S6 kinase, are activated in ovarian cancer cells




The expression level of SFTPD gene in various types of ovarian
cancer was analyzed using Oncomine, a cancer microarray
database and web-based data mining platform from genome-
wide expression analyses (22, 23). We compared the differences
in mRNA level between normal and ovarian cancer tissues. The
prognostic significance of SP-D mRNA expression and survival
in ovarian cancer was analyzed by Kaplan–Meier plotter as
described recently (18).
Immunohistochemistry
Ovarian carcinoma tissue microarrays, containing 10 cases of
ovarian tumor with 2 non-neoplastic tissues, duplicated cores
per case (Biomax, U.S.), were used to examine the expression
of SP-D. The slides were deparaffinised following a series of
washing in histoclear (National Diagnostics) and ethanol. Slides
were boiled in sodium citrate for 20min, washed with Tris-
buffered Saline (TBS) with 0.025% v/v Triton-X 100, and
then incubated with 3% v/v hydrogen peroxide in PBS for
30min before being washed again in TBS with 0.025% Triton
X 100. After blocking the slides using 5% v/v goat serum
in PBS + 0.025% Triton-X 100 in a humidity chamber, the
slides were incubated overnight with rabbit anti-human SP-D
polyclonal antibodies (MRC immunochemistry unit, Oxford)
diluted in PBS + 0.025% Triton-X 100. After a series of washing
with TBS + 0.025% Triton X 100, the slides were incubated
with Goat anti-rabbit IgG-HRP conjugate (Zytomed Systems,
Germany) diluted in PBST, for 1 h at room temperature. DAB
(3,3′-diaminobenzidine) substrate solution (Vector Laboratories)
containing hydrogen peroxide was loaded on the slides for 5min.
Slides were washed in H2O for 5min and then incubated with
Harris’ haematoxylin for 30 s. Slides were stained with 0.1% w/v
sodium bicarbonate for 30 s before dehydration in ethanol and
histoclear. Images were captured using an EOS 1200D Brunel
Microscope Ltd.
Liquid Biopsies
Patients with advanced ovarian cancer included in this study
were enrolled at Mount Vernon Cancer Centre (East and North
Hertfordshire NHS Trust) in the prospective CICATRIx clinical
study that allows collection of blood samples for biomarker
studies. All patients provided written informed consent for
participation in the study and subsequent use of their tissue
and blood specimens for research. The CICATRIx study was
approved by the West Midlands—South Birmingham Ethics
Committee (reference 16/WM/0196).
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ImageStreamx Mark II Flow Cytometry
Whole blood (1ml) from ovarian cancer patient samples (n =
3) was mixed with 9ml of red blood cell lysis (RBC) buffer (G
Biosciences, St. Louis, MO, USA), followed by incubation for
10min at room temperature with gentle agitation. Following
centrifugation at 1,260× g for 10min at 4◦C, the supernatant was
aspirated and 3ml of RBC lysis buffer for second wash. This was
followed by another incubation for 10min at room temperature
with gentle agitation, followed by centrifugation. The resultant
pellet was resuspended in 1.5ml of PBS and then centrifuged
at 1,450 × g for 3min. The cell pellet was resuspended in 1ml
of ice-cold 4% v/v paraformaldehyde for 7min on ice and then
centrifuged for 5min at 250 × g. Subsequent immunostaining
using specific polyclonal antibodies against human SP-D diluted
in FBS-PBS (1:200) was used as previously described in the
solution containing CTCs (and some white blood cells) (24, 25).
Cell Culture and Treatments
SKOV3 (human ovarian clear cell adenocarcinoma) cell line was
purchased from the American Type Culture Collection (ATCC,
Rockville, MD, USA) and used as an in vitro cell model for
epithelial ovarian cancer. SKOV3 cells were cultured in DMEM
supplemented with 10% v/v FBS, 1% v/v penicillin/streptomycin
and 1% L-glutamine (Gibco, MA, USA). Cells were grown
under standard culture conditions (37◦C, 5% v/v CO2). At
approximately 80–90% confluency, the media was discarded, and
cells were washed with fresh PBS. Seeded SKOV3 cells in 6-well
plates were treated with rfhSP-D in a dose- (5, 10, 20µg/ml) and
time- (12, 24, 48 h) dependent manner in triplicates.
Expression of a Recombinant Fragment of
Human SP-D (rfhSP-D)
A recombinant fragment of human SP-D containing trimeric
neck and C-type lectin domains was expressed in E.coli
and purified, as previously described (26, 27). Its three-
dimensional crystallographic structures are well-established
(28, 29). The affinity purified fractions were passed through a
Pierce High Capacity endotoxin removal resin column to remove
lipopolysaccharides (LPS) (Thermo Scientific). The endotoxin
levels were measured using a QCL-1000 Limulus amebocyte
lysate system (BioWhittaker, Walkersville, MD, USA) and were
approximately 5 pg per µg of rfhSP-D.
Immunofluorescence Microscopy for SP-D
SKOV3 cells were grown in a 24-well plate on the top of
coverslips. Cells were fixed with 4% paraformaldehyde (PFA;
Sigma-Aldrich) for 10min at room temperature, and then
permeabilised with 0.5% v/v Triton X 100 (Sigma-Aldrich) for
5min on ice. Next, cells were blocked using 5% v/v FBS diluted
in PBS for 45min and then incubated for another 45min
with rabbit anti-human SP-D polyclonal antibody diluted in
5% FBS-PBS. Cells were washed and incubated with a staining
buffer containing Alexafluor 568 secondary conjugated goat
anti-rabbit antibody, phalloidin 488 and Hoechst (Invitrogen,
Life Technologies). This incubation was performed in the dark
for 45min. After washing with 5% FBS-PBS, the coverslips
were mounted on slides and visualized under a HF14 Leica
DM4000 microscope.
Live Cell Imaging
SKOV3 cells were grown in a Petri dish and allowed to reach
∼30–40% confluency. Cells were treated with rfhSP-D at a final
concentration of 10µg/ml. Cells were then placed under a Zeiss
Axiovert 200M microscope attached to an incubator in order to
examine cell survival and visualize cell motility. Images of the
cells were recorded every 5min for 15 h. X and Y coordinates
were generated through ImageJ software for 25 cells for the first
8 h. Using Pythagoras’ theorem, the distance, the velocity and the
displacement were established.
FIGURE 1 | In silico analyses of SP-D (SFTPD) expression in different subsets
of ovarian cancer patients. SP-D gene expression from the Hendrix et al. (31)
dataset plotted by Oncomine. (A) Mean SP-D gene expression in control
normal ovaries (0), ovarian clear cell adenocarcinoma (1), ovarian endometrioid
adenocarcinoma (2), ovarian mucinous adenocarcinoma (3), and ovarian
serous adenocarcinoma (4). Boxes represent the 25th-75th percentile (with
median line), bars show the 10th−90th percentile and dots show the complete
spread of data. Fold change in SP-D expression was 1: 1.217 (p = 0.123),
2: −1.109 (p = 0.782), 3: −1.201 (p = 0.897) and 4: 1.086 (p = 0.266) when
compared to normal, respectively. SP-D gene expression from the Lu et al.
dataset (B). Mean SP-D gene expression in control normal ovaries (0), ovarian
clear cell adenocarcinoma (1), ovarian endometrioid adenocarcinoma (2),
ovarian mucinous adenocarcinoma (3), and ovarian serous adenocarcinoma
(4). Fold change in SP-D expression was 1: −1.179 (p = 0.855), 2: −1.214
(p = 0.893), 3: −1.255 (p = 0.922) and 4: −1.257 (p = 0.924) when
compared to normal, respectively.
Frontiers in Oncology | www.frontiersin.org 3 July 2019 | Volume 9 | Article 542
Kumar et al. SP-D and Ovarian Cancer
Wound Healing Assay
SKOV3 cells were assessed for their ability to close an artificially
created gap in a cell growth area in the presence or absence of
rfhSP-D. SKOV3 cells were cultured in a petri dish and allowed
to reach 100% confluency. Using a 20 µl pipette tip, the bottom
of the dish was scratched to create an artificial gap. Cells were
placed under a Zeiss Axiovert 200Mmicroscope and images were
recorded every 5min for up to 48 h.
Flow Cytometry
SKOV3 (0.1 × 107) cells were grown in a 6-well plate and
incubated with rfhSP-D (5, and 10µg/ml), along with an
untreated control, for 48 h. The cells were then detached using
2 × Trypsin-EDTA (0.5%) (Fisher Scientific) and centrifuged at
1,500 × g for 5min. Annexin V apoptosis detection kit with PI
(Abcam) was used, according to the manufacturer’s instructions.
After extensive washing with PBS, apoptosis was measured
using Novocyte Flow Cytometer. Compensation parameters
were acquired using unstained, untreated FITC stained, and
untreated PI stained. 12,000 SKOV3 cells were acquired for each
experiment and compensated before plotting the acquired data.
Fluorescence Microscopy
SKOV3 cells were cultured in DMEM-F12 medium,
supplemented with 10% v/v FBS, penicillin (100
U/ml)/streptomycin (100µg/ml), and 2mM L-glutamine
(Fisher Scientific). Cells were grown at 37◦C in the presence of
5% v/v CO2 until 85% confluency was reached. For apoptosis
analysis, 0.5 × 105 cells were grown on microscopy coverslips,
and incubated with rfhSP-D (10µg/ml) in serum free medium
for 48 h. The cells were then washed with PBS three times, and
incubated with FITC Annexin V (1:200), and PI (1:200) diluted
in Annexin V-binding buffer, for 15min at room temperature in
dark. After washing again with PBS, the coverslips were mounted
on the slides, and visualized under a HF14 Leica DM4000
microscope. For mTOR analysis, the cells were incubated with
rfhSP-D (10µg/ml) for 15 h, and washed gently with PBS three
times. The cells were permeablized and fixed with ice-cold 100%
methanol for 10min at −20◦C. Following 1 h incubation with
rabbit anti-human mTOR (1:500) (Sigma-Aldrich) primary
antibody, the cells were washed again with PBS, and incubated
with Hoechst (1:10,000) and Goat anti-rabbit Alexa Fluor R© 488
(1:500) (Abcam) secondary antibody. The mounted coverslips
were visualized on a HF14 Leica DM4000 microscope.
RNA Extraction and Quantitative RT-PCR
RNA was extracted from SKOV3 cells treated and untreated with
rfhSP-D using the Nucleospin kit (Macherey-nagel, Bethlehem,
USA) and the quantity was estimated using nanodrop. Two
microgram of total RNA was used to synthesize cDNA using
the Precision nanoScript 2 Reverse Transcription kit (Primer
design). Relative expression levels of mTOR, DEPTOR, Rictor
and Raptor (19) were assessed by quantitative PCR (Q-PCR)
on an ABI FAST HT9000 PCR instrument, using SYBR
green mastermix (Primer Design). Gene expression levels were
normalized to GAPDH levels. All samples were analyzed in
triplicates (19). RT-qPCR data was analyzed using the 1Cq
method whereby the Cq of the endogenous control was
subtracted from the Cq of the gene of interest and an RQ (relative
quantity) value was calculated by finding 2-1Cq (30).
Western Blotting
Proteins were extracted from SKOV3 cells treated with rfhSP-
D for 24 and 48 h (21) and separated on a 10% v/v SDS-PAGE.
The separated proteins were then electrophoretically transferred
FIGURE 2 | Overall Survival (OS) of ovarian cancer patients expressing high (red) and low (black) SP-D (A). High (n = 1209) and low (n = 447) expression of SP-D is
shown over a 250 month (20 year) period. Low SP-D expression shows a significant improvement in survival than high SP-D expression (p = 0.0099).
Progression-Free Survival (PFS) of ovarian cancer patients expressing high (red) and low (black) SP-D (B). High (n = 444) and low (n = 991) expression of SP-D is
shown over a 250 month (20 year) period. There is greater overall survival in low SP-D expression compared to high SP-D expression (p = 0.00063).
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onto a nitrocellulose membrane (Thermo Scientific) in Wet-
Transfer Buffer. The membrane was incubated in TBS containing
5% w/v dried milk powder and 0.1% v/v Tween Tween-20, for
1 h at room temperature to block non-specific binding. The
membrane was then incubated with primary anti-human SP-
D polyclonal antibodies (raised in rabbit), caspases 3 and 9,
and phospho (Thr389) p70S6K (Cell Signaling Technology) at
4◦C overnight. The membranes were washed in TBS + 0.1%
Tween-20 (3 times, 15min each) before incubation with the
secondary goat anti-rabbit IgG-HRP-conjugated antibody for
1 h at room temperature. Proteins were visualized as previously
described (21).
Statistical Analysis
Graphpad Prism 5.0 was used to generate the graphs and perform
the statistical analysis. When data were of equal variance, an
unpaired student’s t-test was performed. When the data was
of unequal variance, the Mann-Whitney U test was performed.
Values were considered significant when ∗p < 0.05, ∗p < 0.01
and ∗∗∗p < 0.001. Significance was identified between control
and treated samples, as well as between treated samples. Error
bars represent the standard deviation or standard error of the
mean, where specified. Survival curves were generated by the
Kaplan–Meier plots. All results are displayed with p-values from
a logrank test. p < 0.05 were considered significant. Similarly,
with Oncomine, the statistical significance of data (p-values) was
provided by the program.
RESULTS
SP-D Is Expressed in Ovarian Cancer and
Predicts Survival
A recent study using a bioinformatic approach and RT-qPCR
validation indicated that SP-D is overexpressed in ovarian cancer
patients (serous cystadenocarcinoma) compared to healthy
controls (18). In the current study, we performed an extended
FIGURE 3 | Immunohistochemistry for SP-D expression in different pathologies of ovarian tissue array clinical samples (40x magnification): serous papillary
cystadenocarcinoma (A), mucinous adenocarcinoma (B) and endometrioid adenocarcinoma (C). No significant change was seen between different types of OC (p =
0.2235; G). Immunohistochemistry for SP-D expression in different grades of ovarian tissue array clinical samples: mucinous cystadenocarcinoma grade 1 (D), serous
papillary cystadenocarcinoma grade 2 (E) and serous papillary cystadenocarcinoma grade 3 (F). No significant change was seen between different grades of disease
(p = 0.7055, H).
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bioinformatics analysis in order to investigate whether SP-D
is differentially expressed in various types of ovarian cancer
and whether it can serve as a potential prognostic marker for
the disease. We used the OncomineTM dataset and the survival
analysis platforms Kaplan–Meier plotter.
The Hendrix dataset (31) demonstrated that SP-D (SFTPD) is
expressed in a wide range of ovarian cancers such as: clear cell
adenocarcinoma (n = 8), endometrioid adenocarcinoma (n =
37), mucinous adenocarcinoma (n= 13), serous adenocarcinoma
(n = 41) and normal ovaries (n = 4). Some subtle changes were
noted amongst these groups, but they did not reach significance
compared to healthy controls (Figure 1A). Similarly, when the
Lu dataset was accessed (32), a similar picture emerged with
the expression of SP-D mRNA (SFTPD) in normal ovaries
(n = 5), clear cell adenocarcinoma (n = 7), endometrioid
adenocarcinoma (n= 9), mucinous adenocarcinoma (n= 9) and
serous adenocarcinoma (n= 20; Figure 1B).
Overall Survival (OS) in ovarian cancer was measured by
Kaplan-Meier plots. In a cohort of 1656 ovarian cancer patients,
high (n = 1209) and low (n = 447) mRNA expression of
SP-D was measured over a 250-month (20 year) period. Low
SP-D expression shows a significant improvement in survival
than high SP-D expression (p = 0.0099; Figure 2A). Similarly,
Progression-Free Survival (PFS) was also studied in 1435 ovarian
cancer patients of which 444 had high expression of SP-D and
991 low. There was a significant progression-free survival (PFS)
improvement in low SP-D cohort compared to patients with high
SP-D expression (p= 0.00063; Figure 2B).
Ovarian Cancer Tissue Microarray Analysis
Corroborates Bioinformatics Data
We then used an ovarian cancer tissue microarray to perform
immunohistochemistry in a number of clinical samples in order
to validate the in-silico data and identify any changes in protein
expression with respect to type, grade, or stage of the disease.
SP-D was expressed in serous papillary cystadenocarcinoma,
mucinous adenocarcinoma and endometrioid adenocarcinoma
(Figures 3A–C). Scoring of immunostaining did not reveal any
FIGURE 4 | Immunohistochemistry for SP-D expression in different stages of ovarian tissue array clinical samples (40 x magnification): serous papillary
cystadenocarcinoma stage I (A), serous papillary cystadenocarcinoma stage II (B), serous papillary cystadenocarcinoma stage III (C) and serous papillary
cystadenocarcinoma stage IV (D). A nearly significant up-regulation of SP-D was observed in stage II OC compared to stage I OC (p = 0.053; E). Stratification of PFS
in Stages I and II (F) against stages III and IV (G). There was a significant survival improvement in low SP-D cohort compared to patients with high SP-D expression
only in Stages I and II (p = 0.0027, and p = 0.12, respectively).
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FIGURE 5 | ImageStream analysis showing expression SP-D in circulating tumor cells of 3 ovarian cancer patients, magnification x 40. Channel 1 shows the
brightfield pictures of cells, channel 2 shows the nucleus stained with DRAQ5 (red), channel 3 shows SP-D expression using an Alexa Fluor® secondary antibody
(green) and channel 4 is the merged image of channels 1 and 2. SP-D is localized in the cytoplasm, with strong fluorescence intensity.
apparent differences in the SP-D expression (Figure 3G), thus
corroborating the gene expression Oncomine data. We then
measured SP-D expression in clinical samples of different grades:
Grade 1 (n = 6), Grade 2 (n = 14) and Grade 3 (n = 28)
(Figures 3D–F). No apparent differences amongst grades were
noted (Figure 3H).
We also measured SP-D protein expression in different
stages (I-IV) of ovarian cancer (n = 48; Figures 4A–D). No
differences were noted between stages III and IV. However,
when Stages I and II were compared, SP-D was over-
expressed in Stage II compared to Stage I (p = 0.053;
Figure 4E). When we stratified, PFS in Stages I and II
(Figure 4F; n = 163) against stages III and IV (Figure 4G;
n = 1081), there was a significant survival improvement
in low SP-D cohort compared to patients with high SP-D
expression only in Stages I and II. These results are consistent
with Mangogna et al who reported correlation between SP-
D expression in ovarian cancer tissues and poor survival
prognosis (18).
SP-D Is Expressed in Circulating Tumor
Cells (CTCs) From Ovarian Cancer Patients
Liquid biopsies offer a promising alternative to tissue samples,
providing a non-invasive diagnostic approach or serial
monitoring of the disease evolution. Here, we measured
SP-D protein expression in CTCs from three Stage III ovarian
cancer patients (Figure 5) using a novel imaging flow-cytometry
(ImageStream). CTCs were selected based on being positive
for cytokeratin markers, WT-1 and negative for CD45 (a white
blood cell marker). CTCs from all three patients were positive for
SP-D (Figure 5).
rfhSP-D Compromises Migratory Capacity
of SKOV3 Ovarian Cancer Cells in vitro
In view of the abundance of SP-D in ovarian cancer tissues, we
wished to investigate how SP-D can affect ovarian cancer cells in
vitro. We used a well-established rfhSP-D, which has been shown
to induce apopotosis in pancreatic cell lines, to treat cultured
SKOV3 cells.
Wound healing assay was used to have a visual assessment
of cell proliferative and migratory capacity spatially in vitro.
Using a fine pipette tip, an artificial wound was created on a
confluent cell surface followed by treatment with 10µg/ml of
rfhSP-D. Images acquired from the wound healing assay over
48 h showed that untreated SKOV3 cells closed the gap at 24 h,
whereas SP-D treated cells closed the artificially-created gap after
34 h (Figures 6A–F). Therefore, there was a marked inhibition of
growth in the treated cells.
We expanded on these observations by locating an area with
approximately 25–30 cells where images were captured every
5min for up to 12 h. Using ImageJ, the coordinates for 25 cells
were acquired. Using Pythagora’s theorem for each point for
each of the cells, the distance, velocity and displacement for
all 25 cells were calculated. Cells treated with rfhSP-D moved
significantly less and slower compared to untreated cells; there
was a significant decrease in distance (Figure 6G), velocity
(Figure 6H) and displacement (Figure 6I) of rfhSP-D treated
SKOV3 cells compared to untreated cells.
rfhSP-D Induces Apoptosis in SKOV3
Ovarian Cancer Cells
Fluorescence microscopy analysis of rfhSP-D treated SKOV3
cells revealed a positive staining for cell membrane integrity
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FIGURE 6 | Wound healing assay. The artificial wound created on the cell surface in untreated cells (A) and rh-SPD treated cells (B) at 0 h. Untreated cells (C) or
treated cells with rfhSP-D (D) did not appear to close the gap after 12 h. At 24 h untreated cells managed to close the gap (E) whereas rfhSP-D treated cells did so
after 30 h (F). rfhSP-D treated SKOV3 cells have their distance (G), velocity (H), and displacement (I) reduced, compared to control SKOV3 cells. 25 cells were
counted for each experiment. Comparisons ±SEM between untreated (NS) and treated SKOV3 cells with rfhSP-D at 10µg/ml (***p < 0.001).
marker, Annexin V (conjugated to FITC), and disoriented cell
membrane morphology was observed. Thus, PI positive staining
was seen in rfhSP-D treated cells compared to un-treated
controls (Figure 7A), suggesting induction of apoptosis by
the protein.
The quantitative as well as qualitative analyses of
apoptosis induction in SKOV3 cells were performed using
immunofluorescence microscopy and flow cytometry. A
significant proportion of SKOV3 cells following rfhSP-D
treatment showed apoptosis at 48, as revealed by FACS analysis.
20µg/ml of rfhSP-D was effective in inducing the maximum
apoptosis in this cell line at 48 h; i.e., ∼68%. Approximately
31% cells were FITC and PI positive, suggesting that annexin
V/FITC was able to bind to phosphatidylserine (PS) found on
the cell surface of cells undergoing apoptosis. However, the
percentage of SKOV3 cells stained for PI alone was higher
(∼46%), suggesting that these cells were either at the late stage
of apoptosis or undergoing necrosis. The percentage of viable
cells in the untreated sample (90%) was significantly higher as
compared to treated sample, suggesting that apoptosis induction
was protein-specific, where the integrity of the cell membrane
was intact in the untreated cells, and hence, the cells were still
viable (Figure 7B).
In view of these findings, we sought to investigate the effects
of rfhSP-D on the cleavage of caspase-3, a critical mediator
of apoptosis. Cleaved caspase-3 compared to total caspase-
3 expression was increased after 48 h at 20µg/ml rfhSP-D
treatment (Figure 7C).
Moreover, changes in the expression of pro-apoptotic
genes, Bax, Fas and TNF-α following treatment with rfhSP-D
(20µg/ml) at 24 and 48 h were assessed. We chose to include
TNF-α since it is a key mediator of the apoptotic pathway
and has been shown to modulate Fas expression. Bax was
unaffected following the treatment with rfhSP-D in SKOV3 cells
at both time-points (Figures 8A,B), suggesting that the intrinsic
apoptotic pathway may not be directly involved. Fas and TNF-α
were significantly upregulated following treatment with rfhSP-D
at 24 h compared to controls (Figure 8A). At 48 h, there was no
apparent changes in the mRNA expression of TNF-α, but a clear
trend in the over-expression of Fas was noted (Figure 8B).
Treatment of SKOV3 Cells With rfhSP-D
Compromises mTOR Signaling
The mechanistic Target of Rapamycin (mTOR) has been linked
with the pathogenesis of ovarian cancer, especially with its
progression (33). Treatment of SKOV3 cells with rfhSP-D (5,
Frontiers in Oncology | www.frontiersin.org 8 July 2019 | Volume 9 | Article 542
Kumar et al. SP-D and Ovarian Cancer
FIGURE 7 | Fluorescence microscopy to analyze apoptosis in SKOV3 cells treated with rfhSP-D for 48 h. Apoptosis was analyzed using an annexin V/propidium
iodide (PI) staining kit (A). The cell membrane was positively stained for annexin V and the DNA staining is visible in the treated cells indicating that the cells underwent
apoptosis and PI was taken in which stained the DNA of apoptotic cells. No such staining was seen in the untreated cells. The nucleus was stained with Hoechst for
both treated and untreated cells (A). Quantitative analysis of apoptosis using Flow Cytometer (B). SKOV3 cells were treated with rfhSP-D 48 h and apoptosis was
analyzed using annexin V with PI kit. Cells were acquired and plotted for both annexin V/FITC, which showed a shift in the fluorescence intensity of in treated cells (B).
Effects of rfhSP-D on caspase 3 (C). Scanning densitometry of protein expression of cleaved over total caspase 3 in SKOV3 cells treated with rfhSP-D ±SD at 48 h
which were acquired from the western blotting analysis (C). Cleaved Caspase 3 over total ratio was significantly increased after 48 h 20µg/ml. *p < 0.05.
10 and 20µg/ml) for 12 h did not affect the gene or protein
expression of mTOR (data not shown). However, mRNA levels
of both key components of mTORC1 and mTORC2 complexes,
namely Raptor and Rictor, were significantly down-regulated
12 h post-treatment (Figures 9A,B). Rictor downregulation was
mirrored at protein level at 24 h as assessed by Western blotting
(Figure 9C), whereas a reduction in Raptor expression was
evident at 48 h post rfhSP-D (20µg/ml) treatment (Figure 9D).
Fluorescence microscopy analysis following rfhSP-D
(20µg/ml) treatment of SKOV3 cells for 12 h showed
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FIGURE 8 | Effects of rfhSP-D treated SKOV3 cells on Bax, Fas and TNF-α at
24 h (A) and 48 h (B). Fas and TNF-α are significantly up-regulated at 24 h of
treatment compared to controls *P < 0.05.
reduced cytoplasmic levels of mTOR compared to the
untreated controls (Figure 10A). Nuclear accumulation
of mTOR was seen in the treated cells, indicative of a
potential shuttling.
Finally, we assessed the effect of rfhSP-D on mTORC1 activity
by measuring the phosphorylation status of S6 Kinase (S6K)
since an increase in S6K phosphorylation is a sign of an active
mTOR pathway and has been evidenced in late stage ovarian
cancer (19). There was a notable (p = 0.05) decrease in the
phosphorylation level of (Thr389) p70S6K S6K protein following
rfhSP-D (20µg/ml) treatment (Figure 10B).
DISCUSSION
SP-D, which acts as an anti-microbial and anti-allergic humoral
factor at the mucosal surface, has emerged as an innate immune
surveillance molecule against cancer. Its transcriptional and
protein levels have recently been associated with prognosis in a
range of cancers (18). SP-D has been reported to be overexpressed
in ovarian cancer patients (serous cystadenocarcinoma)
compared to healthy controls (18). Here, we extended our
observations by measuring the gene expression levels in
different sub-types of ovarian cancer. We provide evidence
that SP-D is widely expressed in clear cell adenocarcinomas,
endometrioid adenocarcinomas, mucinous adenocarcinomas,
and serous adenocarcinoma. We validated these observations by
immunohistochemistry using tissue microarrays, where SP-D
expression was unchanged in grade or type; however, there was a
modest increase in the expression between Stage I to Stage II.
Low SP-D mRNA expression showed a significant
improvement in overall survival and progression free survival
than higher SP-D expression. A report on non-small cell lung
cancers (NSCLC) revealed that an increased expression of SP-D
in the lungs of NSCLC patients was correlated with metastasis
and poor outcome (34). These data provide evidence for a higher
order of complexity in the regulation and function of SP-D in
cancer. Another study has recently reported that in lung, gastric,
and breast cancers, there is a lower expression of SP-D compared
to healthy controls; in lung cancer, the presence of SP-D could be
associated with a favorable prognosis. On the contrary, in breast,
and ovarian cancers, the presence of SP-D is associated with
an unfavorable prognosis (18). It is possible that SP-D acts in a
tissue- or cell-specific manner, depending on the composition
of the tumor microenvironment. These observations require
further investigation using a wider repertoire of cell lines and
clinical samples. Nevertheless, SP-D emerges here as a potential
biomarker for ovarian cancer.
Thus, we expanded on the clinical observations by measuring
its expression in circulating tumor cells (CTCs) of 3 Stage III
ovarian cancer patients. An abundant expression was noted
using an imaging flow-cytometric approach. This is the first
time that SP-D expression is being documented in CTCs. Blood
based biomarkers such as “liquid biopsies” are becoming an
increasingly attractive area of cancer research due to their non-
invasive nature and importance in detecting the stage and the
spread of the tumor (35). The detection of CTCs and appropriate
biomarkers can, therefore, help not only in diagnosis but also
in real-time therapy monitoring and more efficient personalized
treatments (36).
We also demonstrate an involvement of SP-D in ovarian
cancer and provide a novel insight into the signaling pathways
that are involved using an ovarian cancer cell line in vitro.
When SKOV3 cells were treated with rfhSP-D, there was a
decrease, although moderate, in proliferation, suggesting a direct
anti-proliferative effect of rfhSP-D. There was also a noticeable
decrease in distance, velocity and displacement of SKOV3
cells treated with rfhSP-D, when compared to untreated cells.
Thus, rfhSP-D could exert a cytostatic or cytotoxic effect, as
evident from rfhSP-D induced Caspase 3 cleavage in vitro.
Caspase-3 is a critical regulator of apoptosis, as it contributes
to the proteolytic cleavage of many key proteins, such as
poly adenosine diphosphate-ribose polymerase (PARP) (37).
The rfhSP-D induced apoptosis in SKOV3 cells was further
corroborated by an increase in annexin V staining, which is
used to detect cell death by its ability to bind to PS, a marker
of apoptosis when it is on the outer leaflet of the plasma
membrane. Collectively, our study is in agreement with recent
studies involving a number of malignancies. In a human lung
epithelial cancer cell line (A549), SP-D inhibits cell progression
and metastasis via inhibition of the EGF pathway through
binding to EGFR and compromising the EGFR-EGF complex
(12). rfhSP-D can also alter oxidative stress and high-mobility
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FIGURE 9 | Relative quantification of Rictor (A) and Raptor (B) mRNA expression in SKOV3 cells treated with 5, 10 and 20µg/ml of rfhSPD after 12 h (*p < 0.05,
**p < 0.01 compared to basal levels set at 1.0). Western blotting for Rictor (C) and Raptor (D) showed a downregulation at protein level at 24 and 48 h, respectively
compared to controls; *P < 0.05.
groupA factor 1 (HMGA1) expression leading to induction of the
p53 apoptotic pathway in an eosinophil leukemic cell line (7, 8).
In a more recent study, rfhSP-D induced apoptosis in pancreatic
cancer cell lines via Fas-mediated pathway, followed by cleavage
of caspases 8 and 3 (16).
In this study, we demonstrate that rfhSP-D exerts its anti-
proliferative effects by compromising mTOR signaling and
activating the pro-apoptotic genes, Fas and TNF-α, but not
Bax. Fas belongs to TNF superfamily that can activate caspase
cascade, which can lead to cleavage of caspase 3 as the terminal
molecular event during apoptosis (38–40). TNF-α, another TNF
superfamily member, exerts its effects via TNFR2 to increase
the susceptibility of the target cells to Fas-mediated death (16,
41). With regards to Bax, this is not the first time that a
modest gene expression is noted. When FSTL1 and RAD51AP1
genes were silenced in ovarian cancer cells, a decrease in
proliferation was noted while the Bax gene expression remained
unchanged (24, 42).
To this date, little is known about an association between
SP-D and mTOR. The mTOR pathway has been shown as
an important regulatory epicenter for cell growth, metabolism,
autophagy, gene expression and protein synthesis (43). mTOR
acts through two complexes, mTORC1 and mTORC2, and
Raptor and Rictor are key components of these two complexes,
respectively (4, 44). We, therefore, decided to examine the
effects of rfhSP-D on the mTOR pathway. When we treated
SKOV3 cells with rfhSP-D and measured the expression of key
components of the mTOR pathway, the mRNA and protein
levels of Rictor and Raptor were down-regulated compared
to untreated controls, with a concomitant decrease in the
phosphorylation of S6K (Ser).
Interestingly, although the mTOR protein expression
remained largely unaltered following rfhSP-D treatment, its
translocation from the cytoplasm to the nucleus was noted.
mTOR primarily resides within the cytoplasm (45), but nuclear
localization has also been documented in rhabdomyosarcomas,
human fibroblasts and colon carcinoma cells (46). In a study
using multiple myeloma cell lines, it was reported that treatment
with pomalidomide (IMID R©), an immunomodulatory FDA-
approved drug for the treatment of multiple myeloma, increased
nuclear mTOR and p-mTOR expression levels in the nucleus
with a concomitant decrease of the cytoplasmic fractions (47).
This shuttling correlated with a decrease in cell viability in
this study. Moreover, it has been shown that the mTORC2
complex components, Rictor and Sin1, are dephosphorylated
and dynamically distributed between the cytoplasm and the
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FIGURE 10 | Assessment of mTOR localization in SKOV3 cells. (A) rfhSP-D treatment downregulated the survival pathway, mTOR. Fluorescence microscopy analysis
following rfhSP-D (20 ug/ml) treatment of SKOV3 cells showed reduced cytoplasmic levels of mTOR following treatment as compared to the untreated. Nuclear
accumulation of mTOR was seen in the treated cells. (B) Effects of rfhSP-D on phospho (Thr389) p70S6K in SKOV3 cells treated with rfhSP-D (20µg/ml).
nucleus upon long-term treatment with the mTOR-inhibitor
rapamycin (48). Thus, rfhSP-D can compromise mTOR signaling
via downregulation of Rictor and Raptor, shuttling of mTOR
leading to dysfunction of the downstream signaling cascade
(i.e., dephosphorylation of S6K), and subsequent inhibition of
cell proliferation.
In conclusion, rfhSP-D treatment of SKOV3 cells
downregulates Rictor and Raptor and upregulates pro-apoptotic
factors such as TNF-α and Fas to activate caspase 3 cascade to
induce apoptosis in vitro. New therapeutic strategies involving
immune molecules such as rfhSP-D that target pro-apoptotic
genes and the mTOR pathway merit further investigation.
Finally, the emergence of SP-D as a potential biomarker needs to
be verified in a large cohort of ovarian cancer patients. However,
the prognostic value of SP-D in ovarian cancer, where high
levels correlate with poor survival, together with the in vitro
effects of rfhSP-D, is quite intriguing. One possibility is that
the SP-D protein in ovarian cancer tissues is non-functional
as we have recently observed in a triple-positive breast cancer
cell line that secretes a non-functional variant of SP-D although
the same cell line remains susceptible to apoptosis induction
by rfhSP-D (Murugaiah et al., unpublished data). In case
the ovarian tissue, SP-D is functionally active, it is possible
it binds to components of tumor microenvironment (e.g.,
hyaluronic acid). This interaction is capable of negating the
protective effect of SP-D in vivo. Further studies are required to
delineate the relationship between SP-D, its ligand in the tumor
microenviroment and SP-D receptors on the primary ovarian
cancer cells.
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Surfactant Protein D (SP-D), a pattern recognition innate immune molecule, has been
implicated in the immune surveillance against cancer. A recent report showed an
association of decreased SP-D expression in human prostate adenocarcinoma with
an increased Gleason score and severity. In the present study, the SP-D expression
was evaluated in primary prostate epithelial cells (PrEC) and prostate cancer cell lines.
LNCaP, an androgen dependent prostate cancer cell line, exhibited significantly lower
mRNA and protein levels of SP-D than PrEC and the androgen independent cell lines
(PC3 and DU145). A recombinant fragment of human SP-D, rfhSP-D, showed a dose
and time dependent binding to prostate cancer cells via its carbohydrate recognition
domain. This study, for the first time, provides evidence of significant and specific cell
death of tumor cells in rfhSP-D treated explants as well as primary tumor cells isolated
from tissue biopsies of metatstatic prostate cancer patients. Viability of PrEC was not
altered by rfhSP-D. Treated LNCaP (p53+/+) and PC3 (p53 −/−) cells exhibited reduced
cell viability in a dose and time dependent manner and were arrested in G2/M and G1/G0
phase of the cell cycle, respectively. rfhSP-D treated LNCaP cells showed a significant
upregulation of p53 whereas a significant downregulation of pAkt was observed in both
PC3 and LNCaP cell lines. The rfhSP-D-induced apoptosis signaling cascade involved
upregulation of Bax:Bcl2 ratio, cytochrome c and cleaved products of caspase 7. The
study concludes that rfhSP-D induces apoptosis in prostate tumor explants as well as in
androgen dependent and independent prostate cancer cells via p53 and pAkt pathways.
Keywords: pattern recognition receptor, prostate tumor explants, LNCaP cells, PC3 cells, viability, apoptosis, p53,
pAkt
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INTRODUCTION
Prostate cancer, an adenocarcinoma of epithelial cell-origin, is
the second most frequently diagnosed cancer among men (1).
In its early stages, prostate cancer cells rapidly proliferate in an
androgen dependent manner, and thus, are treated by androgen
deprivation therapy (2). Conventional anti-cancer treatments
such as chemotherapy and radiotherapy improve survival, but
many patients encounter relapse and metastasis. Following the
remittent stage, the cancer progresses to become androgen-
independent where most therapeutic strategies fail.
Immunotherapy by stimulating pattern recognition receptors
of the innate immune system such as toll-like receptors (TLRs)
has shown promise as a preferred adjunct treatment against
cancer (3). Imiquimod, a synthetic imidazoquinoline and an
agonist that targets TLR-7 and induces the production of pro-
inflammatory cytokines including IFN-α, IL-6, and TNF-α,
inhibited cancer growth in the mouse prostate via apoptosis
induction (4, 5).
Collectins are pattern recognition proteins belonging to the
C-type lectin family. They are composed of an N-terminal
cysteine-rich region, a triple-helical collagen domain, an α-
helical coiled-coil neck region, and C-terminal carbohydrate
recognition domain (CRD) (6). Surfactant Protein D (SP-D)
is one of the most studied collectins with a vital role in
host defense against pathogens and allergens, and modulation
of inflammatory response (6). Although SP-D was historically
shown to be lung-resident being produced by type II alveolar and
Clara cells (7), studies during the last decade have established its
extrapulmonary existence in a range of tissues (8). SP-D has also
been shown to be expressed in the male reproductive tracts of
human and mice (9, 10). Elevated levels of SP-D at inflamed sites
in the prostate manifested protection against bacterial infection
(11, 12). Kankavi et al. (13) observed differential expression
of SP-D in glandular structures of inflamed malignant and
non-malignant human prostate tissues. There was a significant
correlation between decreased levels of SP-D and increased
Gleason score, a grading system based on the histologic pattern
of arrangement of carcinoma cells, and tumor volume.
Previously, we reported a novel anti-cancer role of human
SP-D and its recombinant fragment (rfhSP-D) comprising 8
Gly-X-Y repeats neck and CRD region, wherein they reduced
the viability of a range of human cancer cell lines including
eosinophilic leukemia cell line (AML14.3D10) (14). Importantly,
survival of peripheral blood mononuclear cells (PBMCs) derived
from healthy individuals was found to be unaltered (14). rfhSP-
D treated AML14.3D10 cells showed a significant increase in
apoptosis with reduced HMGA1 levels and increased levels of
activated p53 and caspase 9 (14). SP-D has recently been shown
to inhibit the proliferation, migration and invasion of A549
human lung adenocarcinoma cells by binding to N-glycans of
epidermal growth factor receptor (EGFR) via its CRD region,
and interfering with EGF signaling (15). In UV treated apoptotic
Jurkat T cells, SP-D enhanced membrane and nuclear blebbing,
suggesting involvement of SP-D in induction of apoptosis (16).
Exogenous treatment of SKOV3 cells (an ovarian cancer cell line)
with rfhSP-D led to increased caspase 3 cleavage and induction of
pro-apoptotic genes Fas and TNF-α (17).
To take the next logical step from the reported anti-
cancer role of SP-D in tumorigenic cell lines, we examined
anti-prostate cancer role of rfhSP-D using tumor explants
and primary cells derived from tissue biopsies of metastatic
prostate cancer patients. rfhSP-D induced apoptosis selectively
in various prostate cancer cells including the two prostate
cancer cell lines (LNCaP and PC3) in a dose- and time-
dependent manner. Apoptotic signaling involved upregulation
of p53 and downregulation of pAkt. Decreased levels of
Bcl2, with a concomitant increase in Bax, cytochrome c and




The study was approved by the Institutional Ethics Committee
for Clinical Studies, ICMR- National Institute for Research in
Reproductive Health; (Project No.: 260/2014) and Institutional
Ethics Committee, Tata Memorial Hospital (Study no: 1467).
Tissue biopsy samples were collected from 9 suspected
metastatic prostate cancer patients (treatment naïve) undergoing
Transrectal Ultrasound guided multiple core needle biopsy,
with written informed consent. Chemotherapy was initiated in
the patients after confirmation of metastasized prostate cancer.
Information regarding the androgen dependency of the prostate
cancer in these patients was not available. Average age of
the study participants was 67.4 ± 3.97 years with Mean PSA
(Prostate- specific antigen) level of 190.04 ± 85.12 ng/ml and
Median Gleason score of 8± 0.83.
Explant and Cell Culture
Prostate tissue biopsies were collected in cold Phosphate Buffer
saline containing 10% v/v fetal bovine serum (FBS; GIBCO) and
2% v/v Pen-Strep solution (GIBCO) and immediately processed
in sterile conditions. Biopsies were cut into 5mm explants, placed
in the scratched areas of 35mm tissue culture plate (Nunc) and
cultured in RPMI 1640 (GIBCO) supplemented with 10% FBS,
1% Pen-Strep solution, Glucose (1 mg/ml) (HiMedia) and 1%
Sodium Pyruvate (GIBCO) (complete RPMI) for a week. Primary
Cancer Epithelial Cells (PrCEC) isolated from the explants
were sub-cultured using 5mM EDTA (Sigma) in PBS and
passaged further. Isolated PrCEC (Passage 2) were examined for
Cytokeratin (an epithelial cell marker) via immunofluorescence
microscopy (Anti-cytokeratin antibody, Dako, 1:500) and by
Real time RT-PCR analysis for CD164 expression, a marker for
metastatic epithelial cell cancer (18). Isolated PrCECwere stained
for the presence of Alpha-methylacyl-CoA racemase (AMACR)
expression, which is upregulated in prostate cancer with high-
grade prostatic intraepithelial neoplasia (HGPIN) than in the
normal human prostate (19). PrEC, PrCEC and PC3 cells were
stained using mouse monoclonal antibodies to AMACR (Novus
Biologicals, 1:100) or matched-isotype control IgG for 1 h at
4◦C. Phycoerythrin-conjugated rat anti-mouse IgG (Molecular
Probes, Eugene, USA) was used as secondary antibody. The gated
cell population was determined using PE tagged anti-AMACR.
Cells were analyzed via BD FACS Aria III (BD Biosciences, San
Jose, California, USA) flow cytometer.
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Human prostate cancer cell lines, LNCaP (androgen
dependent, p53+/+), DU145 (androgen independent p53+/−)
and PC3 (androgen independent, p53−/−) (ATCC, Rockville,
MD, USA) were cultured in complete RPMI 1640 medium.
Human primary prostate epithelial cells (PrEC; LONZA)
were maintained in Prostate epithelial growth medium
(PrEGM Bulletkit) supplemented with Triiodothyronine
(T3), Transferrin, Bovine Pituitary Extract (BPE), recombinant
human Epidermal growth factor (rhEGF), GA-1000, Insulin,
Hydrocortisone, Epinephrine, and retinoic acid (LONZA,
Cat no. CC-3165). All experiments with Human PrEC were
completed within first five passages. Cells were grown at 37◦C
under 5% v/v CO2 until 70–80% confluency was attained.
rfhSP-D Preparation
The recombinant fragment of human SP-D (rfhSP-D) was
expressed in Escherichia coli BL21 (λDE3) pLysS (Invitrogen),
purified and characterized, as described previously (15).
Endotoxin level in the rfhSP-D preparation was determined using
the QCL-1000 Limulus amebocyte lysate system (BioWhittaker
Inc., USA). The assay was linear over a range of 0.1–1.0
EU/ml (10 EU = 1 ng of endotoxin) and the amount of
endotoxin present in the preparations was found to be <4 pg/µg
of rfhSP-D.
Interaction Between FITC Labeled rfhSP-D
and Prostate Cells
rfhSP-D was labeled with FITC dye (20) and incubated with
prostate epithelial cells and prostate cancer cells at 5, 10, and
20µg/ml concentration in staining buffer for 15, 30, 45, and
60min at 4◦C in the presence of 2mM CaCl2. Cells were washed
to remove unbound rfhSP-D and fixed with 2% PFA for analysis
via BD FACSAria III (BD Biosciences, San Jose, California, USA).
Data was analyzed using FCS Express 6 De Nova software. To
assess the specificity of the interaction, PC3 cells were incubated
with FITC labeled rfhSP-D in the presence of 5mM CaCl2, or
5mM EDTA, or 5mM Glucose in PBS, pH 7.4. Staining buffer
was used as control for these experiments.
Cell Viability Assay
Human PrEC (passage no. 3–5), LNCaP, PC3, or PrCEC (passage
no. 3–5) cells (5× 103) were placed in 96-well tissue culture plates
(Nunc) and grown overnight. Cells were then starved in cell
appropriate serum free media (PrEC and PrCEC for 4 h; LNCaP
cells for 12 h; PC3 cells for 18 h) and treated with rfhSP-D (5,
10, and 20µg/ml) for 24, 48, and 72 h. Cells alone in the culture
medium served as an untreated control. After incubation 10
µl MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide] (5 mg/ml stock) was added to each well and incubated
at 37◦C for 4 h. Formazan crystals were dissolved in acidified iso-
propanol and absorbance was read at 570 nm (Beckman Coulter).
Cell Cycle Analysis
LNCaP or PC3 cells (2× 104) were plated in 12-well tissue culture
plate, starved for 18 h in serum-free RPMI medium serum-free
RPMI medium, and then treated with rfhSP-D (20µg/ml) for
48 h. After incubation, cells were trypsinized, suspended in cold
hypotonic solution containing 0.1% sodium citrate, 0.3 µl/mL
of NP-40 (Sigma), 2 mg/mL RNaseA (Thermo Fisher Scientific),
and 50µg/mL Propidium Iodide (PI; Sigma) for 20min, and
then analyzed using BD FACS Aria III using BD FACS DIVA
software (21).
Fluorescence Microscopy for Nuclear
Morphology
PrEC, LNCaP, or PC3 cells (2 × 103) were grown on coverslips
and incubated with rfhSP-D (20µg/ml) for 48 h to analyze
nuclear morphology following induction of apoptosis. Cells
were fixed in 2% PFA and permeabilized using 1% v/v Triton
X 100 (Sigma). Cells were incubated with Hoechst (1:10,000,
Invitrogen) for 20min in dark. Coverslips were mounted in
vector shield (Vector laboratories, UK) and observed under
confocal microscope (Zeiss, Germany).
TUNEL (Terminal Deoxynucleotidyl
Transferase dUTP Nick end Labeling)
Assay
Prostate tissue biopsies collected from metastatic prostate cancer
patients were incubated with rfhSP-D (40µg/ml) for 48 h in
serum free RPMI medium at 37◦C under 5% v/v CO2. Five
micrometer paraffin embedded sections of 10% NBF (neutral-
buffered formalin) fixed prostate tissue biopsies were placed
on poly L-lysine coated slides. The sections were fixed with
chilled acetone followed by washing with PBS. Slides were
incubated in TUNEL Mix (Roche Diagnostics), containing
terminal deoxynucleotidyl transferase (TdT) and fluorescein
labeled nucleotides for an hour in a moist chamber at 37◦C.
The slides were washed and counterstained with DAPI (4′,6-
diamidino-2-phenylindole). TUNEL positive apoptotic cells
(green-stained cells) were viewed under confocal microscope
(Zeiss, Germany).
Annexin V Assay
For Annexin-V immunostaining, the manufacturer’s protocol
of Annexin V-FITC apoptosis detection kit (Calbiochem) was
followed with some modifications. PrEC, LNCaP, or PC3 were
treated with indicated concentrations of rfhSP-D and harvested
at the end of 24 and 48 h. Cells were trypsinized and washed
with ice cold PBS to remove culture supernatant, followed by
incubation with FITC-tagged Annexin V for 20min in dark.
Subsequently, Annexin V was washed and 1 µl PI was added to
stain the DNA. Cells were immediately analyzed via BD FACS
Aria III.
Western Blot
PC3 or LNCaP cells (1 × 106) were plated in a six-well plate
and incubated with or without rfhSP-D (20µg/ml), in serum-free
RPMI medium for 12 h and 24 h. The cells were lysed in lysis
buffer (50mM Tris-HCL, pH7.5, 150mM NaCl, 1% Triton X,
1mMSodium orthovanadate, 10mM β- glycerophosphate, 2mM
EDTA, 10mM Sodium pyrophosphate) and analyzed by western
blotting. Lysate proteins (30 µg) were separated on 15% SDS-
PAGE polyacrylamide gel and electrophoretically transferred
onto PVDF membranes (Pall Corporation, NY, USA). The blot
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was probed with primary antibodies raised against human SP-
D [a gift from Uffe Holmskov, (13)], Phosphorylated-p53 (Ser
15) (Cell Signaling Technology), pAKT (PathScan R© Multiplex
Western Cocktail I), pan Akt (ABclonal), phospho-Bad-S155
(ABclonal), Bcl-2 associated death promoter (Bad) (Apoptosis
I sampler Kit), Bcl-2-associated X protein (Bax) (Apoptosis I
sampler Kit), B-cell lymphoma 2 (Bcl2) (Apoptosis I sampler
Kit) or caspase 7 (Cell Signaling Technology), followed by HRP-
conjugated secondary antibodies. All western blot images were
acquired by Syngene (Chem Genius) and quantified by Syngene
Gene Tools.
Enzyme-Linked Immnosorbent Assay
(ELISA) for SP-D and Cytochrome c
Cell lysates and culture supernatants were analyzed for SP-
D levels (Duo Set Human SP-D, catlog no. DY1920, R & D
Systems) and Cytochrome c (Human Cyt-C, catlog no. E1516Hu,
BT Assay) using commercially available ELISA kits. Briefly, for
quantification of cytochrome c, PrEC, LNCaP, PC3 cells, or
Prostate tissue biopsies collected from metastatic prostate cancer
patients were incubated with indicated concentrations of rfhSP-
D for 48 h. Cell culture supernatant was analyzed for cytochrome
c released by cells. Color development was stopped using 2N
H2SO4 and optical density was determined at 450 nm using a
microplate reader (Beckman Coulter).
Real Time PCR
PrEC, PrCEC, PC3, and LNCaP cells (1 × 106) were plated in a
six-well plate and total RNA was isolated using Trizol (Takara)
that was further treated with DNase I (Thermo Scientific,
Rockford, USA) at 37◦C for 30min to eliminate genomic DNA
contamination. One to two microgram of total RNA was reverse
transcribed into cDNA using Superscript III first strand synthesis
kit (Invitrogen, USA). One microliter of cDNA was used for real
time PCR reactions using BioRad CFX96 TouchTM real-time
PCR detection system and iQTM SYBR Green Supermix (Bio-
Rad, Hercules, CA, USA). 18S was used as housekeeping control.
Each qPCR experiment was performed in triplicates and each
experiment was repeated 3 times. Primers were designed using
NCBI Primer BLAST Software and their annealing temperatures
and product sizes are mentioned in Table 1.
In silico Analysis of Human SP-D Promoter
Region for Androgen Responsive Elements
In silico analysis was carried out to predict putative androgen
responsive elements (ARE) in promoter regions of human SP-
D gene using MatInspector Genomatix v3.4 Software, GmbH,
Munchen (Germany). The transcription start site (TSS) for SP-
D was determined from the Institute of Bioinformatics and
Applied Biotechnology (IBAB) MGEx-Tdb database. Promoter
regions −10,000 bp upstream and +1,000 bp downstream
from the transcription start site (TSS sites) were submitted
for analysis.
Statistical Analysis
GraphPad PRISM Software version 6.00 (GraphPad Software
Inc., San Diego, CA) was used to plot the graphs and
analyze the data using one-way ANOVA with Bonferroni
corrections for comparison among prostate cells or
unpaired two tailed Student’s t-test for comparing the
rfhSP-D treated groups with control. Data is represented
as mean ± SD. Values of p < 0.05 were considered
statistically significant.
RESULTS
Prostate Epithelial and Cancer Cells
Expressed SP-D
Since it is known that prostate epithelial cells secrete SP-D
(11, 13), we evaluated SP-D expression and its regulation in
PrEC, LNCaP, DU145, and PC3. Figure 1A shows that SP-D is
expressed by prostate epithelial cells and prostate tumor cells; SP-
D expression in LNCaP cells is significantly lower in comparison
with DU145 (p < 0.05), PC3 (p < 0.05), and PrEC (p <
0.05) by western blot and ELISA (PrEC-1.48 ± 0.31 pg of SP-
D/µg of total protein; LNCaP-1.26 ± 0.28 pg/µg; DU145-1.50
± 0.35 pg/µg, data not shown). SP-D was detectable in the cell
culture supernatants of various prostate cells (Range-150 ± 21
to 260 ± 35 pg/ml), suggesting that SP-D is secreted, though
not sufficient enough to induce apoptosis (10–20µg/ml) (14).
It is reported that androgen induces proliferation of prostate
epithelial cells and LNCaP cells via androgen receptors (22).
Furthermore, SP-D expression in rodent prostate is altered on
castration (11). Hence, we evaluated levels of SP-D transcripts
in Dihydrotestosterone (DHT) treated PrEC, LNCaP, and PC3
cells. Treatment with DHT (10 nM) significantly upregulated
SP-D transcripts in both PrEC and LNCaP cells by 1.9 fold
but not in PC3 cells (androgen independent) (Figure 1B). This
suggests that SP-D expression is regulated by androgens (DHT)
in androgen dependent cancer. Increased cell viability was
observed in DHT treated PrEC (111.43 ± 4.69%) and LNCaP
(119.23 ± 2.68%) cells as reported [Figure 1B (ii)]. In silico
analysis of promoter region of human SP-D gene elucidated
10 putative Androgen Responsive Elements (AREs) (Table 2),
suggesting that androgens may regulate SP-D expression. The
functionality of identified ARE has not been evaluated in
this study.
rfhSP-D Binds Differentially to Prostate
Cancer Cells
FITC-labeled rfhSP-D showed a dose and time dependent
binding to PrEC and prostate cancer cells (LNCaP, DU145,
and PC3) (Figure 2). A significantly higher binding was
observed with the androgen independent PC3 cells (MFI-743.86
± 67.41) than the androgen dependent LNCaP cells (MFI-
354.75 ± 54.11) (p < 0.05) (Figure 2A). PrEC (MFI-96.48
± 21.07) showed comparatively less binding with the FITC-
labeled rfhSP-D than any of the cancer cells (PC3, LNCaP,
p < 0.05). Binding of rfhSP-D to all cell types was calcium-
and carbohydrate-dependent that was inhibitable by EDTA and
glucose (Figures 2B,C show representative binding to PC3 cells).
DU145 cells showed results similar to that of PC3 cells (data
not shown).
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TABLE 1 | Primer sequences.
Transcripts Forward primer (5′-3′) Reverse primer (5′-3′) Tm (◦C) Product size (in bp)
SP-D AGGCTGCTTTCCTGAGCATGAC CCATTGGTGAAGATCTCCACACAG 57.8 148
CD164 GACTTTAGCGCCCATCTCCA GCCGTGGAAACGGAACAGAA 68 233
BCL2 GCGTCAACCGGGAGATGTCGCCC TTTCTTAAACAGCCTGCAGCTTTG 66 208
BAX AGTGACCCCTGACCTCACTG GCAGGGGACTGAGATGAACG 68 296
BAD GAGCTCCGGAGGATGAGTGA CAAGTTCCGATCCCACCAGG 68 141
18S GGAGAGGGAGCCTGAGAAAC CCTCCAATGGATCCTCGTTA 64 174
FIGURE 1 | SP-D expression is regulated by Dihydrotestosterone (DHT) in prostate cells. (A) Levels of SP-D protein by immunoblotting (i) and transcripts by real time
RT-PCR (iii) in PrEC, DU145, PC3, and LNCaP cell lysates. Panel (ii) shows densitometric analysis for the SP-D expression in PrEC, DU145, PC3, and LNCaP cells; n
= 3 independent experiments, error bar represents the S.D. *p < 0.05. (B) (i) SP-D transcripts in PrEC, LNCaP, and PC3 cells treated with DHT (10 nM) for 48 h. *p <
0.05 relative to untreated controls; n = 3 independent experiments, error bar represents the S.D. (ii) Cell viability of PrEC, LNCaP, and PC3 cells incubated with DHT
(10 nM) for 48 h by MTT assay. Each bar represents % viability ± S.D of three independent experiments. *p < 0.05, relative to untreated controls.
TABLE 2 | Putative Androgen Responsive Elements in the promoter region of human SP-D genea.
Sr. Start End Anchor Core Sim. Matrix Sim. Strand Sequence
1 ARE 904 922 913 0.898 0.938 + ataagacctcctGTGCtcc
2 ARE 2,339 2,357 2,348 1 0.895 – gaaatgcttaaaGTTCtaa
3 ARE 3,787 3,805 3,796 1 0.912 – ccaaagctttgtGTTCcct
4 ARE 5,430 5,448 5,439 0.878 0.901 + ttttttctttcaGTACttt
5 ARE 5,851 5,869 5,860 1 0.912 + ttttttctttttGTTCctc
6 ARE 7,481 7,499 7,490 1 0.941 + gccataccttatGTTCtgc
7 ARE 7,589 7,607 7,598 1 0.8 + caggtgctatcTGTTgttg
8 ARE 8,303 8,321 8,312 0.875 0.945 – gctgcacccactGTCCtgc
9 ARE 8,366 8,384 8,375 0.869 0.896 – ccctgaccccttGTGCtct
10 ARE 9,883 9,901 9,892 0.959 0.907 – ttctctctggctGTCCtta
aMatInspector Genomatix v3.4 Software was used for in silico analysis of human SP-D gene promoter region −10,000 bp upstream to +1,000 bp downstream from the TSS site.
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FIGURE 2 | rfhSP-D differentially binds to normal prostate epithelial cells and cancer cells. (A) Binding of FITC labeled rfhSP-D to normal prostate epithelial cells
(PrEC) and cancer cell lines (LNCaP and PC3) (representative histograms). Black dotted line represents unstained cells, black line shows rfhSP-D (20µg/ml) binding to
(i) PrEC, (ii) LNCaP, (iii) PC3 in comparison to their respective unstained. Each experiment was repeated three times. (B) Mean Fluorescence Intensity (MFI) of FITC
labeled rfhSP-D binding to PC3 cells (i) at different doses of rfhSP-D and, (ii) time intervals. Data represents mean ± S.D of three independent experiments. *p < 0.05,
vs. unstained cells. (C) Involvement of CRD region of rfhSP-D in its interaction with PC3 cells. (i) PC3 cells were incubated with FITC labeled rfhSP-D alone and in the
presence of 5mM Calcium (Ca2+) or 5mM Ca2+ and 5mM EDTA (EDTA) or 5mM Ca2+ and 5mM Glucose (Glc). A representative FACS histogram of PC3 cells with
FITC-labeled rfhSP-D (20µg/ml) showing decreased binding in presence of EDTA and glucose. (ii) Data are Mean ± S.D. of the mean fluorescence intensity of
rfhSP-D binding to the PC3 cells relative to control; n = 3 independent experiments. *p < 0.05.
Anti-prostate Cancer Activity of rfhSP-D in
PrCEC and Tumor Explants
We first carried out a pilot investigation on the effect of rfhSP-
D on the primary cells derived from tissue biopsies of metastatic
PCa patients (n= 9). Isolated PrCEC (Passage 2) showed positive
staining for Cytokeratin (Figure 3C). Expression of AMACR
(which is upregulated in prostate cancer with high-grade
prostatic intraepithelial neoplasia) in PrCECwas not significantly
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FIGURE 3 | rfhSP-D reduced viability of primary Cancer Epithelial Cells (PrCEC) isolated from the metastatic prostate cancer tissue biopsies and enhanced apoptosis
in tumor explants. (A) FACS analysis of PE tagged anti-AMACR (prostate cancer marker) expression in PrEC (n = 3) (i), PC3 (n = 3) (ii), and isolated PrCEC (n = 9) (iii)
cell population (representative histograms). Dotted black line histogram represents isotype control. The black line histogram indicates AMACR expression. Data (iv)
represents mean of positively stained AMACR cell population (%), error bar represents the S.D. *p < 0.05 vs. PC3. (B) Transcript levels of CD164 (marker for
metastatic epithelial cell cancer) in PrEC (n = 3), PC3 (n = 3), and PrCEC (n = 9). Data represents the mean of three independent experiments, error bar represents
the S.D. *p < 0.05 vs. PrEC. (C) Positive immunofluorescence staining for FITC tagged anti-Cytokeratin, a marker for epithelial cells. Inset: Higher magnification, Scale
bar = 20µm. (D) PrCEC were incubated with different concentrations of rfhSP-D (5, 10, or 20µg/ml) for the indicated time intervals (24, 48, and 72 h) (n = 5). Each
bar represents % viability ± S.D, *p < 0.05, relative to untreated controls. (E) TUNEL assay of tissue biopsies from metastatic prostate cancer patients exogenously
treated with rfhSP-D (40µg/ml) for 48 h. Untreated tissue biopsy (i) showed significantly less number of TUNEL positive cells when compared with the treated biopsy,
(ii) from the same individual. Scale bar, 20µm. (iii) TUNEL+ve cells were quantitated and are shown as the number of TUNEL+ve cells per section (six sections per
tissue biopsy). *p < 0.05, relative to untreated controls.
different than the PC3 cells whereas PrEC cells showed
significantly decreased expression (Figure 3A). PrCEC and PC3
cells showed significantly upregulated expression of CD164 in
comparison with PrEC (Figure 3B). PrCEC cells isolated from
themetastatic PCa patients showed significantly reduced viability
in a dose- and time-dependent manner following treatment
with rfhSP-D (Figure 3D). Importantly, TUNEL assay confirmed
increased apoptosis in rfhSP-D treated tissue biopsies of the same
patients (Figure 3E). Since these metastatic PCa patients were
not evaluated for androgen-dependency, we could not assess if
rfhSP-D induced cancer cell death would vary with androgen
resistance. Therefore, we pursued further studies to delineate
the molecular mechanisms for rfhSP-D mediated apoptosis in
androgen dependent (LNCaP) and independent (PC3) cancer
cell lines.
rfhSP-D Selectively Reduced the Viability
of Prostate Cancer Cells
Reduction in the viability of PCa cells following
rfhSP-D treatment was dose- and time-dependent,
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FIGURE 4 | rfhSP-D treated LNCaP and PC3 cells showed increased cell cycle arrest. (A) (i) Normal prostate epithelial cells (PrEC); prostate cancer cell lines, LNCaP
(ii) and PC3 (iii) were incubated with different concentrations of rfhSP-D (5, 10, or 20µg/ml) for the indicated time intervals (24, 48, and 72 h). Each bar represents %
viability ± S.D. of three independent experiments. *p < 0.05, relative to untreated controls. (B) (i) LNCaP (p53+/+) cells and (ii) PC3 (p53−/−) cells were incubated in
the presence of rfhSP-D (20µg/ml) or in culture medium alone (control) for 48 h and were subjected to flowcytometric cell cycle analysis. The figure is a representative
histogram of one of the three independent experiments. The total population of cells has been divided in the G1, S, and G2 phases and analyzed using BD FACS DIVA
software. Treated LNCaP (p53+/+) cells showed growth arrest in G2/M phase (14.8 ± 1.7%) in comparison with the untreated cells (8.36 ± 1.58%) (p < 0.05).
Treated PC3 (p53−/−) cells showed growth arrest in G0/G1 phase (79.3 ± 3.02%) in comparison with the untreated cells (69.6 ± 4.50%) (p < 0.05).
TABLE 3 | IC50 values of rfhSP-D induced cell death in various prostate cancer
cells at 48 h.
Prostate cancer cells IC50 for rfhSP-D (µg/ml)
PrEC 94.54 ± 3.97
LNCaP 23.14 ± 3.70
PC3 31.98 ± 3.42
DU145 24.80 ± 2.94
irrespective of their androgen sensitivity whereas the
viability of rfhSP-D treated PrEC was unaltered till 48 h
(Figure 4A). The half-maximal inhibitory concentration
(IC50) of rfhSP-D against the PCa cells is tabulated
as Table 3.
rfhSP-D Caused Blockade in the Cell Cycle
of Prostate Cancer Cells
We further analyzed the effect of rfhSP-D on the percentage
of cells in various phases of the cell cycle (Figure 4B). rfhSP-
D treatment significantly reduced the S-phase peak with an
accumulation of cancer cells in either G0/G1 or G2/M cell cycle
phases. At 48 h, we observed growth arrest of LNCaP (p53+/+)
cells in G2/M (14.8± 1.7%) as compared to the untreated control
(8.36 ± 1.58%) (p < 0.05). There was a significant increase
(79.3 ± 3.02%) in G0/G1 population in the rfhSP-D treated PC3
(p53−/−) cells, in comparison with the untreated cells (69.6 ±
4.50%) (p < 0.05). Cell cycle inhibition following treatment with
rfhSP-D was consistent with the cell viability results. No cell
cycle arrest was observed in the PrEC (data not shown), which
confirmed that the rfhSP-Dmediated cell cycle arrest was specific
to cancer cells.
rfhSP-D Induced Apoptosis in LNCaP and
PC3 Cells
Annexin-V, a classical marker of the apoptosis, was evaluated by
flow cytometry. A significant increase in the annexin-V positive
cells was observed post 48 h in rfhSP-D treated LNCaP (19.13 ±
2.69%[Q2] and 25.82± 1.14% [Q4]) (p< 0.05) and PC3 (40.32±
2.24% [Q2] and 7.405± 1.63% [Q4]) (p< 0.05) cells as compared
to treated PrEC (2.63 ± 1.41% [Q2] and 3.9 ± 1.95% [Q4])
(Figure 5A). rfhSP-D promoted karyorrhexis (fragmentation of
nucleus) of LNCaP and PC3 cells at 48 h, as seen in Hoechst
stained cells (Figure 5B).
rfhSP-D Triggered Intrinsic Mitochondrial
Apoptosis in the Prostate Cancer Cells
p53 and PI3K/Akt are involved in several cellular physiological
processes including apoptosis and cell proliferation. Our
previous study had shown involvement of p53 in the rfhSP-D
mediated apoptosis of AML14.3D10 cells (12). Here, rfhSP-D
treated LNCaP cells with a wild type p53, showed significant
upregulation of p53 (Figure 6A). To understand the other likely
mechanisms of apoptosis, p53 null PC3 cells were examined
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FIGURE 5 | Significant increase in apoptosis in rfhSP-D treated prostate cancer cells. (A) Dot blots showing Annexin V-FITC and PI staining of PrEC, LNCaP, and PC3
cells incubated with rfhSP-D (20µg/ml) for 24 and 48 h. Q1 represents necrotic cells, Q2 show Annexin V FITC and PI double positive cells in late apoptosis, Q3 is
unstained cells and Q4 represents Annexin V FITC positive cells in early apoptosis. (i) LNCaP 24 h control, (ii) LNCaP 24 h rfhSP-D treated, (iii) LNCaP 48 h control, (iv)
LNCaP 48 h rfhSP-D treated, (v) PC3 24 h control, (vi) PC3 24 h rfhSP-D treated, (vii) PC3 48 h control, (viii) PC3 48 h rfhSP-D treated, (ix) PrEC 48 h control, (x) PrEC
48h rfhSP-D treated. The figure shows representative histograms from one of the three independent experiments. The total cell population has been divided into four
quadrants and analyzed using FCS Express 6 software. (B) Fluorescence microscopy images showed that rfhSP-D promotes karyorrhexis of LNCaP and PC3 cells at
48 h after staining with highly diluted Hoechst DNA stain (1µg/ml). (i), (iii), and (v) represent normal nuclear morphology of PrEC, LNCaP, and PC3 cells; (ii), (iv), and (vi)
represent effect of rfhSP-D on nuclear morphology of PrEC, LNCaP, and PC3 cells. “White arrows” indicate disintegrated nucleus. Scale bar, 20µm. (vii) Percent
apoptotic cells was recorded in all the cell types with and without rfhSP-D treatment, each bar represents the mean ± S.D. of three independent experiments. *p <
0.05 relative to untreated controls.
(Figure 6B) for differential expression of several kinases (MAPK,
JAK, Stat-1, ERK, and Akt). rfhSP-D significantly decreased the
phospho-active forms of Akt in PC3 cells at 15min (Figure 6B
iii and iv). Interestingly, treated LNCaP cells also showed
significantly decreased pAkt at 30min (Figure 6B i and ii).
Phosphorylated Akt leads to increased phosphorylation of Bad,
an inactive form of Bad. The rfhSP-D induced decrease in pAkt
sequentially led to a significant decrease in phosphorylated Bad
in both the cell lines (Figure 7A). rfhSP-D treatment further led
to a significantly decreased level of Bcl2 and an increased level
of Bax at 24 h (Figure 7B). Both LNCaP and PC3 cells showed
a significant increase in Bax to Bcl-2 ratio (p < 0.05) upon
Frontiers in Oncology | www.frontiersin.org 9 July 2019 | Volume 9 | Article 565
Thakur et al. Anti-prostate Cancer Activity of rfhSP-D
FIGURE 6 | Levels of p53 and pAkt were altered in rfhSP-D treated prostate cancer cells. (A) LNCaP cells (i) incubated with rfhSP-D (20µg/ml) for 12 and 24 h were
analyzed for the levels of anti-phosphorylated-p53(Ser 15) (Cell Signaling Technology) by immunoblotting. Densitometric analysis for the same is shown in panel, (ii) n
= 3 independent experiments. *p < 0.05 vs. control. (B) LNCaP (i) and PC3 (iii) cells treated with rfhSP-D (20µg/ml) for 5, 15, and 30min were analyzed for anti-pAkt
(PathScan Multiplex Western Cocktail I) and anti-pan Akt (ABclonal) expression by western blot. Their respective densitometric analysis is shown as pAkt/Akt ratio in
(ii) and (iv). n = 3 independent experiments. *p < 0.05, **p < 0.01 vs. control. Full length western blots provided as Supplementary Information.
treatment with rfhSP-D. Similarly, transcripts for pro-apoptotic
genes like BAX, BAD were upregulated and transcripts of BCL2
an anti-apoptotic gene was down regulated in a time dependent
manner in LNCaP and PC3 cells (Figure 8). In LNCaP cells,
transcripts for BAX (by 1.5 folds) were upregulated during 12 h of
rfhSP-D incubation; in PC3 cells, transcripts for BAD (by 6 folds)
were significantly upregulated at 6 h of rfhSP-D incubation.
To delineate the penultimate steps of apoptotic cascade,
we assessed levels of cytochrome c and activation of caspases
in rfhSP-D treated prostate cancer cells. At 48 h, rfhSP-D
treatment induced release of cytochrome c attained significance
in culture supernatant of cancer cells (LNCaP, PC3) and
tissue biopsies of prostate cancer when compared to PrEC
(Figure 7D). Cleaved products of the executioner caspase 7 were
significantly increased after 24 h following rfhSP-D treatment
(Figure 7C). From these observations, we infer that rfhSP-D
triggers intrinsic mitochondrial pathway of apoptosis in prostate
cancer cells.
DISCUSSION
The present study established the anti-prostate cancer activity
of rfhSP-D via induction of intrinsic apoptosis in explants and
primary tumor cells isolated from tissue biopsies of metastatic
prostate cancer patients and prostate cancer cell lines: LNCaP
(androgen responsive) and PC3 (androgen resistant). Various
attributes of apoptosis like phosphatidylserine externalization
(Figure 5), mitochondrial dysfunction (Figure 7), and DNA
fragmentation (Figure 5) and various apoptotic markers
(Figure 7) were observed in the rfhSP-D treated LNCaP and PC3
cells. Viability of the normal prostate epithelial cells (PrEC) was
not altered in presence of rfhSP-D (Figure 1).
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FIGURE 7 | rfhSP-D triggers intrinsic apoptotic pathway. (A) LNCaP (i) and PC3 (iii) cells treated with rfhSP-D (20µg/ml) for 12 and 24 h were analyzed for anti-pBad
(Ser 155) (ABclonal) and anti-Bad (Apoptosis I sampler Kit, Cell Signaling Technology) expression by immunoblotting. Panels (ii) and (iv) show densitometric analysis for
the Bad/pBad ratio in LNCaP and PC3 cells respectively. n = 3 independent experiments. *p < 0.05 vs. control. (B) LNCaP (i) and PC3 (iii) cells treated with rfhSP-D
(20µg/ml) for 12 and 24 h were analyzed for anti-Bax (Apoptosis I sampler Kit, Cell Signaling Technology) and anti-Bcl-2 (Apoptosis I sampler Kit, Cell Signaling
Technology) expression by immunoblotting. Panels (ii) and (iv) show densitometric analysis for the Bax/Bcl2 ratio in LNCaP and PC3 cells, respectively. n = 3
independent experiments. *p < 0.05 vs. control, **p < 0.01 vs. control. (C) Immunoblotting for uncleaved anti-Caspase 7(Cell Signaling Technology) and its cleaved
products of molecular mass 32 kDa (upper panel; black arrow) and 20 kDa (lower panel; black arrow) respectively, in rfhSP-D (20µg/ml) treated LNCaP (i) and PC3 (iii)
cells for 24 h. Panels (ii) and (iv) show densitometric analysis for the cleaved caspase 7 and uncleaved caspase 7 in rfhSP-D treated LNCaP and PC3 cells,
respectively. n = 3 independent experiments. *p < 0.05 vs. control. Full length western blots provided as Supplementary Information. (D) Measurement of
Cytochrome c (Human Cyt-C, catalog no. E1516Hu, BT Assay) in cell culture supernatants of normal prostate epithelial cells (PrEC), cancer cell lines (LNCaP and
PC3) and tumor tissue biopsies on exposure to rfhSP-D treatment for 48 h by ELISA. Data are presented as the mean ± S.D from three independent experiments. *p
< 0.05 vs. control. (E) Proposed mechanisms for rfhSP-D mediated apoptosis in PCa cells. Treatment with rfhSP-D upregulates p53 and downregulates pAkt,
resulting in upregulation of Bad, Bax, and release of cytochrome c leading to cleavage of caspase 7 in prostate cancer cells. SP-D interaction with some key
molecules like HMGA1, CD14, SIRPα, and EGFR has been reported previously and may be relevant as part of the proposed mechanisms of p53 and Akt.
Frontiers in Oncology | www.frontiersin.org 11 July 2019 | Volume 9 | Article 565
Thakur et al. Anti-prostate Cancer Activity of rfhSP-D
FIGURE 8 | rfhSP-D treatment induced alterations in the transcripts of anti and pro-apoptotic genes. (A,B) Real time RT-PCR analysis showed an upregulation of
transcripts of BAX (ii, v) BAD (iii, vi) and downregulation of BCL2 (i, iv) in LNCaP and PC3 cells on treatment with rfhSP-D (20µg/ml) for 6, 12, and 24 h. Each bar
represents the mean ± S.D of three independent experiments. * indicates statistical significance and *p < 0.05 relative to rfhSP-D untreated controls.
Human prostate cancer tissues frequently exhibit inactivation
of the tumor suppressor gene p53 which is associated with
therapeutic resistance (23). The p53 pathway plays a crucial
role in the transmission of pro-apoptotic signals (24). Various
therapeutic agents/candidates induce apoptosis of LNCaP
(p53+/+) cells by increasing the levels of phosphorylated
p53 (25–27). Knockdown of p53 resulted in blockade of
docetaxel induced apoptotic cell death in prostate cancer
cells (28). Upregulation of activated p53 levels in a time-
dependent manner by rfhSP-D treatment suggested involvement
of the p53 pathway in the induction of apoptosis of LNCaP
cells. Previously, activation of p53 was also observed in
the eosinophilic leukemic cells (AML14.3D10) undergoing
apoptosis upon treatment with rfhSP-D (14, 29). rfhSP-D
treated AML14.3D10 cells showed significantly reduced levels
of HMGA1, a survival protein (14). PC3 cells, a p53 null
and highly metastatic prostate cancer cell line, also showed
significant apoptosis following treatment with rfhSP-D, which
suggested involvement of a p53 independent mechanism of
apoptosis. Among 25% prostate cancer cases, diallelic deletion
of the Phosphatase and tensin homolog (PTEN) gene and
the associated increase in Akt phosphorylation correlates with
hormone refractory prostate cancer (30). Decreased levels of
activated Akt may lead to decreased levels of phosphorylated
Bad (Bcl-2 associated death promoter). Dephosphorylated Bad
interferes with interaction of activated Bcl2 with Bax. Thus,
increased release of Bax triggers apoptosis (31, 32). Decreased
ratio of transcripts of Bcl-2 to Bax has been associated with
cell death following an apoptotic stimulus (33, 34). Both
LNCaP and PC3 cells, upon treatment with rfhSP-D, showed
a significant increase in Bax to Bcl-2 ratio (p < 0.05),
suggesting that besides activation of p53 pathway, rfhSP-D
also inhibited Akt-PI3K pathway leading to induction of Bax
mediated apoptosis. The present study unravels PI3K/Akt, an
anti-apoptotic pathway, as a novel target of rfhSP-D mediated
anti-prostate cancer activity.
Mitochondria plays a central role in the initiation of intrinsic
apoptosis pathway (35). rfhSP-D treatment mediated disruption
of the mitochondria was elucidated by its reduced ability to
oxidize methyl tetrazolium to form formazan crystals (MTT
assay; Figure 4). Breakdown of mitochondria is followed by
the release of cytochrome c (Figure 7), a key initial step in
the irreversible apoptotic process (35, 36). Culture supernatants
from the rfhSP-D treated prostate cancer cells and cancer tissue
biopsies showed significantly elevated levels of cytochrome c,
confirming induction of intrinsic apoptosis. Once in the cytosol,
the cytochrome c interacts with its adaptor molecule, Apaf-
1, resulting in the processing and activation of pro-caspase-9
(37). Caspase-9, in turn, cleaves and activates pro-caspases−3
and−7, effector caspases responsible for the cleavage of various
proteins leading to the biochemical and morphological features
observed in apoptosis (38). Treatment of the prostate cancer
cells with rfhSP-D resulted in the cleavage and activation of
the effector caspase-7, thus leading to programmed cell death.
Nuclear condensation, membrane and nuclear blebbing and
flipping of phosphatidylserine (PS) on the cell membranes, the
typical morphological characteristics of apoptotic cells, were
observed in the rfhSP-D treated prostate cancer cells, confirming
apoptotic cell death. The proposed mechanisms for the rfhSP-
D mediated apoptosis in prostate cancer cells as revealed in
this study along with some key molecules of these pathways
interacting with/ induced by SP-D as reported previously have
been depicted in Figure 7E.
Recent studies highlighted the suppressive role of SP-D
in extrinsic apoptosis wherein native purified human SP-D
interacted with Jurkat T cells and delayed the progression of
Fas (CD95)-Fas ligand and TRAIL-TRAIL receptor induced, but
not TNF-TNF receptor-mediated apoptosis (39). In a subsequent
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study from the same group in UV irradiated Jurkat T cells,
SP-D reduced the activation of caspase-8, executioner caspase-
3 and exposure of phosphatidylserine (PS) on the membranes
of dying cells, with a concomitant increase in the formation of
nuclear and membrane blebs (16). The involvement of rfhSP-D
in extrinsic apoptotic pathway in prostate cancer cells needs to be
explored further.
rfhSP-D induced a cell cycle arrest in G2/M and G0/G1 phases
of LNCaP and PC3 cells, respectively. We had previously shown
that the rfhSP-D induced elevated p21 expression and inhibited
Cdc2 phosphorylation resulting in reduced activity of Cdc2-
cyclin B1 thus, leading to G2/M arrest in the AML14.3D10 cells
(14). Several genes are common to the pathways involved in
cell cycle regulation and apoptosis (40). The p53 protein plays
a critical role both in the G1/S and G2/M checkpoint while
Retinoblastoma (Rb) protein is a potent inhibitor of the G1 to
S phase transition in the cell cycle (41, 42). Following rfhSP-D
treatment, PC3 cells, which are null p53 but express the wild
type Rb gene, showed an arrest in the G1-phase with significant
reduction in the S-phase cell population. This alluded to the
involvement of a p53 independent mechanism in the rfhSP-D
induced apoptosis in PC3 cells.
Increased interaction of rfhSP-D with the prostate cancer cells
as compared to PrEC, could be due to differential expression of
the receptors. Similar to our previous study with eosinophilic
leukemic cells, rfhSP-D showed interaction with the prostate
cancer cells via carbohydrate recognition domain (CRD) (14).
CRD domain of SP-D is known to interact with CD14, TLR-
2, TLR-4, EGFR, and SIRPα that are reported to be present on
prostate cancer cells and normal prostate tissues (15, 43, 44).
Binding of SP-D with pattern recognition receptors CD14, TLR-
2, and TLR-4 may lead to blockade of their downstream pro-
inflammatory and pro-survival signaling (Figure 7E). Interaction
with SIRPα, involved in the negative regulation of receptor
tyrosine kinase-coupled signaling processes, may result in
recruitment of PI3K, leading to a reduction in the activity of
the downstream kinase Akt (45) (Figure 7E). A recent study
showed that SP-D reduced EGF -EGFR binding through the
interaction between CRD of SP-D and N-glycans of EGFR, thus,
leading to downregulation of EGF signaling in the A549 human
lung adenocarcinoma cells (15) (Figure 7E). Further studies are
needed to elucidate the involvement of CRD and its interacting
partners in downstream signaling of rfhSP-D in the prostate
cancer cells.
Oncogenic mutations disturb the normal cellular functions,
thus, allowing the tumor cells to undergo dysregulated
proliferation, resist pro-apoptotic insults, invade normal tissues,
and most importantly, escape apoptosis. Therefore, induction of
apoptosis in the malignant tumors has evolved as a successful
adjunct anti-cancer strategy. We report that rfhSP-D selectively
triggered intrinsic apoptosis in androgen-dependent as well as
androgen-independent prostate cancer cells, without affecting
normal epithelial cells (PrEC). rfhSP-D also induced apoptotic
cell death in the tissue biopsies from metastatic prostate cancer
patients. Thus, SP-D is likely to act as an integral component
of the human innate immune surveillance against cancer cells.
A great advantage associated with the anti-cancer activity of
rfhSP-D is induction of apoptosis by simultaneous targeting
of multiple cellular signaling pathways including transcription
factors, tumor cell survival factors, protein kinases resulting
in the efficient and selective killing of prostate cancer cells.
Murine models of prostate cancer including the patient-derived
xenograft (PDX) mouse models that mimic human disease
and 3D cell cultures derived from PDX are going to be
valuable tools for the evaluation of therapeutic strategies using
rfhSP-D (46).
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A B S T R A C T
The complement system is an important humoral immune surveillance mechanism against tumours. However,
many malignant tumours are resistant to complement mediated lysis. Here, we report secretion of complement
factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma multiforme (GBM) pa-
tients. We investigated whether the secreted FHR5 exhibited functional activity similar to factor H, including
inhibition of complement mediated lysis, acting as a co-factor for factor I mediated cleavage of C3b, and decay
acceleration of C3 convertase. Immunoblotting analysis of primary GBM cells (B30, B31 and B33) supernatant
showed the active secretion of FHR5, but not of Factor H. ELISA revealed that the secretion of soluble GBM-FHR5
by cultured GBM cells increased in a time-dependent manner. Primary GBM-FHR5 inhibited complement
mediated lysis, possessed co-factor activity for factor I mediated cleavage and displayed decay acceleration of C3
convertase. In summary, we detected the secretion of FHR5 by primary GBM cells B30, B31 and B33. The results
demonstrated that GBM-FHR5 shares biological function with FH as a mechanism primary GBM cells potentially
use to resist complement mediated lysis.
1. Introduction
Glioblastoma multiforme (GBM) is the most lethal brain tumour in
adults with a median survival of less than 15 months (Ohgaki et al.,
2004). One of the biggest clinical challenges in the treatment of GBM is
the highly aggressive behaviour of cells that prevent complete surgical
resection and enhance resistance to conventional radio- and che-
motherapy (Ohgaki et al., 2004; Furnari et al., 2007). Even with com-
plete surgical resection, the long-term survival of GBM patients remains
very poor due to a high recurrence rate (Ohgaki et al., 2004). Recent
findings from The Cancer Genome Atlas confirmed that the immune
microenvironment significantly contributes to therapy resistance and is
associated with worse survival in GBM (Iglesia et al., 2016). In addition,
glioma cells have the capacity to escape immune surveillance, and are
involved in immune suppressive activities to promote the malignant
transformation of GBM tumours (Chang et al., 2016; Mieczkowski et al.,
2015).
GBM is a grade IV astrocytoma, characterised by uncontrolled cel-
lular proliferation, diffuse infiltration, extensive genomic instability,
tendency for necrosis, angiogenesis, and resistance to apoptosis. The
tumour is characterised by high inter- and intra- morphological het-
erogeneity, hence the term “multiforme” (Furnari et al., 2007; Liu et al.,
2012). GBM is a robust malignant tumour distinguished by its local
invasion pattern (Gabrusiewicz et al., 2014; Hermanson et al., 1992).
Clinical symptoms may include progressive headaches, seizures and
focal neurological deficit (Pace et al., 2009; Faithfull et al., 2005;
Oberndorfer et al., 2008; Hermanson et al., 1992). GBM is most often de
novo (primary GBM), which develops quickly within a three-month
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period before the initial symptoms indicate the onset of the tumour.
Primary GBM accounts for approximately 90% of the cases and is
predominately found in patients older than 45. The tumour may also
develop from a lower grade tumour to a higher malignancy (secondary
GBM) over 5-10-years, which is more commonly observed in patients
below the age of 45. These subtypes have distinct genetic aberrations
but are histologically indistinguishable (Furnari et al., 2007; Maher
et al., 2006; Fujisawa et al., 1999). GBM is resistant to destruction by
the immune system. Despite aggressive treatment including surgical
resection and radiotherapy with concomitant chemotherapy, prognosis
remains poor due to GBM recurrence, with a median survival of 14.6
months (Stupp et al., 2005).
The complement system is one of the most potent humoral innate
immune protective mechanisms. Complement is activated via three
pathways (classical, alternative and lectin). The recognition molecules
of each pathway identify non-self and altered self, and the activities of
the complement system eventually eliminate the targets (Kohl, 2006).
All the three complement pathways converge on the generation of C3
convertase, leading to terminal membrane attack complex (MAC),
which is lytic to target cells. The resistance to complement mediated
killing by both normal tissue and human malignancies is due to mem-
brane-bound inhibitors including complement receptor 1 (CR1; CD35),
membrane cofactor protein (MCP; CD46), decay-accelerating factor
(DAF; CD55), and protectin (CD59) (Morgan and Meri, 1994; Gorter
and Meri, 1999). CR1 and MCP act as a co-factor for factor I mediated
degradation of C3b (Fearon, 1979; Seya et al., 1986), while DAF and
CR1 promote the decay of C3 and C5 convertases. Protectin inhibits the
formation of the MAC on cell membranes (Sugita et al., 1988; Meri
et al., 1990).
In addition to membrane bound regulators, the activity of the
complement system is efficiently controlled by soluble factor H (FH),
which is predominantly synthesised by the liver (Davies et al., 1989;
Weiler et al., 1976). FH regulates the alternative pathway by acting as a
cofactor for factor I-mediated cleavage of C3b, competes with factor B
to bind to C3b, and promotes the dissociation of C3 convertase, C3bBb
(Fearon and Austen, 1977; Whaley and Ruddy, 1976). FH is a 150 kDa
soluble protein consisting of 20 complement control protein modules
(CCPs) (also called short consensus repeats; SCR), each composed of
about 60 amino acids (Ripoche et al., 1988). The complement reg-
ulatory activity is located in CCP1–4 (Jokiranta et al., 2000; Sharma
and Pangburn, 1996; Gordon et al., 1995; Kuhn and Zipfel, 1996),
which is also one of the three C3b binding sites. A second C3b binding
site may be localised on CCP 8–15 and the third binding site exists on
CCP 19–20 (Jokiranta et al., 2000, 2005).
FHR5 is a protein of the FH family, which includes FH, FH like
protein 1 (FHL-1), and FHR1-5, which are structurally and im-
munologically related. FHL-1 is an alternatively-spliced product of the
FH gene, whereas FHR1-5 are each encoded by separate genes. FHR5
exists as a glycosylated protein with a plasma concentration of ap-
proximately 5 μg/mL (Skerka et al., 2013) The FHR5 gene is located
downstream of the FH gene on a distinct segment of human chromo-
some 1q32 within the Regulation of Complement Activation (RCA)
gene cluster (Jokiranta et al., 2005; Clark and Bishop, 2015). FHR5 is
the largest human FHR protein (∼65 kDa) and is composed of 9 CCPs.
All FHR proteins contain CCPs which are similar in sequence to CCP 6,
19 and 20 of FH (Ohgaki et al., 2004; Furnari et al., 2007; Iglesia et al.,
2016; Chang et al., 2016; Mieczkowski et al., 2015). However, FHR5 is
the only FHR to contain additional CCPs, which are similar to
CCP10–14 of FH. CCP3-7 of FHR5 show 46%, 75%, 57%, 48% and 71%
amino acid identity with CCP10–14 of FH, respectively (Jokiranta et al.,
2005). The extensive sequence similarities between FHR1-5 and FH
allow FHRs to be recognised by polyclonal anti-FH antibodies. The C-
terminal FHR5 CCP8 and 9 share sequence identity of 64% with CCP19
and 42% with CCP 20 of FH whereas there is a more distant sequence
homology between FHR5 CCP1-2 and CCP6 and CCP7 of FH (Medjeral-
Thomas and Pickering, 2016; McRae et al., 2001). FHR5 has the ability
to bind to C3b, heparin, C-reactive protein, and iC3b (the cleavage
product of C3b). The function of FHR5 is not well understood (Csincsi
et al., 2015). Weak co-factor activity for cleavage of C3b by factor I and
decay-acceleration activity of C3bBb convertase have been attributed to
FHR5 (Jokiranta et al., 2005; McRae et al., 2005). However, studies
have also reported that FHR5 can deregulate complement by competing
with FH for binding to surface polyanions and C3b (Csincsi et al., 2015;
Goicoechea de Jorge et al., 2013).
Here, we report that primary tumour cells, directly isolated from
GBM patients post-surgery, secrete FHR5 in culture (GBM-FHR5). Our
results show that the primary GBM-FHR5 is functionally active and
regulates complement by acting as a co-factor for factor I mediated
cleavage of C3b, and degrading (decaying) C3 convertase.
2. Materials and methods
2.1. Isolation of primary GBM Cells from tumour samples
Primary GBM cells were obtained directly from surgical resections
of three patients at the John Radcliffe Hospital, Oxford, UK following
local ethical board approval. Briefly, a small piece of each tumour tissue
was removed and placed into Accutase (Sigma-Aldrich) for 15 min to
dissociate into single cells. All primary cells used in this study, namely
B30, B31 and B33, were grown in DMEM-F12 medium (Life
Technologies) supplemented with 10% v/v heat inactivated fetal calf
serum (FCS; Life Technologies), and 1% penicillin/streptomycin (Life
Technologies) at 37 °C in 5% v/v CO2. The cells were passaged up to
three times.
2.2. FHR5 purification from B30, B31 and B33 cells
2 × 106 B30, B31, or B33 cells were grown in 75 cm3 culture flasks
in serum free DMEM/F12 with penicillin/streptomycin until the cells
were 80% confluent. The culture supernatant was centrifuged for 5 min
at 2000 rpm to remove cells in suspension. The supernatant was dia-
lysed overnight against buffer containing 25 mM Tris−HCl pH 7.5,
140 mM NaCl, 0.5 mM EDTA, pH 7.5 and passed through an anti-FH
Sepharose column (CNBr-activated Sepharose to which rabbit anti-
human FH IgG fraction was coupled) (MRC Immunochemistry Unit,
Oxford) (Soames and Sim, 1997).
The column was then washed with 10 bed volumes of the same
buffer. Bound protein was eluted with 3 M MgCl2, adjusted to pH 6.8.
The eluted fractions were dialysed overnight against distilled water
followed by 4 h dialysis against 10 mM potassium phosphate, 140 mM
NaCl, 0.5 mM EDTA, pH 7.5. The final protein concentration was
measured with a nanodrop spectrophotometer, reading at 280 nm. FH
was purified as a control protein from normal human serum using the
same technique. Procedures are based on those in Yu et al. (2014),
although a different antibody preparation was used.
2.3. SDS-PAGE
SDS-PAGE was performed using the Laemmli (1970) method to
observe the proteins purified from primary GBM cells and to assess the
purity of human FH. The samples were added to 2 x treatment buffer
with or without the reducing agent i.e. beta mercaptethanol (Sigma-
Aldrich) in a 1:1 v/v ratio and were denatured for 10 min at 100 °C.
Standard Protein markers (Thermo-Scientific) and the denatured sam-
ples were loaded onto the gel and separated via electrophoresis for
90 min at 120 V. The gel was stained overnight on a rotary shaker with
Coomassie blue stain solution (0.1% w/v Coomassie blue (Sigma-Al-
drich), 10% v/v acetic acid, 20% v/v methanol, followed by de-staining
for 2 h using de-stain solution (10% v/v acetic acid, 20% v/v methanol)
to visualise the bands.
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2.4. Western blot
0.2 × 106 cells/mL of primary GBM cells B30, B31, B33 and cell line
H2 (control: glioblastoma cell line; Gasque et al. (1992) (kindly pro-
vided by Prof Seppo Merri from University of Helsinki) were plated in
12 well plates in the presence of DMEM-F12 and 1% penicillin/strep-
tomycin to obtain serum-free culture supernatant. Cells were grown at
37 °C in 5% CO2 until 80% confluency was reached. The culture su-
pernatant was centrifuged for 5 min at 10,000 rpm. Each supernatant
was run on a 12% SDS-PAGE gel under reducing conditions. The protein
bands were transferred to a nitrocellulose membrane in 1 x transfer
buffer (25 mM Tris-HCl, 190 mM glycine, 20% v/v methanol pH 8.3) at
70 V for 2 h at 4 °C. After blocking non-specific binding sites overnight
with 2% w/v bovine serum albumin (BSA) at 4 °C, the membrane was
incubated for 1 h at room temperature (RT) with primary polyclonal
rabbit anti-human FH (10 μg/mL IgG; MRC Immunochemistry Unit,
Oxford) in 1 x PBS (Thermo-Scientific). The membrane was washed
using 1 x PBS + 0.05% Tween20 (PBST) and incubated with secondary
anti-rabbit IgG-horseradish peroxidase (HRP) conjugate (5 μg/mL)
(Sigma Aldrich) for 1 h at RT. After washing, bound antibodies were
detected and visualised using 3,3′diaminobenzidine (DAB; Sigma Al-
drich). A similar blot was also probed with goat anti-FHR5 polyclonal
antibodies (R&D; cat. no. AF3845-SP).
2.5. ELISA
The culture supernatant (100 μL) from 0.2 × 106 B30, B31 or B33
primary cells/mL grown in serum free media was dispensed in tripli-
cates in a microtiter plate, with the addition of another 100 μL of car-
bonate bicarbonate buffer (Sigma-Aldrich) to each well. Human FH and
BSA (100 μg/mL) were added to separate wells as positive and negative
control proteins. After overnight incubation at 4 °C, the wells were
washed with 1 x PBST and non-specific binding sites were blocked by
incubation with 2% BSA for 2 h at 37 °C. The wells were washed again,
the primary polyclonal rabbit anti-human FH antibody (10 μg/mL IgG)
in PBS was added, and incubated for 1 h at 37 °C. After washing, bound
antibodies were detected using anti-rabbit IgG-HRP secondary antibody
(5 μg/mL) in PBS for 1 h at 37 °C. Wells were washed and o-
Phenylenediamine (Sigma-Aldrich) was added in the dark. The A450 nm
was measured using a microplate absorbance reader (Bio-Rad).
2.5.1. Haemolytic assay
Sheep erythrocytes (TCS Bioscience) were washed with PBS-5 mM
EDTA. The cell concentration was adjusted to 1 × 109 cells/mL using
DGVB-Mg-EGTA (2.5 mM sodium barbital, 71 Mm NaCl, 7 mM MgCl2,
10 mM EGTA, 0.1% w/v gelatin, 2.5% w/v glucose pH 7.4). The pre-
sence of EGTA and MgCl2 allows activation of the complement alter-
native pathway only. Serum depleted of FH family proteins (FH, FHL-1,
and FHR1-5) was made by passing normal human serum (TCS
Bioscience) through a polyclonal anti-FH Sepharose column in the
presence of 0.1 mM EDTA at 4 °C and freezing the flow-through im-
mediately at −80 °C (McRae et al., 2005). A dot blot was performed on
the serum that had been passed through the column using polyclonal
anti-human FH and anti-rabbit IgG-HRP (1:1000) antibodies to ensure
FH family proteins were absent. 40 μL of FH family depleted serum was
diluted in 160 μL of DGVB-Mg-EGTA followed by a 2-fold serial dilution
on a microtiter plate on ice and 100 μL of sheep erythrocytes were
added to each well. Following incubation for 30 min at 37 °C and cen-
trifugation (5000 rpm, 10 min, 4 °C), the supernatants were removed,
and the absorbance was measured at 541 nm. To determine percentage
haemolysis, 100 μL of sheep erythrocytes with 100 μL of water was
included separately to determine total cell lysis and 100 μL of sheep
erythrocytes with 100 μL of DGVB-Mg-EGTA was included as a blank.
On ice, 20 μL of depleted serum that caused 50% haemolysis, was
mixed with varying concentrations of GBM-FHR5 (0.2–4 μM), 100 μL of
sheep erythrocytes and sufficient DGVB-Mg-EGTA (to bring the mix to
200 μL). Human FH (0.2–4 μM) was used instead of FHR5 as a control.
The samples were incubated for 30 min at 37 °C followed by immediate
centrifugation at 4 °C. The absorbance at 541 nm was measured for each
supernatant and the percentage haemolysis was calculated.
2.6. Co-factor assay
The Factor I co-factor activity assay was adapted from Brandstatter
et al. (2012). Briefly, 3 μg of C3b (0.55 μM)(Complement Technology),
45 ng of factor I (4 nM)(Complement Technology) and 0.39–78 μg
(0.2–4 μM) of FHR5 or 0.9–18 μg (0.2-4μM) FH were added to 10 mM
sodium phosphate, pH 6.0 to a final volume of 30 μL. Samples without
FH or FHR5 were included as controls. The samples were incubated at
37 °C for 10 min and separated under reducing conditions via SDS-
PAGE and subjected to Coomassie blue staining.
2.7. Decay acceleration activity
The decay acceleration assay was modified from Brandstatter et al.
(2012). Briefly, a microtiter plate was coated with 50 μL containing
250 ng of C3b in 50 mM carbonate bicarbonate buffer, pH 9.6 overnight
at 4 °C. Generation of nickel chloride stabilised C3 convertase was
achieved by the addition of 400 ng of Factor B (Complement Tech-
nology) and 25 ng of factor D (Complement Technology), in the pre-
sence of 2 mM nickel chloride (Sigma-Aldrich), 25 mM NaCl and 4% w/
v BSA to a total volume of 150 μL. The samples were incubated for 2 h
at 37 °C. After extensive washing with PBS, varying concentrations of
FHR5 (1.3 to 26μg, resulting in concentration 0.2–4 μM) were diluted in
PBS to a total volume of 100 μL and added directly to each well then
incubated for 30 min at 37 °C. Samples with and without FH or FHR5
were included as controls. After extensive washing, intact complexes
(not decayed) were detected with goat anti-human factor B antibody
(40 μg/mL; Complement Technology) in PBS for 1 h at 37 °C. The wells
were washed and rabbit anti-goat IgG-HRP (1.5 μg/mL) (Thermo-Sci-
entific) in PBS was added to each well and incubated for 1 h at 37 °C,
followed by washing. To each well, o-Phenylenediamine was added for
5 min in the dark and the A450 nm was measured.
3. Results
3.1. Secretion of FHR5 by B30, B31 and B33 GBM cells
We first examined the presence of FH family proteins in the culture
supernatant of B30, B31 and B33 primary GBM cells. Using western blot
analysis, we were able to detect FHR5 in serum free culture supernatant
of primary GBM cells, demonstrating that these cells secreted FHR5,
migrating at ∼65 kDa under reducing conditions (Fig. 1A). H2 super-
natant (Fig.1B) differed from the primary cells supernatant as bands
were displayed for FH at 150 kDa and FH like -1 (FHL-1) at 42 kDa. FH,
FHL-1 and FHR1–4 were undetectable in B30, B31 and B33 culture
supernatant. The identity of FHR5 was a established by use of an anti-
FHR5 polyclonal antibody (Fig. 1C). Subsequently, we affinity-purified
the protein using a polyclonal anti-human factor H Sepharose column
(Fig. 2). In order to eliminate interference with the presence of FH in
fetal calf serum, the culture supernatant was obtained from cells grown
in serum-free media. A prominent band was visualised at ∼65 kDa
under reducing conditions, the molecular weight for FHR5. No higher
or lower bands were present, indicating that there were no impurities or
other FH family proteins eluted. The lack of additional bands also
confirmed that the protein was not a cleaved product of full length FH.
In addition, the purified protein continued to migrate at ∼65 kDa even
under non-reducing conditions (Fig. 2B), ruling out the possibility of
the purified protein being C4b binding protein (with which polyclonal
anti-FH also cross-reacts). A protein yield of 400 μg for B30, 300 μg for
B31 and 300 μg for B33 was obtained from 50 mL serum-free DMEM/
F12 with penicillin/streptomycin collected from the cells at 80%
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confluence. Using ELISA, we analysed the protein secretion at regular
intervals of cell growth. There was a significant time dependent in-
crease in FHR5 secretion over 48 h of growth (Fig. 3). These data show
that FHR5 is secreted by primary GBM cells B30, B31 and B33, but FH
and other members of the FH family are not.
3.2. GBM-FHR5 inhibits complement-mediated lysis of sheep erythrocytes
Sheep erythrocytes have cell surfaces rich in sialic acid and are used
as the standard non-activator for human complement analysis. The
ability of FHR5 from B30, B31 and B33 cells to recognise sialic acids
and inhibit activation of the complement system was assessed by re-
placing serum depleted of FH family proteins (confirmed by dot blot)
with purified GBM-FHR5. We first carried out the haemolytic assay in
serum depleted of FH family proteins which demonstrated that sheep
erythrocytes were lysed in a dose dependent manner. When sheep er-
ythrocytes were incubated with varying concentrations of FHR5, hae-
molysis was reduced dose dependently (Fig. 4). 4 μM of FHR5 was
needed to achieve complete inhibition of cell haemolysis, whereas 1 μM
of FH was needed to reduce lysis to zero.
Fig. 1. Western blot analysis of serum free
primary GBM supernatant. 0.2 × 106 (A) B30,
B31, B33 (B) and H2 cells (control) Cells were
grown for 48 h at 37 °C with 5% v/v CO2 in the
absence of fetal calf serum. The culture super-
natant was collected and an SDS-PAGE was run
(reduced samples). FH was included as a con-
trol. The samples were transferred onto ni-
trocellulose membrane and probed with poly-
clonal rabbit polyclonal anti-FH (10 μg IgG/
mL) and anti-rabbit IgG-HRP (5 μg/mL) anti-
bodies for 1 h. The detected protein band was
visualised using 3,3′diaminobenzidine. (c) The
purified proteins were also probed with goat
anti-FHR5 polyclonal antibodies (1:1000; R&D:
cat. no. AF3845-SP).
Fig. 2. Purification of FHR5 from primary GBM
cells. The supernatant from cultured B30, B31
and B33 cells were dialysed against wash buffer
I overnight. The dialysate was passed through a
polyclonal anti-human FH Sepharose column.
The bound protein was eluted and dialysed
against distilled water over night and dialysis
buffer I for 4 h. (A) A reduced SDS-PAGE. (B) A
non-reduced SDS-PAGE. FH is shown as a con-
trol in A.
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3.3. GBM-FHR5 shows co-factor activity for factor I-mediated cleavage of
C3b
A co-factor assay was performed to measure the ability of FHR5 to
act as a co-factor for factor I-mediated cleavage of C3b. Factor I, C3b
and GBM-FHR5 or FH were mixed and incubated to allow FHR5 or FH
to bind to C3b and enable factor I mediated cleavage. Co-factor activity
for factor I was visualised by SDS-PAGE analysis through the loss of or
reduced intensity of C3b α- chain and the appearance of two cleaved
inactivated C3b (iC3b) fragments at 68 kDa and 43 kDa (Fig. 5A-D).
Reactions containing 0.6–4 μM of GBM-FHR5 mediated factor I clea-
vage of C3b. However, at 0.2 μM (Fig. 5A-C) cleavage was not detected
whereas reactions containing 0.2 μM of FH did display C3b cleavage in
the presence of factor I (Fig. 5D). In the absence of FHR5 and FH, factor
I alone was unable to cleave C3b.
3.4. GBM-FHR5 has decay acceleration activity for C3 convertase
To establish whether GBM-FHR5 had decay acceleration activity as
a mechanism to inhibit the alternative pathway, a dissociation assay
was carried out. A modified ELISA technique was used to determine the
ability of FHR5 to exert decay acceleration activity. Nickel chloride-
stabilised C3 convertase was formed and subsequently treated with
FHR5 and the control protein, FH. The addition of GBM-FHR5 was
successful in dissociating Bb fragment from C3bBb(Ni2+) in a dose-
dependent manner (Fig. 6), as shown by the inverse correlation be-
tween FHR5 concentration and intact C3 convertase.
4. Discussion
The function of human FHR5 is currently controversial and only
limited data is available. There are studies which show that FHR5 has a
complement “activating” role (by competing with the down-regulatory
effect of FH) (Goicoechea de Jorge et al., 2013) whereas it is also re-
ported that FHR5 can inhibit complement (McRae et al., 2005). An
earlier study by Junnikkala et al demonstrated the expression of FH and
FHL-1 in GBM H2 cell line, which were found to regulate complement
activation (Junnikkala et al., 2000). We therefore investigated whether
primary GBM cells would express the same factor H family proteins and
if the endogenous product would inhibit or activate complement.
To our knowledge, this is the first study to show that primary GBM
cells (B30, B31 and B33), obtained directly from three different GBM
patients who underwent brain surgery, were found to secrete FHR5, but
not FH. We were able to detect the presence of FHR5 through western
blot as the polyclonal anti-FH antibody detected a band at 65 kDa,
which corresponds to FHR5. The primary anti-FH polyclonal antibody
used can detect FH family proteins as they all share high sequence
homology, especially FHR5, as it is the only FHR to share sequence
homology with CCP 10-14 of FH (Skerka et al., 2013). FH, FHL-1 and
CFHR1–4 were not detected in the culture supernatant of the three
primary GBM cells examined in this study. The secretion of FH family
proteins was also studied in the H2 cell line to compare the difference
between primary cells and a cell line. As expected, H2 cells were found
to secrete FH and FHL-1 as previously demonstrated by Junnikkala
et al. (2000). The difference in FH family expression between both cell
types, highlight the importance of studying primary cancer cells. The
absence of FH from primary GBM culture is of interest as it is known to
be the most abundant soluble complement inhibitor. We were able to
rule out the possibility of the detected protein being a cleaved product
of FH as the purification process only produced a single band at 65 kDa
for each primary GBM cell (Fig. 2) whereas a cleaved product would
show up as having more than one band. Since the purified protein
continued to run at 65 kDa on SDS-PAGE under non-reducing condi-
tions, it became evident that the isolated protein was not C4BP
(Fig. 2B).
Protein production of FHR5 was supported by an ELISA, which
demonstrated that over a 48-h growth period, the concentration of
FHR5 gradually increased: with more primary GBM cells present, the
greater the quantity of FHR5 secreted. The significant increase in FHR5
secretion over 48 h as well as the lack of FH suggested FHR5 may have a
role in the control of complement activation in tumour cells. A previous
study by Gasque et al demonstrated that certain glioma cells express FH
mRNA; however, its role in complement resistance was not studied
(Gasque et al., 1992). They had also shown that an oligodendrocyte cell
line (HOG) was able to secrete FH upon IFN-α cytokine stimulation.
However, in our study, we observed that primary GBM B30, B31 and
B33 produced FHR5 without the addition of cytokines. As FHR5 has a
high sequence homology with FH, we wanted to establish whether it
was functionally active and could potentially inhibit activation of the
complement alternative pathway.
We have demonstrated, via in vitro assays, that purified FHR5 from
primary GBM cells is biologically active and our study support a func-
tion of FHR5 as a down-regulator of complement. The functional ac-
tivity was assessed using various techniques including the haemolytic
assay. The assay revealed that all three primary GBM-FHR5 exhibited
dose-dependent inhibition of sheep erythrocyte lysis (Fig. 4). It is likely
Fig. 3. FHR5 secreted by primary GBM cells. 0.2 × 10 (Liu et al., 2012) pri-
mary GBM cells B30, B31 and B33 were grown in the absence of fetal calf serum
for 6 h, 12 h, 24 h and 48 h. The culture supernatants were coated onto mi-
crotitre plates in 0.05 M carbonate bi-carbonate buffer, wells were blocked with
2% BSA and probed with polyclonal anti-FH (10 μg IgG/mL) and anti-rabbit
IgG-HRP (5 μg/mL) antibodies. FH (100 ug/mL) and 2% w/v BSA were coated
on plates as controls. The experiments were carried out in triplicates. Data were
analysed between the mean A450 for culture supernatants and the mean A450
for 2% BSA. *P < 0.05, error bars represent standard deviation.
Fig. 4. Inhibition of haemolysis by FHR5. The volume 20 μL of FH family de-
pleted serum capable of giving 50% haemolysis was mixed with DGVB-Mg-
EGTA, sheep erythrocytes and varying concentrations of FHR5 or FH
(0.2–4 μM). Haemolysis observed is displayed as percentage of the lysis of FH
family depleted serum without additions. The experiments were carried out in
triplicates. Error bars represent standard deviation.
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that the implication of FHR5 inhibiting complement activity is to pro-
mote tumour survival as tumour cells readily exploit many strategies to
overcome immune attack (Jurianz et al., 1999).
Since GBM-FHR5 down-regulated complement lysis of sheep ery-
throcytes, we wanted to investigate the mechanism through which this
inhibitory effect was brought about. Co-factor activity of recombinant
FHR5 has been reported (McRae et al., 2005). Therefore, we wanted to
study whether this activity was present in GBM-FHR5. GBM-FHR5 was
able to act as a co- factor for factor I mediated cleavage of C3b (Fig. 5).
It was clear from SDS-PAGE analysis that the presence of FHR5 had
enabled factor I to cleave C3b into inactive iC3b fragments of 68 and
43 kDa. This demonstrated that co-factor activity is a mechanism by
which primary GBM-FHR5 can inhibit complement activation.
Human FH displays decay accelerating activity as a mechanism to
inhibit activation of the alternative pathway (Brandstatter et al., 2012).
We therefore examined the ability of GBM-FHR5 to decay C3 con-
vertase. The inverse correlation depicted on the graph between FHR5
concentration and intact C3 convertase showed that FHR5 was able to
decay C3 convertase dose dependently although the activity was less
than that of FH (Fig. 6). This was interesting as McRae et al. (2005)
were unable to demonstrate recombinant FHR5 decay acceleration ac-
tivity using the solid phase assay; however, primary GBM-FHR5 were
able to show decay acceleration using this assay (McRae et al., 2005).
It is interesting that GBM FHR5 downregulates activation of com-
plement lysis, acts as a co-factor for factor I mediated cleavage of C3b
and accelerates the decay of C3 convertase as these functions had been
attributed to CCPs 1–4 of FH. FHR5 does not share homology with FH
CCP 1-4 which suggests these biological activities may also be asso-
ciated with CCPs 10–14 or 19–20 of FH as these CCPs share high se-
quence homology with FHR5.
In summary, our study shows that primary GBM cells B30, B31 and
B33 secrete FHR5, which share biological function with human FH.
Primary GBM-FHR5 is biologically active and can inhibit complement
activation, act as a cofactor for factor I mediated cleavage and degrade
C3 convertase in-vitro. These findings warrant additional studies to
evaluate the relevance in in-vivo immune surveillance. The elucidation
of FHR5 functional activity would potentially help to design efficient
complement mediated immunotherapies against GBM.
Fig. 5. GBM-FHR5 has factor I-cofactor activity. Varying doses between 0.2–4 μM of GBM-FHR5 were incubated with 3 μg of C3b, 45 ng of Factor I in 10 mM sodium
phosphate (pH 6.0) for 10 min at 37 °C. Reactions without GBM-FHR5 or FH and were included as controls. Cleavage of C3b was analysed by SDS-PAGE using
Coomassie blue staining.
Fig. 6. FHR5 promotes decay acceleration activity on C3 convertase. C3 con-
vertase was generated in microtiter plates with 250 ng of C3b, 400 ng of factor
B, 25 ng of factor D, 2 mM nickel chloride, 25 mM NaCl and 4% BSA for 2 h at
37 °C. Varying concentrations of FHR5 (0.2–4 μM) were added and incubated
for 30 min at 37 °C. FH and samples without FH and FHR5 were included as
controls. Intact C3 convertase was detected by goat anti-human factor B and
rabbit anti-goat IgG-HRP antibody. The colour was developed with o-
Phenylenediamine. The experiment was repeated in triplicates. Error bars re-
present standard deviation.
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The complement system is an ancient innate immune defense mechanism that can
recognize molecular patterns on the invading pathogens. Factor H, as an inhibitor of
the alternative pathway, down-regulates complement activation on the host cell surface.
Locally synthesized factor H at the site of infection/injury, including lungs, can act as a
pattern recognition molecule without involving complement activation. Here, we report
that factor H, a sialic acid binder, interacts with influenza A virus (IAV) and modulates IAV
entry, as evident from down-regulation of matrix protein 1 (M1) in H1N1 subtype-infected
cells and up-regulation of M1 expression in H3N2-infected A549 cells. Far-western
blot revealed that factor H binds hemagglutinin (HA, ∼70 kDa), neuraminidase (NA,
∼60 kDa), and M1 (∼25 kDa). IAV-induced transcriptional levels of IFN-α, TNF-α,
IL-12, IL-6, IFN-α, and RANTES were reduced following factor H treatment for the
H1N1 subtype at 6 h post-infection. However, for the H3N2 subtype, mRNA levels of
these pro-inflammatory cytokines were enhanced. A recombinant form of vaccinia virus
complement control protein (VCP), which like factor H, contains CCP modules and has
complement-regulatory activity, mirrored the results obtained with factor H. Both factor
H (25%), and VCP (45%) were found to reduce luciferase reporter activity in MDCK cells
transduced with H1N1 pseudotyped lentiviral particles. Factor H (50%) and VCP (30%)
enhanced the luciferase reporter activity for H3N2, suggesting an entry inhibitory role of
factor H and VCP against H1N1, but not H3N2. Thus, factor H canmodulate IAV infection
and inflammatory responses, independent of its complement-related functions.
Keywords: innate immunity, complement, factor H, vaccinia virus complement control protein, influenza A virus,
pseudotyped lentiviral particles, cytokine storm
INTRODUCTION
Influenza A virus (IAV) is a severe respiratory pathogens, belonging to the Orthomyxoviridae
family and responsible for outbreaks with high morbidity, and mortality in both humans
and animals (1). IAV exhibits antigenic variations within viral surface glycoproteins, including
hemagglutinin (HA), and neuraminidase (NA) (2). HA is the most important viral glycoprotein
that can bind to sialic acid on host cells, enabling cellular fusion and viral entry (3). HA
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epitopes are also known to trigger synthesis of neutralizing
antibodies by B cells, allowing IAV to escape from immune
surveillance, leading to seasonal epidemics (4). NA cleaves sialic
acid moieties, which enables release of virions, and promotes IAV
dispersion (5). There are around 16 antigenic variants of HA
and 9 of NA, which are found in numerous combinations and
subtypes (2, 6). Among all subtypes of IAV, H1N1 and H3N2
are the predominant IAV subtypes for seasonal flu in humans,
with annual epidemics estimated to result in ∼5 million cases of
severe illness and half a million respiratory deaths (7). Current
circulating human IAV strains are likely to continue acquiring
mutations resulting in antigenic drift and shift of HA and NA
glycoproteins (8, 9), which enhance the virus’ ability to evade host
immune system, promoting rapid viral invasion and replication.
Airway and alveolar epithelial cells are the primary targets
for IAV, which uses sialic acid as receptors, causing damage
to the alveolar epithelium (10, 11). Individuals infected with
IAV may become susceptible to acute respiratory distress
syndrome (ARDS) (12, 13). Lung epithelial cells express mucin
glycoproteins, such as MUC5AC, MUC5B, and MUC1, which
play an important role in restricting IAV infectivity (14–16).
These mucins are rich in sialic acid, serve as viral receptors,
and restrict viral binding to the target cells (16–18). However,
NA can attenuate the biological activity of these mucins (18,
19). The D151G mutation is a well-known mutation in NA
glycoprotein, which is responsible for its interaction with human
α2-6 and avian α2-3 linked sialic acid, mediating the H3N2 viral
association with sialic acid receptors. However, this mutation is
reported to reduce the enzymatic action of NA that is required
for HA detachment from its receptors (19, 20). Early defense
against invading IAV by the innate immune system is crucial
in limiting viral replication and invasion. The complement
system, a major humoral wing of innate immunity, offers a
crucial protective mechanism against IAV infection (21). This
includes neutralization, aggregation, opsonization and lysis of
viral particles, and induction of phagocytosis via complement
receptors (22, 23). A number of in vitro and in vivo studies have
established the protective role of the complement system against
IAV (24–27).
In the alternative pathway of the complement system, factor H
is an important negative regulator that interacts with negatively
charged surfaces containing sialic acids and glycosaminoglycans,
and protects cellular structures from C3 convertase formation,
hence diminishing complement activation. Factor H is a
soluble, 155 kDa glycoprotein present at a concentration of
128–654µg/ml in human plasma (28). It is composed of 20
complement control protein (CCP) modules with different
ligand binding properties. There is plenty of evidence of the
local extrahepatic synthesis of factor H [reviewed in (30)].
Factor H binds to many pathogens via charge interactions
(29), and for pathogens, surface-bound factor H may be of
benefit for their survival. Factor H binds to sialic acids on
Neisseria gonorrhoeae (30) and the outer surface of OspE of
Borrelia burgdorferi, providing complement resistance to these
pathogenic microbes. Its interaction with soluble West Nile
virus NS1 protein has also been described (31). Furthermore,
Plasmodium falciparum binds factor H and factor H-like protein
1 (FHL-1) to prevent complement-mediated lysis in themosquito
midgut via the plasmodial transmembrane gliding-associated
protein 50 (GAP50) (32). Factor H can also bind to the surface
of mycobacteria, restrict their uptake by macrophages, and
modulate pro-inflammatory cytokine responses (33).
Viruses employ diverse strategies to protect their viral
lipid envelopes from complement lysis by encoding or
recruiting complement inhibitors, with structural and functional
similarities to complement control proteins (CCP). Vaccinia
virus complement control protein (VCP) is a well-known
complement inhibitor, secreted by vaccinia virus infected
cells. VCP has inhibitory activity for both classical and
alternative pathways (34). Further examples of viral regulation of
complement includes binding of West Nile virus non-structural
protein (NS1) to factor H, or association of Nipah virions with
factor I, thus restricting complement activation (31, 35). In
addition, NS1 serves as a key inhibitor of innate immunity
as it blocks the synthesis and signaling of type 1 interferons
(IFNs) (36). NS1 also induces apoptosis in human airway
epithelial cells during IAV infection via caspase-dependent
mechanisms (37).
Since factor H can bind to sialic acids, a natural ligand for
IAV, it is of interest to examine potential influence of factor
H in competitively inhibiting IAV interaction with host cell
surfaces. This study was designed to investigate the complement
independent functions of factor H in the regulation of IAV
infection in vitro. Here, we report the ability of human factor H
and recombinant VCP to act as entry inhibitors of IAV.
MATERIALS AND METHODS
Viruses and Reagents
The IAV subtypes used in this study, including the pH1N1
(A/England/2009) and H3N2 (A/HK/1999), were provided
by Wendy Barclay (Imperial College, London) and Leo
Poon (University of Hong Kong), respectively. The plasmids
used for the production of H1N1 and H3N2 pseudo-typed
viral particles were obtained from Addgene; pHIV-Luciferase
(Addgene plasmid #21375); psPAX2 (Addgene plasmid #
12260); and Vesicular Stomatitis Virus (VSV-G) (Addgene
plasmid #8454). pcDNA3.1-swineH1-flag (H1 from swine
H1N1 A/California/04/09) (Invitrogen), pcDNA3.1-swine N1-
flag (N1 from swine H1N1 A/California/04/09), and pCDNA
H3 (from A/Denmark/70/03 (H3N2) (Invitrogen) were obtained
commercially. pI.18-N2 [N2 from A/Texas/50/2012/(H3N2)]
plasmid was a gift from Nigel Temperton (University of
Kent). Anti-influenza antibodies used were obtained from BEI
Resources, NIAID, NIH, USA, and used as previously described
(38); these include polyclonal anti-influenza Virus H3 HA,
A/Hong Kong/1/1968 and monoclonal anti-influenza virus H1
HA, A/California /04/2009.
Purification of Human Complement
Factor H
Complement factor H was purified from human plasma, as
described previously (39), using an affinity column made up of
a monoclonal antibody against human factor H (MRCOX23)
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coupled to CNBr-activated Sepharose (GE healthcare, UK).
Freshly thawed human plasma (Fisher Scientific) was adjusted
to 5mM EDTA, pH 8, and dialyzed overnight against Buffer
I (25mM Tris-HCL, 140mM NaCl, and 0.5mM EDTA, pH
7.5). MRCOX23 Sepharose column was washed with three bed
volumes of buffer I, and dialyzed plasma was passed through
the column. The column was then washed again with the same
buffer and factor H was eluted using 3M MgCl2, pH 6.8. The
eluted fractions were dialyzed against H2O overnight, followed
by 10mM potassium phosphate pH 7.4. The samples were then
analyzed for purity by 12% v/v SDS-PAGE.
Purification of Recombinant Vaccinia Virus
Complement Control Protein Expressed in
HEK293 Cell Line
The VCP gene (accession X13166.1) was codon-optimized
for expression in human embryonic kidney (HEK) cells
by GeneArt R© using GeneOptimizer R© (Geneart GmbH,
Regensburg). For lentiviral expression, amplified VCP cDNA
was ligated into the pLenti6/V5-D-TOPO vector, using the
ViraPower Lentiviral Directional TOPO Expression kit,
according to the manufacturer’s instructions (K4950-00
Invitrogen Corp, Carlsbad CA). Following transformation into
DH5α chemically competent E. coli cells, a number of colonies
were analyzed for correct insertion and orientation using colony
PCR. Transient transfection of the plasmid pLenti6/V5/VCP
in HeLa cells and indirect immunofluorescence using anti-V5
antibody (Invitrogen # R960-25) was performed to verify the
VCP expression. Replication-incompetent lentiviral stock was
made by co-transfection with the ViraPowerTM Packaging Mix
(pLP1, pLP2, and pLP/VSVG: K4975-00, Invitrogen Corp) in
HEK 293FT cells (ATCC CRL-1573) cells using Lipofectamine
2000 R© reagent (Life Technologies Inc.), according to the
manufacturer’s instructions. Forty-eight hours after co-
transfection, viral supernatant was collected, concentrated by
centrifugation, and the titer was determined using standard
procedures. A number of stable HEK 293FT cell lines expressing
VCP were generated under neomycin selection (0.5 g/L) and
screened for VCP expression by Western blot analysis. Three
clones of HEK-293 cells secreting high levels of the VCP were
selected and cultured. Secreted VCP was purified using a heparin
column. Column-bound proteins were eluted with a linear salt
gradient (0–0.5M NaCl). Fractions were collected and analyzed
via SDS-PAGE and western blotting.
Cell Culture and Treatments
Madin Darby Canine Kidney (MDCK) and Adenocarcinomic
human alveolar basal epithelial cells (A549) cells (ATCC,
Rockville, MD, USA) were cultured in complete DMEM media,
supplemented with 10% v/v fetal calf serum, 2mM L-glutamine,
and penicillin (100 U/ml)/streptomycin (100µg/ml) (Thermo
Fisher), at 37◦C under 5% v/v CO2, with fresh complete medium
added every 2–3 days until 80% confluence was reached. Cell lines
used in this study were subjected to a maximum of 7 passages for
in vitro experiments.
Production of IAV Subtypes and
Pseudotyped Viral Particles, and TCID50
(Median Tissue Culture Infectious Dose)
Assay
50,000 MDCK cells at 80% confluency were infected either
with pH1N1 (2 × 104) or H3N2 (3.3 × 104) particles
and incubated in complete DMEM medium at 37◦C for
1 h. Unbound viral particles were removed and replaced
with infection medium, composed of DMEM with 0.3%
bovine serum albumin (BSA), 1% penicillin/streptomycin, and
1µg/ml of l-1-tosylamido-2-phenylethyl chloromethyl ketone
(TPCK)— Trypsin (Sigma –Aldrich), and incubated for 3 days
under culture conditions, as mentioned above. Post infection,
supernatant was subjected to ultra-centrifugation (25,000 ×
g) for 90min at 4◦C. Purified viral particles were then re-
suspended in PBS, and purity of the virus was analyzed by
SDS-PAGE and western blotting. Production of pseudotyped
particles was carried out, as described earlier (38). Briefly,
HEK293T cells were co-transfected with 20µg of respective IAV
pCDNAs, including pcDNA3.1-swineH1-flag (H1 from swine
H1N1 A/California/04/09) (Invitrogen), pcDNA3.1-swine N1-
flag (N1 from swine H1N1 A/California/04/09) (Invitrogen),
pcDNA-H3 [H3 from A/Denmark/70/03/(H3N2)], pI.18-N2
[N2 from A/Texas/50/2012/(H3N2)], pHIV-Luciferase backbone
(Addgene), and psPAX2 (Addgene). VSV-G was generated
similarly, without H1N1 and H3N2 pcDNAs. The released
H1N1, H3N2, and VSV-G pseudotyped lentiviral particles were
harvested in the supernatant at 48 h. Harvested supernatant was
centrifuged at 5,000 × g for 20min, and the clear supernatant
without any debris was concentrated using ultra centrifugation
(25,000× g) for 90min. The ultra-centrifuged lentiviral particles
were re-suspended in sterile PBS and analyzed via TCID50,
western blotting and luciferase activity assay. TCID50 assay
was carried out to determine the viral titer and cytopathic
effects of infected cells (40). Briefly, MDCK cells (1 × 105)
were infected with either purified pH1N1 and H3N2 viral
parties or pseudotyped lentiviral particles, incubated at 37◦C
for 3 days under 5% v/v CO2, until a cytopathic effect was
observed in terms of structural changes in MDCK cells caused
by viral invasion.
Hemagglutination Inhibition Assay
In a 96 microtiter well plate, 25 µl of PBS was added to each well.
In the first column, a starting concentration (total volume 50 µl)
of 20 µg of factor H was serially diluted (25 µl) to achieve final
quantities of 20, 10, 5, and 2.5 µg of factor H per well. Twenty-
five microliters of respective IAV subtype particles were added to
wells, except for PBS control wells, at the dilutions corresponding
to their respective HA titer to initiate hemagglutination. Plates
were gently mixed and incubated at 37◦C for 1 h. Fifty microliter
of 0.75% v/v guinea pig RBCs was added to each well; plates
were gently mixed and incubated at room temperature for 1 h.
Inhibition of hemagglutination appeared as a halo or circle of
settled cells in the center of round-bottomed wells. Absence
of inhibition was observed as a uniform red color across the
well (hemagglutination).
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ELISA to Detect Interaction of Factor H
and VCP With IAV Subtypes
Factor H or VCP (5, 2.5, 1.25, and 0.625 µg/well in 100
µl volume) were coated onto 96-well microtiter plates using
carbonate-bicarbonate buffer (CBC), pH 9.6, and incubated at
4◦C overnight. After washing the microtiter wells with PBS, the
wells were blocked with 2% w/v BSA in PBS and incubated
at 37◦C for 2 h, followed by three PBST (PBS + 0.05% v/v
Tween 20) washes. Twenty microliters of H1N1 or H3N2 virus
(1.36 × 106 pfu/ml) in PBS were added to each well and
incubated at 37◦C for 2 h in the presence of 5mM CaCl2.
VSV-G pseudotyped lentivirus was used as a negative control.
Following PBST washes, the corresponding wells were incubated
with primary antibodies (100 µl/well): polyclonal anti-influenza
virus H3 and monoclonal anti-influenza virus H1 (1:5,000) (BEI-
Resources). The wells were again washed with PBST three times
and probed with Protein A-HRP-conjugate, or goat anti-mouse
IgG-horseradish peroxidase (HRP)-conjugate (1:5,000) (Fisher
Scientific), followed by incubation at 37◦C for 1 h. Color was
developed using 3,3′, 5,5′-tetramethylbenzidine (TMB) substrate
(Sigma-Aldrich), and reaction was stopped using 1M H2SO4,
followed by measuring absorbance at 450 nm, using iMarkTM
microplate absorbance reader (Bio-Rad).
Cell Binding Assay to Detect IAV
Interference With Factor H and VCP
A549 cells (1 × 105 cells/well) were seeded in 96 microtiter
wells and incubated at 37◦C overnight in 5% v/v CO2. Once
80% confluency was reached, the cells were washed twice with
sterile PBS. Factor H or VCP (10, 5, 2.5, 1.25µg/ml), pre-
incubated with H1N1 and H3N2 (1.36 × 106 pfu/ml) IAV
subtypes, were added to the wells (in 5mMCaCl2) and incubated
at room temperature for 2 h. BSA was used as a negative control.
Following washes with PBS three times, the corresponding wells
were fixed with 4% v/v paraformaldehyde (Fisher Scientific) for
5min at room temperature. The wells were then blocked with 2%
w/v BSA for 2 h at 37◦C. Polyclonal anti-influenza virus H3 (BEI-
Resources) and monoclonal anti-influenza H1 (BEI-Resources)
were added to the appropriate wells and incubated at 37◦C
for 1 h. After gentle washes with PBSST, the wells were probed
with protein A-HRP conjugate or goat anti-mouse IgG-HRP-
conjugate (Thermo-Fisher) diluted in PBS in 1:5,000 dilution and
incubated at 37◦C for 1 h. The wells were washed again with
PBST; the color was developed by adding TMB substrate and the
reaction was stopped by using 1M H2SO4. The absorbance was
read at 450 nm using an ELISA plate reader.
Far-Western Blotting
Purified H1N1/H3N2 (1.36 × 106 pfu/ml) virus particles were
run on a 12% (w/v) SDS-PAGE, and transferred onto a PVDF
membrane for 2 h at 320mA in transfer buffer (25mM Tris–
HCl, pH 7.5, 20% v/vmethanol, and 190mMglycine).Membrane
was blocked with PBS+5% w/v BSA (Sigma-Aldrich) at room
temperature, followed by PBST washes. The membrane was then
incubated with 10µg/ml of factor H or VCP overnight at 4◦C,
and probed appropriately with either monoclonal mouse anti-
human factor H (MRCOX23) (MRC Immunochemistry Unit,
Oxford) (1 mg/ml) or rabbit anti-VCP polyclonal antibody (0.5
mg/ml) (King Faisal Specialist Hospital and Research Center,
Saudi Arabia) at room temperature for 1 h. Following PBST
washes (three times, 10min each), the membrane was incubated
with secondary antibody, rabbit anti-mouse IgG HRP conjugate
(1:1,000) (Sigma-Aldrich) or Protein A-HRP-conjugate for 1 h
at room temperature. The secondary antibody was removed,
followed by PBST washes; then the membrane was developed
using 3,3′-diaminobenzidine (DAB).
Infection Assay for Extracting RNA
A549 (5 × 105/well) cells were cultured in complete DMEM
and grown overnight at 37◦C in a CO2 incubator. Once 85%
cell confluency was reached, the cells were washed gently with
fresh PBS and replaced with DMEMwithout FBS. Forty µg/ml of
factor H or VCP was added to corresponding wells, with a MOI
= 1:1 of pH1N1, and H3N2 or pseudotyped viral particles (333
µl/ml) at room temperature for 1 h and at 4◦C for another hour.
The unbound virus and protein were removed by pipetting out
the supernatant. The cells were washed gently again with PBS,
and placed in 1ml of infection medium to initiate viral infection
of the host cells being incubated for 2 and 6 h. After removing
the supernatant, the infected cells were washed with PBS and
detached using 2 × Trypsin-EDTA (0.5%) (Fisher Scientific),
centrifuged at 1,500 x g for 5min, and the cell pellet was frozen at
−80◦C for RNA extraction.
Quantitative RT-PCR Analysis
The virus infected cell pellets were lysed using lysis buffer (50mM
Tris–HCl, pH 7.5, 200mM NaCl, 5mM EDTA pH 8, 0.1% v/v
Triton X-100). GenElute Mammalian Total RNA Purification Kit
(Sigma-Aldrich) was used to extract the total RNA, as per the
manufacturer’s instructions. Once RNA was extracted, DNase I
(Sigma-Aldrich) treatment was performed to remove any DNA
contaminants, followed by quantifying the amount of RNA
at A260 nm using a NanoDrop 2000/2000c (Fisher-Scientific).
The purity of RNA was assessed using the ratio A260/A280.
Two micrograms of total RNA was used to synthesize cDNA,
using High Capacity RNA to cDNA Kit (Applied Biosystems)
and cDNA conversion was performed. The primer BLAST
software (Basic Local Alignment Search Tool) was used to design
primer sequences as listed in Table 1. The qRT-PCR assay was
performed using the StepOne Plus system (Applied Biosciences).
Each qPCR reaction was conducted in triplicates, containing
75 nM of forward and reverse primers, 5 µl Power SYBR
Green MasterMix (Applied Biosystems), and 500 ng of cDNA.
qPCR samples were run for 50◦C and 95◦C for 2 and 10min,
followed by running the amplification template for 40 cycles,
each cycle involving 15 s at 95◦C and 1min at 60◦C. Eighteen
seconds RNA was used as an endogenous control to normalize
the gene expression.
Statistical Analysis
The graphs were generated using the GraphPad Prism 6.0
software, A one-way ANOVA test was carried out for statistical
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significance. Significant values were considered based on ∗p <
0.05, ∗∗p< 0.01, and ∗∗∗p< 0.001, between treated and untreated
conditions. Error bars show the SD or SEM, as indicated in the
figure legends.
RESULTS
Factor H Inhibits Hemagglutination of
Guinea Pig Red Blood Cells by IAV
Factor H was purified from human plasma, using monoclonal
MRCOX23 Sepharose affinity column (39). The purity of the
eluted protein was confirmed by SDS-PAGE; the molecular
weight of factor H was evident at ∼155 kDa (Figure 1A).
Recombinant VCP appeared pure and migrated at ∼35 kDa
(Figure 1B). Guinea pig RBCs were used to determine if addition
TABLE 1 | Primers used for target genes in qPCR.

























IFN-α 5′-TTT CTC CTG CCT GAA GGA
CAG-3′
5′-GCT CAT GAT TTC TGC TCT
GAC A-3′
of factor H would inhibit hemagglutination by IAV subtypes
(Figure 2). Five IAV strains of H3N2 or H1N1 subtypes were
tested. The basic principle of this assay relies on the specific
feature of envelope viral glycoproteins that can interact with
sialic acid on RBCs. In the absence of viral particles, RBCs
sedimented under gravity, forming a distinct red halo at the
bottom of the microtiter well (Figure 2). However, in the
presence of viral particles, glycoproteins of virus (HA or NA in
this case) interact and bind with sialic acid on RBCs, forming
clumps, leading to a lattice formation, where RBCs remain in
suspension. Factor H partially inhibited the hemagglutination
of IAV strains. Low concentration of factor H (2.5µg/ml)
was more potent in inhibiting hemagglutination of H1N1 than
H3N2 strains. Hemagglutination of all strains was effective using
10µg/ml of factor H. It is possible that factor H binds to
the IAV particles, restricting the binding of virus to RBCs,
allowing them to form a halo at the bottom of the wells. PBS
alone, in the absence of IAV particles, led to the formation
of a halo at the bottom of the microtiter well, suggesting
no hemagglutination.
Factor H and VCP Bind IAV Envelope
Glycoproteins
Since factor H was able to inhibit hemagglutination by H1N1
and H3N2 IAV subtypes, a direct ELISA was set up with factor
H -coated plates to establish possible interaction with IAV
viruses (Figure 3). We also examined, for the first time, the
likely interaction between IAV and VCP, which contains CCP
modules (4) like human factor H. A/England/2009 (H1N1) and
A/Hong Kong/1999 (H3N2) strains were used in this study. A
comparable dose-dependent binding by factor H and VCP was
evident with H1N1 (Figure 3A) and H3N2 (Figure 3B) subtypes.
VSV-G pseudotyped lentivirus was used as a negative control,
FIGURE 1 | 12% (w/v) SDS-PAGE analysis of complement factor H purified from human plasma (A), and a recombinant form of vaccinia virus complement control
protein (VCP) expressed in HEK 293FT cells (B). The purified protein was run under reducing conditions: Factor H appears as ∼155 kDa band, and VCP was
observed at ∼35 kDa.
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FIGURE 2 | Hemagglutination assay. Inhibition of hemagglutination by purified
human factor H was tested on human IAV subtypes. Guinea pig red blood
cells were incubated with either PBS or IAV subtypes with and without various
concentrations of factor H (20, 10, 5, and 2.5 µg).
which did not show any binding with either factor H or VCP.
The ability of factor H and VCP to interfere with IAV binding to
A549 cells was then assessed via the cell binding assay (Figure 4).
An increase of IAV binding in presence of factor H and VCP was
seen at the concentration of 10µg/ml for both H1N1 and H3N2
IAV subtypes, and the binding occurred in a dose and calcium
dependent manner (Figure 4), suggesting that factor H and VCP
enhance binding of IAV to target cells, which in turn interferes
with viral infection in a complement-independent manner. The
binding of factor H and VCP was more effective in the case
of H1N1 than H3N2. We then set up a far western blot to
identify viral particles binding to factor H and VCP (Figure 5).
In this assay, virus subtypes (H1N1 and H3N2) separated on
SDS-PAGE were transferred to a nitrocellulose membrane and
were probed with either 10µg/ml factor H or VCP. The far
western blot also revealed the binding of factor H and VCP to
HA (∼70 kDa), and M1 (∼25 kDa) of both H1N1 and H3N2
IAV subtypes (Figure 5). Furthermore, factor H also bound to
FIGURE 3 | Binding between factor H or VCP with H1N1 (A), and H3N2 (B)
IAV subtypes were determined via ELISA. Microtiter wells were coated with
various concentrations of factor H, VCP or VSV-G (0.625, 1.25, 2.5, and 5
µg/well) in carbonate bicarbonate buffer, pH 9.6 overnight at 4◦C. H1N1 or
H3N2 virus (1.36 × 106 pfu/ml) was added to each well in the presence of
5mM CaCl2 and probed with either monoclonal anti-influenza virus H1 or
polyclonal anti-influenza virus H3 antibody. VSV-G pseudotyped particles were
used as a negative RNA virus control. The data were expressed as mean of
three independent experiments done in triplicates ± SEM.
NA (∼55 kDa) of H3N2 strain more strongly compared to
H1N1 strain.
Modulation of IAV Infectivity by Factor H
and VCP in A549 Cells
In view of factor H and VCP binding to key IAV proteins, an
infection assay was set up to assess the impact of this interaction
on viral infectivity and replication by factor H and VCP.
A549 lung epithelial cells, infected with H1N1 and H3N2 with
and without factor H or VCP (40µg/ml), showed differential
expression of M1 mRNA levels at 2 and 6 h post-infection
(Figure 6). In the case of H1N1, both factor H and VCP led to
the down-regulation (−4 log10) of viral M1 transcription at 6 h.
However, an up-regulation was seen with H3N2 (2log10) subtype
following factor H and VCP treatment, suggesting that the
inhibitory effect by these proteins is strain specific (Figure 6A).
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FIGURE 4 | Cell-binding assay to show binding of factor H (A) and VCP (B) to A549 cells challenged with H1N1 and H3N2. A549 cells (1 × 105 cells/ml) were
seeded in a 96-well microtiter plate and incubated at 37◦C overnight. Decreasing concentrations of factor H and VCP (10, 5, 2.5, and 1.25 µg), pre-incubated with
IAV subtypes, were added to the corresponding wells, and incubated at room temperature for 1 h. After removing unbound protein and viral particles, the wells were
fixed with 4% v/v paraformaldehyde, and probed with monoclonal anti-influenza virus H1 or polyclonal anti-influenza virus H3 antibodies. BSA was used as a negative
control protein. Three independent experiments were carried out in triplicates and error bars expressed as ± SEM.
Factor H and VCP Trigger an
Anti-inflammatory Response in the Case of
H1N1
qPCR data revealed that factor H and VCP treatment resulted
in the modulation of both pro and anti-inflammatory responses
(Figures 6B,C). Following factor H treatment of IAV-challenged
A549 cells, the mRNA levels of TNF-α were down-regulated
at 2 h (−5log10) and 6 h (−8log10) in H1N1 infected cells
(Figure 6B). However, an opposite effect was seen with H3N2
infected cells; the expression level of TNF-α was up-regulated,
although not dramatically, at 2 h (3log10), as well as at 6 h
(3.5log10) (Figure 6B). In H1N1 challenged cells, the mRNA
levels of IL-6 (−3.5log10) and RANTES (−0.5log10) were also
down-regulated at 2 h time point in the presence of factor
H. Conversely, IL-6 (2.5log10) and RANTES (1.5log10) levels
were up-regulated in H3N2 challenged cells at 2 and 6 h (IL-
6/3log10) (RANTES/2.5log10) treatment with factor H. Factor H
also down-regulated IL-12 levels in H1N1 (1log10) subtype at
6 h, but enhanced in H3N2 challenged cells at both 2 and 6 h.
We also show here, for the first time, the effect of VCP, which
contains 4 CCP modules like human factor H, on IAV infection;
it mirrored the results obtained with factor H (Figure 6B). A
greater down-regulation of TNF-α (−5log10), IL-6 (−3.5log10)
and IL-12 (−1.5log10) levels were seen at 6 h following VCP
treatment when compared to untreated control (cells + H1N1)
(Figure 6B). VCP treated H1N1 challenged A549 cells showed a
reduced level of RANTES at 2 h (−0.7log10), which was raised
slightly at 6 h. In the case of H3N2, effects similar to factor H
were observed (Figure 6B). TNF-α, IL-6, IL-12, and RANTES
were increased at 6 h VCP treatment. Higher levels of pro-
inflammatory cytokines, including TNF-α, IL-6, and IFN-α have
been detected in IAV infected patients (41), and correlate with
severe infectivity. H1N1 infected patients have higher levels of IL-
6 in their lungs and serum (42, 43). Therefore, down-regulation
of IL-6 by both factor H and VCP in H1N1 infected A549
cells suggests a possible anti-inflammatory role of these two
proteins in a strain specific manner. In addition, the ability of
factor H (−2log10) and VCP (−2.5log10) to down-regulate type
1 IFN-α (Figure 6C) at 6 h was also seen in H1N1. However,
higher expression levels of IFN-α were detected in the case of
H3N2 in the presence of factor H (2 log10) and VCP (1.7 log10)
(Figure 6C).
Factor H and VCP Act as Entry Inhibitors of
H1N1 Viral Infection
In this study, lentiviral pseudotypes were generated to determine
cell entry strategies of H1N1 and H3N2 subtypes of IAV.
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FIGURE 5 | Far western blot analysis to show factor H (A) and VCP (B) binding with purified H1N1 and H3N2. IAV subtypes (1.36 × 106pfu/ ml) were first run on the
SDS-PAGE under reducing conditions and transferred onto a nitrocellulose membrane. The transferred membrane was then incubated with 10µg/ml of factor H or
VCP. The membrane was probed with either monoclonal mouse anti-human factor H or polyclonal rabbit anti-VCP antibody. Factor H and VCP bound to HA (∼70
kDa), NA (∼55 kDa), and M1 (∼25 kDa) in the case of both IAV subtypes. The identities of factor H and VCP bound IAV glycoproteins were validated using a separate
blot that was directly probed with monoclonal anti-HA (C), anti-NA (D), and anti-M1 (E) antibodies.
Production of lentiviral pseudotypes was carried out by co-
transfecting HEK293T cells with plasmid containing the coding
sequence of IAV glycoprotein combinations such as H1+N1
and H3+N2, pHIV-Luciferase backbone, and psPAX2 plasmids
via a calcium phosphate transfection method. Post transfection,
H1N1 and H3N2 pseudotyped particles were harvested at
48 h, purified, and analyzed via western blotting. The HA
expression level was detected using anti-H1 polyclonal antibody;
HA was evident around ∼70 kDa (Figure 7A). MDCK cells
were transduced with purified H1N1 and H3N2 pseudotyped
particles to measure the luciferase reporter activity, with and
without factor H or VCP (40µg/ml). Nearly 25% reduction
in the luciferase reporter activity was observed for factor H
compared to cells only, challenged with H1N1 pseudotyped
particles (Figure 7B). However, factor H enhanced the luciferase
activity by 50% in cells transduced with H3N2 pseudotyped
particles. In the case of VCP,∼45% reduction of luciferase activity
for cells transduced with H1N1-pseudotyped particles was noted,
whereas it caused ∼30% increase of luciferase activity in cells
transduced with H3N2 pseudotyped particles (Figure 7B). Thus,
factor H and VCP seem to act as entry inhibitors only in the
case of H1N1.
DISCUSSION
Pathogens have evolved a range of defense mechanisms to
overcome the immune response modifying their infectivity and
dissemination in the host (44, 45). The complement system, a
major arm of the innate immune system, consists of several
soluble factors and cell surface receptors that interact with and
react to invading pathogens. Some pathogens mimic and recruit
complement inhibitors, such as factor H and C4b binding protein
(C4BP) to escape complement (46–48).
Factor H is an abundant plasma protein, which has a
regulatory function in the homeostasis of the complement system
and in the protection of bystander host cells and tissues from
injury via the complement activation of the alternative pathway
(31). The most important point in the complement activation
is the regulation of C3 convertase, which is monitored by
factor H, a well-established sialic acid binder. A number of
bacteria can recruit factor H via the presentation of specific
binding proteins, including factor H binding proteins (fHbp)
of Neisseria meningitidis (49), CspA and outer surface protein
E of Borrelia burgdorferi (50, 51), staphylococcal binder of IgG
from Staphylococcus aureus (52), and pneumococcal surface
Frontiers in Immunology | www.frontiersin.org 8 March 2020 | Volume 11 | Article 355
Murugaiah et al. Complement Factor H-IAV Interaction
FIGURE 6 | Replication of IAV subtypes and inflammatory responses of A549 cells. (A) Following entry inhibition, replication of IAV subtypes (H1N1 and H3N2) is
affected by factor H and VCP in human A549 cells. M1 expression was monitored in A549 cells challenged with either H1N1 or H3N2 IAV subtypes (MOI 1) at
6 h. A549 cells were challenged with H1N1 and H3N2 pre-incubated with or without factor H and VCP (40µg/ml). Cell pellets were harvested at 6 h post-infection.
(Continued)
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FIGURE 6 | 18S rRNA was used as an endogenous control. Significance was determined using the unpaired one-way ANOVA test (**p < 0.01, and ***p < 0.001) (n
= 3). (B) Transcription expression profile of cytokines and chemokines produced by A549 in response to H1N1 and H3N2 challenge with and without factor H. 18S
rRNA expression was used as an endogenous control. Cells only was used as a calibrator sample to calculate relative quantitation (RQ); RQ = 2−11Ct. Experiments
were conducted in triplicates, and error bars represents ± SEM. Unpaired one-way ANOVA test was used calculate the significance (*p < 0.05, **p < 0.01, and ***p <
0.001) (n = 3). (UT, untreated sample; T, treated sample). (C) Expression levels of type I interferon alpha (IFN-α) following 6 h treatments with factor H and VCP. 18S
rRNA was used as an endogenous control. RQ = 2−11Ct was used to calculate the RQ value. Significance was determined using the unpaired one-way ANOVA test
(**p < 0.01) (n = 3).
FIGURE 7 | Factor H and VCP inhibit transduction of MDCK cells by H1N1-pseudotyped lentiviral particles. Western blotting to show expression of hemagglutinin
(HA) in purified H1N1 and H3N2 pseudotyped lentiviral particles (A). HA expression was evident at ∼70 kDa. Luciferase reporter activity of H1N1 and H3N2
pseudotyped lentiviral particles-transduced cells with factor H and VCP (B). Significance was determined using the unpaired one-way ANOVA test (**p < 0.01 and
***p < 0.001) (n = 3).
protein C of Streptococcus pneumoniae (53). The factor H ligands,
expressed by pathogens, are structurally distinct from each other,
but they share the related binding site on factor H that can
be localized on a common site of the CCP20 module (45).
These interactions increase the binding ability of CCP 19-20
modules to C3b, resulting in a stable complex between factor H,
C3b and microbial targets, with an enhanced co-factor activity.
Pseudomonas aeruginosa express sialic acid on their surfaces,
which reduces complement deposition via probable factor H
recruitment. Sialic acid also recruits siglec-7/9 leading to immune
escape (54). In addition, factor H binds to ApoE on High Density
Lipoprotein (HDL) via CCP 5-7 modules, and is used by the
bacteria to mimic the plasma HDL to increase their survival in
the blood (35).
Here, we investigated the complement-independent function
of factor H in the regulation of IAV infection. Since VCP is
an efficient complement inhibitor and a homolog of factor H
(34), we included it in the present study. VCP is a ∼35 kDa
secretory protein of vaccinia virus, encoded by the C3L open
reading frame (ORF), and contains four CCP modules (34). VCP
has been shown to inhibit complement lysis of sheep RBCs, by
binding to C3b and C4b (34), and serves as a cofactor in the
factor I-mediated cleavage of C3b and C4b (34). Additionally,
VCP has been shown to inhibit formation of C3 convertase
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and accelerate the decay of the alternative pathway (55). In the
present study, a direct and complement independent interaction
of factor H and VCP with H1N1 and H3N2 IAV subtypes
were examined via hemagglutination assay, ELISA, cell binding,
and far western blotting. In the hemagglutination assay, factor
H inhibited hemagglutination of both H1N1 and H3N2 IAV
subtypes; 10µg/ml being the most effective with H1N1 and
H3N2 subtypes.
VCP 4 modules contain a heparin binding site, as does factor
H (56). It is possible that in a manner similar to factor H
(57, 58), the heparin binding site found within the VCP protein
enhances its decay-accelerating action against C3 convertase.
SRBCs have high surface sialic acid. Factor H binds to this
and protects them from the complement alternative pathway.
On removal of the sialic acid with neuraminidase, SRBCs
become susceptible to complement lysis. However, other studies
suggest that the decay activity rate of VCP does not reduce
following neuraminidase-treatment of SRBCs (57, 58), indicating
a difference in reaction with sialic acids. Furthermore, a weaker
decay rate was seen with CCP 2–4 mutants of VCP. Factor
H and VCP seem to bind H1N1 and H3N2 via HA (∼70
kDa) and NA (∼55 kDa) in addition to recognizing M1. It is
well-known that the viral HA can bind to sialic acid residues
on surface glycoprotein and its receptor binding depends on
the nature of the glycosidic linkage (59). The binding of HA
to sialic acids, like factor H, is the initial event in the virus
association with human epithelial cells. In addition, the resulting
disruption of the neuraminic acid residues can enable the virus
to cross over the epithelial cells, thus entering new cells to initiate
viral replication.
The immune response of A549 cells following IAV challenge
in the presence and absence of factor H or VCP was examined
using qRT-PCR. The ability of factor H and VCP to modulate
viral replication, due to entry inhibition, was determined using
M1 mRNA expression levels between protein treated and un-
treated A549 cells challenged with H1N1 or H3N2 subtypes. Both
factor H and VCP modulated the IAV replication in a strain
dependent manner. In the case of H1N1, both factor H and VCP
showed reduced viral M1 expression; however, an increased M1
expression was seen for H3N2, suggesting that the inhibitory
effect of these proteins is strain-dependent. This suggests that
both factor H andVCP could act as entry inhibitors against H1N1
subtype, but not H3N2.
Several studies have demonstrated both direct and indirect
correlation between cytokine levels and viral replication (60,
61). IAV targets lung epithelial cells, and following initial
exposure, progeny viral particles proliferate to infect other
cells, including alveolar macrophages (62). Thus, an acute
inflammatory response is triggered by the activation of pro-
inflammatory cytokines and chemokines (62, 63), where higher
levels lead to a dramatic cytokine storm; altered levels of TNFs,
IFNs, interleukins and chemokines have been detected in IAV
infected patients (41). Over-synthesis of IFN levels during early
stages of IAV infection causes irreversible lung damage in
mice infected with H5N1; however, IFN signaling may also be
crucial in preventing H5N1 dissemination (64, 65). TNFs are
key soluble factors in the cytokine storm; H5N1 infected mice
deficient in TNF receptors, as well as H5N1 infected mice treated
with anti-TNF-α antibodies, show no change in survival rate
compared to healthy controls (66). Furthermore, IL-6 and IL-
1 are the crucial pro-inflammatory cytokines produced by the
host during influenza infection. Expression of IL-1 is detected
in the early stage of IAV infection, followed by an increased IL-
6 expression (67). H5N1 infected mice lacking in IL-6 receptor
have demonstrated a poor survival outcome, suggesting the
protective role of IL-6 pathway in the cytokine storm (67).
Therefore, an unbalanced cytokine storm can also lead to damage
in the vascular barrier, causing tissue oedema, capillary leakage,
failure of multiple organs, and death (67). However, no specific
singular mechanism is reported when it comes to triggering a
cytokine storm with respect to influenza strains.
In this study, alterations of cytokine levels were observed in
H1N1 and H3N2 challenged A549 cells in the presence of factor
H and VCP. Factor H treatment resulted in down-regulation of
TNF-α at 2 and 6 h in H1N1 infected cells. In the case of H3N2
infected cells, expression of TNF-α was up-regulated at 2 and 6 h
after treatment. ReducedmRNA levels of IL-6 and RANTES were
also seen at 2 h treatment with factor H, which slightly increased
at 6 h. Conversely, enhanced levels of IL-6 and RANTES were
observed in H3N2 infected cells following 2 and 6 h treatment
with factor H.
In the case of VCP, TNF-α IL-6, and IL-12 levels were
found to be down-regulated at 6 h treatment. H1N1 infected
cells treated with VCP also showed reduced levels of RANTES
at 2 h. H3N2 infected A549 cells following VCP treatment
revealed similar effects as factor H. Up-regulation of TNF-
α, IL-6, IL-12, and RANTES were observed at 6 h following
VCP treatment. Previous studies have reported enhanced serum
levels of pro-inflammatory cytokines, including TNF-α, IL-6, and
IFN-α in individuals infected with IAV (68). IL-6 and TNF-
α may be the key contributors to virus mediated respiratory
diseases, including Acute Respiratory Distress syndrome (ARDS)
and acute lung injury (69). During IAV infection, alveolar
macrophages are activated, which are the primary phagocytic
cells that produce robust amounts of IL-6 and TNF-α (70).
Macrophages infected with IAV have also been shown to produce
chemokines such as RANTES and monocytes chemotactic
protein-1 (MCP-1). This further recruits mononuclear cells to
the lungs and facilitates viral clearance (71), and enhances
production of those cytokines (e.g., TNF-α, IL-6, RANTES, and
IL-8) that are also implicated in the pathogenesis of influenza
virus. RANTES, IL-1β, IL-6, and TNF-α induced by influenza
result in pro-inflammatory Th1-type immune responses in the
infected host (71). Dysregulation of cytokine and chemokine
levels during influenza has been demonstrated to promote tissue
injury and impaired viral clearance. Additionally, suppression
of IFN-α was also evident with factor H and VCP in H1N1
challenged A549 cells. In the case of H3N2, both factor H and
VCP increased the expression of IFN-α, which may possibly
induce protection of A549 cells against H3N2 viral particles in
neighboring as well as non-infected cells. Thus, increased IFN-
α by factor H and VCP may also suggest that in the infected
A549 cells, factor H and VCP may cause digestion of viral RNA
and viral proteins. Down-regulation of IFN-α levels in H1N1
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infected cells may suggest the possibility of factor H and VCP
treatment to reduce the rate of viral replication. Thus, treatments
with factor H and VCP may elicit an anti-viral response,
restricting the activation of innate immune cells and associated
lung pathology.
Targeting viral entry into a host cell is an emerging approach
for developing anti-viral therapy as viral propagation can be
either restricted or blocked at an early stage of viral cycle,
minimizing drug resistance by released virions. In this study, we
have generated lentiviral pseudotypes, a safe surrogate model to
mimic the structure and surfaces of IAV in order to determine if
factor H and VCP act as an entry inhibitors in cells transduced
with pseudotyped IAV particles that are restricted to only one
replicative cycle. Factor H treatment resulted in 25% reduction
of luciferase reporter activity in MDCK cells transduced with
H1N1 pseudotyped particles. However, the addition of factor
H increased the luciferase activity by 50% in cells challenged
with H3N2 pseudotyped particles. VCP was found to reduce
luciferase reporter activity of H1N1 transduced MDCK cells by
45%. As is the case with factor H, VCP also enhanced the reporter
activity of MDCK cells transduced with H3N2 pseudotyped
lentiviral particles by 30%, suggesting the ability of factor H
and VCP to enhance viral infectivity through binding to cell
surface bound HA found on infected MDCK cells. Our results
are consistent with a previous study showing anti-viral activity
of Stachyflin, which was found to be resistant against H3N2 due
to differences in potential binding pockets for Stachyflin on HA
molecule (72).
In conclusion, data from restriction of M1 mRNA levels,
pro-inflammatory cytokine responses, and luciferase reporter
activity highlights the potential of factor H and VCP as cell
entry inhibitors against the H1N1 IAV subtype. It appears
that factor H and VCP restrict viral entry for H1N1, whilst
conversely promoting H3N2 entry, which may be due to the
inherent antigenic variations in binding sites for HA or NA.
Further studies are required to pinpoint the specific molecular
interactions of factor H and VCP against HA and NA by
investigating a range of IAV strains with antigenic variability.
This will not only provide further data on the pathogenesis of
IAV infection, but also the utility of factor H and VCP, and
their recombinant CCP modules, as possible cell entry inhibitors
against IAV.
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Human surfactant protein D (SP-D) belongs to the family of collectins that is composed
of a characteristic amino-terminal collagenous region and a carboxy-terminal C-type
lectin domain. Being present at the mucosal surfaces, SP-D acts as a potent innate
immune molecule and offers protection against non-self and altered self, such as
pathogens, allergens, and tumor. Here, we examined the effect of a recombinant
fragment of human SP-D (rfhSP-D) on a range of breast cancer lines. Breast cancer
has four molecular subtypes characterized by varied expressions of estrogen (ER),
progesterone (PR), and epidermal growth factor (EGF) receptors (HER2). The cell viability
of HER2-overexpressing (SKBR3) and triple-positive (BT474) breast cancer cell lines
[but not of a triple-negative cell line (BT20)] was reduced following rfhSP-D treatment
at 24 h. Upregulation of p21/p27 cell cycle inhibitors and p53 phosphorylation (Ser15)
in rfhSP-D-treated BT474 and SKBR3 cell lines signified G2/M cell cycle arrest. Cleaved
caspases 9 and 3 were detected in rfhSP-D-treated BT474 and SKBR3 cells, suggesting
an involvement of the intrinsic apoptosis pathway. However, rfhSP-D-induced apoptosis
was nullified in the presence of hyaluronic acid (HA) whose increased level in breast
tumor microenvironment is associated with malignant tumor progression and invasion.
rfhSP-D bound to solid-phase HA and promoted tumor cell proliferation. rfhSP-D-treated
SKBR3 cells in the presence of HA showed decreased transcriptional levels of p53
when compared to cells treated with rfhSP-D only. Thus, HA appears to negate the
anti-tumorigenic properties of rfhSP-D against HER2-overexpressing and triple-positive
breast cancer cells.
Keywords: innate immunity, surfactant protein D, immune surveillance, breast cancer, hyaluronic acid
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INTRODUCTION
The immune surveillance of transformed cells by innate and
adaptive immunity remains one of the targeted areas of
research for developing therapeutic strategies (1, 2). In vivo
and in vitro studies using cancer models have demonstrated
compelling involvement of effector immune cells, soluble factors,
and signaling pathways in anti-tumor immune responses.
However, the immune system can also aid in the progression
of transformed cells by triggering immunosuppression and
promoting angiogenesis and metastasis of tumor cells (3, 4).
Human surfactant protein D (SP-D) is a potent innate
immune molecule found at pulmonary and non-pulmonary
mucosal surfaces (5). It is a member of the collectin family that
is involved in the clearance of pathogens and apoptotic/necrotic
cells and in the modulation of inflammatory responses (6).
SP-D is composed of an N-terminal cysteine-rich domain, a
triple-helical collagenous region, an α-helical coiled neck region,
and a C-terminal C-type lectin or carbohydrate recognition
domain (CRD) (7). The trimeric CRDs recognize carbohydrate or
charged patterns on pathogens and allergens, while the collagen
region is involved in interactions with receptor molecules present
on immune cells in order to trigger clearance mechanisms such
as agglutination, enhanced phagocytosis, and oxidative burst (6).
SP-D is primarily synthesized and secreted into the airspace
of the lungs by alveolar type II and Clara cells, with a key
role in surfactant homeostasis by reducing surface tension (6).
However, its extrapulmonary existence is well-established now,
ranging from themucosa of the gastrointestinal and reproductive
tracts (including ovaries) and nasal cavity to the brain and in
various exocrine ducts (8, 9), conjunctiva, cornea, lacrimal gland,
nasolacrimal ducts (8), and synovial fluid (10). Protective effects
of SP-D against a range of pathogens (6, 11) and allergens (12–16)
are well-documented in the literature. However, recent studies
have raised the possibility that SP-D may have an important
defense role against tumor.
A direct interaction of SP-D with a number of cancer cells
(leukemia, lung, prostate, and pancreatic) has been reported to
result in the suppression of cancer progression, migration, and
invasion, as well as enhanced apoptosis (17–21). The rfhSP-D-
treated acute myeloid leukemia (AML) cells were shown to result
in cell cycle arrest via activation of G2/M checkpoints, with an
increased level of p21 and Try15 phosphorylation of cdc2. rfhSP-
D treatment in AML cells also caused activation of pro-apoptotic
markers, such as cleaved caspase 9 and downregulation of pro-
survival protein HMGA1 (21, 22). Exogenous SP-D treatment
has been shown to downregulate epidermal growth factor (EGF)
signaling by preventing the binding of EGF to the EGF receptor
(EGFR), hence suppressing the cell proliferation, invasion, and
migration of A549 human lung adenocarcinoma cells (23).
Recently, rfhSP-D has been shown to induce apoptosis in p53
mutant (mt) and wild-type (wt) pancreatic adenocarcinoma
(PDAC) cell lines (Panc-1p53 mt, MiaPaCa-2p53 mt, and Capan-
2p53wt), via the TNF/Fas-mediated extrinsic pathway (17).
Furthermore, rfhSP-D can also suppress epithelial–mesenchymal
transition (EMT) and related gene signatures (Vimentin, Zeb1,
and Snail) and cell invasiveness in Panc-1 andMiaPaCa-2 cells via
downregulation of TGF-β (24). In an ovarian cell line, SKOV3,
rfhSP-D again triggered apoptosis via the Fas-mediated pathway
(18). In both pancreatic and ovarian cancer cell lines, rfhSP-D
treatment caused activation of caspase 3 cleavage and induction
of pro-apoptotic genes such as Fas and TNF-α. Furthermore, the
mTOR pathway was also affected by rfhSP-D treatment in both
ovarian and pancreatic cancer cell lines. rfhSP-D-treated SKOV3
cells show downregulation of Rictor and Raptor mRNA levels,
suggesting inhibition of cell proliferation (17, 18). Additionally,
the anti-tumor role of rfhSP-D has been reported in androgen-
resistant and androgen-responsive prostate cancer cells via p53
and pAkt pathways (19). In a recent bioinformatics study, a
higher expression of SP-D in ovarian and lung cancer was found
to be associated with a favorable prognosis (20). These studies
therefore suggest that SP-D has an immune surveillance function
against tumor cells. In this context, this study was aimed at
investigating the role of SP-D in breast cancer.
Breast cancer is the most common cancer diagnosed in
women worldwide, contributing to almost 60% mortality rate
in lower-income countries (25). There is a large variation in
the survival rates worldwide, with an estimated 5-year survival
rate of 80% in developed countries and below ∼40% in low-
income countries (26). Designing effective treatments are crucial
to improve the survival rates and to ensure the best possible
quality of life for cancer survivors. After lung cancer, breast
carcinomas are the second most leading cause of mortality
(27); ∼17.5 million new cases of breast cancer are diagnosed
globally, and 8.7 million deaths documented (28). As per
GLOBOCAN 2018, ∼2 million new cases were identified, and
6.6% of cancer-related deaths were caused by breast cancer.
Furthermore, the 5-year prevalence rate of breast cancer was
found to be ∼6.8 million (25). Breast cancer is characterized by
an abnormal growth of malignant cells in the mammary glands.
The physiological conditions that lead to breast tumorigenesis
include inherited genetic mutation and epigenetic modifications,
which can lead to premalignant transformation of mammary
cells (29). The development of advanced breast tumor is a
consequence of immune selection and immune evasion (30).
Breast cancer is subdivided into different molecular subtypes:
luminal A, luminal B, triple negative, human EGF receptor
(HER)2-enriched, basal, and normal-like tumors (31, 32).
The development and metastasis of cancer, including breast
cancer, appear to be influenced by innate immune surveillance
molecules and associated inflammatory mediators in the tumor
microenvironment (33, 34).
Here, we examined possible protective effects of rfhSP-
D in triple-negative (ER−/PR−/HER2−), triple-positive
(ER+/PR+/HER2+), and HER2+-overexpressing breast
cancer cell lines. We also examined a possible interaction
between SP-D and hyaluronic acid (HA; polymeric nonsulfated
glycosaminoglycan), the most abundant component of the
extracellular matrix (ECM), which plays an important role in
inflammation, angiogenesis, fibrosis, and cancer progression
(35). The interaction of breast cancer cells with HA can sustain
tumor growth and promote malignant progression. The altered
synthesis of HA in early and late stages of ductal breast carcinoma
in situ (DCIS) microenvironment is correlated with tumor stage
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progression and invasion (36). Several studies provide strong
evidence that HA participates in the regulation of breast tumor
cell migration and invasion in vitro and tumor growth and
progression in vivo (37–39). We report, for the first time, that
rfhSP-D interacts with HA that negates its anti-tumor properties;
i.e., in the presence of HA, rfhSP-D is unable to induce apoptosis
in triple-positive and HER2-overexpressing breast cancer cell
lines. Therefore, neutralizing the negative effect of HA on
rfhSP-D can have crucial implications for the development of
therapeutic strategies.
MATERIALS AND METHODS
Expression and Purification of rfhSP-D
Expression and purification of rfhSP-D were performed as
published earlier (19). Briefly, Escherichia coli BL21 (λDE3)
pLysS bacterial strain (Invitrogen) was transformed with plasmid
pUK-D1, composed of cDNA sequences for α-helical neck
and CRD region of human SP-D. Twenty-five milliliters of
bacterial primary inoculum was inoculated into 500 ml of Luria-
Bertani medium containing 100 µg/ml ampicillin and 34 µg/ml
chloramphenicol (Sigma-Aldrich) and grown to anOD600 of 0.6.
The bacterial cells were then induced with 0.5 mM isopropyl
β-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3 h.
The IPTG-induced bacterial cell pellet was treated with lysis
buffer (50 mM Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA
pH 8, 0.1% v/v Triton X-100, 0.1 mM phenyl-methyl-sulfonyl
fluoride, 50 µg/ml lysozyme) and subsequently sonicated (five
cycles, 30 s each). The sonicated was centrifuged at 12,000 × g
for 30 min, followed by denaturation and renaturation of rfhSP-
D inclusion bodies using refolding buffer (50 mM Tris–HCl
pH 7.5, 100 mM NaCl, 10 mM 2-mercaptoethanol) containing
8 M urea. The dialysate was then loaded onto a maltose–
agarose affinity column (5 ml; Sigma-Aldrich), and rfhSP-D was
eluted using 10 mM EDTA buffer containing 50 mM Tris–HCl
pH 7.5 and 100 mM NaCl. Eluted rfhSP-D fractions were then
tested for endotoxin levels using a QCL-1000 Limulus amebocyte
lysate system (Lonza). The endotoxin levels were found to be
∼5 pg/µg of rfhSP-D. The purity of protein was analyzed via
15% w/v SDS-PAGE, and its immunoreactivity was assessed via
western blotting.
Cell Culture and Treatments
Human breast cancer cell lines, triple-negative BT20
(ER−/PR−/HER2−) (ATCC-HTB19), triple-positive BT474
(ER+/PR+/HER2+) (ATCC-HTB20), and HER2-positive
SKBR3 (ER−/PR−/HER2+) (ATCC-HTB30), were cultured
in complete RPMI medium (Sigma-Aldrich), supplemented
with 10% v/v fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin (Sigma-Aldrich), 100 µg/ml streptomycin
(Sigma-Aldrich), and 1 mM sodium pyruvate (Sigma-Aldrich)
and left to grow at 37◦C under 5% v/v CO2. Since these cell
lines were adherent, cells were detached using 2× trypsin–EDTA
(0.5%) (Fisher Scientific) for 10 min at 37◦C, then centrifuged
at 1,500 rpm for 5 min, and resuspended in complete RPMI.
Cell number and viability were assessed by mixing an equal
volume of the cell suspension and Trypan Blue (0.4% w/v)
(Fisher Scientific) and by counting using a hemocytometer with
a Neubauer chamber (Sigma-Aldrich).
Fluorescence Microscopy
BT20, BT474, and SKBR3 (50,000) cells were grown on coverslips
and incubated with rfhSP-D (10 µg/ml) in serum-free RPMI
medium for 1 h for cell binding analysis and 24 h for
apoptosis induction. For binding experiments, the coverslips
were washed three times with phosphate-buffered saline (PBS)
and incubated with polyclonal anti-rabbit human SP-D antibody
(1:200) (Medical Research Council Immunochemistry Unit,
Oxford) for 1 h at room temperature (RT). Following washes
with PBS, the cells were incubated with goat anti-rabbit IgG
conjugated to Alexa Fluor R© 488 (1:200) (Abcam) and Hoechst
(1:10,000) (Sigma-Aldrich) for immunofluorescence analysis. For
apoptosis induction analysis, the cells were incubated with FITC
Annexin V (1:200) and propidium iodide (PI) (1:200) diluted in
AnnexinV-binding buffer for 15min at RT in dark. After washing
with PBS three times, the coverslips were mounted on slides and
viewed under an HF14 Leica DM4000 microscope.
Flow Cytometry
BT20, BT474, and SKBR3 (0.4 × 106) cells were grown in a six-
well-plate and incubated with rfhSP-D (20 µg/ml), along with an
untreated control, for 24 h. The cells were then detached using
2 × trypsin–EDTA (0.5%) (Fisher Scientific) and centrifuged at
1,500 × g for 5 min. Staurosporine (1 µM/ml; Sigma-Aldrich)
was used as a positive control of apoptosis. Following washes
with PBS, the cells were incubated for 15 min with goat anti-
rabbit IgG conjugated to Alexa Fluor R© 488 (1:200) (Abcam) and
Hoechst (1:10,000) (Sigma-Aldrich) for apoptosis analysis. After
washing with PBS three times, apoptosis was measured using
a NovoCyte flow cytometer. Compensation parameters were
acquired using unstained, untreated FITC-stained, and untreated
PI-stained cells for all three cell lines. For solid-phase studies, six-
well-plates were coated with HA (20 µg/ml) (a kind gift from
Prof. Ivan Donati, Department of Life Sciences, University of
Trieste) overnight at 4◦C with and without rfhSP-D (20 µg/ml).
The wells were washed with PBS, and 0.4 × 106 cells were
added to the HA/rfhSP-D-coated wells and incubated 37◦C for
24 h. For proliferative studies, the cells were washed with PBS
and incubated with anti-mouse Ki-67 (BioLegend) diluted in a
permeabilization reagent of the FIX&PERMkit (Fisher Scientific)
for 30 min at RT. After PBS washes, the cells were probed
with a goat anti-mouse-FITC conjugate (1:200) (Fisher Scientific)
for 30 min at RT in the dark. Cells (12,000) were acquired
for each experiment and compensated before plotting the
acquired data.
Purification of Full-Length SP-D From
Breast Cancer Cell Lines
BT20, BT474, and SKBR3 (0.4 × 106) culture media were
collected and centrifuged at 5,000 rpm for 10 min. The
supernatants were passed through a maltose–agarose affinity
column. The bound full-length SP-D was eluted using an elution
buffer, containing 50 mM Tris–HCl pH 7.5, 100 mM NaCl,
and 10 mM EDTA. Full-length SP-D protein yield of 1 µg/ml
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was obtained from 100 ml of culture medium. The purity of
eluted fractions (10µg/ml) was analyzed via 15%w/v SDS-PAGE,
and its immunoreactivity was determined via western blotting.
For western blotting analysis, the eluted full-length SP-D was
heated for 10 min at 100◦C and subjected to SDS-PAGE (12%
v/v). The proteins were then electrophoretically transferred onto
a nitrocellulose membrane (320 mA for 2 h) in 1× transfer
buffer (25 mM Tris–HCl pH 7.5, 190 mM glycine, and 20%
methanol). The membrane was blocked using 5% w/v dried milk
powder (Sigma-Aldrich) in PBS overnight at 4◦C, followed by
washing with PBS three times for 5 min each. The membrane was
then incubated with polyclonal anti-rabbit human SP-D antibody
(MRC Immunohistochemistry Unit, Oxford) (1:1,000), followed
by probing with protein A–HRP (Sigma-Aldrich) (1:1,000).
Following washing with PBST, the membrane was developed
using a 3′-diaminobenzidine (DAB) substrate kit.
Apoptosis Analysis of Breast Cancer Cells
Treated With BT474-Derived Full-Length
SP-D
The purified full-length SP-D from breast cancer culture was
subjected to apoptosis assay using an Annexin V/FITC kit
(BioLegend). BT20, BT474, and SKBR3 cells (0.4 × 106) were
incubated with 20 µg/ml of culture-purified SP-D and incubated
for 24 h. The cells were then detached using 2 × trypsin–
EDTA (0.5%) (Fisher Scientific) and centrifuged at 1,500 × g
for 5 min. Following washes, the cells were then incubated
with both FITC and PI dye (1:200) for 15 min in the dark.
After washing with PBS, the cells were subjected to flow
cytometric analysis. Compensation parameters were acquired
using unstained, untreated FITC-stained, and untreated PI-
stained cells for all three cell lines.
Immunohistochemical Analysis
Surgical breast cancer tissues and adjacent peritumoral
mammary parenchymas were selected following ethical
approval by the University Hospital of Palermo Ethical Review
Board (approval number 09/2018). TNBC, HER2+, luminal B,
and luminal A breast cancer tissues were used, while normal
breast tissue was used as a control. Immunohistochemistry
(IHC) was performed using a polymer detection method. Briefly,
tissue samples were fixed in 10% v/v buffered formalin and
paraffin embedded. Four-micrometer-thick tissue sections were
deparaffinized and rehydrated. The antigen unmasking technique
was carried out using Novocastra Epitope Retrieval Solutions,
pH 6 EDTA based (Leica Biosystems), in a thermostatic bath
at 98◦C for 30 min. Sections were brought to RT and washed
in PBS. After neutralization of the endogenous peroxidase with
3% v/v H2O2 and Fc blocking (Novocastra, Leica Biosystems),
the samples were incubated overnight at 4◦C with mouse
anti-human SP-D monoclonal antibody (1:800) (Abcam).
Staining was revealed via a polymer detection kit (Novocastra,
Leica Biosystems) and 3-amino-9-ethylcarbazole (AEC, Dako,
Denmark) substrate chromogen. Slides were counterstained
with Harris hematoxylin (Novocastra, Leica Biosystems). Alcian
blue staining was carried out to detect the presence of mucins
in breast cancer tissue sections, according to the manufacturer’s
kit Bioptica (04-160802). Slides were analyzed under the Axio
Scope A1 optical microscope (Zeiss) and microphotographs were
collected through the Axiocam 503 color digital camera (Zeiss)
using the Zen 2 software.
Adhesion Assay
BT20, BT474, and SKBR3 (0.5 × 105) cells were labeled with
FAST DiI fluorescent dye (Molecular Probes, Invitrogen) and
allowed to adhere to 96microtiter wells pre-coated with 20µg/ml
of HA, rfhSP-D, and bovine serum albumin (BSA). The adhesion
of cells was measured after 35 min of incubation at 37◦C under
5% CO2. The non-adhered cells were washed off with PBS,
and the remaining cells were lysed using 10 mM Tris–HCl pH
7.4 + 0.1% v/v SDS. The plate was read at 544 nm using Infinite
200 (Tecan). Results were expressed as adhesion percentage with
reference to a standard curve established using an increasing
number of FAST DiI-labeled cells.
Intracellular Signaling Analysis
Signaling pathway was analyzed using the PathScan Intracellular
Signaling Array Kit (Cell Signaling Technology). Briefly,
0.5 × 106 breast cancer cell lines were grown in a six-well-plate
in serum-free RPMI medium. Cells were then left to adhere to
HA and rfhSP-D (20 µg/ml) pre-coated plates and incubated at
37◦C for 25 min. The unbound cells were then washed with cold
PBS and lysed in ice-cold cell lysis buffer containing a cocktail
of protease inhibitors (Roche Diagnostics). The Array Diluent
Blocking buffer was added to each well on themulti-well gasket at
RT for 15min. After decanting the Array Blocking Buffer, 75µl of
the total lysate (0.8 mg/ml) was added to each well and incubated
for 2 h at RT on an orbital shaker. The well contents were
decanted and washed with 100 µl of 1× Array Wash Buffer three
times (5 min each wash). The wells were then incubated with
biotinylated detection cocktail antibody for 1 h at RT, followed by
incubation with streptavidin-conjugated DyLight 680 for 30 min.
The fluorescence readout was measured via LI-COR Biosciences
Infrared Odyssey imaging system (Millennium Science), and data
were processed by the software Image Studio 5.0.
Western Blotting
BT20, BT474, and SKBR3 (0.4 × 106) cells were seeded in a
six-well-plate and treated with rfhSP-D (20 µg/ml) for 24 h,
along with an untreated control, in a serum-free RPMI medium.
After removing the medium, the cells were lysed using a lysis
buffer (50 mM Tris–HCl pH 6.8, 2% v/v SDS, 2% v/v β-
mercaptoethanol, 10% v/v glycerol and 0.1% w/v bromophenol
blue). The lysed cells were then sonicated for 15 s, and the
sonicated samples were heated for 10 min at 100◦C and
subjected to SDS-PAGE (12% v/v). The proteins were then
electrophoretically transferred onto a nitrocellulose membrane
(320 mA for 2 h) in 1× transfer buffer (25 mM Tris–HCl pH
7.5, 190 mM glycine, and 20% v/v methanol). The membrane
was blocked using 5% w/v dried milk powder (Sigma-Aldrich) in
PBS overnight at 4◦C, followed by washing with PBS three times
(5 min each). For apoptosis studies, the membrane was incubated
with rabbit anti-human caspase primary antibodies (anti-cleaved
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caspase 9 and anti-cleaved caspase 3; Cell Signaling) at RT for 1 h.
The membrane was washed with PBST (PBS+ 0.05% Tween 20)
three times, 10 min each, followed by incubation with secondary
goat anti-rabbit IgG horseradish peroxidase (HRP) conjugate
(1:1,000; Fisher Scientific) for 1 h at RT. Following washes with
PBST, the membrane was developed using a DAB substrate kit
(Thermo Fisher).
ELISA
For HA (1,500 kDa) binding analysis, a constant concentration
of HA (20 µg/ml) was coated overnight at 4◦C using
carbonate/bicarbonate (CBC) pH 9.6 buffer, followed by blocking
with 2% w/v BSA at 37◦C. Recombinant maltose binding protein
(MBP) was used as a negative control in this experiment.
After three washes with PBST, rfhSP-D (5, 10, or 20 µg/ml)
was incubated in buffer containing 5 mM CaCl2 for 2 h
at 37◦C. After washing with PBST three times, the binding
was assessed by polyclonal anti-rabbit human SP-D antibody
(1:5,000) and incubated at 37◦C for 1 h. The wells were washed
again with PBST three times and incubated with protein A–
HRP secondary conjugate (1:5,000) (Sigma-Aldrich) for 1 h at
37◦C. After washes with PBST, the binding was detected using
3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich).
The reaction was stopped using 2 N H2SO4, and the absorbance
was read at 450 nm using an iMarkTM microplate absorbance
reader (Bio-Rad).
Quantitative RT-PCR
BT20, BT474, and SKBR3 (0.4 × 106) cells were added to
six-well-plate pre-coated with HA (20 µg/ml), HA + rfhSP-D
(20 µg/ml), and rfhSP-D (20 µg/ml) and incubated at 37◦C
for various time points. The cell pellet for each time point
was subjected to RNA extraction using GenElute Mammalian
Total RNA Purification Kit (Sigma-Aldrich). RNA samples were
then treated with DNase I (Sigma-Aldrich), and the total RNA
concentration and purity were determined using a 260:280 nm
ratio using NanoDrop 2000/2000c (Thermo Fisher Scientific).
Two micrograms of total RNA was used for cDNA synthesis
using High Capacity RNA to cDNA kit (Applied Biosystems).
Primer sequences used in this study were designed for specificity
using the Primer-BLAST software (Basic Local Alignment
Search Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). p21 and
p27 mRNA levels were estimated by quantitative RT-PCR (qRT-
PCR) using the following primers: 5′-TGGAGACTCTCAGGG
TCGAAA-3′ and 5′-CGGCGTTTGGAGTGGTAGAA-3′ for p21,
and 5′-CCGGTGGACCACGAAGAGT-3′ and 5′-GCTCGCCTC
TTCCATGTCTC-3′ for p27. Briefly, the qPCR reaction consisted
of 5 µl of iQ SYBR Green Supermix (Bio-Rad, Milan, Italy),
75 nM of forward and reverse primers, and 500 ng template
cDNA in a 10 µl final reaction volume. qRT-PCR was performed
on a Rotor-Gene 6000 (Corbett, Explera, Ancona, Italy). The
melting curve of the reactions was recorded between 55 and
99◦C with a hold every 2 s. The comparative quantification
(CQ) method was used to determine the relative amount of gene
expression in each sample, and the data analyzed using Rotor-
Gene 1.7 software (Corbett Research) (40). The CQ method
is specific in calculating the efficiencies of each gene for each
individual PCR and is based on the second differential maximum
method. The samples were normalized using the expression
of human TATA binding protein (TBP) rRNA. Assays were
conducted in triplicates.
Statistical Analysis
Graphs were generated using GraphPad Prism 6.0; the statistical
analysis was carried out using an unpaired one-way ANOVA test.
Error bars represent SD or SEM (n = 3), as indicated in the
figure legends. The significant values were measured based on
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 between
treated and untreated samples.
RESULTS
A Recombinant Form of Truncated Human
SP-D Binds Breast Cancer Cell Lines
rfhSP-D comprising the eight Gly-X-Y repeats and the neck
and CRD regions of human SP-D was affinity-purified and
migrated at ∼20 kDa on SDS-PAGE under reducing conditions
(Figure 1A). The immunoreactivity of purified rfhSP-D was
confirmed via western blotting using polyclonal anti-human
SP-D antibody raised in rabbit against native human SP-D
purified from lung lavage (Figure 1B). BSA was used as a
negative control protein. Purified rfhSP-D (5 µg/ml) bound
breast cancer cell lines, triple-negative BT20 (ER−/PR−/HER2−),
triple-positive BT474 (ER+/PR+/HER2+), and HER2-positive
SKBR3 (ER−/PR−/HER2+) (Figure 1D). The nucleus of the cell
was stained with Hoechst dye, while the membrane localization
of the bound rfhSP-D was revealed using green FITC/anti-
human SP-D conjugate. All rfhSP-D-treated breast cancer cell
lines showed a similar “cluster”-like binding pattern on the cell
membrane (Figure 1D). No FITC was detected in the untreated
controls (Figure 1C), probed with both primary and secondary
antibodies, suggesting the specificity of rfhSP-D binding.
Apoptosis Induction by rfhSP-D in Breast
Cancer Cell Lines
The quantitative and qualitative analyses of apoptosis induction
by rfhSP-D were performed using flow cytometry (Figures 2A,B)
and immunofluorescence microscopy (Figures 2C,D). A
significant proportion of BT474 and SKBR3 breast cancer cells
treated with rfhSP-D (20 µg/ml) underwent apoptosis at 24 h
as revealed by FACS analysis (Table 1). BT474 (∼61%) and
SKBR3 (∼68%) cell lines were more susceptible to apoptosis
induction when immobilized rfhSP-D (20 µg/ml) (Figure 2A)
was used; there was no effect on the BT20 cell line. rfhSP-D in
solution also induced apoptosis in BT474 (∼34%) and SKBR3
(∼53%) (Figure 2B); again, rfhSP-D had no significant effect on
the BT20 cell line (Figure 2A, Table 1). The integrity of the cell
membrane was intact in untreated cells, and hence, the cells were
still viable, blocking the translocation of phosphatidylserine (PS)
from the inner cell membrane to outer plasma membrane and
preventing the PS–Annexin V interaction. Nearly 56% BT474
and SKBR3 cells were both stained positive for FITC and PI,
suggesting that annexin V/FITC was able to bind to PS found
on the cell surface of the cells undergoing apoptosis. However,
there were more BT474 cells that stained for PI alone than the
SKBR3 cell line, suggesting that BT474 cells were either at the
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FIGURE 1 | SDS-PAGE (A) and immunoblot profile (B) of the purified
recombinant form of human surfactant protein D (rfhSP-D). Expression of
rfhSP-D under the bacteriophage T7 promoter, expressed as ∼20 kDa
insoluble protein. Eluted fractions were passed through a maltose–agarose
column, which appeared as a single band at ∼20 kDa. Immunoreactivity of
(Continued)
FIGURE 1 | affinity-purified rfhSP-D was examined via western blotting; lane
1: BSA as a negative control; lane 2: purified rfhSP-D (5 µg/ml). Binding of
rfhSP-D (10 µg/ml) to breast cancer cell lines using fluorescence microscopy,
following 1 h incubation at 4◦C (C,D). The nucleus of the cells was stained with
Hoechst (1:10,000), and both untreated (cells only) (C) and rfhSP-D-treated
(D) cells were probed with polyclonal anti-human SP-D/FITC antibody (1:200).
Membrane localization of the bound proteins was only detected in the treated
cells, while no FITC was detected in the untreated control (cells only).
late stage of apoptosis or undergoing necrosis. The percentage of
viable cells in the untreated (cells only) sample was significantly
higher as compared to the treated sample, BT474 (∼92%)
and SKBR3 (∼96%), suggesting that apoptosis induction was
a rfhSP-D protein-specific effect (Figure 2A). Staurosporine
(1 µM/ml) was used as a positive control for apoptosis studies.
Staurosporine-treated BT20, BT474, and SKBR3 showed ∼70%
of apoptosis induction at 24 h (Figures 2A,B). Staurosporine
is a well-known therapeutic, potent apoptosis inducer, which
is suggested to inhibit tumor cell growth and proliferation by
triggering cell death via an intrinsic apoptotic pathway (41).
Fluorescence microscopy analysis in BT474 and SKBR3 cell
lines treated with rfhSP-D revealed a positive staining for cell
membrane integrity marker, Annexin V (conjugated to FITC),
and disoriented cell membrane morphology (Figures 2C,D).
Thus, PI-positive staining was seen only in treated cell lines
(Figure 2D) compared to untreated control cells (Figure 2C),
indicating no occurrence of late apoptotic or necrosis. In
contrast, no positive staining of Annexin V or PI was detected in
BT20 treated cells, which were similar to the untreated control.
rfhSP-D Induces Apoptosis in BT474 and
SKBR3 Cell Lines via Intrinsic Pathway
Since rfhSP-D caused apoptosis in BT474 and SKBR3 cells, we
further examined the likely apoptotic pathway being triggered
following rfhSP-D treatment. Apoptosis can be initiated through
intrinsic or extrinsic pathways. Expression of caspases was tested
in rfhSP-D-treated breast cancer cell lines. Western blotting
analysis of rfhSP-D-treated BT474 and SKBR3 cells at 24 h
revealed cleavage of caspase 9 (∼37 kDa) and 3 (∼17 kDa),
suggesting the involvement of the intrinsic apoptosis pathway
(Figure 3). As expected, cleavage of caspases 3 (Figure 3A) and
9 (Figure 3B) was not detected in BT20 and untreated (cells
only) controls. Furthermore, cleaved caspase 8 was tested as a
marker for the extrinsic pathway, but no difference was observed
between rfhSP-D-treated cell lines and untreated controls (data
not shown).
Expression of Human SP-D and HA in
Breast Cancer Tissues
The expression of human SP-D was analyzed in eight cases of
invasive ductal carcinoma, no special type (NSP), comprising
two cases for each molecular class (luminal A, luminal B,
Her2-Neu, and triple negative) based on the expression of the
estrogen receptor (ER), the progesterone receptor (PR), and the
human EGF receptor 2 (Her2-Neu) status. Among biological
variables considered, besides the different molecular class, the
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FIGURE 2 | Flow cytometric analysis of apoptosis induction in breast cancer
cells treated with 20 µg/ml of immobilized (A) and solution-phase (B) rfhSP-D
for 24 h. For both Annexin V/FITC and DNA/PI staining, 12,000 cells were
acquired and plotted. A significant difference was seen among treated and
untreated (cells only) samples, as evident by the shift in the fluorescence
intensity. The data were expressed as the mean of three independent
experiments (n = 3) done in triplicates ± SEM. Statistical significance was
established using the unpaired one-way ANOVA test (**p < 0.01 and
****p < 0.0001). The percentage of apoptosis was calculated by normalizing
the treated cells with their untreated counterparts. Fluorescence microscopy
analysis of apoptosis induction in breast cancer cells treated with rfhSP-D
(20 µg/ml) for 24 h, using an Annexin V with a propidium iodide (PI) staining kit;
untreated (cells only) controls (C) and rfhSP-D-treated cells (D). The nucleus
(Continued)
FIGURE 2 | was stained with Hoechst (1:10,000), and the cell membrane was
stained positively with Annexin V and PI (1:200) in treated cell lines, suggesting
that cells treated with rfhSP-D induced apoptosis at 24 h, where translocation
of PS to the outer plasma membrane was able to bind Annexin V due to loss
of membrane integrity and PI stain was taken, which stained the DNA of
apoptotic cells. No Annexin V/PI staining was detected in untreated cells.
neoplastic tissues presented a different grade tumor, computed
with the Nottingham score, varying from moderate (G2) to
undifferentiated (G3). Indeed, the molecular classification allows
us to identify four different classes based on the expression
of the ER and PR and the human EGF receptor 2 (Her2-
Neu) status and called luminal A, luminal B, Her2-Neu, and
triple negative, respectively. The molecular subtypes reflect
the neoplastic heterogeneity of breast cancer and differ in
gene expression patterns, clinical and morphological features,
response to treatment, and outcome. Our aim was to evaluate
the presence and distribution of SP-D in all molecular subtypes
of breast cancer to dissect its biological role in neoplastic
progression and to consider a potential predictive and/or
prognostic marker of mammary carcinoma. Our data appear to
suggest heterogeneous inter-tumor and intra-tumor expressions
of SP-D within the molecular subtypes. IHC staining for SP-
D highlighted its cytoplasmic expression in both the neoplastic
tissue and the healthy peritumoral mammary parenchyma, as
previously demonstrated (20). Indeed, the presence of SP-D
was evident in cytoplasmic labeling and was highly expressed
by the ductal epithelium of peritumoral mammary parenchyma
and the neoplastic subclones of luminal A type, while its
reduced expression was evident in triple-negative breast cancer
(TBNC) (Figure 4A). For the luminal B and HER2 groups, a
heterogeneous expression of SP-D was observed (Figures 4i,ii).
We also examined serial sections for the localization of HA
within the tumor microenvironment following histochemical
analysis of normal and breast cancer tissue specimens. As shown
in Figure 4i, Alcian blue staining highlighted the presence of
acid mucins, containing HA and sialic acid (42–44), in the
tumor stroma, around the tumor cells and was very faint in the
peritumoral mammary parenchyma in all the molecular classes
of breast cancer considered. The luminal B and HER2 specimens
were characterized by a variable SP-D expression within the
tumor. In the luminal B and HER2 groups, Alcian blue staining
also showed a greatly heterogeneous expression of HA. Thus,
a stronger staining for Alcian blue was evident where a lower
presence of SP-D was detected, suggesting that a modification
of ECM might be associated with a variable distribution of SP-D
(Figures 4A,G–L).
rfhSP-D Binds to High-Molecular-Weight
HA
Confirmation of the presence of HA in the breast cancer tissues
prompted us to examine if rfhSP-D binds to HA and can
modulate the nature of rfhSP-D–breast cancer cell interaction.
In direct binding ELISA, rfhSP-D bound to solid-phase
high-molecular-weight (1,500 kDa) HA in a dose-dependent
manner (Figure 5A). Immobilized rfhSP-D (20 µg/ml) alone as
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TABLE 1 | Flow cytometric analysis of apoptosis induction in breast cancer cells treated with 20 µg/ml of immobilized and solution-phase rfhSP-D for 24 h.













BT20 5 7 70 5 12 70
BT474 8 61 70 8 34 70
SKBR3 4 68 70 4 53 70
FIGURE 3 | Caspase activation in breast cancer cell lines following rfhSP-D
treatment at 24 h. Western blot analysis showed presence of cleaved caspase
3 at 17kDa in the cells treated with rfhSP-D for 24 h. (A) Western blot analysis
showed presence of cleaved caspase 9 at 37kDa (B), suggesting induction of
the intrinsic pathway.
well as HA (20 µg/ml)-bound rfhSP-D were then allowed to
interact with breast cancer cell lines. Cell adhesion assay was
performed by labeling the cells with the fluorescent probe FAST
DiI (Figure 5B). All three breast cancer cell lines (BT20, BT474,
and SKBR3) were able to adhere to HA, to rfhSP-D, and to
HA-bound rfhSP-D. rfhSP-D enticed a greater cell adhesion when
compared to HA alone or HA-bound rfhSP-D; all three cell lines
bound to similar extent (Figure 5B).
HA Binding Modulates the Ability of
rfhSP-D to Induce Apoptosis
The implication of HA–rfhSP-D interaction on apoptosis
induction in breast cancer cells was investigated (Figure 6A).
Breast cancer cells incubated with pre-coated HA, HA + rfhSP-
D, and rfhSP-D-only wells, along with untreated (cells only) cells,
were stained after 24 h with Annexin V/FITC; the quantification
of apoptosis was carried out using flow cytometry (Figure 6A).
Addition of HA to rfhSP-D reduced apoptosis induction by
∼45%. Since we noticed a reduced apoptosis induction by
HA+ rfhSP-D, we considered if rfhSP-D induced a proliferative
response in combination with HA. Thus, HA + rfhSP-D-treated
breast cancer cells were stained with mouse anti- Ki-67 antibody
to detect the percentage proliferation (Figure 6B). Ki-67 is a well-
known nuclear protein associated with active cell proliferation
and is expressed throughout the active cell cycle, including
G1, S, G2, and M phases. Addition of HA in rfhSP-D-treated
SKBR3 cells resulted in ∼30% cell proliferation (Figure 6B),
suggesting that HA negated pro-apoptotic effects of rfhSP-D
in breast cancer cell lines. In the case of BT474, only ∼47%
of proliferative cells were seen among rfhSP-D-treated BT474
cells, while HA + rfhSP-D-treated BT474 cells showed a higher
proliferation (∼95%) (Figure 6B). HA-only-treated BT474 cells
showed∼88% of Ki-67-positive cells, while∼66% of proliferative
cells were seen in HA-treated SKBR3 cells. However, proliferation
of BT20 cells was not affected by rfhSP-D or HA treatment,
suggesting that these cells continue to grow. These percentage
proliferations are compared to untreated control (cells only).
Given the presence of SP-D in the breast cancer tissues, we made
an attempt to purify SP-D from the culture supernatants of the
breast cancer cells on the assumption that breast cancer cells can
also be a likely source of SP-D in the tumor microenvironment.
We could purify SP-D only from BT474 cell culture (Figure 6C).
However, the purified SP-D was not able to induce apoptosis in
BT474 cells (Figure 6D).
rfhSP-D Treatment Upregulated Cell Cycle
Inhibitors and Induced p53-Dependent
Apoptosis
Activated p53 is a known mediator of DNA damage,
oxidative burst, cell cycle arrest, and induction of apoptosis.
Therefore, we analyzed the levels of activated p53 in rfhSP-
D-treated breast cancer cells. Increased levels of p53
phosphorylation at Ser15 was detected in rfhSP-D-treated
SKBR3 cells (Figure 7A), while downregulation was seen
in the BT20 cell line (Figure 7A), suggesting that p53
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FIGURE 4 | (Continued)
Frontiers in Immunology | www.frontiersin.org 9 July 2020 | Volume 11 | Article 1171
Murugaiah et al. Innate Immune Surveillance by SP-D
FIGURE 4 | (i) SP-D and Hyaluronic acid (HA) presence in different histotypes of neoplastic breast (A–L), and normal ductal mammary epithelium (M–O). (A,D,G,J). A
high variability of SP-D expression between different histotypes is shown, although the positivity of the signal is always attributable to neoplastic cells, as can be
observed from the higher- resolution images in the right part of the figure (B,E,H,K). AEC (red) chromogen was used to visualize the binding of anti-human SP-D
antibodies. (C,F,I,L,O) Histochemical staining with Alcian Blue highlighted HA distribution in breast cancer and normal tissue sections; in particular, the staining was
visible in tumor-associated stroma. (ii) Immunohistochemical and histochemical analysis in Luminal-B and Her2+/ER-/PR- breast carcinoma sections of SP-D (A–F)
and HA (G–L) expression, respectively (B). A high variability of SP-D and HA expression within the same isotypes is shown. It is possible to notice a slight inverse
correlation between SP-D and HA expression. AEC (red) chromogen was used to visualize the binding of anti-human SP-D antibodies, whereas histochemical staining
with Alcian Blue highlighted HA distribution.
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FIGURE 5 | Interaction of rfhSP-D with HA. Binding of varied concentrations of rfhSP-D to HA (20 µg/ml) by ELISA (A). The effects of rfhSP-D on Breast cancer cell
lines adhesion (B). Breast cancer cells were labeled with the FAST DiI fluorescent dye and allowed to adhere to 96 microtiter wells pre-coated with HA, rfhSP-D, and
BSA. The data is expressed as the mean of three independent experiments. The adhesion of cells was measured after 35 minutes of incubation at 37◦C under 5%
CO2. Results are expressed as adhesion percentage with reference to a standard curve established using an increasing number of FAST DiI -labeled cells. The data is
expressed as the mean of three independent experiments (n = 3) done in triplicates ± SEM. Statistical significance was established using the unpaired one-way
ANOVA test (**p < 0.01 and ***p < 0.001). The statistical analysis was performed between rfhSP-D and HA + rfhSP-D -treated breast cancer cells.
upregulation may also have contributed to p53-dependent
apoptosis induction in SKBR3 cells. In addition, increased
transcript levels of p21 and p27 were observed in rfhSP-
D-treated BT474 and SKBR3 cell lines (Figure 7B) at
12-h time point, suggesting the possibility of cdc2–cyclin
B1 reduction leading to G2/M cell cycle arrest. Reduced
levels of phosphorylated p53, caspase 3, p21, and p27 were
observed in HA + rfhSP-D-treated SKBR3 and BT474 cells
(Figures 7A,B), suggesting reduced apoptosis induction by
the addition of HA. In the case of BT20, no significant
difference was found in terms of p21 and p27 mRNA
expression levels between rfhSP-D- and HA + rfhSP-D-treated
BT20 cells.
DISCUSSION
In this study, we show that rfhSP-D binds to all breast
cancer cell lines tested: BT20 (ER−/PR−/HER2−), BT474
(ER+/PR+/HER2+), and SKBR3 (ER−/PR−/HER2+). However,
the receptor, SP-D is binding to on the cancer cell surface, is
not yet known. Exogenous treatment with rfhSP-D reduced cell
viability of BT474 and SKBR3 cell lines and induced apoptosis
at 24 h. Cell viability and apoptosis assays were carried out
using varied concentrations of rfhSP-D (5, 10, and 20 µg/ml)
and different time points (12, 24, and 48 h), but only 20 µg/ml
concentration of rfhSP-D was effective in inducting the optimal
cell viability reduction and apoptosis induction at 24 h. rfhSP-D-
treated BT474 and SKBR3 cells showed a significant reduction
in viable cells compared to untreated control (cells only), as
evident from Trypan blue exclusion and MTT assay (data not
shown). However, no effect of rfhSP-D was seen on the triple-
negative (BT20) cell line in terms of cell viability. Recent studies
have shown the ability of the CRD region of human SP-D to
interact with N-glycans of EGFR, resulting in downregulation
of EGF signaling in A549 cell line (23). It is likely that rfhSP-
D-mediated apoptosis is due to HER2 expression on BT474 and
SKBR3 cells; a lack of it seems to increase BT20 cells resistant
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FIGURE 6 | Apoptosis induction in BT20, BT474, and SKBR3 cell lines following HA challenge in the presence and absence of rfhSP-D (A). The data were expressed
as the mean of three independent experiments (n = 3). A significant difference was seen among treated and untreated samples, as made evident by the shift in the
fluorescence intensity. Staurosporine (1 µM/ml) was used as a positive control. Proliferative effects of rfhSP-D treatment on BT474 and SKBR3 breast cancer cell lines
(B). BT474 and SKBR3 cells were seeded in wells pre-coated with HA, HA + rfhSP-D, and rfhSP-D alone. The percentage of proliferative cells was evaluated by
staining with mouse anti-human KI-67 antibody, and KI-67-stained cells were measured via flow cytometry. The data were generated from at least three independent
(Continued)
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FIGURE 6 | experiments (n = 3) and presented as mean ± SD (*p < 0.1, **p < 0.01, and ****p < 0.0001). The statistical analysis was performed between rfhSP-D
and HA + rfhSP-D-treated breast cancer cells. The secretion levels of FL-SP-D were confirmed and analyzed via western blotting (C). Culture medium collected from
BT20, BT474, and SKBR3 cell lines was passed through a maltose Agarose column, and the eluted fractions were validated via western blotting; FL-SP-D was
detected at ∼43 kDa only for BT474. Both BT20 and SKBR3 cell lines did not secrete any FL-SP-D. Secreted FL-SP-D by BT474 was tested for its ability to induce
apoptosis (D). No effect of secreted FL-SP-D was seen in terms of cell viability and apoptosis induction.
FIGURE 7 | Intracellular signaling to show phosphorylation of p53 in rfhSP-D-treated BT20 and SKBR3 cell lines (A). Breast cancer cell lines were allowed to adhere
to HA or HA-bound rfhSP-D, and the phosphorylation status of p53 was evaluated using total cell lysates with a PathScan Antibody Array Kit (Cell Signaling). Data
were generated from at least three independent experiments and presented as mean ± SD. rfhSP-D treatment resulted in upregulation of p21 and p27 cell cycle
inhibitors (B). BT20, BT474, and SKBR3 (0.4 × 106) cells were seeded in a six-well-plate pre-coated with rfhSP-D and HA + rfhSP-D. The treated cells were lysed
and pelleted down. The pelleted cells were subjected to RNA isolation, followed by cDNA synthesis and qPCR. The comparative quantification method was
performed to calculate the efficiencies of each gene for each individual PCR and is based on the second differential maximum method or takeoff analysis. The takeoff
results obtained with p21/p27 primers were normalized with the housekeeping gene TBP. qPCR assay was conducted in triplicates, and error bars represent ± SEM.
Unpaired one-way ANOVA test was used to determine the significance; *p < 0.05, **p < 0.01, and ***p < 0.001 (n = 3). The statistical analysis was performed
between rfhSP-D and HA + rfhSP-D-treated breast cancer cells.
to the rfhSP-D effect. Whether HER2 is implicated in mediating
rfhSP-D-induced apoptosis is under investigation.
The ability of rfhSP-D to induce apoptosis at 24 h in SKBR3
and BT474 cell lines was evident from a significant increase
in the number of Annexin V-/PI-positive breast cancer cells
examined via flow cytometry and fluorescence microscopy. The
cell surface of the healthy cells is composed of asymmetrically
distributed lipids on the inner and outer surfaces of the plasma
membrane. PS is one of these lipids, which is restricted to the
inner surface of the plasma membrane and, thus, is only exposed
to the cytoplasm of the cell. However, when apoptosis is triggered
by stress factors, lipid asymmetry is lost, and PS translocates to
the outer leaflet of the plasmamembrane (45). Annexin V is a 36-
kDa calcium-binding intracellular protein that binds to PS (45).
Thus, Annexin V can also stain cells undergoing necrosis due to
a ruptured membrane that permits the access of Annexin V to
the entire plasma membrane. Western blotting analysis of rfhSP-
D-treated BT474 and SKBR3 breast cancer cells revealed cleavage
of caspases 9 and 3 at 12-h treatment. Caspases are well-known
cysteine-aspartic proteases that play a crucial role in apoptosis;
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caspase 9 is triggered by cellular stress (e.g., DNA damage), via
its binding to apoptotic protease-activating factor 1 (Apaf-1).
Apaf-1/procaspase 9, in turn, triggers executioner caspases 3 and
7 (46). Caspase 3 is an essential apoptotic executor, triggered by
endoproteolytic cleavage at Asp175, which leads to inactivation
of PARP (a known marker of apoptosis) (45, 47). These findings
indicated that rfhSP-D-mediated apoptosis induction in SKBR3
and BT474 cell lines is likely to occur via the intrinsic apoptotic
pathway (48). Recently, an integral role of rfhSP-D in innate
immune surveillance against prostate cancer has been reported.
rfhSP-D-mediated apoptosis has been suggested to take place
by two distinct mitochondrial apoptotic mechanisms (19). It is
also possible that p53 upregulation in rfhSP-D-treated BT474
and SKBR3 cell lines may lead to downregulation of the pAkt
pathway, resulting in increased levels of Bad and Bax, triggering
the release of cytochrome c, caspase 9 cleavage, and apoptosis
induction. Furthermore, previous studies have also reported the
interaction of SP-D with HMGA1, CD14, CD91–calreticulin
complex, SIRPα, and EGFR (19, 22, 23, 49). The involvement
of SP-D with these key molecules is likely to be relevant as a
part of a possible mechanism/receptor through which rfhSP-
D is likely mediating its apoptotic functions on breast cancer
cells. As reported in previous studies, the CRD of SP-D can
interact with pattern recognition receptors TLR-2, TLR-4 (50),
and CD14 (22), which may block pro-inflammatory and pro-
survival downstream signaling on breast cancer cells. However,
further investigation is crucial to understand the involvement of
CRD and its possible interacting partners involved in triggering
the downstream mechanism of apoptosis induction.
During the development of breast tumorigenesis, the
tumor cells interact with surrounding stroma to create a
tumor microenvironment, supporting the growth, survival, and
invasion of cancer cells. The ECM is an essential constituent of
the niche, leading to progression of malignant tumor formation
and proliferation. ECM is composed of a wide range of
proteoglycans and glycosaminoglycans, which offers a structural
support and promotes tissue organization, thus contributing to
cell survival, proliferation, invasion, angiogenesis, and immune
cell infiltration (35, 51). HA is one of the specific components of
ECM, which is synthesized as a large linear anionic polymer at
the cell surface. The role of HA during inflammation-mediated
breast cancer has been established (52, 53). In vitro studies have
reported the ability of HA to regulate tumor cell migration and
invasion and tumor growth and progression using in vivomodels
(39). Synthesis and accumulation of HA have been detected in
invasive breast cancer cells compared to normal breast epithelial
tissues (39). Additionally, HA synthase 2 facilitates invasion in
breast cancer cells (51). Furthermore, tumor cells overexpressing
HA synthase 2 have been shown to enhance angiogenesis and
stromal cell recruitment, suggesting that increased levels of
HA in the tumor stroma support breast carcinoma (51). Pro-
tumorigenic roles of increased HA expression in breast tumors
and possible mechanisms through whichHAmight trigger tumor
proliferation are areas of great interest. Therefore, we examined
the interaction between rfhSP-D and HA and its implication on
the adhesion and proliferation of BT20, BT474, and SKBR3 breast
cancer cells.
Direct binding ELISA revealed that rfhSP-D bound to HA
in a dose-dependent manner. The ability of breast cancer cells
to interact with HA-bound rfhSP-D was examined via a cell
adhesion assay. Cell adhesion assay was performed to assess
the effect of rfhSP-D or HA treatment on the ability of breast
cancer cells to adhere. A greater cell adhesion binding pattern
was observed with rfhSP-D alone, when compared to HA-bound
rfhSP-D orHA alone. Thismay be due to the interaction of rfhSP-
D-treated cells with apoptotic-related receptors and pathways
leading to apoptosis induction. Apoptotic and proliferative assays
were also performed to investigate the effect of HA-bound rfhSP-
D in comparison to rfhSP-D alone. SKBR3 cells seeded on HA-
bound rfhSP-D resulted in an increased cell proliferation (1.7-
fold), when compared to rfhSP-D alone. In the case of rfhSP-D-
treated BT474 cells, addition of HA resulted in a two-fold increase
of proliferative cells. However, the percentage of proliferating
cells in the presence of HA-bound rfhSP-D was not significantly
different from that in HA alone or untreated SKBR3 and BT474
cells. Therefore, these findings suggest that pro-apoptotic effects
of rfhSP-D are modulated by HA addition. However, there
was no significant difference in the proliferation of BT20 cells
among all the conditions, suggesting that these cells continue
to grow and are not affected by rfhSP-D treatment alone or in
conjunction with HA. It is also possible that addition of HA
may modulate the interaction of rfhSP-D-treated cells with pro-
apoptotic signaling pathways, thereby restricting the possibility
of apoptosis induction. Thus, addition of HA could facilitate cell
proliferation by interacting with proliferative signaling cascades
(e.g., Ras-ERK and PI3K-Akt). Even though breast cancer tissues
express SP-D (Figures 4i,ii), the presence of HAwithin the breast
tumor microenvironment seems to provide a self-protective coat,
thus negating the anti-tumorigenic properties of SP-D. Since
BT474 and SKBR3 cells treated with rfhSP-D undergo apoptosis
and addition of HA to rfhSP-D enhances cell proliferation, it
is likely that breast cancer cells can use HA in their tumor
microenvironment as an escape mechanism from apoptosis
induction triggered by rfhSP-D.
To further understand the mechanism of apoptosis
induction by rfhSP-D treatment, the likely signaling pathways
involved in tumor adhesion, proliferation, and cell death were
analyzed. rfhSP-D treatment resulted in increased levels of p53
phosphorylation (at Ser15), possibly mediated by oxidative stress
caused by rfhSP-D (17, 49). p53 is an essential transcriptional
modulator of apoptosis and plays a crucial role in cellular
response to DNA damage as well as other genomic alterations.
Phosphorylated p53 and increased levels of P21/P27 expression
may cause inactivation of cyclin B–cdc2 complexes that are
crucial in regulating G2/M cell cycle transition, causing DNA
repair or induction of apoptosis (17). However, decreased levels
of caspase 3 and p53 were detected in HA + rfhSP-D-treated
cells, possibly suggesting its resistance to apoptosis by addition
of HA. Although the p21 trigger is p53 dependent in certain
events such as DNA damage, there are several scenarios in which
p21 expression is independent of p53 status, such as normal
tissue development and differentiation. p21 can lead to tumor
evolution directed toward tumor growth by slowing down the
accumulation of DNA damage. Induction of p21 expression has
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been shown to be crucial for promoting motility of tumor cells
and tumorigenesis. Due to controversial roles of p21, it can be
considered as an oncogenic protein and/or tumor suppressor,
depending on its cytoplasmic localization. The dual roles of
p21 as an oncogenic or tumor suppressor make it difficult to
study the mechanisms involved in p53–p21-mediated apoptosis
induction or cancer progression.
Targeting HA synthesis, accumulation, degradation, or HA–
receptor interaction represents a potential therapeutic approach
for treatment of breast and other cancers. The use of 4-
MU to inhibit HA synthesis has been shown to reduce
breast cancer proliferation and migration (54–57). 4-MU
treatment has also been shown to inhibit intracellular and
cell surface HA (57), in addition to suppression of Akt
phosphorylation. Use of hyaluronidases to degrade HA in the
tumor microenvironment has also been considered as a potential
therapeutic approach for cancer. Bacteriophage hyaluronidase
has been shown to effectively inhibit growth, migration, and
invasion of breast cancer cells (58). Hyaluronidase treatment has
also shown promising outcomes in pancreatic cancer in clinical
trials (59–61). Furthermore, recombinant human hyaluronidase
(rHUPH20) has been shown to improve drug delivery of
antibody-based trastuzumab targeted therapy in HER2+ breast
cancer (62). A recent study has shown that HA degradation
by pegvorhyaluronidase (PVHA) can remodel the TME in a
murine model of breast cancer so as to increase the uptake of
anti-ProgrammedDeath-Ligand 1 (PD-L1) therapeutic antibody.
PVHA treatment coincided with a dramatic effectiveness of anti-
PD-L1 antibody in reducing the tumor growth (63).
Involvement of rfhSP-D and its associated pro-apoptotic
properties in cancer models might be a novel therapeutic agent
to target multiple cellular signaling pathways, including tumor
cell survival factors, transcriptional factors, protein kinases, and
pro-apoptotic gene signatures. The mechanism which enables
rfhSP-D to induce apoptosis and inhibit tumor cell proliferation
is tumor specific due to the differential effects on the cell
types and probably expression of putative receptors. The nature
of interaction between HA + rfhSP-D and cellular receptors
is currently under investigation. The function of SP-D in the
biology of cancer is complex and is strongly dependent on the
tumor microenvironment. As SP-D and HA are overexpressed
in breast cancer and other carcinomas, targeting both HA and
SP-D is clinically relevant to inhibit HA-mediated intracellular
signaling that negates the pro-apoptotic role of rfhSP-D. It is
important to note that FL-SP-D purified from BT474 was not
able to induce apoptosis in any of the three breast cancer cell
lines. The plausible reasons could be that the tumor cells produce
a dysfunctional protein owing to mutations, protein misfolding,
and/or altered oligomerization.
In conclusion, rfhSP-D treatment was able to induce
apoptosis in BT474 and SKBR3 cell lines involving the
intrinsic apoptotic pathway, while having no effect on the
triple-negative BT20 cell line. In addition, HA-bound rfhSP-
D was able to restore cell growth, suggesting that these
breast cancer cells may use HA as an escape mechanism to
overcome pro-apoptotic effects of rfhSP-D. The mechanisms by
which HA-bound rfhSP-D restores cell proliferation are yet to
be elucidated.
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C4b Binding Protein (C4BP) is a major fluid phase inhibitor of the classical and lectin
pathways of the complement system. Complement inhibition is achieved by binding to
and restricting the role of activated complement component C4b. C4BP functions as a
co-factor for factor I in proteolytic inactivation of both soluble and cell surface-bound C4b,
thus restricting the formation of the C3-convertase, C4b2a. C4BP also accelerates the
natural decay/dissociation of the C3 convertase. This makes C4BP a prime target for
exploitation by pathogens to escape complement attack, as seen in Streptococcus
pyogenes or Flavivirus. Here, we examined whether C4BP can act on its own in a
complement independent manner, against pathogens. C4BP bound H1N1 and H3N2
subtypes of Influenza A Virus (IAV) most likely via multiple sites in Complement Control
Protein (CCP) 1-2, 4-5, and 7-8 domains of its a-chain. In addition, C4BP CCP1-2 bound
H3N2 better than H1N1. C4BP bound three IAV envelope proteins: Haemagglutinin (~70
kDa), Neuraminidase (~55 kDa), and Matrix protein 1 (~25kDa). C4BP suppressed H1N1
subtype infection into the lung epithelial cell line, A549, while it promoted infection by
H3N2 subtype. C4BP restricted viral entry for H1N1 but had the opposite effect on H3N2,
as evident from experiments using pseudo-typed viral particles. C4BP downregulated
mRNA levels of pro-inflammatory IFN-a, IL-12, and NFkB in the case of H1N1, while it
promoted a pro-inflammatory immune response by upregulating IFN- a, TNF-a, RANTES,
and IL-6 in the case of H3N2. We conclude that C4BP differentially modulates the efficacy
of IAV entry, and hence, replication in a target cell in a strain-dependent manner, and acts
as an entry inhibitor for H1N1. Thus, CCP containing complement proteins such as factor
H and C4BP may have additional defense roles against IAV that do not rely on the
regulation of complement activation.
Keywords: complement, C4BP, influenza A virus, inflammation, pseudo-typed lentiviral particlesorg January 2021 | Volume 11 | Article 5853611
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The complement system plays a crucial role in our early response
against invading pathogens, including viruses. The complement
system is activated via three pathways—Classical, Alternative,
and Lectin. The classical pathway is activated through the
binding of C1q to IgG or IgM-containing immune complexes
or other non-immunoglobulin targets. Non-self-carbohydrate
targets are recognized by Mannose Binding Lectin (MBL) or
ficolins triggering the lectin pathway. The activation of classical
or lectin pathways leads to the cleavage of C4 and C2, yielding C3
convertase (C4b2a), which then cleaves C3 to form C3b. For the
alternative pathway, C3 is spontaneously hydrolyzed to a C3b-
like form [C3(H2O)] due to the hydrolysis of the internal
thioester bond. The C3(H2O) binds to Factor B, which enables
Factor D to cleave Factor B to Bb. This then forms C3(H2O)Bb,
which is homologous to the C3 convertase, C4b2a. C3(H2O)Bb
then cleaves C3 to C3b, and C3b can bind covalently to target
surfaces, on which it forms more convertase, C3bBb. The
binding of the C3b to C4b2a or C3bBb converts them into
classical or alternative pathway C5 Convertases, respectively. The
subsequent cleavage of C5 by the C5 convertases initiates the
formation of the Membrane Attack Complex (C5b-C9). This
complex binds to the microbial surface and can cause lysis of
lipid bilayer membranes (1).
The complement system is kept in check by various regulatory
proteins to prevent runaway reactions leading to unnecessary
inflammation and death of healthy cells. One such humoral
regulator is C4b Binding Protein (C4BP). C4BP, like other
complement regulators Factor H, CR1, CD46, CD55, and the
Factor H-related family, is encoded by a gene present in the long
arm of chromosome 1 and is synthesized and secreted mainly by
hepatocytes (2). The normal range of C4BP in human plasma is
estimated to be approximately 150–300 µg/ml (3). C4BP regulates
complement activation by controlling C4b mediated reactions (4).
C4BP, a 570 kDa glycoprotein, functions as a primary fluid phase
regulator of the classical and lectin pathways (5). It consists of seven
identical 70 kDa a-chains and a 45 kDa b-chain that are linked at
their carboxy-terminal ends by short amphipathic helices further
stabilized bydisulfide bonds (6). Thea- chains andb-chain contain
eight and three ComplementControl Protein (CCP) domains, each
of ~60 amino acids, respectively. The polymerization of the
polypeptide chains of C4BP occurs via a short C-terminal region,
downstream of CCP8 (7). Each molecule of C4BP can bind only
fourmolecules of C4b due to steric hindrance, although each of the
sevena- chains has a C4b binding site (8). The binding site for C4b
has been localized to CCP1-3, especially within a cluster of
positively charged residues at the interface of CCP1 and CCP2 (9,
10). C4BP has been shown to inhibit the formation of C3 and C5
convertases, accelerate the decay of the convertases, and act as a co-
factor for Factor I which cleaves and thereby inactivates fluid phase
and cell-boundC4b (9–12). The co-factor activity of the protein has
been linked to CCP1-4 (13).
Consistent with its role as an immunomodulator, C4BP also
engages with pathogens. Flaviviruses limit complement
activation by binding C4BP through their NS1 protein: the
bound C4BP inactivates soluble or membrane-bound C4b (5).Frontiers in Immunology | www.frontiersin.org 2Streptococcus pyogenes uses its Protein H to recruit C4BP in
order to facilitate the invasion of endothelial cells and reduce the
chances of its opsonization by bound C3b, or attack by the MAC
(14). C4BP probably is also recruited by other pathogens to limit
C3 opsonization, MAC mediated lysis, and immune system
activation by C3a/C5a (15).
C4BPhas been reported to have properties that are independent
of its involvement in complement regulation. For example, C4BP
is known to facilitate the uptake of adenoviruses by hepatocytes via
its interaction with heparin-sulfate proteoglycans found on cell
surfaces (16). C4BP induces proliferation and activation of B
lymphocytes by binding with CD40 (17). Interaction between
CD40, CD154, and C4BP inhibits apoptosis in epithelial cells.
C4BP has also been implicated in inhibiting DNA release from
necrotic cells in conjunction with Protein S by binding to
phosphatidylserine (18–20). C4BP also have an association with
the clotting system as the b-chain binds the vitamin K-dependent
anticoagulant protein S (21).
In this study, we investigated potential complement-
independent defense functions of C4BP against Influenza A
Virus (IAV). Influenza virus causes an upper respiratory tract
infection affecting the nose, throat, bronchi, and sometimes the
lungs. Of the three genera of Influenza virus that belong to the
Orthomyxoviridae family, IAV is known to cause pandemics.
IAV causes Influenza in birds and a few species of mammals,
including humans and pigs. Its wide host range has led to
pandemics such as the 1918 Spanish flu, which caused 20–50
million deaths (22). It has several subtypes based on variants of
two proteins on the surface of the viral envelope. These proteins
are Hemagglutinin (HA), which causes RBCs to agglutinate, and
Neuraminidase (NA), which breaks the glycoside bonds of
neuraminic acid (23). Currently, there are 18 known variations
of HA, and 11 known variations of NA, theoretically allowing
198 different combinations (24, 25). Some of the well-known
combinations are H1N1 that caused the 1918 Spanish flu, 1977
Russian flu, and 2009 flu Pandemic, H3N2 that caused the 1968
Hong Kong flu and H2N2 that caused 1957 Asian flu (26).
Human infection by IAV is achieved through oral or nasal
cavities, where the viral HA binds sialic acids in order to attach to
lung epithelial cells (27). The HA protein of the human-infecting
IAV has increased specificity for a-2,6-linked sialic acid (28). Sialic
acid, a nine-carbon acidic monosaccharide, is commonly found
with a-2,6-linkages and a few a-2,3-linkages on human tracheal
epithelial cells (29). Once bound to the cell surface, the viral particle
undergoes receptor-mediated endocytosis. We show here that IAV
interacts with the a chain of C4BP mainly via CCP domains 4–5,
CCP domains 7–8, and to a lesser extent CCP domains 1–2. C4BP
acts as anentry inhibitor forH1N1subtypewhenchallengedagainst
A549 (lung epithelial) cells and suppresses the pro-inflammatory
cytokine storm induced by IAV.MATERIALS AND METHODS
Purification of Native C4BP
C4BP was isolated from human plasma as described previously
(30). Briefly, C4BP was purified from neutral euglobulinJanuary 2021 | Volume 11 | Article 585361
Varghese et al. C4BP Interaction With Influenzaprecipitate by affinity chromatography using C4c-Sepharose,
equilibrated in 5 mM EDTA/25 mM potassium phosphate
buffer, pH 7.0. The column was washed in the same buffer and
then bound protein was eluted by a linear gradient of NaCl from
0 to 2 M; C4BP was eluted at 0.8 M NaCl. The peak fractions
were run on 12% w/v acrylamide SDS-PAGE to assess purity and
adjusted to 1 mg/ml concentration. The immunoreactivity of this
plasma purified C4BP was assessed via western blotting.
Expression and Purification of
Recombinant Complement Control Protein
Deletants of C4BP a-Chain
Recombinant a-chain of C4BP (rC4BP) and C4BP a-chain CCP
deletants (Table 1) were provided by Prof. Anna Blom, Lund
University, Malmo, Sweden. Briefly, CCP deletant constructs
were expressed in Human Embryonic Kidney (HEK) 293 cells
(ATCC number 1573-CRL). The transfected cells were selected
using neomycin analogue G418 (400 mg/ml), and colonies
expressing the highest amount of CCP deletants were assessed
by immunoblotting. The medium collected from transfected cells
was subjected to the purification of CCP deletants using mAb
104 affinity columns (directed against CCP1) or mAb 67
(directed against CCP4) coupled to Affi-Gel 10 (2.6 × 12 cm
column; Bio-Rad) (10). The recombinant CCP deletants were
eluted using 3M guanidinium chloride, and the purified fractions
were subjected to SDS-PAGE with 12% w/v acrylamide/
bisacrylamide (10).
Preparation of Viral Stocks and Titration
A/England/2009 (H1N1) was a gift from Wendy Barclay,
Department of Infectious Disease, Imperial College London,
and the A/HK/99 (H3N2) was a gift from Leo Poon, Division
of Public Health Laboratory Sciences, University of Hong Kong.Frontiers in Immunology | www.frontiersin.org 3Madin Darby Canine Kidney (MDCK) (ATCC® CCL-34™)
cells, grown to 70% confluence in a 175 cm2 flask (Fisher
Scientific) in growth medium (DMEMF/12 with GlutaMAX™
Supplement (Gibco), + 10% v/v Heat Inactivated Fetal Bovine
Serum (FBS) (Gibco) + 1% v/v Penicillin-Streptomycin (PS)
(Gibco) at 37°C under 5% v/v CO2, were washed with PBS
twice to remove any residual serum-complemented DMEM
media. H1N1 and H3N2 IAV subtypes were added to the
MDCK cells diluted in serum-free DMEM (Gibco) and allowed
to incubate for 1 h at 37°C. The medium was removed, and cells
were washed with Phosphate-buffered saline (PBS) (0.01M
sodium phosphate, 0.0027M KCl, and 0.137M NaCl, pH 7.4 at
25°C) (Fisher Bioreagents) to remove any unbound viruses. The
cells were then incubated for 3 days at 37°C in the infectionmedium
[DMEM + 1% penicillin/streptomycin + 0.3% w/v bovine serum
albumin (BSA) + 1 µg/ml of l-1-Tosylamide-2-phenylethyl
chloromethyl ketone (TPCK)-Trypsin] (Sigma-Aldrich)]. TPCK
treated Trypsin mediates the cleavage of HA0 into two subunits
HA1 and HA2, which are required to make HA fusion competent.
After the incubation, the medium was collected and centrifuged in
sealed containers at 3,000 × g at 4°C for 15 min. The supernatant
containing the viral particles was harvested, and the titer of the
particles was determined via 50% Tissue culture Infective Dose
(TCID50) Assay. Purified virus stocks were serially diluted in a 96-
well plate up to 10−7-fold with ½ log10 increments. 1 × 10
5 MDCK
cells were added to eachwell and incubated for 3 days at 37°Cunder
5% v/v CO2. UninfectedMDCK cells were used as negative control.
The titter of the virus was determined to be 1 × 106 PFU/ml by
TCID50 using the Reed–Muench method (31).
Production of Pseudo-Typed Lentiviral
Particles
Pseudo-typed Lentiviral Particles were produced as previously
described by Murugaiah et al., 2020 (32). Briefly, HEK 293T cells
were cultured in RPMI 1640 (Gibco), supplemented with 10%
v/v heat inactivated Fetal Bovine Serum (FBS) (Gibco), 1% v/v
Penicillin-Streptomycin (Gibco) at 37°C under 5% v/v CO2. Cells
were co-transfected using 20 µg of the Envelope Protein-Coding
plasmids that yield the viral envelope proteins [H1 and N1 or H3
and N2 or Vesicular Stomatitis Virus G protein (VSV-G)], an
HIV-backbone containing a modified pro-viral HIV-1 genome
with the env deleted and designed to express the firefly luciferase
reporter and second or third-generation lentiviral vector
packaging plasmid (Table 2). The culture supernatant was
collected after 48 h (by centrifugation at 1,500 × g for 5 min).TABLE 1 | C4BP deletants used in this study.












pcDNA3.1-swineH1-flag (H1 from swine H1N1 A/California/04/
09) (Codon optimized H1 (Genecust))
pcDNA-H3 [H3 from A/Denmark/70/03/(H3N2)]
(Codon optimized H3 (Geneart))
pCMV-VSV-G (Addgene
plasmid # 8454)
pcDNA3.1-swine N1-flag (N1 from swine H1N1 A/California/04/
09) (Codon optimized N1 (Genecust))
pI.18-N2 (N2 from human H3N2 A/Texas/50/
2012)
Backbone Plasmid pHIV-Luciferase (Addgene plasmid # 21375)
Packaging Plasmid psPAX2 (Addgene plasmid # 12260)January 2021 | Volume 11 | Article 585361
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mM Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA, 0.1% v/v
Triton X-100) and were centrifuged at 1,500 × g for 5 min to
remove cell debris. The total lysate and supernatant were filtered
with a 22 µm filter. The pseudo-typed lentiviral particles were
harvested by centrifuging the filtered cell lysate and the
supernatant at 5,000 × g for 10 min at 4°C in a closed
container. The lentiviral particles in the supernatant were then
concentrated by ultracentrifugation at 25,000 × g for 3 h at 4°C
(33). The pseudo-typed lentiviral particles produced were
characterized by western blotting (32).
ELISA to Detect C4BP-Virus Interaction
Microtiter wells of 96-well plates (Nunc # 4912) were coated
(4°C, overnight) with the virus [100 µl of H1N1 or H3N2
subtypes (1,000 PFU/ml)] in carbonate-bicarbonate buffer, pH
9.6 (Sigma # c3041). Other wells were coated with 100 µl/well of
C4BP, a-chain CCP mutants, at 5, 2.5, 1.25 µg/ml in the same
buffer. In another experiment, 5 µg/ml of rC4BP was similarly
coated. Unbound proteins or viruses were removed by washing
the wells three times with PBST Buffer (PBS + 0.05% Tween 20)
(Fisher Scientific). The wells were then blocked using 2% w/v
BSA in PBS (Fisher Scientific) for 2 h at 37°C and washed three
times using PBST. Decreasing concentrations of C4BP (5, 2.5,
1.25 µg/ml) were added to the wells in which the virus was coated
to study its binding to immobilized viral particles. In parallel
experiments, 1,000 PFU/ml of purified H1N1 and H3N2 were
added to the protein-coated wells to study the binding of the
virus to immobilized C4BP or rC4BP. The wells were incubated
for 2 h at 37°C and then washed with PBST to remove any
unbound viruses or protein. VSV-G pseudo-typed lentivirus was
used as a negative control. The wells were probed using
polyclonal rabbit anti-human C4BP (1 mg/ml of purified IgG;
MRC Immunochemistry Unit, Oxford) to detect the virus-bound
C4BP. Monoclonal Anti-Influenza Virus H1 HA, A/California/
04/2009 (H1N1)pdm09, Clone 5C12 (produced in vitro) (BEI-
Resources, NIAID, NIH, USA), Polyclonal Anti-Influenza Virus
H3 HA, A/Hong Kong/1/1968 (H3N2) (antiserum, Goat, NR-
3118) (BEI-Resources, NIAID, NIH, USA), and polyclonal anti-
VSV-G (1 mg/ml of purified IgG; Imperial College London) were
used to detect H1N1, H3N2 and pseudo-typed lentivirus
particles, respectively that were bound to the immobilized
C4BP. All antibodies were used at a dilution of 1:5,000 for 1 h
at 37°C. Unbound antibodies were removed by washing three
times using PBST. Anti-mouse IgG-Horseradish peroxidase
(HRP) (Promega, #W4021), goat anti-rabbit IgG HRP (1:1,000;
Promega # W4011), or Protein A-HRP (Invitrogen) were used as
appropriate at 1:5,000 dilution as secondary antibodies (1 h at
37°C). 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate set
(Biolegend) was used as per the manufacturer’s instruction,
and 1 M sulfuric acid (Fisher Chemical) was used to stop the
reaction. The plate was read at 450 nm using an iMark™
microplate absorbance reader (BioRad).
Western Blot
H1N1 and H3N2 (7.5 × 105 PFU/ml), treated with NuPAGE LDS
Sample Buffer (4X) (Invitrogen™) were subjected to 12% w/vFrontiers in Immunology | www.frontiersin.org 4reducing SDS-PAGE (120 min, 90 V). The proteins were then
transferred to Polyvinylidene fluoride (PVDF) membranes
(Millipore) by electroblotting (320 mA for 2 h) at 4°C. The
membrane was then blocked using 5% w/v skimmed milk in PBS
for 16 h at 4°C.
For far-western blot, the membrane was washed with PBS and
incubated with 5 µg/ml of C4BP for 1 h at room temperature and
another 1 h at 4°C on a rotary shaker. After washing with PBST,
the PVDF membrane was probed using rabbit polyclonal
anti-human C4BP antibody (1mg/ml) (1:1,000; MRC
Immunochemistry Unit, Oxford) for 1 h at room temperature
on a rotary shaker. Following three washes with PBST, the
membrane was probed again with goat anti-rabbit IgG HRP
conjugate (1:1,000; Promega #W4011) for 1 h; the blot was
developed using 3,3′-diaminobenzidine (DAB) (Sigma) as
a substrate.
For direct western blot for viral proteins, the PVDF
membrane, containing electro-transferred viral proteins, was
incubated with appropriate antibodies: these included
monoclonal anti-IAV H1, polyclonal anti-IAV H3, Monoclonal
anti-IAV Neuraminidase (NA), Clone NA2-1C1 (produced in
vitro) (BEI-Resources, NIAID, NIH, USA), Polyclonal Anti-
Influenza Virus N2 Neuraminidase (NA), A/shorebird/
Delaware/127/1997 (H6N2) (antiserum, Goat) (BEI-Resources,
NIAID, NIH, USA), Monoclonal Anti-Influenza A Virus Non-
structural Protein 1 (NS1), Clone NS1-1A7 (produced in vitro)
(BEI-Resources, NIAID, NIH, USA), or Monoclonal anti-Matrix
protein 1 (M1) antibody (Abcam) as required for 1 h at room
temperature on a rotary shaker. Following three washes with
PBST, the membrane was probed with either anti-mouse HRP or
Protein A-HRP conjugate, as appropriate for 1 h at room
temperature on a rotary shaker. Following three washes with
PBST, the blot was developed using DAB.
A549 Cell Infection Assay
Human alveolar basal epithelial cells derived from an
adenocarcinoma (A549) (ATCC® CCL-185™) (5 × 105) were
cultured for 12 h in each well of a 12-well plate in growth
medium. Post-attachment, the cells were serum starved by
incubating them in serum-free DMEM for 24 h. H1N1 and
H3N2 subtypes (MOI 1) were incubated with C4BP (10, 20, or 40
µg/ml) in PBS for 1 h and added to A549 cells in serum-free
DMEM. After 1 h incubation at 37°C, the medium was removed,
and cells were washed with PBS to remove any unbound IAV.
Infection medium (DMEM + 1% v/v Penicillin-Streptomycin +
0.3% w/v BSA + 1 µg/ml of TPCK-Trypsin) was added to the
cells and incubated for 2 or 6 h. The cells were then harvested by
scraping with a sterile disposable cell scraper and centrifuging at
1,500 × g for 5 min. Total RNAwas extracted using the GenElute™
Mammalian Total RNA Miniprep Kit (Sigma). Contaminating
DNA was removed by treating the RNA samples with DNase I
(Sigma) for 15 min. DNase I was inactivated by heating at 70°C
for 10 min. The quantity and quality of the extracted RNA
were assessed using a Nanodrop 2000 spectrophotometer
(Thermo Fisher) via absorbance at 260 nm and 260:280 nm
ratio. mRNA was converted to cDNA using TaqMan™ High
Capacity RNA to cDNA Kit (Applied Biosystems™). The cDNAJanuary 2021 | Volume 11 | Article 585361
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using a StepOnePlus System (Applied Biosystems™) at 95°C for
5 min, followed by 45 cycles of 95°C for 10 s, 60°C for 10 s,
and 72°C for 10 s. The specificity of the assay was established
by melting-curve analysis. The relative expression (RQ)
was calculated by using C4BP untreated cells infected with
respective viruses as the calibrator. The RQ value was
calculated using the formula: RQ = 2−DDCt. Primers were
generated for specificity using the Primer-BLAST software
(Basic Local Alignment Search Tool) (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) (Table 3).
Luciferase Assay
MDCK cells were seeded in a 96-well plate (1 × 105 cells per well)
and were serum starved. The cells were infected for 24 h in the
infection medium with 50 µl of the H1N1 and H3N2 pseudo-
typed particles that were pre-incubated with C4BP for 1 h, or
pseudo-typed particles that were not treated with C4BP. Post-
infection, luciferase activity in the cells was measured using
Pierce™ Firefly Luc One-Step Glow Assay Kit (Thermo Fisher)
and CLARIOstar Plus Plate Reader (BMG Labtech).
Statistical Analysis
GraphPad Prism 8.0 software was used to create all graphs. Two-
way ANOVA was used to find the statistical significance of the
data generated. Significant values were considered based on *p <
0.1, **p < 0.05, ***p < 0.01, and ****p < 0.001 between treated
and untreated conditions. Error bars show the standard
deviation among the samples.RESULTS
C4BP Directly Binds to Influenza A Virus in
a Dose-Dependent Manner
Native C4BP, purified from plasma, was run on a 12% w/v
reducing SDS-PAGE, which revealed a band corresponding to
a-chain (~70 kDa), and one corresponding to b-chain (~45 kDa)
(Figure 1A). The immunoreactivity of the protein was determined
by performing a western blot with rabbit polyclonal anti-human
C4BP antibodies, which yielded a band corresponding to the a-
chain (~70 kDa) of C4BP. However, the b-chain (~45 kDa) was
barely visible (Figure 1B). Indirect ELISA was then performed to
examine the binding of C4BP to IAV subtypes. Binding of
immobilized C4BP to the virus (Figure 2A), and conversely, ofFrontiers in Immunology | www.frontiersin.org 5immobilized virus to C4BP (Figure 2B) was observed. As evident
in Figures 2A, B, C4BP bound to H3N2 and H1N1 in a dose-
dependent manner; binding to H3N2 was greater than to H1N1
(Figure 2A) subtype. Recombinant C4BP alpha chain (rC4BP)
(Supplementary Figure 1) was also used to confirm its binding to
the virus. No significant difference in binding efficiency was
observed between the recombinant C4BP and the plasma
purified C4BP (Figures 2C, D).
C4BP Binds HA, NA, and M1 Proteins of
Influenza A Virus
In order to identify the IAV proteins that interact with C4BP,
far-western blot analysis was performed. When SDS-PAGE
separated IAV proteins were probed with C4BP, it revealed
that C4BP interacted with IAV viral proteins Hemagglutinin
(HA) (~70 kDa), Neuraminidase (NA) (~55 kDa) and Matrix
protein 1 (M1) (~25kDa) (Figure 3A). The identities of C4BP
bound IAV glycoproteins were confirmed using separate blots
that were directly probed with anti-HA (Figure 3B), anti-NA
(Figure 3C), anti-M1 (Figure 3D), or anti-NS1 antibodies
(Figure 3E). IAV proteins separated by SDS-PAGE were
probed directly with anti-C4BP antibodies to rule out non-
specific interaction between the antibody and IAV proteins
(Figure 3F). NS1 protein has similar molecular weight to M1,
but the blot with antibodies confirmed M1 as the 25kDa species
involved in binding.
Influenza A Virus Binding Sites Within
C4BP a-Chain Appear to Be Localized
Within CCP4-5 and CCP7-8 Modules
To identify the likely binding site on C4BP for the IAV, an
indirect ELISA was performed using recombinant C4BP a-chain
mutants lacking individual CCP domains. Recombinant C4BP
lacking CCP4, 5, 7, or 8 showed relatively weaker binding to
H1N1 and H3N2 subtypes. The deletion of CCP domain 8
reduced binding by approximately 75% for both subtypes
when compared to full-length C4BP. Deletion of CCP7
resulted in reduced binding for H1N1 (~49%) as well as H3N2
(~62%). The CCP4 and 5 deletion mutants lost ~80% binding
activity for H3N2 and ~60% for H1N1. Approximately 20% loss
of binding for H1N1 was observed in the case of CCP1 and 2
deletants, but the same deletants showed ~80% reduction in
binding to H3N2. The loss of CCP domains 3 and 6 caused a
small increase in binding by approximately 10% for both IAV
subtypes. This indicates that C4BP binds both IAV subtypesTABLE 3 | Forward and reverse primers used for qRT-PCR.
Target Forward primer Reverse primer
18S 5′-ATGGCCGTTC TTAGTTGGTG-3′ 5′-CGCTGAGCCA GTCAGTGTAG-3′
IL-6 5′-GAAAGCAGCA AAGAGGCACT-3′ 5′-TTTCACCAGG CAAGTCTCCT-3′
IL-12 5′-AACTTGCAGC TGAAGCCATT-3′ 5′-GACCTGAACG CAGAATGTCA-3′
TNF-a 5′-AGCCCATGTT GTAGCAAACC-3′ 5′-TGAGGTACAG GCCCTCTGAT-3′
M1 5′AAACATATGTCTGATAAC GAAGGAGAACAGTTCTT-3′ 5′GCTGAATTCTACCT CATGGTCTTCTTGA-3′
RANTES 5′-GCGGGTACCAT GAAGATCTCTG-3′ 5′-GGGTCAGAATC AAGAAACCCTC-3′
IFN-a 5′-TTT CTC CTG CC T GAA GGA CAG-3′ 5′-GCT CAT GAT TTC TGC TCT GAC A-3′January 2021 | Volume 11 | Article 585361
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(Figure 4). However, in the case of the H3N2 subtype, and to a
lesser extent H1N1 subtype, it appears that there is an additional
binding interaction with CCPs 1-2 (Figure 4B). This may be
consistent with greater binding to H3N2. VSV-G pseudo-typedFrontiers in Immunology | www.frontiersin.org 6lentivirus that was used as negative control showed no significant
binding (Figure 4C).
C4BP Inhibits H1N1 Replication
HA, NA, and M1 are essential IAV proteins which have many
functions from viral entry to virion budding, bringing about IAV
infectivity and replication. Therefore, we investigated the effect of
C4BP on cell infection. A549 cells were challenged with either
H1N1 or H3N2 for 6 h that were previously incubated with
C4BP. The efficacy of replication was estimated by comparing
the M1 expression levels of the virions treated with C4BP (10, 20,
or 40 µg/ml) to the cells infected with IAV but, not treated with
C4BP. M1 mRNA levels were downregulated by C4BP in the case
of H1N1 (−4 log10), suggesting that the interaction of C4BP with
H1N1 reduced the replication efficiency of the virus at an early
stage of the replication cycle. However, in the case of A549 cells
challenged with H3N2, M1 mRNA levels were found to be
upregulated (2 log10), suggesting an increase in IAV replication
efficacy. Taken together, these results suggest that C4BP
differentially modulates viral entry, and thus, replication
efficacy among the IAV subtypes (Figure 5).
C4BP Is an Entry Inhibitor for H1N1
As C4BP was found to interact with HA and NA, the IAV
proteins that play an integral role in viral host cell recognition
and entry, lentiviral pseudo-particles were used to study the
entry process independent of other IAV components. The
pseudo-particles expressing the respective IAV coat proteins
with an HIV-Luciferase backbone were used as a safer
alternative to assess the role of C4BP as an entry modulator of
H1N1 and H3N2. This system contains a single packaging
plasmid (psPAX2) encoding genes including Gag, Pol, and Tat.
pHIV-Luciferase was used as a lentiviral transfer plasmid, which
is flanked by long terminal repeat (LTR) sequences and designed
to express the firefly luciferase reporter. Thus, pHIV-Luciferase is
replication-incompetent which contains an additional sequence
deletion in the 3′ LTR leading to viral self-inactivation post-
integration. Purified H1+N1 and H3+N2 pseudo-typed particles
pre-incubated with C4BP (20 mg) were used to infect MDCK
cells. The lentiviral particles not treated with C4BP were used as
controls. A ~56% reduction in luciferase reporter activity was
observed when MDCK cells infected with C4BP-treated H1+N1
pseudo-typed particles were compared to their untreated
counterparts. However, an opposite effect, although not so
dramatic, was observed following C4BP treatment in the case
of H3N2 unmatched pseudo-particles. A ~17% increase in
luciferase activity was observed in the treated samples when
compared to the control (Figure 6). C4BP protein seems to be
acting as an entry inhibitor for H1N1, but a weak facilitator of
infection by H3N2.C4BP Modulates Pro-inflammatory
Cytokine/Chemokine Response
in IAV-Challenged A549 Cells
Pro-inflammatory cytokines and chemokines, such as IL-1, IL-6,
IL-12, IFN-a, and NF-kB transcription factor, are a hallmark ofA
B
FIGURE 1 | Characterization of purified C4BP. (A) SDS-PAGE (12% w/v
acrylamide/bisacrylamide) was loaded with 5 µg of purified C4BP in lane 2, along
with a protein ladder with a range of 250 to 10 kDa (Thermofisher) in lane 1. The
denatured and reduced samples were run for 120 min at 90 V and stained with
Coomassie brilliant blue to reveal protein bands corresponding to the a-chain
(~70kDa) and a faint band corresponding to b-chain of C4BP (~45 kDa).
(B) Immunoreactivity of the purified C4BP was analyzed by western blotting. A
PVDF membrane with 1.25, 2.5, and 5 µg of purified C4BP in lanes 2, 3, and 4,
respectively, along with a protein ladder with a range of 250 to 10 kDa
(Thermofisher) in lane 1 was probed using rabbit-anti-human C4BP polyclonal
antibodies (1:1,000) at room temperature for 1 h, followed by incubation with
secondary goat anti-rabbit IgG HRP-conjugate (1:1,000) for 1 h at room
temperature. Bands corresponding to a-chain (~70 kDa) and the b-chain
(~45 kDa) of the C4BP were observed after developing the color using 3,3′-
diaminobenzidine (DAB) substrate.January 2021 | Volume 11 | Article 585361
Varghese et al. C4BP Interaction With InfluenzaIAV infection (34). In order to understand the effect of C4BP on
the pro-inflammatory cytokines produced during IAV infection,
A549 cells were challenged with H1N1 and H3N2 viruses
(MOI 1) preincubated with C4BP. qRT-PCR was then carried
out using total RNA from the cells (Figure 7), using cells infected
with IAV that were not treated with C4BP as the control. C4BP
treated H1N1 challenged A549 cells showed lower levels of IFN-
a (-2 log10) at both 2 and 6 h, whereas cells challenged with C4BP
treated H3N2 exhibited higher levels of IFN-a 6 h post-infection
(Figure 7A). IL-12 is essential for the generation of cell-mediated
immunity via the production of IFN-g by helper type 1 T (Th1)
cells, which leads to the elimination of the virus (35). Levels
of IL-12 at 2 h in case of A549 cells challenged with either C4BP
treated H1N1 or H3N2 were not detectable (Figure 7B). At 6 h
in C4BP treated H1N1 challenged cells, IL-12 levels were
downregulated (−2 log10), while in cells challenged with C4BP
treated H3N2 the levels were upregulated (1 log10) (Figure 7B).
As interferon response is triggered by the detection of viral
components within infected cells, and IL-12 induction requires
live viruses, these results are consistent with the previously
observed levels of M1 transcript.
The transcription factor, NF-kB, is a regulator of antiviral
cytokines such as IFN-b, which initiates a strong type I IFN
immune response. IAV induces IFN expression via NF-kB as
viral titer levels are higher in cells treated with an anti-IFN-a/b
receptor antibody and not in dominant-negative IkBaFrontiers in Immunology | www.frontiersin.org 7expressing cells (36). NF-kB mRNA levels at 2 h were slightly
upregulated in C4BP treated H1N1 challenged cells and no
significant change in its levels were observed in cells challenged
with C4BP treated H3N2 (Figure 7C). Cells infected with C4BP
treated H1N1 at 6 h exhibited lower levels of NF-kB (−1 log10),
and no significant changes were observed in C4BP treated H3N2
infected cells (Figure 7C). The lower levels of NF-kB can be
attributed to either low viral titer in the case of H1N1 or the IAV
non-structural protein NS1 which acts as a major suppressor of
NF-kB activation (37).
Increased levels of IL-6, TNF-a, and IFN-g, have been
detected in individuals infected with acquired acute as well as
severe seasonal IAV-infected patients (38, 39). Production of
TNF-a during IAV infection correlates with morbidity and
mortality rates in IAV infected humans and macaques (40, 41).
Six hours post-infection, TNF-a mRNA levels were upregulated
(2 log10) in A549 cells infected with C4BP treated H1N1 or
H3N2, while at the earlier 2-h time point a slight upregulation
was observed (Figure 7D).
RANTES is a C-C chemokine and a potent chemoattractant
for monocytes, T lymphocytes, basophils, and eosinophils. IAV,
via its HA, can induce RANTES expression, probably through
the activation of NF-kB, and cause airway hypersensitivity by
inducing the continuous infiltration of eosinophils (42). C4BP
treated H1N1 challenged A549 cells exhibited lower levels of
RANTES expression (−2 log10) at 2 h compared to the control;A B
DC
FIGURE 2 | Binding interaction of immobilized C4BP to IAV subtypes (A), and immobilized IAV subtypes to C4BP (B). Microtiter wells were coated with a varied
concentration of C4BP (5, 2.5, and 1.25 µg/ml) protein and incubated with constant volume of viruses (1,000 PFU/ml). Bound C4BP-IAV was probed with
monoclonal anti-influenza virus H1 and polyclonal anti-influenza virus H3 antibody (1:5,000). Another ELISA was performed by coating a constant concentration of
IAV subtypes (1,000 PFU/ml) and incubated with a varied concentration of C4BP protein (5, 2.5, and 1.25 µg/ml). IAV-C4BP interaction was detected using
polyclonal rabbit anti-human C4BP antibodies and anti-rabbit IgG-HRP-conjugated antibody (1:5,000). A validation ELISA to show the detection of H1N1 (C) and
H3N2 (D) binding to a recombinant C4BP (rC4BP) and plasma purified C4BP. Microtiter wells were coated with immobilized rC4BP and the plasma purified C4BP
(5 µg/ml), and incubated with H1N1 or H3N2 (1,000 PFU/ml). The binding between immobilized proteins and IAV subtypes were detected using monoclonal anti-
influenza virus H1 and polyclonal anti-influenza virus H3 antibody (1:5,000). VSV-G pseudo-typed lentiviral particles were used as a negative control; no significant
binding was observed. The data were expressed as the mean of three independent experiments done in triplicates ± SEM.January 2021 | Volume 11 | Article 585361
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H3N2 (Figure 7E). RANTES expression (2 log10) was
upregulated at 6 h in the case of both subtypes (Figure 7E).
Enhanced levels of IL-6 have been observed in the serum and
lungs of IAV infected patients. It is unknown whether IL-6 in
IAV infected patients contributes to lung pathology caused by
the viral infection or if increased levels of IL-6 contribute to a
protective mechanism against IAV (39, 43). Levels of IL-6 at 2 h
in C4BP treated A549 cells challenged with either virus were not
detectable (Figure 7F). At 6 h in C4BP treated H3N2 infected
cells, IL-6 levels (2 log10) were upregulated; in cells challenged
C4BP treated H1N1 the IL-6 levels (0.5 log10) were also
upregulated (Figure 7F). Studies also suggest that signals
mediated by IL-6 are crucial for survival against a non-lethal
dose of H1N1 infection, and IL-6/IL-6R deletion inhibits H1N1
clearance together with reduced neutrophils levels in the lungs of
infected mice (44).DISCUSSION
The Influenza virus, an upper respiratory tract pathogen, is
known to have caused some of the deadliest pandemics in
history. To develop better IAV treatment strategies and
mitigate the risk of the current viral strains evolving to a more
pathogenic one by reassorting among themselves, a better
understanding of the immune mechanisms against IAV is
required. Here, we examined the complement-independent
role of C4BP, a complement regulator, against IAV. ManyFrontiers in Immunology | www.frontiersin.org 8pathogens such as adenoviruses, Yersinia pestis, and Aspergillus
spp. are known to bind C4BP to promote survival and
proliferation (15). C4BP is a major fluid phase inhibitor of the
classical and the lectin pathways, making it a prime target for the
exploitation by pathogens to circumvent the host’s potent
humoral immune system, such as complement. In this study,
we sought to understand the interactions between C4BP and IAV
in a serum-free system and explore any complement-
independent functions of C4BP with respect to IAV.
We first established protein-protein interactions between
C4BP and IAV subtypes. C4BP a chain was found to bind
IAV subtypes (Figures 2A, B), and H3N2 was found to bind
C4BP with higher affinty than H1N1. This interaction with the a
chain of C4BP was further confirmed using rC4BP (Figures 2C,
D). The C4BP a chain was found to interact with viral envelope
protein HA, NA, and surprisingly, M1 (Figure 3). As the M1
protein lies beneath the lipid layer, the interaction likely occurs
by the abundantly present non-packaged M1 that are released
from ravaged cells during late stages of infection to help increase
the odds of survival of the virus (45).
It was also possible that C4BP interacted with IAV NS1, but
the signal was masked by the interaction of C4BP with M1 due to
the low concentrations of NS1 when compared to M1, as
proteins share similar molecular weights. Avirutnan et al. have
shown that Flavivirus NS1 restricted the activation of classical
and lectin pathways by binding to C4BP, thereby enabling the
virus to evade C4b mediated lysis (5). Since both NS1 proteins
share independent immunoregulatory functions, the binding of
Influenza NS1 with C4BP was also considered. Far western blotA B
D E F
C
FIGURE 3 | Far Western blot analysis showing C4BP binding to H1N1 and H3N2 proteins. PVDF membrane containing H1N1 and H3N2 virus proteins, separated
by SDS-PAGE was blocked with 5% w/v skimmed milk and incubated with 5 µg/ml of C4BP (A) or without C4BP (F) followed by washing steps. The membrane
was probed with rabbit-anti-human C4BP polyclonal antibodies (1:1,000) at room temperature for 1 h, followed by washing and incubation with secondary goat anti-
rabbit IgG HRP-conjugate (1:1,000) for 1 h at room temperature. Bands corresponding to Hemagglutinin (HA) (~70 kDa), Neuraminidase (NA) (~55 kDa), and Matrix
protein 1 (M1) (25 kDa) in the case of both H1N1 and H3N2 subtypes were revealed after developing colour using 3,3′-diaminobenzidine. The identities of C4BP
bound IAV glycoproteins were confirmed using separate blots that were directly probed with anti-HA (B), anti-NA (C), anti-M1 (D), or anti-NS1 (E) antibodies.January 2021 | Volume 11 | Article 585361
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M1 that C4BP bound to at ~26 kDa; probing with monoclonal
Anti-IAV NS1did not reveal any bands corresponding to NS1
protein. Furthermore, multiple sequence alignment and identity-Frontiers in Immunology | www.frontiersin.org 9similarity analysis on IAV NS1 [(Accession #: P03495; P03496)
and Flavivirus NS1 (Accession #: Q6J3P1 Residues: 779-1130)
(P29991) Residues: 776-1127; P06935 (Residues: 788-1139)]
performed using Clustal Omega and Sequence Manipulation
Suite (Data not shown) revealed IAV NS1 and Flavivirus NS1
have sequence similarity scores that are lower than 25%.
Use of deletion mutants lacking specific CCP domains of
C4BP revealed that H1N1 and H3N2 subtypes interacted via
multiple CCP domains, CCP1-2, CCP4-5, and CCP7-8 of the
C4BP a-chain. It is known that the Flavivirus NS1-C4BP binding
is mediated through CCP2-5 and 8. Since CCP8 is near to the C-
terminal oligomerization domain, its loss could affect the
conformational structure of C4BP, which can affect the
accessibility of NS1 to CCP2-5 (5). Similarly, the deletion of
CCP8 reduced IAV-C4BP binding by ~75% (Figure 4). Deletion
of CCP4-5 inhibited binding by ~79% to H3N2 and ~67% to
H1N1 (Figure 4). C4BP binds C4b through CCP1-3, with
domains 2 and 3 being the most critical for the interaction
(10). The loss of CCP1-2 reduced binding efficiency of H3N2
and, to a lesser extent, of H1N1 to C4BP (~80% for H3N2 and
~20% for H1N1) (Figure 4). It is possible that the IAV virus, like
other pathogens such as S. pyogenes, Neisseria gonorrhoeae,
Bordetella pertussis, Moraxella catarrhalis, Borrelia recurrentis,
Candida albicans, and Hemophilus influenzae, is exploiting the
natural binding site for C4b (8). This preference for the site can
be attributed to its immutability, accessibility and the fact that
the region may contain intrinsic properties which favor ligand
binding (46). Furthermore, this increased binding affinity
between CCP1-2 and H3N2 may explain the difference in the
binding efficiency of C4BP to H3N2 when compared to H1N1, as
seen in Figure 2. As plasma purified C4BP is a glycoprotein, and
therefore, is likely to contain N-glycosides that are sialylated; it is
possible for sialic acid residues to bind to HA/NA. C4BP
[UniProtKB - P04003 (C4BPA_HUMAN)] has N-linked
glycosylation only in CCP3 and CCP8 and so sialic acid is
likely to occur only at these sites. Our results do not implicate
CCP3 in binding, but it remains a possibility that CCP8 binding
could involve sialic acid.
It is likely that C4BP is regulating viral replication levels by
modulating viral entry. To establish this, second-generation
matched and unmatched lentiviral vectors, pseudo-typed for
H1+N1 and H3+N2, respectively, were generated. This system
was selected as a safe alternative method to mimic the structure
and surfaces of IAV and prove that C4BP acts as an entry
inhibitor in cells transduced with pseudo-typed IAV particles
that are restricted to only one replicative cycle. A luciferase
reporter assay revealed a 56% reduction in H1N1 pseudo-typed
viruses treated with C4BP that entered the cells, corresponding
with the 4-fold decrease observed in the M1 mRNA levels of
H1N1 infected cells (Figures 5 and 6), while a slight increase
(~17%) was observed in case of the H3N2 pseudo-particles
(Figure 6), consistent with M1 levels. This suggests that C4BP
acts as an entry inhibitor for H1N1 while it has limited restrictive
potential against H3N2.
Recently, factor H, the principal regulator of the alternative
pathway, and vaccinia virus complement control protein (VCP),A
B
C
FIGURE 4 | C4BP interacts with IAV through multiple CCP domains. ELISA
showing binding of C4BP CCP deletion mutants to (A) H1N1, (B) H3N2 and
(C) VSV-G: microtiter wells were coated with 5 µg/ml of the mutant C4BP
protein (as described in Table 1). 1000 PFU/ml of H1N1 or H3N2 virus was
added to all the wells. After incubation and washing steps, the bound virus
was measured with either monoclonal anti-influenza virus H1, polyclonal anti-
influenza virus H3 or polyclonal anti-VSV-G antibody. Results are normalised
against full length C4BP a chain. The data were expressed as the mean of
three independent experiments done in triplicates ± SEM. Significance was
determined using the two-way ANOVA test (*p < 0.05, **p < 0.01, and
****p < 0.0001) (n = 3).January 2021 | Volume 11 | Article 585361
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manner similar to C4BP (32). MDCK cells infected with H1+
N1pseudo-typed lentiviral particles resulted in approximately
25% and 45% reduction in luciferase activity after treatment with
factor H or VCP, respectively. However, a 50% increase in
luciferase activity in MDCK infected with H3+N2 pseudo-
typed lentiviral particles was observed when treated with factor
H, and 30% when treated with VCP was observed. Hence, the
treatment with these proteins resulted in restriction of IAV entry
and replication by 4-fold for the H1N1 subtype, while promoting
entry and replication by 2-fold for H3N2. Thus, using lentiviral
vectors, pseudo-typed for H1+N1 and H3+N2, Murugaiah et al.
demonstrated the ability of Factor H and VCP to modulate IAV
entry, in a subtype dependent manner, similar to C4BP (32).
As seen in the case of C4BP, Murugaiah et al. also suggested
that FH and VCP to accomplished the subtype dependent entry
modulation via interaction with HA, NA, and M1. Additionally,
FH and VCP were also shown to trigger an anti-inflammatory
response in case of H1N1 subtype while leading to pro
inflammatory response in H3N2 subtype. The inflammatory
response was also modulated in a subtype-specific manner.
Transcriptional levels of IFN-a, TNF-a, IL-12, IL-6, and IFN-
a were upregulated, while RANTES was downregulated
following factor H treatment for the H1N1 subtype at 6 h
post-infection. In the case of the H3N2 subtype, mRNA levels
of these pro-inflammatory cytokines were enhanced (32). The
findings of this study highlight a possible common mechanism
that is used by C4BP, VCP, and Factor H that contain CCP
domains in modulating the entry of IAV subtypes. The heparin-Frontiers in Immunology | www.frontiersin.org 10binding sites on Factor H (surface of CCP7, CCP13 and CCP20)
and VCP (tip of module 4) are also found on C4BP a chain (CCP
domains 1-2) (9, 47). These sites may provide a possible
explanation for the effect observed on viral entry modulation
among the IAV subtypes. In this study, we have shown that IAV
subtypes bind C4BP via the heparin-binding site containing CCP
domain 1-2 (Figure 4). We suspect the overlapping heparin-
binding and IAV binding sites may contribute to the variation
observed between the subtypes. C4BP has been shown to
enhance adenovirus uptake in hepatocytes by providing a
bridge between the adenovirus fiber knob domain and cell
surface Heparan Sulfate Proteoglycans (HSP) (16); we
speculate that the increased efficiency observed between the
binding of C4BP’s CCP1-2 domain and H3N2 subtype
compared to H1N1 subtype may contribute to the increased
H3N2 virion entry in a similar fashion. The similarity of the
results between the interaction of C4BP, Factor H, and VCP to
IAV subtypes further support this idea and requires further study
by treating cells with heparinase prior to C4BP treatment and
infection to confirm whether the variation between the subtypes
may be modulated by the interaction with HSP.
Another explanation for differences in outcome in spite of
C4BP binding both viruses may arise from the local variations
found between H1 and H3 or N1 and N2 or the variation in
C4BP binding sites to HA or NA. HA and NA are classified into
two groups regardless of their serotype identification. In case of
NA, N1 belongs to group 1, which lacks an additional cavity next
to the active site that is created by the movement of “150 loop”
during conformational changes caused by the binding of
substrate to the active site (48). N2 belongs to group 2 whichFIGURE 6 | C4BP modulates viral entry in a strain-dependent manner.
Luciferase reporter activity of C4BP treated MDCK cells infected with
matched H1+N1 and unmatched H3+N2 lentiviral pseudo-particles. H1N1
particles exhibited a 55% decrease in viral entry compared to controls, while
a 17% increase in viral entry in case of H3N2 was observed. Results are
normalized against cells infected with the particles not treated with C4BP.
Significance was determined using the unpaired one-way ANOVA test
(****p < 0.0001) (n = 3).FIGURE 5 | C4BP restricts replication of H1N1 and promotes replication of
H3N2 in target human A549 cells. M1 expression of both H1N1 and H3N2
IAV after infection of A549 cells for 6 h was measured by qRT-PCR. A549
cells were challenged either with H1N1 or H3N2 (MOI 1) that were incubated
with varying concentration of C4BP (10, 20, and 40 µg/ml). Cell pellets were
harvested at 6 h to analyze the M1 expression of IAV. Cells were lysed, and
RNA extracted was converted into cDNA. Infection was measured via qRT-
PCR using M1 primers; 18S rRNA was used as an endogenous control. The
relative expression (RQ) was calculated by using cells infected with respective
viruses that were not treated with C4BP as the calibrator. The RQ value was
calculated using the formula: RQ = 2−DDCt. Assays were conducted in
triplicates, and error bars represent ± SEM. Significance was determined
using the two-way ANOVA test (****p < 0.0001) (n = 3).January 2021 | Volume 11 | Article 585361
Varghese et al. C4BP Interaction With Influenzalacks the “150 loop”, and hence, the additional cavity (48). NA
functions in virus internalization by enabling movement of the
virus across the cell surface from an endocytosis inactive site on
the cell to an active site, thereby increasing the efficiency of viral
uptake (49). NA has also been shown to boost HA-dependent
influenza virus fusion and infectivity by employing a cell-cell
fusion assay and an HIV-based pseudo-typed infectivity assay
(50). It is possible that the structural differences between N1 and
N2 after binding to C4BP may affect their role in virus
internalization. Similarly, HA can also be classified into two
groups based on structural characteristics, with H1 in group 1
and H2 in group 2 (51). Hence, localized variations found on HA
could influence potential binding pocket for C4BP on the HA, as
seen in the case of Stachyflin (52). These structural variations in
HA and NA may also explain the increased binding observed
between C4BP and H3N2. It will be important to investigate the
effect of differential interplay between HA and NA of H1N1 and
H3N2 viruses on the infection modulation activity of C4BP.
Additionally, the variation in binding efficiency of CCP1-2
between H3N2 and H1N1 suggests that the binding while
overlapping, does not occur at identical sites, as seen in the
case of C4BP binding to C4b, S. pyogenes, or B. pertussis (46, 53,
54). It may be possible that this variation and difference in
binding efficiency further affects downstream interactions such
as C4BP or IAV’s interaction with other receptors or proteins
that may affect viral entry (55, 56).
During an IAV infection, elevated levels of cytokines and
chemokines are observed, including IL-6, TNF-a, IFNs, IL-1b,
RANTES, IL-8, MIP1b, and MCP1 (57–60). Inflammation is a
critical part of the immune response against IAV infection.
Cytokines such as TNF-a, IL-12, and IFNs are known to play
a significant role to cellular inflammation. To study the
modulation of these cytokines by C4BP, we performed qPCR
on A549 cells infected with C4BP treated H1N1 or H3N2
(treated) and standardized them against A549 cell infectedFrontiers in Immunology | www.frontiersin.org 11under similar conditions using viruses that were not treated
with C4BP (untreated) to obtain the relative expression levels of
the cytokines. Type I interferons like IFN a and IFN b are critical
mediators of virus clearance during an IAV infection. Six hours
post-infection in the treated cells, IFN-a mRNA levels were
downregulated in case of H1N1 (−2 log10) and upregulated (2.5
log10) in case of C4BP treated H3N2 infected cells (Figure 7A).
This suggests the formation of an antiviral state in the infected
and its neighbouring cells, thereby reducing viral replication and
disease severity (61, 62). The elevated levels of IFN-a mRNA
observed in A549 cells challenged with the C4BP treated H3N2
subtype suggest that C4BP is being protective by promoting a
type 1 interferon response despite not acting as an entry inhibitor
for H3N2. The cytokine mRNA expression was downregulated
(−2 log10) in the case of both viruses 2 h post-infection and can
be attributed to the low viral load present at the time
(Figure 7A).
We found that IL-12 mRNA levels were too low to be detected
2 h post-infection, but the relative mRNA upregulation (1 log10)
was observed 6 h post-infection in cells infected with C4BP
treated H3N2 compared to its control (Figure 7B). This clearly
indicates the presence of a response that would culminate in the
prevention of viral replication, activation of cytotoxic T
lymphocytes and early NK cell-dependent gamma interferon
production (63). The entry inhibitory effect of C4BP on H1N1
subtype, and the subsequent lower viral replication and load is
further demonstrated by the downregulation (−2 log10) of IL-12
mRNA in the C4BP treated H1N1-infected cells compared to
their untreated counterparts 6 h post-infection (Figure 7B).
The TNF-a–NF-kB axis leads to the expression of a number
of inflammatory genes, induction of apoptosis and production of
ROS (64–66). NF-kB mRNA in cells infected with C4BP treated
H1N1, 2 h post-infection was found to be relatively upregulated
(~0.3 log10), while a downregulation (~−0.7 log10) of the mRNA
was recorded 6 h post-infection when compared to the untreatedA B
D E F
C
FIGURE 7 | Cytokine modulation by C4BP of IAV infected A549 cells. H1N1 or H3N2 incubated with 10µg/ml of C4BP was used to infect A549 cells. Cell pellets
were harvested at 2 h and 6 h to analyse the expression of cytokines and chemokines. Cells were lysed, and purified RNA was converted into cDNA. The expression
levels of cytokines IFN-a (A), IL-12 (B), NF-kB (C), TNF-a (D), IL-6 (F) and chemokine RANTES (E) were measured using qRT-PCR, and the data were normalised
via 18S rRNA expression as a control. The relative expression (RQ) was calculated by using cells infected with respective viruses not treated with C4BP as the
calibrator. The RQ value was calculated using the formula: RQ = 2−DDCt. Assays were conducted in triplicates, and error bars represent ± SEM. Significance was
determined using the two-way ANOVA test (**p < 0.01, and ****p < 0.0001) (n = 3).January 2021 | Volume 11 | Article 585361
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H3N2, we found an upregulation of NF-kB mRNA 6 h post-
infection, while no significant modulation was observed 2 h post-
infection (Figure 7C). This variation in NF-kB mRNA levels 6 h
post-infection among the IAV subtype further confirms the
subtype dependent entry inhibitory action of C4BP on IAV.
When compared to their untreated counterparts, the cells
infected with either C4BP treated H1N1 or H3N2 were found
to upregulate TNF-a mRNA (Figure 7D), indicating a robust
inflammatory response at both 2 h (0.2 log10) and 6 h (~1.7 log10)
post-infection (67, 68).
RANTES is an important chemokine that been associated
with extensive inflammation of the lung in cases of avian
Influenza and increased mortality in IAV challenged CCR5−/−
mice (69). RANTES mRNA expression levels in treated H1N1
challenged cells 2 h post-infection, was found to be significantly
downregulated (−2 log10) while it was not detected in case of
H3N2 (Figure 7E). RANTES mRNA levels in cells were
upregulated observed in case of both C4BP treated viral
subtypes (2 log10) 6 h post-infection, suggesting an active
recruitment of leukocytes to the inflammatory sites (Figure 7E).
Another cytokine associated with both pro-inflammatory and
anti-inflammatory effects is IL-6 (70). Its synthesis is upregulated
during infection to simulate the adaptive immune response by
inducingdifferentiationof activatedBcells andCD4+Tcells (71). In
the case of IAV infection, IL-6 seemed to have a protective role in
murine models, promoting viral clearance and limiting
inflammation (72). IL-6 mRNA levels at 6 h was found to be
upregulated in case of H1N1 (0.5 log10) and H3N2 (1.5 log10)
(Figure 7F) after C4BP treatment. These results suggest that C4BP
may entice differential adaptive immune response.
It would be interesting to study if C4BP can also bind avian
IAV. Another area to explore further would be investigate in
humanized murine models to understand better the impact of
C4BP-IAV interaction in the microenvironment of the
respiratory system, and elucidation of mechanism resulting in
the subtype-dependent entry modulation of IAV by C4BP.
In conclusion, we show that C4BP differentially regulates the
efficacy of Influenza A virus replication in a subtype-dependent
manner by modulating their entry into the cells, and provide an
interesting candidate to be developed into a HA and NA-based
inhibitor against IAV infections. Recombinant forms of CCP4+5
and/or CCP7+8 are likely to be excellent vehicles for therapeutic
development against IAV pandemic H1N1 subtype.DATA AVAILABILITY STATEMENT
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